0001193125-15-179302.txt : 20150508 0001193125-15-179302.hdr.sgml : 20150508 20150508144559 ACCESSION NUMBER: 0001193125-15-179302 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150508 DATE AS OF CHANGE: 20150508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: pSivida Corp. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 15846035 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 10-Q 1 d911428d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

COMMISSION FILE NUMBER 000-51122

 

 

pSivida Corp.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   26-2774444

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

480 Pleasant Street

Watertown, MA

  02472
(Address of principal executive offices)   (Zip Code)

(617) 926-5000

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

There were 29,412,365 shares of the registrant’s common stock, $0.001 par value, outstanding as of May 6, 2015.

 

 

 


Table of Contents

PSIVIDA CORP. AND SUBSIDIARIES

INDEX TO FORM 10-Q

 

         Page  
PART I:  

FINANCIAL INFORMATION

  
Item 1.  

Unaudited Financial Statements

  
 

Condensed Consolidated Balance Sheets – March 31, 2015 and June 30, 2014

     3   
 

Condensed Consolidated Statements of Comprehensive (Loss) Income – Three and Nine Months Ended March  31, 2015 and 2014

     4   
 

Condensed Consolidated Statement of Stockholders’ Equity – Nine Months Ended March 31, 2015

     5   
 

Condensed Consolidated Statements of Cash Flows – Nine Months Ended March 31, 2015 and 2014

     6   
 

Notes to Condensed Consolidated Financial Statements

     7   
Item 2.  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     16   
Item 3.  

Quantitative and Qualitative Disclosures about Market Risk

     22   
Item 4.  

Controls and Procedures

     22   
PART II:  

OTHER INFORMATION

  
Item 1A.  

Risk Factors

     23   
Item 6.  

Exhibits

     35   
Signatures      36   
Certifications   

 

2


Table of Contents

PART I. FINANCIAL INFORMATION

 

Item 1. Unaudited Financial Statements

PSIVIDA CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share amounts)

 

     March 31,
2015
    June 30,
2014
 

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 23,007      $ 15,334   

Marketable securities

     8,651        2,944   

Accounts and other receivables

     430        517   

Prepaid expenses and other current assets

     989        547   
  

 

 

   

 

 

 

Total current assets

  33,077      19,342   

Property and equipment, net

  280      297   

Intangible assets, net

  2,080      2,765   

Other assets

  115      117   

Restricted cash

  150      150   
  

 

 

   

 

 

 

Total assets

$ 35,702    $ 22,671   
  

 

 

   

 

 

 

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$ 812    $ 464   

Accrued expenses

  1,371      1,524   

Deferred revenue

  35      138   
  

 

 

   

 

 

 

Total current liabilities

  2,218      2,126   

Deferred revenue

  5,584      5,584   

Deferred rent

  53      37   
  

 

 

   

 

 

 

Total liabilities

  7,855      7,747   
  

 

 

   

 

 

 

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding

  —        —     

Common stock, $.001 par value, 60,000,000 shares authorized, 29,412,365 and 29,298,558 shares issued and outstanding at March 31, 2015 and June 30, 2014, respectively

  29      29   

Additional paid-in capital

  292,439      290,864   

Accumulated deficit

  (265,520   (277,013

Accumulated other comprehensive income

  899      1,044   
  

 

 

   

 

 

 

Total stockholders’ equity

  27,847      14,924   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

$ 35,702    $ 22,671   
  

 

 

   

 

 

 

See notes to condensed consolidated financial statements

 

3


Table of Contents

PSIVIDA CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)

(In thousands, except per share amounts)

 

     Three Months Ended     Nine Months Ended  
     March 31,     March 31,  
     2015     2014     2015     2014  

Revenues:

        

Collaborative research and development

   $ 110      $ 1,676      $ 25,355      $ 2,149   

Royalty income

     218        316        801        1,032   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

  328      1,992      26,156      3,181   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

Research and development

  3,339      2,269      8,890      7,267   

General and administrative

  2,041      1,946      5,645      5,468   

Gain on sale of property and equipment

  —        (4   —        (76
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

  5,380      4,211      14,535      12,659   
  

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income from operations

  (5,052   (2,219   11,621      (9,478
  

 

 

   

 

 

   

 

 

   

 

 

 

Other income:

Interest income

  6      1      12      3   

Other income, net

  4      —        4      —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income

  10      1      16      3   
  

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before income taxes

  (5,042   (2,218   11,637      (9,475

Income tax benefit (expense)

  44      31      (144   87   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

$ (4,998 $ (2,187 $ 11,493    $ (9,388
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income per common share:

Basic

$ (0.17 $ (0.08 $ 0.39    $ (0.35
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

$ (0.17 $ (0.08 $ 0.38    $ (0.35
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average common shares:

Basic

  29,412      27,672      29,367      26,842   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

  29,412      27,672      30,612      26,842   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

$ (4,998 $ (2,187 $ 11,493    $ (9,388
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive (loss) income:

Foreign currency translation adjustments

  (45   5      (141   100   

Net unrealized gain (loss) on marketable securities

  1      (1   (4   (1
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive (loss) income

  (44   4      (145   99   
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive (loss) income

$ (5,042 $ (2,183 $ 11,348    $ (9,289
  

 

 

   

 

 

   

 

 

   

 

 

 

See notes to condensed consolidated financial statements

 

4


Table of Contents

PSIVIDA CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)

 

     Common Stock      Additional            Accumulated
Other
    Total  
     Number of
Shares
     Par Value
Amount
     Paid-In
Capital
     Accumulated
Deficit
    Comprehensive
Income
    Stockholders’
Equity
 

Balance at July 1, 2014

     29,298,558       $ 29       $ 290,864       $ (277,013   $ 1,044      $ 14,924   

Net income

     —           —           —           11,493        —          11,493   

Other comprehensive loss

     —           —           —           —          (145     (145

Exercise of stock options

     113,807         —           235         —          —          235   

Stock-based compensation

     —           —           1,340         —          —          1,340   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at March 31, 2015

  29,412,365    $ 29    $ 292,439    $ (265,520 $ 899    $ 27,847   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

See notes to condensed consolidated financial statements

 

5


Table of Contents

PSIVIDA CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

     Nine Months Ended
March 31,
 
     2015     2014  

Cash flows from operating activities:

    

Net income (loss)

   $ 11,493      $ (9,388

Adjustments to reconcile net income (loss) to cash flows from operating activities:

    

Amortization of intangible assets

     579        582   

Depreciation of property and equipment

     79        103   

Stock-based compensation expense

     1,340        963   

Amortization of bond premium on marketable securities

     66        26   

Gain on sale of property and equipment

     —          (76

Changes in operating assets and liabilities:

    

Accounts receivable and other current assets

     (388     1,016   

Accounts payable and accrued expenses

     221        (833

Deferred revenue

     (103     (290

Deferred rent

     16        11   
  

 

 

   

 

 

 

Net cash provided by (used in) operating activities

  13,303      (7,886
  

 

 

   

 

 

 

Cash flows from investing activities:

Purchases of marketable securities

  (8,677   (2,714

Maturities of marketable securities

  2,900      3,350   

Purchases of property and equipment

  (71   (75

Proceeds from sale of property and equipment

  —        76   

Change in restricted cash

  —        (150
  

 

 

   

 

 

 

Net cash (used in) provided by investing activities

  (5,848   487   
  

 

 

   

 

 

 

Cash flows from financing activities:

Proceeds from issuance of stock, net of issuance costs

  —        18,149   

Exercise of stock options

  235      909   
  

 

 

   

 

 

 

Net cash provided by financing activities

  235      19,058   
  

 

 

   

 

 

 

Effect of foreign exchange rate changes on cash and cash equivalents

  (17   (3
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

  7,673      11,656   

Cash and cash equivalents at beginning of period

  15,334      6,899   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

$ 23,007    $ 18,555   
  

 

 

   

 

 

 

Supplemental disclosure of cash flow information:

Cash paid for income taxes

$ 263    $ —     

Supplemental disclosure of non-cash investing and financing activities:

Purchase of property and equipment

  —        141   

Stock issuance costs

  —        86   

 

6


Table of Contents

PSIVIDA CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. Operations and Basis of Presentation

The accompanying condensed consolidated financial statements of pSivida Corp. and subsidiaries (the “Company”) as of March 31, 2015 and for the three and nine months ended March 31, 2015 and 2014 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2014, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive (loss) income and cash flows for the periods indicated. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.

The Company is a leader in the development of sustained-release pharmaceutical products for treating eye diseases. Its approved products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of the four approved sustained-release products for treating retinal diseases. The Company’s lead product candidate Medidur™ for posterior uveitis is in pivotal clinical trials. Marketing of its lead licensed product ILUVIEN® for diabetic macular edema (“DME”) commenced in the U.S. in the fiscal 2015 third quarter. The Company’s pre-clinical development program is focused on developing products for chronic retinal diseases utilizing our core technology platforms. The Company’s strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements.

Medidur, the Company’s lead development product, is an injectable, micro-insert designed to treat posterior uveitis, a blinding eye disease, on a sustained basis for 36 months. Medidur uses the same micro-insert used in ILUVIEN for DME (same design, same drug, same polymers, same release rate) and delivers a lower dose of the same drug as Retisert®, the Company’s approved implant for posterior uveitis. The Company is developing Medidur independently.

In recent meetings, the Company reached agreement with the U.S. Food and Drug Administration (“FDA”) on a regulatory path for Medidur that should allow a new drug application (“NDA”) to be filed in the first half of 2017. The FDA indicated that, pending clinical trial results, it would accept an NDA based on data from the ongoing Medidur Phase III trial (which has a 12-month primary endpoint), data from a second Phase III trial with a shorter six-month primary endpoint and data referenced from the already completed Phase III ILUVIEN trials. The ongoing Phase III trial for Medidur completed enrollment with 129 patients in the fiscal 2015 third quarter. The last 12-month follow-up visit is scheduled in March 2016, and the Company expects top-line data in the second calendar quarter of 2016. The Company has already initiated a second Phase III Medidur trial, which will recruit up to 150 patients in India. Both trials will follow participants for three years.

The Company had previously planned to file an NDA with data from only the first Phase III trial and data referenced from the ILUVIEN studies, subject to FDA confirmation. Because of the shorter six-month primary endpoint permitted for the second trial, the Company expects that the new regulatory path will allow it to file the Medidur NDA with only a several month delay from the time frame anticipated with one Phase III trial. The Company had budgeted for a second Phase III trial, pending FDA guidance, so the second trial does not affect the Company’s liquidity projections.

The Company plans to commercialize Medidur with a newly designed, proprietary inserter that uses a standard 27 gauge needle routinely used in intraocular injections. As a result of the new design, the Company will conduct a utilization study on the new inserter, with data to be submitted as part of the Medidur NDA. Data from this study is expected to be available before data from the other trials and should not delay the NDA submission.

 

7


Table of Contents

ILUVIEN, the Company’s most recently approved product, is an injectable, sustained-release micro-insert that provides treatment of DME for three years from a single administration. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (“Alimera”), and the Company is entitled to a share of the net profits (as defined) from Alimera’s sales of ILUVIEN on a country-by-country basis. ILUVIEN was launched in the U.S. in late February 2015 and is now widely available to physicians in the U.S. It is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.

ILUVIEN was also launched in Portugal in January 2015, and has been commercially available in the United Kingdom and Germany since June 2013. ILUVIEN has marketing approvals in 17 EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies.

Distribution, regulatory and reimbursement matters for ILUVIEN for DME in Australia and New Zealand have been sublicensed. The Company is entitled to 20% of any royalties and 33% of all other payments received by our licensee, including any milestone payments.

The Company’s pre-clinical research is primarily focused on developing pharmaceutical products to provide targeted and systemic sustained delivery of drugs and large biologic molecules for treatment of various conditions, and to provide sustained delivery of therapeutic agents to treat wet and dry age-related macular degeneration, glaucoma and osteoarthritis.

The Company has a history of operating losses and has financed its operations primarily from the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners and from proceeds of sales of its equity securities. The Company believes that its cash, cash equivalents and marketable securities of $31.7 million at March 31, 2015 will enable the Company to maintain its current and planned operations (including its two Medidur trials) into calendar year 2017. This estimate excludes any potential net profits receipts from sales of ILUVIEN.

New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which requires an entity to recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP. In April 2015, the FASB tentatively deferred the effective date of ASU 2014-09, while also tentatively permitting early adoption. If such deferral is ratified, ASU 2014-09 will become effective on July 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the impact this standard will have on its financial statements.

 

2. License and Collaboration Agreements

Alimera

Under the collaboration agreement with Alimera, as amended in March 2008 (the “Alimera Agreement”), the Company licensed to Alimera the rights to develop, market and sell certain product candidates, including ILUVIEN, and Alimera assumed all financial responsibility for the development of licensed products. In September 2014, the Company earned a $25.0 million milestone from Alimera as a result of the FDA approval of ILUVIEN, which was recorded as revenue in the quarter ended September 30, 2014 and received in October 2014. In addition, the Company is entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera, measured on a quarter-by-quarter and country-by-country basis. Alimera may recover 20% of previously incurred and unapplied net losses (as defined) for commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company’s net profit share to 16% in each country until those net losses are recouped. In the event that Alimera sublicenses commercialization in any country, the Company is entitled to 20% of royalties and 33% of non-royalty consideration received by Alimera, less certain permitted deductions. The Company is also entitled to reimbursement of certain patent maintenance costs with respect to the patents licensed to Alimera.

 

8


Table of Contents

The Company’s performance obligations ended on December 31, 2009 and, accordingly, all amounts received thereafter under the Alimera Agreement are recognized as revenue upon receipt or at such earlier date, if applicable, on which any such amounts are both fixed and determinable and reasonably assured of collectability.

Revenue under the Alimera Agreement totaled $70,000 and $47,000 for the three months ended March 31, 2015 and 2014, respectively, and $25.1 million and $95,000 for the nine months ended March 31, 2015 and 2014, respectively.

Pfizer

In June 2011, the Company and Pfizer entered into an Amended and Restated Collaborative Research and License Agreement (the “Restated Pfizer Agreement”) to focus solely on the development of a sustained-release bioerodible micro-insert designed to deliver latanoprost for human ophthalmic disease or conditions other than uveitis (the “Latanoprost Product”). Pfizer made an upfront payment of $2.3 million and the Company agreed to use commercially reasonable efforts to fund the development for at least one year, including assumption of an investigator-sponsored Phase I/II dose-escalation study. The Company may, at its option, conduct Phase II clinical trials, which have not been initiated, for the purpose of demonstrating Proof-of-Concept (“POC”). If the Company were to issue a final report demonstrating POC, Pfizer would have a 90-day exercise option for an exclusive, worldwide license to develop and commercialize the Latanoprost Product in return for a $20.0 million payment and potential double-digit sales-based royalties and prescribed development, regulatory and sales performance milestone payments. If the Company elects to cease development of the Latanoprost Product prior to POC, Pfizer could exercise its option for the same worldwide license upon payment of a lesser option fee, with comparable reductions in any future milestones and royalties. If Pfizer does not exercise its option when available, the Restated Pfizer Agreement will automatically terminate, with any remaining deferred revenue balance recorded as revenue at that time, provided, however, that the Company would retain the right to develop and commercialize the Latanoprost Product.

As a result of the material modification of the Pfizer arrangement, the estimated selling price of the combined deliverables under the Restated Pfizer Agreement of $6.7 million is being recognized as collaborative research and development revenue over the expected performance period using the proportional performance method. The Company recorded no revenue and $9,000 for the three months ended March 31, 2015 and 2014, respectively, and no revenue and $65,000 for the nine months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, the Company continues to evaluate the Latanoprost Product and, consequently, the Company cannot currently estimate the remaining performance period. As a result, total deferred revenue of approximately $5.6 million at each of March 31, 2015 and June 30, 2014 was classified as noncurrent. Costs associated with developing the Latanoprost Product are reflected in operating expenses in the period in which they are incurred.

Pfizer owned approximately 6.3% of the Company’s outstanding common stock at March 31, 2015.

Bausch & Lomb

Pursuant to a licensing and development agreement, as amended, Bausch & Lomb has a worldwide exclusive license to make and sell Retisert in return for royalties based on sales. Bausch & Lomb was also licensed to make and sell Vitrasert, an implant for sustained treatment of CMV retinitis, but discontinued sales in the second quarter of fiscal 2013 following patent expiration.

Royalty income from Bausch & Lomb totaled $218,000 and $316,000 for the three months ended March 31, 2015 and 2014, respectively, and $801,000 and $1.0 million for the nine months ended March 31, 2015 and 2014, respectively. Accounts receivable from Bausch & Lomb totaled $223,000 at March 31, 2015 and $302,000 at June 30, 2014.

Enigma Therapeutics

The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with Enigma Therapeutics Limited (“Enigma”) for the development of BrachySil, the Company’s BioSilicon™ product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and milestone payments based on aggregate product sales. Enigma is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any patent maintenance costs, sales-based royalties and

 

9


Table of Contents

sublicensee sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. The Company has no consequential performance obligations under the Enigma license agreement and, accordingly, any amounts to which the Company is entitled under the agreement are recognized as revenue on the earlier of receipt or when collectability is reasonably assured. There was no revenue related to the Enigma agreement in the three month periods ended March 31, 2015 and 2014 and $100,000 and $102,000 of revenues for the nine month periods ended March 31, 2015 and 2014, respectively. As of March 31, 2015, no deferred revenue was recorded for this agreement.

Evaluation Agreements

The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third party drug candidates in the treatment of various diseases. Consideration received is generally recognized as revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the evaluation agreement. Revenues under evaluation agreements totaled $35,000 and $1.6 million for the three months ended March 31, 2015 and 2014, respectively, and $104,000 and $1.9 million for the nine months ended March 31, 2015 and 2014, respectively.

 

3. Intangible Assets

The reconciliation of intangible assets for the nine months ended March 31, 2015 and for the year ended June 30, 2014 was as follows (in thousands):

 

     Nine Months Ended
March 31, 2015
     Year Ended
June 30, 2014
 

Patented technologies

     

Gross carrying amount at beginning of period

   $ 41,689       $ 38,941   

Foreign currency translation adjustments

     (3,313      2,748   
  

 

 

    

 

 

 

Gross carrying amount at end of period

  38,376      41,689   
  

 

 

    

 

 

 

Accumulated amortization at beginning of period

  (38,924   (35,511

Amortization expense

  (579   (778

Foreign currency translation adjustments

  3,207      (2,635
  

 

 

    

 

 

 

Accumulated amortization at end of period

  (36,296   (38,924
  

 

 

    

 

 

 

Net book value at end of period

$ 2,080    $ 2,765   
  

 

 

    

 

 

 

The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization of intangible assets totaled $190,000 and $196,000 for the three months ended March 31, 2015 and 2014, respectively, and $579,000 and $582,000 for the nine months ended March 31, 2015 and 2014, respectively. The carrying value of intangible assets at March 31, 2015 of $2.1 million (approximately $1.5 million attributable to the Durasert™ technology and $0.6 million attributable to the BioSilicon technology (including Tethadur™)) is expected to be amortized on a straight-line basis over the remaining estimated useful life of 2.75 years, or approximately $756,000 per year.

 

10


Table of Contents
4. Marketable Securities

The amortized cost, unrealized loss and fair value of the Company’s available-for-sale marketable securities at March 31, 2015 and June 30, 2014 were as follows (in thousands):

 

     March 31, 2015  
     Amortized
Cost
     Unrealized
Loss
     Fair Value  

Corporate bonds

   $ 8,656       $ (5    $ 8,651   
  

 

 

    

 

 

    

 

 

 

 

     June 30, 2014  
     Amortized
Cost
     Unrealized
Loss
     Fair Value  

Corporate bonds

   $ 2,446       $ (1    $ 2,445   

Commercial paper

     499         —           499   
  

 

 

    

 

 

    

 

 

 

Total marketable securities

$ 2,945    $ (1 $ 2,944   
  

 

 

    

 

 

    

 

 

 

During the nine months ended March 31, 2015, $8.7 million of marketable securities were purchased and $2.9 million of such securities matured. At March 31, 2015, the marketable securities had maturities ranging from 38 days to 11 months, with a weighted average maturity of 7.1 months.

 

5. Fair Value Measurements

The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

 

    Level 1 – Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities.

 

    Level 2 – Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets).

 

    Level 3 – Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities.

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At March 31, 2015 and June 30, 2014, substantially all of the Company’s interest-bearing cash equivalent balances were concentrated in one institutional money market fund that has investments consisting primarily of certificates of deposit, commercial paper, time deposits, U.S. government agencies, treasury bills and treasury repurchase agreements. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.

 

11


Table of Contents

The Company’s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. Certain of the Company’s corporate debt securities were valued based on quoted prices for the specific securities in an active market and were therefore classified as Level 1. The remaining marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services’ pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2. The following tables summarize the Company’s assets carried at fair value measured on a recurring basis at March 31, 2015 and June 30, 2014 by valuation hierarchy (in thousands):

 

     March 31, 2015  
     Total carrying
value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 17,205       $ 17,205       $ —         $ —     

Marketable securities

           

Corporate bonds

     8,651         8,651         —           —     
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 25,856    $ 25,856    $ —      $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     June 30, 2014  
     Total carrying
value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 14,260       $ 14,260       $ —         $ —     

Marketable securities

           

Corporate bonds

     2,444         1,936         508         —     

Commercial paper

     500         —           500         —     
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 17,204    $ 16,196    $ 1,008    $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

 

6. Accrued Expenses

Accrued expenses consisted of the following at March 31, 2015 and June 30, 2014 (in thousands):

 

     March 31, 2015      June 30, 2014  

Personnel costs

   $ 618       $ 952   

Professional fees

     286         249   

Clinical

     418         316   

Other

     49         7   
  

 

 

    

 

 

 
$ 1,371    $ 1,524   
  

 

 

    

 

 

 

 

7. Stockholders’ Equity

In March 2014, the Company sold 1,700,000 shares of its common stock in a registered direct offering to a single institutional investor at a price of $4.11 per share for gross proceeds of $7.0 million. Placement agent fees and other share issue costs approximated $191,000.

In December 2013, the Company entered into an at-the-market (“ATM”) program pursuant to which the Company may, at its option, offer and sell shares of its common stock from time to time for an aggregate offering price of up to $19.2 million, representing the then remaining balance of the Company’s shelf registration statement. In connection with execution of the ATM program, the Company incurred transaction costs of $153,000. In addition, the Company pays the sales agent a commission of up to 3.0% of the gross proceeds from the sale of such shares. During the three and nine month periods ended March 31, 2015, the Company did not sell any shares under this program. During the three and nine months ended March 31, 2014, the Company sold 57,770 and 381,562 common shares, respectively, for net proceeds of $224,000 and $1.5 million, respectively, reflecting a weighted-average gross selling price of $3.98 per share.

In July 2013, the Company sold 3,494,550 shares of its common stock in an underwritten public offering at a price of $3.10 per share for gross proceeds of $10.8 million. Underwriting commissions and other share issue costs approximated $890,000.

 

12


Table of Contents

Warrants to Purchase Common Shares

During each of the nine month periods ended March 31, 2015 and 2014, there were a total of 1,176,105 outstanding and exercisable warrants to purchase common shares at a weighted-average exercise price of $3.67. At March 31, 2015, the remaining term of these warrants ranged from 0.8 to 2.4 years, representing a weighted average period of 1.6 years.

Incentive Plan

The Company’s 2008 Incentive Plan (the “2008 Plan”) provides for the issuance of stock options and other stock awards to directors, employees and consultants. At March 31, 2015, a total of 6,341,255 shares of common stock were authorized for issuance under the 2008 Plan, of which 1,080,817 were available for grant of future awards. The total number of shares issuable under the 2008 Plan is subject to annual increases pursuant to the terms of the plan. The following table provides a reconciliation of stock option activity under the 2008 Plan for the nine months ended March 31, 2015:

 

     Number of
Options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2014

     3,791,001       $ 3.08         

Granted

     831,200         4.48         

Exercised

     (113,807      2.07         

Forfeited

     (17,445      3.88         
  

 

 

    

 

 

       

Outstanding at March 31, 2015

  4,490,949    $ 3.36      6.43    $ 3,653   
  

 

 

    

 

 

    

 

 

    

 

 

 

Outstanding at March 31, 2015 - vested or unvested and expected to vest

  4,407,364    $ 3.35      6.39    $ 3,623   
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at March 31, 2015

  2,931,157    $ 3.04      5.28    $ 3,143   
  

 

 

    

 

 

    

 

 

    

 

 

 

Option grants for the nine months ended March 31, 2015 consisted of 701,200 options to employees with ratable annual vesting over 4 years, 90,000 options to non-executive directors with 1-year cliff vesting and 40,000 options to a newly appointed non-executive director with ratable annual vesting over 3 years. All option grants have a 10-year contractual life. The weighted-average grant date fair value of these option grants was $3.33 per share. A total of 579,408 options vested during the nine months ended March 31, 2015. In determining the grant date fair value of options, the Company uses the Black-Scholes option pricing model. The Company calculated the Black-Scholes value of options awarded during the nine months ended March 31, 2015 based on the following key assumptions:

 

Option life (in years)

5.50 - 6.25

Stock volatility

79% - 93%

Risk-free interest rate

1.70% - 2.00%

Expected dividends

0%

 

13


Table of Contents

Stock-Based Compensation Expense

The Company’s statements of comprehensive (loss) income included total compensation expense from stock-based payment awards for the three and nine months ended March 31, 2015 and 2014, as follows (in thousands):

 

     Three Months Ended
March 31,
     Nine Months Ended
March 31,
 
     2015      2014      2015      2014  

Compensation expense included in:

           

Research and development

   $ 182       $ 142       $ 492       $ 373   

General and administrative

     432         299         848         590   
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 614    $ 441    $ 1,340    $ 963   
  

 

 

    

 

 

    

 

 

    

 

 

 

At March 31, 2015, there was approximately $2.3 million of unrecognized compensation expense related to unvested options under the 2008 Plan, which is expected to be recognized as expense over a weighted-average period of approximately 1.8 years.

 

8. Income Taxes

The Company recognizes deferred tax assets and liabilities for estimated future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established if, based on management’s review of both positive and negative evidence, it is more likely than not that all or a portion of the deferred tax assets will not be realized. Because of its historical losses from operations, the Company established a valuation allowance for the net deferred tax assets. The Company recorded an income tax benefit of $44,000 for the three months ended March 31, 2015 and an income tax expense of $144,000 for the nine months ended March 31, 2015. The Company recorded an income tax benefit of $31,000 and $87,000 for the three and nine months ended March 31, 2014, respectively. The current year-to-date income tax expense predominantly reflects $263,000 of federal alternative minimum tax payments based upon taxable income for the tax year ended December 31, 2014, which was primarily attributable to receipt of the $25.0 million FDA approval milestone. The tax benefits in each period predominantly represented earned foreign research and development tax credits.

For the three and nine months ended March 31, 2015 and 2014, the Company had no significant unrecognized tax benefits. At March 31, 2015 and June 30, 2014, the Company had no accrued penalties or interest related to uncertain tax positions.

 

9. Commitments and Contingencies

The Company’s lease for its U.S. office and laboratory space in Watertown, Massachusetts extends through April 2019, with a five-year renewal option at market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. The Company’s obligations under the lease are secured by a cash-collateralized $150,000 irrevocable standby letter of credit.

At March 31, 2015, the Company was subject to various routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company’s financial position, results of operations or cash flows.

 

10. Net (Loss) Income per Share

Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the basic weighted average number of common shares outstanding the total number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.

 

14


Table of Contents

The following table reconciles the number of shares used to compute basic and diluted net (loss) income per share:

 

     Three Months Ended March 31,      Nine Months Ended March 31,  
     2015      2014      2015      2014  

Number of common shares - basic

     29,412,365         27,672,327         29,366,919         26,841,623   

Effect of dilutive securities:

           

Stock options

     —           —           989,990         —     

Warrants

     —           —           255,301         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Number of common shares - diluted

  29,412,365      27,672,327      30,612,210      26,841,623   
  

 

 

    

 

 

    

 

 

    

 

 

 

Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:

 

     Three Months Ended March 31,      Nine Months Ended March 31,  
     2015      2014      2015      2014  

Options outstanding

     4,490,949         3,893,739         1,881,524         3,893,739   

Warrants outstanding

     1,176,105         1,176,105         552,500         1,176,105   
  

 

 

    

 

 

    

 

 

    

 

 

 
  5,667,054      5,069,844      2,434,024      5,069,844   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

15


Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Note Regarding Forward-Looking Statements

Various statements made in this Quarterly Report on Form 10-Q are forward-looking and involve risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Such statements give our current expectations or forecasts of future events and are not statements of historical or current facts. All statements other than statements of current or historical facts are forward-looking statements, including, without limitation, any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. We often, although not always, identify forward-looking statements by using words or phrases such as “likely”, “expect”, “intend”, “anticipate”, “believe”, “estimate”, “plan”, “project”, “forecast” and “outlook”.

The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: ability to achieve profitable operations and access to capital; fluctuations in operating results; further impairment of intangible assets; decline in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; effects of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; safety and efficacy of Medidur; cost of clinical trials and data necessary to support an NDA for, timing of filing the NDA for, FDA acceptance of NDA for, and regulatory approval and successful commercialization of Medidur; development of the Latanoprost Product and any exercise by Pfizer of its option; ability of Tethadur to successfully deliver large biologic molecules and development of products; ability to successfully develop product candidates, complete clinical trials and receive regulatory approvals; ability to market and sell products; success of current and future license agreements; termination of license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in this Quarterly Report on Form 10-Q, including the Risk Factors set forth in Part II, Item 1A of this Form 10-Q. You should read and interpret any forward-looking statements together with these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements.

Our forward-looking statements speak only as of the date on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied in such statements will not be realized.

Our Business

We are a leader in the development of sustained-release pharmaceutical products for treating eye diseases. Our approved products deliver drugs at a controlled and steady rate for months or years. We have developed three of the four approved sustained-release products for treating retinal diseases. Our lead product candidate Medidur™ for posterior uveitis is in pivotal clinical trials. Marketing of our lead licensed product ILUVIEN® for diabetic macular edema (“DME”) commenced in the U.S. in the fiscal 2015 third quarter. Our pre-clinical development program is focused on developing products for chronic retinal diseases utilizing our core technology platforms. Our strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements.

Medidur, our lead development product, is an injectable, micro-insert designed to treat posterior uveitis, a blinding eye disease, on a sustained basis for 36 months. Medidur uses the same micro-insert used in ILUVIEN for DME (same design, same drug, same polymers, same release rate) and delivers a lower dose of the same drug as Retisert®, our approved implant for posterior uveitis. We are developing Medidur independently.

 

16


Table of Contents

In recent meetings, we reached agreement with the U.S. Food and Drug Administration (“FDA”) on a regulatory path for Medidur that should allow a new drug application (“NDA”) to be filed in the first half of 2017. The FDA indicated that, pending clinical trial results, it would accept an NDA based on data from the ongoing Medidur Phase III trial (which has a 12-month primary endpoint), data from a second Phase III trial with a shorter six-month primary endpoint and data referenced from the already completed Phase III ILUVIEN trials. The ongoing Phase III trial for Medidur completed enrollment with 129 patients in our fiscal 2015 third quarter. The last 12-month follow-up visit is scheduled in March 2016, and we expect top-line data in the second calendar quarter of 2016. We have already initiated a second Phase III Medidur trial, which will recruit up to 150 patients in India. Both trials will follow participants for three years.

We had previously planned to file an NDA with data from only the first Phase III trial and data referenced from the ILUVIEN studies, subject to FDA confirmation. Because of the shorter six-month primary endpoint permitted for the second trial, we expect that the new regulatory path will allow us to file the Medidur NDA with only a several month delay from the time frame we anticipated with one Phase III trial. We had budgeted for a second Phase III trial, pending FDA guidance, so the second trial does not affect our liquidity projections.

We plan to commercialize Medidur with a newly designed, proprietary inserter that uses a standard 27 gauge needle routinely used in intraocular injections. As a result of the new design, we will conduct a utilization study on the new inserter, with data to be submitted as part of the Medidur NDA. Data from this study is expected to be available before data from the other trials and should not delay the NDA submission.

ILUVIEN, our most recently approved product, is an injectable, sustained-release micro-insert that provides treatment of DME for three years from a single administration. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (“Alimera”), and we are entitled to a share of the net profits (as defined) from Alimera’s sales of ILUVIEN on a country-by-country basis. ILUVIEN was launched in the U.S. in late February 2015 and is now widely available to physicians in the U.S. It is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.

ILUVIEN was also launched in Portugal in January 2015, and has been commercially available in the United Kingdom and Germany since June 2013. ILUVIEN has marketing approvals in 17 EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies.

Distribution, regulatory and reimbursement matters for ILUVIEN for DME in Australia and New Zealand have been sublicensed. We are entitled to 20% of any royalties and 33% of all other payments received by our licensee, including any milestone payments.

Our pre-clinical research is primarily focused on developing pharmaceutical products to provide targeted and systemic sustained delivery of drugs and large biologic molecules for treatment of various conditions, and to provide sustained delivery of therapeutic agents to treat wet and dry age-related macular degeneration, glaucoma and osteoarthritis.

Durasert™, Medidur™, BioSilicon™ and Tethadur™ are our trademarks, Retisert® is Bausch & Lomb’s trademark, and ILUVIEN® is Alimera’s trademark.

All information in this Form 10-Q with respect to ILUVIEN, including regulatory and marketing information, and Alimera’s plans and intentions, reflects information reported by Alimera.

Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in conformity with GAAP requires that we make certain estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates, judgments and assumptions on historical experience, anticipated results and trends, and on various other factors that we believe are reasonable under the circumstances at the time. By their nature, these estimates, judgments and assumptions are subject to an inherent degree of uncertainty. Actual results may differ from our estimates under different assumptions or conditions. In our Annual Report on Form 10-K for the year ended June 30, 2014 (“fiscal year 2014”), we set forth our critical accounting policies and estimates, which included revenue recognition, recognition of expense in outsourced clinical trial agreements and valuation of intangible assets. There have been no material changes to our critical accounting policies from the information provided in our Annual Report on Form 10-K for fiscal year 2014.

 

17


Table of Contents

Results of Operations

Three Months Ended March 31, 2015 Compared to Three Months Ended March 31, 2014:

 

     Three Months Ended
March 31,
     Change  
     2015      2014      Amounts      %  
     (In thousands except percentages)  

Revenues

           

Collaborative research and development

   $ 110       $ 1,676       $ (1,566      (93 )% 

Royalty income

     218         316         (98      (31 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

  328      1,992      (1,664   (84 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses:

Research and development

  3,339      2,269      1,070      47

General and administrative

  2,041      1,946      95      5

Gain on sale of property and equipment

  —        (4   4      na   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

  5,380      4,211      1,169      28
  

 

 

    

 

 

    

 

 

    

 

 

 

Loss from operations

  (5,052   (2,219   (2,833   (128 )% 

Other income:

Interest income

  6      1      5      500

Other income, net

  4      —        4      na   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total other income

  10      1      9      900
  

 

 

    

 

 

    

 

 

    

 

 

 

Loss before income taxes

  (5,042   (2,218   (2,824   (127 )% 

Income tax benefit

  44      31      13      42
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

$ (4,998 $ (2,187 $ (2,811   (129 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues

Collaborative research and development revenues totaled $110,000 for the three months ended March 31, 2015 compared to $1.7 million for the three months ended March 31, 2014. This decrease was primarily attributable to the prior year recognition of $1.5 million of contingent consideration under a completed feasibility study agreement.

We are entitled to share in net profits, on a quarter-by-quarter and country-by-country basis, from sales of ILUVIEN by our licensee. ILUVIEN for DME has been sold in the U.S. since late February 2015, in Portugal since January 2015 and in the U.K. and Germany since the quarter ended June 2013. We received $31,000 of net profits in the fiscal 2015 third quarter. We do not know when or if sales of ILUVIEN will result in any future net profits in countries where it is sold, entitling us to our net profits share, or how much we will be entitled to receive.

Royalty income decreased by $98,000, or 31%, to $218,000 for the three months ended March 31, 2015 compared to $316,000 for the three months ended March 31, 2014.

Research and Development

Research and development increased by $1.1 million, or 47%, to $3.3 million for the three months ended March 31, 2015 from $2.3 million for the same quarter a year earlier, primarily reflecting increased CRO costs for the clinical development of Medidur for posterior uveitis. We expect to continue to incur significant research and development expense for Medidur during the remainder of fiscal year 2015 and in future periods until completion of Medidur clinical development.

 

18


Table of Contents

General and Administrative

General and administrative increased by $95,000, or 5%, to $2.0 million for the three months ended March 31, 2015 from $1.9 million for the same period in the prior year, primarily attributable to higher stock-based compensation expense.

Income Tax Benefit

Income tax benefit was $44,000 for the three months ended March 31, 2015 compared to $31,000 for the three months ended March 31, 2014, and consisted predominantly of refundable foreign research and development tax credits.

Nine Months Ended March 31, 2015 Compared to Nine Months Ended March 31, 2014:

 

     Nine Months Ended
March 31,
     Change  
     2015      2014      Amounts      %  
     (In thousands except percentages)  

Revenues

           

Collaborative research and development

   $ 25,355       $ 2,149       $ 23,206            ** 

Royalty income

     801         1,032         (231      (22 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

  26,156      3,181      22,975         ** 
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses:

Research and development

  8,890      7,267      1,623      22

General and administrative

  5,645      5,468      177      3

Gain on sale of property and equipment

  —        (76   76      na   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

  14,535      12,659      1,876      15
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) from operations

  11,621      (9,478   21,099      223
  

 

 

    

 

 

    

 

 

    

 

 

 

Other income:

Interest income

  12      3      9      300

Other income, net

  4      —        4      na   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total other income

  16      3      13      433
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

  11,637      (9,475   21,112      223

Income tax (expense) benefit

  (144   87      (231   (266 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income (loss)

$ 11,493    $ (9,388 $ 20,881      222
  

 

 

    

 

 

    

 

 

    

 

 

 

 

** percentages not meaningful due to the effect of the $25.0 million non-recurring revenue in the current year-to-date period

Revenues

Collaborative research and development revenues totaled $25.4 million for the nine months ended March 31, 2015 compared to $2.1 million for the nine months ended March 31, 2014. This increase was primarily attributable to recognition of the $25.0 million FDA approval milestone earned for ILUVIEN, partially offset by a $1.8 million reduction in revenues from funded technology evaluation agreements. We received $43,000 of ILUVIEN net profits during the nine months ended March 31, 2015.

 

19


Table of Contents

Royalty income decreased by $231,000, or 22%, to $801,000 for the nine months ended March 31, 2015 compared to $1.0 million for the nine months ended March 31, 2014.

Research and Development

Research and development increased by approximately $1.6 million, or 22%, to $8.9 million for the nine months ended March 31, 2015 from $7.3 million for the prior year-to-date period, primarily reflecting a $1.3 million increase in CRO costs for the clinical development of Medidur for posterior uveitis, as well as higher personnel-related expenses and pre-clinical study costs.

General and Administrative

General and administrative increased by $177,000, or 3%, to $5.6 million for the nine months ended March 31, 2015 from $5.5 million for the same period in the prior year, primarily attributable to increased stock-based compensation, partially offset by lower facility costs.

Income Tax (Expense) Benefit

Income tax expense of $144,000 for the nine months ended March 31, 2015 primarily reflected payment of $263,000 of federal alternative minimum taxes based upon taxable income for the tax year ended December 31, 2014. In addition, refundable foreign research and development tax credits totaled $119,000 and $87,000 for the nine months ended March 31, 2015 and 2014, respectively.

Liquidity and Capital Resources

During the years ended June 30, 2014 and 2013 and the nine months ended March 31, 2015, we financed our operations from the receipt of license fees, milestone payments, research and development funding and royalty income from our collaboration partners and from proceeds of sales of equity securities. At March 31, 2015, our principal sources of liquidity were cash, cash equivalents and marketable securities that totaled $31.7 million.

We have a history of operating losses and, at March 31, 2015, we had a total accumulated deficit of $265.5 million. We do not currently have any assured sources of future revenue, and we expect negative cash flows from operations on a quarterly basis until such time as we receive sufficient revenues from commercialization of ILUVIEN or one or more of our other product candidates achieve regulatory approval and provide us sufficient revenues. We believe that our capital resources at March 31, 2015 will enable us to fund our current and planned operations (including our two Medidur trials) into calendar year 2017. This estimate excludes any potential receipts of net profits under our Alimera collaboration agreement. Our ability to fund our planned operations beyond then is expected to depend on cash receipts from ILUVIEN or other products and from any future collaboration or other agreements and/or any financing transactions. There is no assurance that we will receive significant, if any, revenues from sales of ILUVIEN or cash from any other sources.

Whether we will require, or desire, to raise additional capital will be influenced by many factors, including, but not limited to:

 

    whether, when and to what extent we receive revenues with respect to commercialization of ILUVIEN;

 

    the timing and cost of development, approval and marketing of Medidur for posterior uveitis;

 

    whether and to what extent we internally fund, whether and when we initiate, and how we conduct other product development programs;

 

    the amount of Retisert royalties and other payments we receive under collaboration agreements;

 

    whether and when we initiate Phase II clinical trials for the Latanoprost Product and whether and when Pfizer exercises its option;

 

    whether and when we are able to enter into strategic arrangements for our product candidates and the nature of those arrangements;

 

    timely and successful development, regulatory approval and commercialization of our products and product candidates;

 

    the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims;

 

20


Table of Contents
    changes in our operating plan, resulting in increases or decreases in our need for capital; and

 

    our views on the availability, timing and desirability of raising capital.

If we determine that it is desirable or necessary to raise additional capital in the future, we do not know if it will be available when needed or on terms favorable to us or our stockholders. Our existing ATM facility permits us to sell shares of common stock with an aggregate offering price of up to $10.7 million at March 31, 2015, but we do not know whether and to what extent we will seek to sell shares pursuant to that program and, if we are able to do so, on what terms. The state of the economy and the financial and credit markets at the time or times we seek any additional financing may make it more difficult and more expensive to obtain. If available, additional equity financing may be dilutive to stockholders, debt financing may involve restrictive covenants or other unfavorable terms and potential dilutive equity, and funding through collaboration agreements may be on unfavorable terms, including requiring us to relinquish rights to certain of our technologies or products.

Our consolidated statements of historical cash flows are summarized as follows (in thousands):

 

     Nine Months Ended
March 31,
        
     2015      2014      Change  

Net income (loss):

   $ 11,493       $ (9,388    $ 20,881   

Changes in operating assets and liabilities

     (254      (96      (158

Other adjustments to reconcile net income (loss) to cash flows from operating activities

     2,064         1,598         466   
  

 

 

    

 

 

    

 

 

 

Net cash provided by (used in) operating activities

$ 13,303    $ (7,886 $ 21,189   
  

 

 

    

 

 

    

 

 

 

Net cash (used in) provided by investing activities

$ (5,848 $ 487    $ (6,335
  

 

 

    

 

 

    

 

 

 

Net cash provided by financing activities

$ 235    $ 19,058    $ (18,823
  

 

 

    

 

 

    

 

 

 

Net cash provided by operating activities was $13.3 million for the nine months ended March 31, 2015 compared to net cash used in operating activities of $7.9 million in the prior year period, representing a favorable net change of $21.2 million. Collaborative research and development and royalty income cash inflows increased by $23.2 million, primarily the result of the $25.0 million FDA milestone payment received in October 2014, partially offset by lower cash inflows from technology evaluation agreements and Retisert royalties. Operating cash outflows increased by approximately $2.0 million on a comparative basis and consisted primarily of an approximate $2.3 million increase in CRO payments associated with our Medidur clinical development program and $263,000 of federal alternative minimum taxes, partially offset by decreases of approximate $560,000 principally related to incentive compensation awards, professional fees and facility costs.

Net cash used by investing activities consisted principally of $5.8 million of purchases of marketable securities, net of maturities, during the nine months ended March 31, 2015. This compared to net cash provided by investing activities in the prior year period, which consisted primarily of $636,000 of maturities of marketable securities, net of purchases.

Net cash provided by financing activities for the nine months ended March 31, 2015 consisted of $235,000 of proceeds from the exercise of stock options. Net cash provided by financing activities for the nine months ended March 31, 2014 consisted of $16.7 million of aggregate net proceeds from a March 2014 registered direct offering and a July 2013 underwritten public offering of common shares, $1.5 million of net proceeds from sales of common shares under the ATM facility and $909,000 of proceeds from the exercise of stock options.

We had no borrowings or line of credit facilities as of March 31, 2015.

Off-Balance Sheet Arrangements

We had no off-balance sheet arrangements as of March 31, 2015 that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to investors.

 

21


Table of Contents
Item 3. Quantitative and Qualitative Disclosures about Market Risk

Foreign Currency Exchange Rates

We conduct operations in two principal currencies, the U.S. dollar and the Pound Sterling (£). The U.S. dollar is the functional currency for our U.S. operations, and the Pound Sterling is the functional currency for our U.K. operations. Changes in the foreign exchange rate of the U.S. dollar and Pound Sterling impact the net operating expenses of our U.K. operations. The strengthening of the U.S. dollar during the three months ended March 31, 2015 compared to the prior year’s quarter resulted in a net decrease in research and development expenses of $42,000. For every incremental 5% strengthening or weakening of the weighted average exchange rate of the U.S. dollar in relation to the Pound Sterling, our research and development expense for the three months ended March 31, 2015 would have decreased or increased by $23,000, respectively. All cash and cash equivalents, and most other asset and liability balances, are denominated in each entity’s functional currency and, accordingly, we do not consider our statement of comprehensive (loss) income exposure to realized and unrealized foreign currency gains and losses to be significant.

Changes in the foreign exchange rate of the Pound Sterling to the U.S. dollar also impacted total stockholders’ equity. As reported in the statement of comprehensive (loss) income, the relative strengthening of the U.S. dollar in relation to the Pound Sterling at March 31, 2015 compared to June 30, 2014 resulted in $141,000 of other comprehensive loss for the nine months ended March 31, 2015 due to the translation of £569,000 of net assets of our U.K. operations, predominantly the BioSilicon (including Tethadur) technology intangible asset, into U.S. dollars. For every incremental 5% strengthening or weakening of the U.S. dollar at March 31, 2015 in relation to the Pound Sterling, our stockholders’ equity at March 31, 2015 would have decreased or increased, respectively, by $42,000.

 

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2015. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure, particularly during the period in which this Quarterly Report on Form 10-Q was being prepared. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2015, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

22


Table of Contents

PART II: OTHER INFORMATION

The following description of risk factors includes any material changes to, and supersedes, the risk factors previously disclosed in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014 filed with the Securities and Exchange Commission (the “SEC”) on September 11, 2014.

Item 1A. Risk Factors

RISKS RELATED TO OUR COMPANY AND OUR BUSINESS

We do not know if or when we will achieve profitable operations from product sales, royalties and net profits participations and we may need additional capital to fund our operations, which may not be available on favorable terms or at all.

We have a history of operating losses, and at March 31, 2015, we had a total accumulated deficit of $265.5 million. During the past three fiscal years, we financed our operations primarily from sales of equity, as well as license fees, research and development funding and royalty income from our collaboration partners. We do not currently have any assured sources of revenue and we expect negative cash flows from operations in subsequent quarters until we receive sufficient revenues from commercialization of ILUVIEN or one or more of our other product candidates achieve regulatory approval and provide us sufficient revenues. We believe that our capital resources of $31.7 million at March 31, 2015 should enable us to fund our operations as currently planned (including our two Medidur Phase III trials) into calendar year 2017. This estimate excludes any potential net profits receipts from sales of ILUVIEN. We expect our ability to fund our planned operations beyond then will depend on the amount and timing of those payments, as well as proceeds from any future collaboration or other agreements and/or financing transactions.

Whether we will require, or desire, to raise additional capital will be influenced by many factors, including, but not limited to:

 

    whether, when and to what extent we receive revenues with respect to the commercialization of ILUVIEN;

 

    the timing and cost of development, approval and marketing of Medidur for posterior uveitis;

 

    whether and to what extent we internally fund, whether and when we initiate, and how we conduct other product development programs;

 

    the amount of Retisert royalties and other payments we receive under collaboration agreements;

 

    whether and when we initiate Phase II clinical trials for the Latanoprost Product and whether and when Pfizer exercises its option;

 

    whether and when we are able to enter into strategic arrangements for our product candidates and the nature of those arrangements;

 

    timely and successful development, regulatory approval and commercialization of our products and product candidates;

 

    the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims;

 

    changes in our operating plan, resulting in increases or decreases in our need for capital; and

 

    our views on the availability, timing and desirability of raising capital.

If we determine that it is desirable or necessary to raise additional capital in the future, we do not know if it will be available when needed or on terms favorable to us or our stockholders. Our existing ATM facility permits us to sell shares of common stock with an aggregate offering price of up to $10.7 million at March 31, 2015, but we do not know whether and to what extent we will seek to sell shares pursuant to that program and, if we are able to do so, on what terms. The state of the economy and the financial and credit markets at the time or times we seek any additional financing may make it more difficult or more expensive to obtain. If available, additional equity financing

 

23


Table of Contents

may be dilutive to stockholders, debt financing may involve restrictive covenants or other unfavorable terms and potential dilutive equity, and funding through collaboration agreements may be on unfavorable terms, including requiring us to relinquish rights to certain of our technologies or products.

If the recorded value of our intangible assets under GAAP is further impaired, our financial results could be materially adversely affected.

At March 31, 2015, we had $2.1 million of intangible assets relating to our Durasert and BioSilicon (including Tethadur) technologies on our balance sheet following impairment charges of $14.8 million as of December 31, 2011. We conduct impairment analyses of our intangible assets as required under GAAP and could take additional impairment charges in the future if the recorded values for our intangible assets were to exceed our assessment of the recoverability of the fair market value of those assets. Adverse events relating to the clinical development, regulatory approval and success of commercialization of products using those technologies and significant changes in our market capitalization could result in impairment charges. Further impairment charges on our intangible assets could have a material adverse effect on our results of operations in the quarter of the impairment.

Our operating results may fluctuate significantly from period to period.

Our operating results have fluctuated significantly from period to period in the past and may continue to do so in the future due to many factors, including:

 

    developments with respect to our products and product candidates, including pre-clinical and clinical trial results, regulatory developments and marketing and sales results;

 

    timing, receipt and amount of revenues, including receipt and recognition of collaborative research and development, milestone, royalty, net profit and other payments;

 

    announcement, execution, amendment and termination of collaboration agreements;

 

    scope, duration and success of collaboration agreements;

 

    costs of internally funded research and development costs, including pre-clinical studies and clinical trials;

 

    general and industry-specific adverse economic conditions that may affect, among other things, our and our collaborators’ operations and financial results; and

 

    changes in accounting estimates, policies or principles and intangible asset impairments.

Due to fluctuations in our operating results, quarterly comparisons of our financial results may not necessarily be meaningful, and investors should not rely upon such results as an indication of future performance. In addition, investors may react adversely if our reported operating results are less favorable than in a prior period or are less favorable than those anticipated by investors in the financial community, which may result in decreases in our stock price.

There is no assurance our Retisert royalty income will continue at current levels or at all.

Retisert royalty income has declined significantly. We do not expect that it will grow materially, if at all, and it may continue to decline. There is no assurance that Bausch & Lomb will continue to market Retisert, which received marketing approval in 2005, and accordingly that we will continue to receive royalties from the sale of Retisert. Bausch & Lomb no longer markets Vitrasert.

RISKS RELATED TO THE DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCTS AND PRODUCT CANDIDATES

There is no assurance that our licensee will be successful in commercializing ILUVIEN for DME or if or when we will receive revenues from its commercialization of ILUVIEN for DME or the extent of those revenues. If our licensee is unable to successfully commercialize ILUVIEN for DME, it would adversely affect our future results of operations and financial position.

Our future financial results depend heavily on Alimera’s ability to successfully commercialize ILUVIEN for

 

24


Table of Contents

DME. We do not know if, when, or to what extent we will receive revenues from the commercialization of ILUVIEN for DME. We are entitled to a net profit participation on a country-by-country and quarter-by-quarter basis on sales of ILUVIEN where Alimera markets ILUVIEN directly, such as the EU and U.S., and to a percentage of royalties and non-royalty consideration where Alimera sublicenses the marketing of ILUVIEN, such as Australia and New Zealand. The amount and timing of any revenues we receive will be affected, among other things, by the manner in which Alimera markets ILUVIEN, the amounts and timing of sales of ILUVIEN, commercialization costs incurred by Alimera’s direct marketing efforts, and the terms of sublicense agreements.

The commercialization of ILUVIEN is a significant undertaking by Alimera, and ILUVIEN for DME is its first and only product. We do not know whether Alimera will be successful in financing, achieving additional marketing approvals for, obtaining adequate pricing and reimbursement for, successfully commercializing and achieving market acceptance of, and generating revenues to pSivida from, ILUVIEN for DME. Marketing in the U.S. and in additional countries in the EU will require further expansion of Alimera’s commercial infrastructure. Alimera’s efforts to commercialize ILUVIEN successfully will be affected, among other things, by:

 

    Alimera’s ability to recruit, manage and retain personnel, expand its sales, marketing and other infrastructure, and manage its growth;

 

    Alimera’s ability to effectively market ILUVIEN, including accessing and persuading adequate numbers of ophthalmologists to prescribe ILUVIEN;

 

    the lack of other products to be offered by Alimera’s sales personnel, which may put Alimera at a competitive disadvantage relative to companies with more extensive product lines;

 

    Alimera’s ability to obtain regulatory approvals to market ILUVIEN and appropriate labeling, and to expand its marketing into countries where it has obtained approvals;

 

    Alimera’s ability to obtain desirable pricing, insurance coverage and reimbursement for ILUVIEN;

 

    potential delays in the commercial launch in one or more countries;

 

    manufacturing or supply issues;

 

    risks related to operating in international jurisdictions; and

 

    Alimera’s ability to generate adequate financial resources.

If Alimera is not successful in commercializing ILUVIEN for DME and generating payments to us, it would adversely affect our business, operating results and financial condition.

Sales of ILUVIEN for DME may be materially adversely affected by pricing and reimbursement decisions of regulatory bodies, insurers and others.

Prices, coverage and reimbursement to consumers of ILUVIEN for DME, like other drugs, are generally regulated by third-party payors, such as government health administration authorities and plans, private health insurers and other organizations and affect ILUVIEN’s sales. The timing and complexity of those reimbursements also affect sales. Prices in the EU are generally lower and coverage and access to drugs more limited than in the U.S. For example, in the U.K. and Scotland, National Health Service coverage is limited to the treatment of the eyes of chronic DME patients unresponsive to existing therapies that have undergone cataract surgery, subject to simple patient access schemes. Alimera may not achieve satisfactory agreements with statutory or other insurers. In Germany, although ILUVIEN is sold without price restriction, physicians must submit individual funding requests for each patient. We do not know what levels of pricing will be approved or reimbursed for ILUVIEN, or what restrictions will be placed on its use or reuse in countries other than the U.K. and Germany. Alimera has delayed the launch of ILUVIEN in France until satisfactory agreement is reached on pricing with the French authorities. In the U.S., Alimera is offering extended payment terms to physicians in the launch year to accommodate expected time lags in the processing of reimbursement claims. Future sales of ILUVIEN and, accordingly, our net profits share may be adversely affected by pricing and reimbursement decisions, and such effects may be material.

The micro-insert for ILUVIEN and Medidur delivers FAc, a corticosteroid that has certain adverse side effects in the eye, which may affect the success of this micro-insert for treatment of DME and posterior uveitis.

The micro-insert for both ILUVIEN and Medidur delivers the non-proprietary corticosteroid fluocinolone

 

25


Table of Contents

acetonide (FAc), which is associated with cataract formation and elevated intraocular pressure and may increase the risk of glaucoma and related surgery to manage those side effects. Although Retisert, which delivers FAc to treat posterior uveitis, and ILUVIEN for DME have both been approved by the FDA, there is no assurance that Medidur will be safe and efficacious for the treatment of posterior uveitis in light of its expected side effects from FAc. These side effects may limit the population for which marketing authorization is granted or for which reimbursement is provided in one or more jurisdictions and/or adversely affect sales of Medidur, if approved, and/or ILUVIEN.

There is no assurance that Medidur will be found to be safe and effective for the treatment of posterior uveitis.

We are optimistic that Medidur will be as efficacious for the treatment of posterior uveitis, but with a better side effect profile than Retisert, comparable to ILUVIEN. However, this is only a hypothesis, and there is no assurance that the ongoing Phase III program for Medidur will demonstrate these results. While early interim data from an investigator-sponsored study of Medidur are consistent with this hypothesis, the results of that trial have not been published, the study involves only 11 patients and it is not intended to be a clinical trial that can serve as the basis for approval of Medidur. Data from the Retisert and ILUVIEN trials and early data from this investigator-sponsored study may not accurately predict the results of our Medidur Phase III program. There is no assurance that the Phase III program for Medidur will provide the necessary evidence of safety and efficacy required for approval by the FDA and other regulatory authorities. Actions by the FDA and other regulatory authorities with respect to Retisert and ILUVIEN are not predictive of the FDA’s action with respect to Medidur.

There is no assurance that we will be able to file an NDA for Medidur in the first half of 2017, or that, if filed FDA will accept the NDA for review.

Filing an NDA for Medidur will require positive results from our two Phase III trials. We have only recently initiated the second trial. Among other things, there is no assurance that enrollment in the second trial will be completed in the time frame we anticipate, that there will not be further regulatory requirements from U.S. or Indian regulators that would affect our timing, that we will be able to analyze the data from the two trials in the time frame that we anticipate, or that the data will be favorable. As a result, there is no assurance that an NDA will be filed for Medidur in the first half of 2017.

Even if we file an NDA for Medidur, there is no assurance that FDA will accept the NDA for review. While we believe we have agreement with FDA regarding the clinical trials and other data required for FDA to accept the Medidur NDA for review, FDA has significant discretion in determining whether to accept an NDA for review and there is no assurance that FDA will find the design of our clinical trials or the other data we include in an NDA to be sufficient to accept the NDA for review. Any delay in the filing of an NDA for Medidur or FDA’s refusal to accept the NDA for review could materially and adversely affect our business and the price of our common stock.

There is no assurance that Pfizer will exercise its option with respect to the Latanoprost Product, in which case we will not receive any further financial consideration under the Restated Pfizer Agreement.

Development of the Latanoprost Product through at least Phase II clinical trials is at our option and expense. Pfizer has an option for an exclusive, worldwide license to develop and commercialize the Latanoprost Product upon our completion of Phase II clinical trials or upon our cessation of development of the Latanoprost Product at any time prior to completion of those trials. There is no assurance that we will commence or complete Phase II clinical trials for the Latanoprost Product; that, if completed, the trials will be successful; that Pfizer will, in any event, exercise its option; that, if exercised, Pfizer will commence Phase III clinical trials; or that the Latanoprost Product will achieve successful Phase III trial results, regulatory approvals or commercial success. As a result, there is no assurance that we will receive any further licensing, milestone or royalty payments under the Restated Pfizer Agreement.

We do not know if we will be able to deliver proteins (including antibodies) and peptides with our Tethadur technology or that we will be able to develop product candidates or approved products using this technology.

Although we are optimistic that our Tethadur technology platform can provide sustained delivery of proteins (including antibodies) and peptides, and our data from in vitro studies have shown that the long-term sustained release of antibodies such as Avastin is achievable using Tethadur, our research is at an early stage. There is no assurance that our subsequent research will sustain these results or that we will be able to develop product candidates or approved products using Tethadur to deliver proteins and peptides.

Product development is very uncertain. If we do not develop product candidates to enter clinical trials, if we or any licensees do not initiate or complete clinical trials for our product candidates or if our product candidates do not receive the necessary regulatory approvals, neither we nor any licensees will be able to commercialize those product candidates and generate revenues for us.

Other than Medidur for posterior uveitis, for which pivotal Phase III trials are ongoing, all of our product

 

26


Table of Contents

development is at earlier stages. Product development at all stages involves a high degree of risk, and only a small proportion of research and development programs result in product candidates that advance to pivotal clinical trials or result in approved products. There is no assurance that any feasibility study agreements we have, or enter into, with third parties, or our own research and development programs will result in any new product candidates, or that we or any licensees will commence clinical trials for any new product candidates or continue clinical trials once commenced. If clinical trials conducted by or for us or any licensees for any product candidates do not provide the necessary evidence of safety and efficacy, those product candidates will not receive the necessary regulatory approvals, cannot be sold, and will not generate revenues for us. Initial or subsequent clinical trials may not be initiated by or for us or any licensees for product candidates or may be delayed, terminated or fail due to many factors, including the following:

 

    decisions not to pursue development of product candidates due to pre-clinical or clinical trial results;

 

    lack of sufficient funding;

 

    inability to attract clinical investigators for trials;

 

    inability to recruit patients in sufficient numbers or at the expected rate;

 

    decisions by licensees not to exercise options for products or not to pursue products licensed to them;

 

    adverse side effects;

 

    failure of trials to demonstrate a product candidate’s safety and efficacy;

 

    failure to meet FDA or other regulatory agency requirements for clinical trial design, or inadequate clinical trial design;

 

    inability to follow patients adequately after treatment;

 

    changes in the design or manufacture of a product;

 

    failures by, changes in our (or our licensees’) relationship with, or other issues at, contract research organizations (CROs), third-party vendors and investigators responsible for pre-clinical testing and clinical trials;

 

    inability to manufacture sufficient quantities of materials for use in clinical trials;

 

    stability issues with clinical materials;

 

    failure to comply with current good laboratory practices (GLP), good clinical practices (GCP), good manufacturing practices (cGMP) or similar foreign regulatory requirements that affect the conduct of pre-clinical and clinical studies and the manufacturing of products;

 

    requests by regulatory authorities for additional data or clinical trials;

 

    governmental or regulatory agency assessments of pre-clinical or clinical testing that differ from our (or our licensees’) interpretations or conclusions;

 

    governmental or regulatory delays, or changes in approval policies or regulations; and

 

    developments, clinical trial results and other factors with respect to competitive products and treatments.

Results from pre-clinical testing and early clinical trials often do not accurately predict results of later clinical trials. Data obtained from pre-clinical and clinical activities are susceptible to varying interpretations, which may delay, limit or prevent regulatory approval. Data from pre-clinical studies, early clinical trials and interim periods in multi-year trials are preliminary and may change, and final data from pivotal trials for such products may differ significantly. Adverse side effects may develop that delay, limit or prevent the regulatory approval of products, or cause such regulatory approvals to be limited or even rescinded. Additional trials necessary for approval may not be undertaken or may ultimately fail to establish the safety and efficacy of our product candidates.

The FDA or other relevant regulatory agencies may not approve our product candidates for manufacture and sale, and any approval by the FDA does not ensure approval by other regulatory agencies or vice versa (which could require us to comply with numerous and varying regulatory requirements, possibly including additional clinical testing). Any product approvals we or our licensees achieve could also be withdrawn for failure to comply with

 

27


Table of Contents

regulatory standards or due to unforeseen problems after the products’ marketing approval. In either case, marketing efforts with respect to the affected product would have to cease. In addition, the FDA or other regulatory agencies may impose limitations on the indicated uses for which a product may be marketed. The imposition by the FDA or other relevant regulatory organizations of any such limitations on the indicated uses for which any of our products may be marketed would reduce the size of, or otherwise limit, the potential market for the product subject to such limitations.

In addition to testing, regulatory agencies impose various requirements on manufacturers and sellers of products under their jurisdiction, such as packaging, labeling, manufacturing practices, record keeping and reporting. Regulatory agencies may also require post-marketing testing and surveillance programs to monitor a product’s effects. Furthermore, changes in existing regulations or the adoption of new regulations could prevent us from obtaining, or affect the timing of, future regulatory approvals.

We do not currently have sales and marketing capacity, and there is no assurance that we will be able to develop the capacity to successfully market and sell any products we independently develop.

Our strategy includes independently developing products and marketing and selling them ourselves. Successfully commercializing products requires substantial efforts by experienced, skillful personnel as well as significant expenditure of funds. However, we currently have no marketing or sales staff and no experience in commercializing products. We may not be able to hire and manage a successful sales and marketing capability or have the resources necessary to fund the development of this capability for the independent commercialization of our products.

The success of our current and possible future collaborative and licensing arrangements depends and will depend heavily on the experience, resources, efforts and activities of our licensees, and if they are not successful in developing and marketing our products, it will adversely affect our revenues, if any, from those products.

Our business strategy includes continuing to leverage our technology platforms by entering into collaborative and licensing arrangements for the development and commercialization of our product candidates, where appropriate. The success of current and future collaborative and licensing arrangements do and will depend heavily on the experience, resources, skill, efforts and activities of our licensees. Our licensees have had, and are expected to have, significant discretion in making decisions related to the development of product candidates and the commercialization of products under these collaboration agreements. Risks that we face in connection with our collaboration and licensing strategy include the following:

 

    our collaborative and licensing arrangements are, and are expected to be, subject to termination under various circumstances, including on short notice and without cause;

 

    we are required, and expect to be required, under our collaborative and licensing arrangements, not to conduct specified types of research and development in the field that is the subject of the arrangement or not to sell products in such field, limiting the areas of research, development and commercialization that we can pursue;

 

    our licensees may develop and commercialize, either alone or with others, products that are similar to or competitive with our products;

 

    our licensees may change the focus of their development and commercialization efforts or decrease or fail to increase spending related to our products or product candidates, thereby limiting the ability of these products to reach their potential;

 

    our licensees may lack the funding, personnel or experience to develop and commercialize our products successfully or may otherwise fail to do so; and

 

    our licensees may not perform their obligations, in whole or in part.

We currently have collaboration and licensing arrangements with various companies, most significantly Alimera and Bausch & Lomb. While Bausch & Lomb has significant experience in the ophthalmic field and substantial resources, there is no assurance whether, and to what extent, that experience and those resources will be devoted to Retisert, and we do not expect revenues from Retisert to increase materially and they may decline further. Although we believe potential revenues from ILUVIEN for DME are important to our future results of operation and

 

28


Table of Contents

financial condition, Alimera has limited experience and limited financial resources, and ILUVIEN for DME is Alimera’s first and only commercial product. If our current and future licensees are not successful in developing and marketing our products, it will adversely affect our revenues, if any, from those products.

Our current licensees may terminate their agreements with us at any time or fail to fulfill their obligations under those agreements, and, if they do, we will lose the benefits of those agreements.

Our licensees have rights of termination under our agreements with them and could terminate those agreements without cause on short notice. Further, our licensees may fail to fulfill their obligations under their agreements, or we may disagree with them over the rights and obligations under those agreements, which could result in breach of the agreements and/or termination. Exercise of termination rights by one or more of our licensees or by us may leave us without the financial benefits and development, marketing or sales resources provided under the terminated agreement. It could be necessary for us to replace, or seek to provide ourselves, the services provided by the licensee, and there is no assurance we would be successful in doing so. It could delay, impair or stop the development or commercialization of products or product candidates licensed to them or require significant additional capital investment by us, which we may not have the resources to fund. If any of our licensees do not perform their obligations under our agreements or if any of those agreements are terminated, it could have an adverse effect on our business, financial condition and results of operations

If competitive products receive regulatory approval or reach the market earlier, are more effective, have fewer side effects, are more effectively marketed or cost less than our products or product candidates, they may not be approved, may not achieve the sales we anticipate and could be rendered noncompetitive or obsolete.

We believe that pharmaceutical, drug delivery and biotechnology companies, research organizations, governmental entities, universities, hospitals, other nonprofit organizations and individual scientists are seeking to develop drugs, therapies, products, approaches or methods to treat our targeted diseases or their underlying causes. For our targeted diseases, competitors have alternate therapies that are already commercialized or are in various stages of development, ranging from discovery to advanced clinical trials. Any of these drugs, therapies, products, approaches or methods may receive government approval or gain market acceptance more rapidly than our products and product candidates, may offer therapeutic or cost advantages, or may more effectively treat our targeted diseases or their underlying causes, which could result in our product candidates not being approved, reduce demand for our products and product candidates or render them noncompetitive or obsolete.

Many of our competitors and potential competitors have substantially greater financial, technological, research and development, marketing and personnel resources than we do. Our competitors may succeed in developing alternate technologies and products that, in comparison to the products we have and are seeking to develop:

 

    are more effective and easier to use;

 

    are more economical;

 

    have fewer side effects;

 

    offer other benefits; or

 

    may otherwise render our products less competitive or obsolete.

Many of these competitors have greater experience in developing products, conducting clinical trials, obtaining regulatory approvals or clearances and manufacturing and marketing products than we do.

Our products and product candidates may not achieve and maintain market acceptance and may never generate significant revenues.

In both domestic and foreign markets, the commercial success of our products and product candidates will require not only obtaining regulatory approvals, but also obtaining market acceptance by retinal specialists and other doctors, patients, government health administration authorities and other third-party payors. Whether and to what extent our products and product candidates achieve and maintain market acceptance will depend on a number of factors, including demonstrated safety and efficacy, cost-effectiveness, potential advantages over other therapies, our and our collaborative partners’ marketing and distribution efforts and the reimbursement policies of government and other third-party payors. In particular, if government and other third-party payors do not recommend our

 

29


Table of Contents

products and product candidates, limit the indications for which they are recommended, or do not provide adequate and timely coverage and reimbursement levels for our products, the market acceptance of our products and product candidates will be limited. Both government and other third-party payors attempt to contain healthcare costs by limiting coverage and the level of reimbursement for products and, accordingly, they may challenge the price and cost-effectiveness of our products, or refuse to provide coverage for our products. If our products and product candidates fail to achieve and maintain market acceptance, they may fail to generate significant revenues and our business may be significantly harmed.

Guidelines, recommendations and studies published by various organizations could reduce the use of our products and potential use of product candidates.

Government agencies, professional societies, practice management groups, private health and science foundations and organizations focused on various diseases may publish guidelines, recommendations or studies that affect our or our competitors’ products and product candidates. Any such guidelines, recommendations or studies that reflect negatively on our products or product candidates, either directly or relative to our competitive products, could result in current or potential decreased use, sales of, and revenues from one or more of our products and product candidates. Furthermore, our success depends in part on our and our partners’ ability to educate healthcare providers and patients about our products and product candidates, and these education efforts could be rendered ineffective by, among other things, third-parties’ guidelines, recommendations or studies.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

We rely heavily upon patents and trade secrets to protect our proprietary technologies. If we fail to protect our intellectual property or infringe on others’ technologies, our ability to develop and market our products and product candidates may be compromised.

Our success is dependent on whether we can obtain patents, defend our existing patents and operate without infringing on the proprietary rights of third parties. As of April 30, 2015, we had 234 patents and 116 pending patent applications, including patents and pending applications covering our Durasert, Tethadur and other technologies. Intellectual property protection of our technologies is uncertain. We expect to seek to patent and protect our proprietary technologies. However, there is no assurance that any additional patents will be issued to us as a result of our pending or future patent applications or that any of our patents will withstand challenges by others. In addition, we may not have sufficient funds to patent and protect our proprietary technologies to the extent that we would desire, or at all. If we were determined to be infringing any third-party patent, we could be required to pay damages, alter our products or processes, obtain licenses, pay royalties or cease certain operations. We may not be able to obtain any required licenses on commercially favorable terms, if at all. In addition, many foreign country laws may treat the protection of proprietary rights differently from, and may not protect our proprietary rights to the same extent as, laws in the U.S. and Patent Co-operation Treaty countries.

Prior art may reduce the scope or protection of, or invalidate, our patents. Previously conducted research or published discoveries may prevent our patents from being granted, invalidate issued patents or narrow the scope of any protection obtained. Reduction in scope of protection or invalidation of our licensed or owned patents, or our inability to obtain patents, may enable other companies to develop products that compete with our products and product candidates on the basis of the same or similar technology. As a result, our patents and those of our licensors may not provide any, or sufficient, protection against competitors. While we have not been, and are not currently, involved in any litigation over intellectual property, such litigation may be necessary to enforce any patents issued or licensed to us or to determine the scope and validity of third party proprietary rights. We may also be sued by one or more third parties alleging that we infringe their intellectual property rights. Any intellectual property litigation would likely result in substantial costs to us and diversion of our efforts, and could prevent or delay our discovery or development of product candidates. If our competitors claim technology also claimed by us, and if they prepare and file patent applications in the U.S. or other jurisdictions, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office or the appropriate foreign patent office to determine priority of invention, which could result in substantial cost to us and diversion of our efforts. Any such litigation or interference proceedings, regardless of the outcome, could be expensive and time consuming. Litigation could subject us to significant liabilities to third parties, requiring disputed rights to be licensed from third parties and/or requiring us to cease using certain technologies.

 

30


Table of Contents

We also rely on trade secrets, know-how and technology that are not protected by patents to maintain our competitive position. We try to protect this information by entering into confidentiality agreements with parties that have access to it, such as our corporate partners, collaborators, employees, and consultants. Any of these parties could breach these agreements and disclose our confidential information, or our competitors may learn of the information in some other way. If any material trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our competitive position could be materially harmed.

RISKS RELATED TO OUR BUSINESS, INDUSTRY, STRATEGY AND OPERATIONS

If we fail to retain key personnel, our business could suffer.

We are dependent upon the principal members of our management and scientific staff. In addition, we believe that our future success in developing and marketing our products will depend on whether we can attract and retain additional qualified management and scientific personnel as well as a sales and marketing staff. There is strong competition for qualified personnel within the industry in which we operate, and we may not be able to attract and retain such personnel. As we have a small number of employees and we believe our products are unique and highly specialized, the loss of the services of one or more of the principal members of our management or scientific staff, or the inability to attract and retain additional personnel and develop expertise as needed, could have a material adverse effect on our results of operations and financial condition.

If we are subject to product liability suits, we may not have sufficient insurance to cover damages.

The testing, manufacturing, and marketing and sale of the products utilizing our technologies involve risks that product liability claims may be asserted against us and/or our licensees. Our current clinical trial and product liability insurance may not be adequate to cover damages resulting from product liability claims. Regardless of their merit or eventual outcome, product liability claims could require us to spend significant time, money and other resources to defend such claims, could result in decreased demand for our products and product candidates, or result in reputational harm, and could result in the payment of a significant damage award. Our product liability insurance coverage is subject to deductibles and coverage limitations and may not be adequate in scope to protect us in the event of a successful product liability claim. Further, we may not be able to acquire sufficient clinical trial or product liability insurance in the future on reasonable commercial terms, if at all.

Consolidation in the pharmaceutical and biotechnology industries may adversely affect us.

There has been consolidation in the pharmaceutical and biotechnology industries. Consolidation could result in the remaining companies having greater financial resources and technological capabilities, thus intensifying competition, and fewer potential collaboration partners or licensees for our product candidates. In addition, if a consolidating company is already doing business with any of our competitors, we could lose existing or potential future licensees or collaboration partners as a result of such consolidation.

If we or our licensees fail to comply with environmental laws and regulations, our or their ability to manufacture and commercialize products may be adversely affected.

Medical and biopharmaceutical research and development involves the controlled use of hazardous materials, such as radioactive compounds and chemical solvents. We and our licensees are subject to federal, state and local laws and regulations in the U.S. and abroad governing the use, manufacture, storage, handling and disposal of such materials and waste products. We and they could be subject to both criminal liability and civil damages in the event of an improper or unauthorized release of, or exposure of individuals to, hazardous materials. In addition, claimants may sue us or them for resulting injury or contamination, and the liability may exceed our or their ability to pay. Compliance with environmental laws and regulations is expensive, and current or future environmental regulations may impair the research, development or production efforts of our company or our licensees and harm our operating results.

If we or our licensees encounter problems with product manufacturing, there could be delays in product development or commercialization, which would adversely affect our future profitability.

Our ability and that of our licensees to conduct timely pre-clinical and clinical research and development

 

31


Table of Contents

programs, obtain regulatory approvals, and develop and commercialize our product candidates will depend, in part, upon our and our licensees’ ability to manufacture our products and product candidates, either directly or through third parties, in accordance with FDA and other regulatory requirements. The manufacture, packaging and testing of our products and product candidates are regulated by the FDA and similar foreign regulatory entities and must be conducted in accordance with applicable cGMP and comparable foreign requirements. Any change in a manufacturing process or procedure used for one of our products or product candidates, including a change in the location at which a product or product candidate is being manufactured or in the third-party manufacturer being used, may require the FDA’s and similar foreign regulatory entities’ prior review and/or approval in accordance with applicable cGMP or other regulations. Additionally, the FDA and similar foreign regulatory entities may implement new standards, or change their interpretation and enforcement of existing standards, for the manufacture, packaging and testing of products at any time.

There are a limited number of manufacturers that operate under cGMP and other foreign regulations that are both capable of manufacturing our products and product candidates and are willing to do so. Alimera has contracted with individual third-party manufacturers for the manufacture of ILUVIEN and its components. If any of Alimera’s third-party manufacturers breach their agreements or are unable or unwilling to perform for any reason or fail to comply with cGMP and comparable foreign requirements, Alimera may not be able to locate alternative acceptable manufacturers, enter into favorable agreements with them or get them approved by the applicable regulatory authorities in a timely manner. Delays in the commercial production of ILUVIEN could delay or impair Alimera’s marketing of ILUVIEN, which, in turn, could adversely affect Alimera’s generation of net profits for us.

Failure by us, our collaborative partners, or our or their third-party manufacturers, to comply with applicable manufacturing requirements could result in sanctions being imposed on us or our collaborative partners, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product, operating restrictions and criminal prosecutions. In addition, we or our collaborative partners may not be able to manufacture our product candidates successfully or have a third party manufacture them in a cost-effective manner. If we or our collaborative partners are unable to develop our own manufacturing facilities or to obtain or retain third-party manufacturing on acceptable terms, we may not be able to conduct certain future pre-clinical and clinical testing or to supply commercial quantities of our products. We manufacture supplies in connection with pre-clinical or clinical studies conducted by us and our licensees. Our licensees have the exclusive rights to manufacture commercial quantities of products, once approved for marketing. Our and our licensees’ reliance on third-party manufacturers entails risks, including:

 

    failure of third parties to comply with cGMP and other applicable U.S. and foreign regulations and to employ adequate quality assurance practices;

 

    inability to obtain the materials necessary to produce a product or to formulate the active pharmaceutical ingredient on commercially reasonable terms, if at all;

 

    supply disruption, deterioration in product quality or breach of a manufacturing or license agreement by the third party because of factors beyond our or our licensees’ control;

 

    termination or non-renewal of a manufacturing or licensing agreement with a third party at a time that is costly or difficult; and

 

    inability to identify or qualify an alternative manufacturer in a timely manner, even if contractually permitted to do so.

Problems associated with international business operations could affect our or our licensees’ ability to manufacture and sell our products. If we encounter such problems, our or their costs could increase and development of products could be delayed.

We currently maintain offices and research and development facilities in the U.S. and the U.K., and our goal is to develop products for sale by us and our licensees in major world healthcare markets. Manufacturing of pharmaceutical products requires us or our licensees to comply with regulations regarding safety and quality and to obtain country and jurisdiction-specific regulatory approvals and clearances. We or our licensees may not be able to comply with such regulations or obtain or maintain needed regulatory approvals and clearances, or may be required to incur significant costs in doing so. In addition, our operations and future revenues may be subject to a number of risks associated with foreign commerce, including the following:

 

    staffing and managing foreign operations;

 

32


Table of Contents
    political and economic instability;

 

    foreign currency exchange fluctuations;

 

    foreign tax laws, tariffs and freight rates and charges;

 

    timing and availability of export licenses;

 

    inadequate protection of intellectual property rights in some countries; and

 

    obtaining required government approvals.

Legislative or regulatory changes may adversely affect our business, operations and financial results.

Our industry is highly regulated and new laws, regulations and judicial decisions, and new interpretations of existing laws, regulations and judicial decisions, may adversely affect our business, operations and financial results.

U.S. federal and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (PPACA), represents one of the most significant healthcare reform measures in decades. The PPACA is intended to expand U.S. healthcare coverage primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the PPACA could significantly reduce payments from Medicare and Medicaid for any product candidates that obtain marketing approval in the future. Federal and state legislatures within the U.S. and foreign governments will likely continue to consider changes in existing healthcare legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any products for which we may obtain regulatory approval; our ability to set a price that we believe is fair for our products; our ability to obtain coverage and reimbursement approval for a product; our ability to generate revenues and achieve or maintain profitability; or the level of taxes that we are required to pay.

In addition, other legislative changes have been proposed and adopted since PPACA. The Budget Control Act (BCA) of 2011 includes provisions to reduce the federal deficit. The BCA, as amended, resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013. More recent legislation extends reductions through 2024. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, and/or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the BCA, could have an adverse impact on our anticipated product revenues.

The FDAAA granted the FDA enhanced authority over products already approved for sale, including authority to require post-marketing studies and clinical trials, labeling changes based on new safety information and compliance with risk evaluations and mitigation strategies approved by the FDA. The FDA’s exercise of this relatively new authority could result in delays and increased costs during product development, clinical trials and regulatory review and approval, increased costs following regulatory approval to assure compliance with new post-approval regulatory requirements, and potential restrictions on the sale or distribution of approved products following regulatory approval.

Changes in the regulatory approval policy during the development period, changes in or the enactment of additional regulations or statutes, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. For example, the July 9, 2012 reauthorization of the PDUFA extended by two months the period in which the FDA is expected to review and approve certain NDAs. Although the FDA has recently stated that it expects to meet PDUFA’s updated timing goals, it has in the past provided its managers discretion to miss them due to heightened agency workload or understaffing in the review divisions. Accordingly, it remains unclear whether and to what extent the FDA will adhere to PDUFA timing goals in the future, which could delay approval and commercialization of our product candidates.

 

33


Table of Contents

RISKS RELATED TO OUR COMMON STOCK

The price of our common stock may be volatile.

The price of our common stock (including common stock represented by CHESS Depositary Interests (CDIs)) may be affected by developments directly affecting our business, as well as by developments out of our control or not specific to us. The biotechnology sector, in particular, and the stock market generally are vulnerable to abrupt changes in investor sentiment. Prices of securities and trading volumes of companies in the biotechnology industry, including ours, can swing dramatically in ways unrelated to, or that bear a disproportionate relationship to, our performance. The price of our common stock (and CDIs) and their trading volumes may fluctuate based on a number of factors including, but not limited to:

 

    clinical trials and their results, and other product and technological developments and innovations;

 

    FDA and other domestic and international governmental regulatory actions, receipt and timing of approvals of our product candidates, and any denials and withdrawal of approvals;

 

    competitive factors, including the commercialization of new products in our markets by our competitors;

 

    advancements with respect to treatment of the diseases targeted by our product candidates;

 

    developments relating to, and actions by, our collaborative partners, including execution, amendment and termination of agreements, achievement of milestones and receipt of payments;

 

    the success of our collaborative partners in marketing any approved products and the amount and timing of payments to us;

 

    availability and cost of capital and our financial and operating results;

 

    actions with respect to pricing, reimbursement and coverage, and changes in reimbursement policies or other practices relating to our products or the pharmaceutical industry generally;

 

    meeting, exceeding or failing to meet analysts’ or investors’ expectations, and changes in evaluations and recommendations by securities analysts;

 

    economic, industry and market conditions, changes or trends; and

 

    other factors unrelated to us or the biotechnology industry.

In addition, low trading volume in our common stock or our CDIs may increase their price volatility. Holders of our common stock and CDIs may not be able to liquidate their positions at the desired time or price. Finally, we will need to continue to meet the listing requirements of the NASDAQ Global Market, including the minimum stock price, and the Australian Securities Exchange (ASX), for our stock and CDIs to continue to be traded on those exchanges, respectively.

If the holders of our outstanding warrants and stock options exercise their warrants and options, ownership of our common stock holders may be diluted, and our stock price may decline.

As of March 31, 2015, we had outstanding warrants and options to acquire approximately 5.7 million shares of our common stock, or approximately 16.2% of our shares on a fully diluted basis. The issuance of shares of our common stock upon exercise of these warrants and stock options could result in dilution to the interests of other holders of our common stock and could adversely affect our stock price.

We do not currently intend to pay dividends on our common stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.

At the present time, we intend to use available funds to finance our operations. Accordingly, while payment of dividends rests within the discretion of our board of directors, no cash dividends on our common shares have been declared or paid by us and we have no intention of paying any such dividends in the foreseeable future.

 

34


Table of Contents
Item 6. Exhibits

 

  31.1 Certification of Principal Executive Officer required by Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  31.2 Certification of Principal Financial Officer required by Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  32.1 Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  32.2 Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  101 The following materials from pSivida Corp.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive (Loss) Income; (iii) Condensed Consolidated Statement of Stockholders’ Equity; (iv) Condensed Consolidated Statements of Cash Flows; and (v) Notes to Condensed Consolidated Financial Statements

 

35


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

pSivida Corp.
Date: May 8, 2015 By:

/s/ Paul Ashton

Name: Paul Ashton
Title: President and Chief Executive Officer

 

36

EX-31.1 2 d911428dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.

CERTIFICATIONS

I, Paul Ashton, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of pSivida Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2015

 

/s/ Paul Ashton

Name: Paul Ashton
Title: President and Chief Executive Officer
(Principal Executive Officer)
EX-31.2 3 d911428dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.

CERTIFICATIONS

I, Leonard S. Ross, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of pSivida Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2015

 

/s/ Leonard S. Ross

Name: Leonard S. Ross
Title: Vice President, Finance
(Principal Financial Officer)
EX-32.1 4 d911428dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Quarterly Report of pSivida Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Ashton, President and Chief Executive Officer of the Company, certify that to the best of my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2015

 

/s/ Paul Ashton

Name: Paul Ashton
Title: President and Chief Executive Officer
(Principal Executive Officer)
EX-32.2 5 d911428dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Quarterly Report of pSivida Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leonard S. Ross, Vice President, Finance of the Company, certify that to the best of my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2015

 

/s/ Leonard S. Ross

Name: Leonard S. Ross
Title: Vice President, Finance
(Principal Financial Officer)
EX-101.INS 6 psdv-20150331.xml XBRL INSTANCE DOCUMENT 3.10 29412365 25000000 4.11 0 18555000 3.67 25000000 29412365 29412365 60000000 0 0.001 5000000 0.001 0 5584000 2218000 29000 899000 812000 -265520000 1371000 27847000 49000 35702000 292439000 286000 35000 0 7855000 618000 53000 5600000 0 23007000 280000 25856000 989000 150000 430000 2080000 17205000 8651000 115000 150000 35702000 2300000 33077000 0.063 3.67 756000 31700000 418000 25856000 17205000 8651000 8651000 899000 -265520000 29412365 29000 292439000 36296000 2080000 38376000 600000 1500000 129 0 223000 5000 8656000 8651000 4407364 3.36 2931157 3.04 6341255 3.35 1080817 4490949 3653000 3623000 3143000 6899000 35511000 38941000 29298558 29298558 60000000 0 0.001 5000000 0.001 0 5584000 2126000 29000 1044000 464000 -277013000 1524000 14924000 7000 22671000 290864000 249000 138000 7747000 952000 37000 5600000 0 15334000 297000 17204000 547000 150000 517000 2765000 1000 14260000 2944000 117000 22671000 2945000 2944000 19342000 316000 1008000 508000 500000 16196000 14260000 1936000 2444000 500000 1044000 -277013000 29298558 29000 290864000 38924000 2765000 41689000 302000 1000 2446000 2445000 499000 499000 3.08 3791001 -0.35 -7886000 26841623 -0.35 5069844 26841623 100000 150000 99000 -1000 2149000 -1016000 -9475000 76000 -9478000 -9289000 3000 1032000 3181000 2714000 75000 -9388000 3000 963000 -3000 -290000 12659000 7267000 582000 11656000 -87000 103000 19058000 76000 26000 487000 909000 5468000 -833000 963000 11000 1176105 18149000 141000 3350000 86000 1176105 3893739 590000 373000 102000 381562 1500000 3.98 1900000 65000 95000 1000000 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>6.</b></td> <td valign="top" align="left"><b>Accrued Expenses</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Accrued expenses consisted of the following at March&#xA0;31, 2015 and June&#xA0;30, 2014 (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>March&#xA0;31,&#xA0;2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Personnel costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">618</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">952</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Professional fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">286</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">249</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Clinical</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">418</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">316</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,371</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,524</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>2.</b></td> <td valign="top" align="left"><b>License and Collaboration Agreements</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Alimera</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Under the collaboration agreement with Alimera, as amended in March 2008 (the &#x201C;Alimera Agreement&#x201D;), the Company licensed to Alimera the rights to develop, market and sell certain product candidates, including ILUVIEN, and Alimera assumed all financial responsibility for the development of licensed products. In September 2014, the Company earned a $25.0 million milestone from Alimera as a result of the FDA approval of ILUVIEN, which was recorded as revenue in the quarter ended September&#xA0;30, 2014 and received in October 2014. In addition, the Company is entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera, measured on a quarter-by-quarter and country-by-country basis. Alimera may recover 20% of previously incurred and unapplied net losses (as defined) for commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company&#x2019;s net profit share to 16% in each country until those net losses are recouped. In the event that Alimera sublicenses commercialization in any country, the Company is entitled to 20% of royalties and 33% of non-royalty consideration received by Alimera, less certain permitted deductions. The Company is also entitled to reimbursement of certain patent maintenance costs with respect to the patents licensed to Alimera.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s performance obligations ended on December&#xA0;31, 2009 and, accordingly, all amounts received thereafter under the Alimera Agreement are recognized as revenue upon receipt or at such earlier date, if applicable, on which any such amounts are both fixed and determinable and reasonably assured of collectability.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Revenue under the Alimera Agreement totaled $70,000 and $47,000 for the three months ended March&#xA0;31, 2015 and 2014, respectively, and $25.1 million and $95,000 for the nine months ended March&#xA0;31, 2015 and 2014, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Pfizer</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In June 2011, the Company and Pfizer entered into an Amended and Restated Collaborative Research and License Agreement (the &#x201C;Restated Pfizer Agreement&#x201D;) to focus solely on the development of a sustained-release bioerodible micro-insert designed to deliver latanoprost for human ophthalmic disease or conditions other than uveitis (the &#x201C;Latanoprost Product&#x201D;). Pfizer made an upfront payment of $2.3 million and the Company agreed to use commercially reasonable efforts to fund the development for at least one year, including assumption of an investigator-sponsored Phase I/II dose-escalation study. The Company may, at its option, conduct Phase II clinical trials, which have not been initiated, for the purpose of demonstrating Proof-of-Concept (&#x201C;POC&#x201D;). If the Company were to issue a final report demonstrating POC, Pfizer would have a 90-day exercise option for an exclusive, worldwide license to develop and commercialize the Latanoprost Product in return for a $20.0 million payment and potential double-digit sales-based royalties and prescribed development, regulatory and sales performance milestone payments. If the Company elects to cease development of the Latanoprost Product prior to POC, Pfizer could exercise its option for the same worldwide license upon payment of a lesser option fee, with comparable reductions in any future milestones and royalties. If Pfizer does not exercise its option when available, the Restated Pfizer Agreement will automatically terminate, with any remaining deferred revenue balance recorded as revenue at that time, provided, however, that the Company would retain the right to develop and commercialize the Latanoprost Product.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As a result of the material modification of the Pfizer arrangement, the estimated selling price of the combined deliverables under the Restated Pfizer Agreement of $6.7 million is being recognized as collaborative research and development revenue over the expected performance period using the proportional performance method. The Company recorded no revenue and $9,000 for the three months ended March&#xA0;31, 2015 and 2014, respectively, and no revenue and $65,000 for the nine months ended March&#xA0;31, 2015 and 2014, respectively. As of March&#xA0;31, 2015, the Company continues to evaluate the Latanoprost Product and, consequently, the Company cannot currently estimate the remaining performance period. As a result, total deferred revenue of approximately $5.6 million at each of March&#xA0;31, 2015 and June&#xA0;30, 2014 was classified as noncurrent. Costs associated with developing the Latanoprost Product are reflected in operating expenses in the period in which they are incurred.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Pfizer owned approximately 6.3% of the Company&#x2019;s outstanding common stock at March&#xA0;31, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Bausch&#xA0;&amp; Lomb</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Pursuant to a licensing and development agreement, as amended, Bausch&#xA0;&amp; Lomb has a worldwide exclusive license to make and sell Retisert in return for royalties based on sales. Bausch&#xA0;&amp; Lomb was also licensed to make and sell Vitrasert, an implant for sustained treatment of CMV retinitis, but discontinued sales in the second quarter of fiscal 2013 following patent expiration.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Royalty income from Bausch&#xA0;&amp; Lomb totaled $218,000 and $316,000 for the three months ended March&#xA0;31, 2015 and 2014, respectively, and $801,000 and $1.0 million for the nine months ended March&#xA0;31, 2015 and 2014, respectively. Accounts receivable from Bausch&#xA0;&amp; Lomb totaled $223,000 at March&#xA0;31, 2015 and $302,000 at June&#xA0;30, 2014.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Enigma Therapeutics</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with Enigma Therapeutics Limited (&#x201C;Enigma&#x201D;) for the development of BrachySil, the Company&#x2019;s BioSilicon&#x2122; product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and milestone payments based on aggregate product sales. Enigma is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any patent maintenance costs, sales-based royalties and sublicensee sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. The Company has no consequential performance obligations under the Enigma license agreement and, accordingly, any amounts to which the Company is entitled under the agreement are recognized as revenue on the earlier of receipt or when collectability is reasonably assured. There was no revenue related to the Enigma agreement in the three month periods ended March&#xA0;31, 2015 and 2014 and $100,000 and $102,000 of revenues for the nine month periods ended March&#xA0;31, 2015 and 2014, respectively. As of March&#xA0;31, 2015, no deferred revenue was recorded for this agreement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Evaluation Agreements</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third party drug candidates in the treatment of various diseases. Consideration received is generally recognized as revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the evaluation agreement. Revenues under evaluation agreements totaled $35,000 and $1.6 million for the three months ended March&#xA0;31, 2015 and 2014, respectively, and $104,000 and $1.9 million for the nine months ended March&#xA0;31, 2015 and 2014, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>9.</b></td> <td valign="top" align="left"><b>Commitments and Contingencies</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s lease for its U.S. office and laboratory space in Watertown, Massachusetts extends through April 2019, with a five-year renewal option at market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. The Company&#x2019;s obligations under the lease are secured by a cash-collateralized $150,000 irrevocable standby letter of credit.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> At March&#xA0;31, 2015, the Company was subject to various routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company&#x2019;s financial position, results of operations or cash flows.</p> </div> 0.38 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>10.</b></td> <td valign="top" align="left"><b>Net (Loss) Income per Share</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the basic weighted average number of common shares outstanding the total number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table reconciles the number of shares used to compute basic and diluted net (loss) income per share:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Nine&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Number of common shares - basic</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,412,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,672,327</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,366,919</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,841,623</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Effect of dilutive securities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Stock options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">989,990</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Warrants</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">255,301</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Number of common shares - diluted</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,412,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,672,327</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,612,210</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,841,623</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Nine&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Options outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,490,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,893,739</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,881,524</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,893,739</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Warrants outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,176,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,176,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">552,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,176,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,667,054</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,069,844</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,434,024</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,069,844</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following tables summarize the Company&#x2019;s assets carried at fair value measured on a recurring basis at March&#xA0;31, 2015 and June&#xA0;30, 2014 by valuation hierarchy (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>March&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total&#xA0;carrying<br /> value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level 3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,205</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,205</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Marketable securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,856</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,856</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>June 30, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total&#xA0;carrying<br /> value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level 3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,260</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,260</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Marketable securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">508</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Commercial paper</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,204</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,008</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The reconciliation of intangible assets for the nine months ended March&#xA0;31, 2015 and for the year ended June&#xA0;30, 2014 was as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> March&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year&#xA0;Ended<br /> June&#xA0;30,&#xA0;2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Patented technologies</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross carrying amount at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,941</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,313</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,748</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross carrying amount at end of period</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38,376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated amortization at beginning of period</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(38,924</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(35,511</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization expense</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(579</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(778</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,207</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,635</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated amortization at end of period</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36,296</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(38,924</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net book value at end of period</p> </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,080</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,765</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company calculated the Black-Scholes value of options awarded during the nine months ended March&#xA0;31, 2015 based on the following key assumptions:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="13%"></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Option life (in years)</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="WHITE-SPACE: nowrap">5.50&#xA0;-&#xA0;6.25</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock volatility</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="WHITE-SPACE: nowrap">79%&#xA0;-&#xA0;93%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Risk-free interest rate</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="WHITE-SPACE: nowrap">1.70%&#xA0;-&#xA0;2.00%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected dividends</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center">0%</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 0.79 10-Q pSivida Corp. PSDV <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Nine&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Options outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,490,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,893,739</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,881,524</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,893,739</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Warrants outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,176,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,176,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">552,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,176,105</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,667,054</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,069,844</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,434,024</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,069,844</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table provides a reconciliation of stock option activity under the 2008 Plan for the nine months ended March&#xA0;31, 2015:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> Options</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br /> Intrinsic<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">(in years)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> (in&#xA0;thousands)</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at July&#xA0;1, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,791,001</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.08</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">831,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.48</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(113,807</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(17,445</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.88</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at March&#xA0;31, 2015</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,490,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.36</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.43</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,653</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at March&#xA0;31, 2015 - vested or unvested and expected to vest</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,407,364</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.35</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.39</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,623</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercisable at March&#xA0;31, 2015</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,931,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,143</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 3.33 Accelerated Filer P1Y9M18D <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Operations and Basis of Presentation</b></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The accompanying condensed consolidated financial statements of pSivida Corp. and subsidiaries (the &#x201C;Company&#x201D;) as of March&#xA0;31, 2015 and for the three and nine months ended March&#xA0;31, 2015 and 2014 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the &#x201C;SEC&#x201D;). These financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June&#xA0;30, 2014. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June&#xA0;30, 2014, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company&#x2019;s financial position, results of operations, comprehensive (loss) income and cash flows for the periods indicated. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (&#x201C;GAAP&#x201D;) requires management to make assumptions and estimates that affect, among other things, (i)&#xA0;reported amounts of assets and liabilities; (ii)&#xA0;disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii)&#xA0;reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended March&#xA0;31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is a leader in the development of sustained-release pharmaceutical products for treating eye diseases. Its approved products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of the four approved sustained-release products for treating retinal diseases. The Company&#x2019;s lead product candidate Medidur&#x2122; for posterior uveitis is in pivotal clinical trials. Marketing of its lead licensed product ILUVIEN&#xAE; for diabetic macular edema (&#x201C;DME&#x201D;) commenced in the U.S. in the fiscal 2015 third quarter. The Company&#x2019;s pre-clinical development program is focused on developing products for chronic retinal diseases utilizing our core technology platforms. The Company&#x2019;s strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Medidur, the Company&#x2019;s lead development product, is an injectable, micro-insert designed to treat posterior uveitis, a blinding eye disease, on a sustained basis for 36 months. Medidur uses the same micro-insert used in ILUVIEN for DME (same design, same drug, same polymers, same release rate) and delivers a lower dose of the same drug as Retisert<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup>, the Company&#x2019;s approved implant for posterior uveitis. The Company is developing Medidur independently.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In recent meetings, the Company reached agreement with the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) on a regulatory path for Medidur that should allow a new drug application (&#x201C;NDA&#x201D;) to be filed in the first half of 2017. The FDA indicated that, pending clinical trial results, it would accept an NDA based on data from the ongoing Medidur Phase III trial (which has a 12-month primary endpoint), data from a second Phase III trial with a shorter six-month primary endpoint and data referenced from the already completed Phase III ILUVIEN trials. The ongoing Phase III trial for Medidur completed enrollment with 129 patients in the fiscal 2015 third quarter. The last 12-month follow-up visit is scheduled in March 2016, and the Company expects top-line data in the second calendar quarter of 2016. The Company has already initiated a second Phase III Medidur trial, which will recruit up to 150 patients in India. Both trials will follow participants for three years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company had previously planned to file an NDA with data from only the first Phase III trial and data referenced from the ILUVIEN studies, subject to FDA confirmation. Because of the shorter six-month primary endpoint permitted for the second trial, the Company expects that the new regulatory path will allow it to file the Medidur NDA with only a several month delay from the time frame anticipated with one Phase III trial. The Company had budgeted for a second Phase III trial, pending FDA guidance, so the second trial does not affect the Company&#x2019;s liquidity projections.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company plans to commercialize Medidur with a newly designed, proprietary inserter that uses a standard 27 gauge needle routinely used in intraocular injections. As a result of the new design, the Company will conduct a utilization study on the new inserter, with data to be submitted as part of the Medidur NDA. Data from this study is expected to be available before data from the other trials and should not delay the NDA submission.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> ILUVIEN, the Company&#x2019;s most recently approved product, is an injectable, sustained-release micro-insert that provides treatment of DME for three years from a single administration. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (&#x201C;Alimera&#x201D;), and the Company is entitled to a share of the net profits (as defined) from Alimera&#x2019;s sales of ILUVIEN on a country-by-country basis. ILUVIEN was launched in the U.S. in late February 2015 and is now widely available to physicians in the U.S. It is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> ILUVIEN was also launched in Portugal in January 2015, and has been commercially available in the United Kingdom and Germany since June 2013. ILUVIEN has marketing approvals in 17 EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Distribution, regulatory and reimbursement matters for ILUVIEN for DME in Australia and New Zealand have been sublicensed. The Company is entitled to 20% of any royalties and 33% of all other payments received by our licensee, including any milestone payments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s pre-clinical research is primarily focused on developing pharmaceutical products to provide targeted and systemic sustained delivery of drugs and large biologic molecules for treatment of various conditions, and to provide sustained delivery of therapeutic agents to treat wet and dry age-related macular degeneration, glaucoma and osteoarthritis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has a history of operating losses and has financed its operations primarily from the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners and from proceeds of sales of its equity securities. The Company believes that its cash, cash equivalents and marketable securities of $31.7 million at March&#xA0;31, 2015 will enable the Company to maintain its current and planned operations (including its two Medidur trials) into calendar year 2017. This estimate excludes any potential net profits receipts from sales of ILUVIEN.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company&#x2019;s financial position, results of operations and cash flows or do not apply to the Company&#x2019;s operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In May 2014, the FASB issued Accounting Standards Update No.&#xA0;2014-09, <i>Revenue from Contracts with Customers</i> (Topic 606) (&#x201C;ASU 2014-09&#x201D;), which requires an entity to recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP. In April 2015, the FASB tentatively deferred the effective date of ASU 2014-09, while also tentatively permitting early adoption. If such deferral is ratified, ASU 2014-09 will become effective on July&#xA0;1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the impact this standard will have on its financial statements.</p> </div> 13303000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s statements of comprehensive (loss) income included total compensation expense from stock-based payment awards for the three and nine months ended March&#xA0;31, 2015 and 2014, as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Compensation expense included in:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">182</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">142</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">492</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">432</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">848</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">590</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">614</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">441</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,340</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 0.00 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Accrued expenses consisted of the following at March&#xA0;31, 2015 and June&#xA0;30, 2014 (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>March&#xA0;31,&#xA0;2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Personnel costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">618</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">952</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Professional fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">286</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">249</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Clinical</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">418</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">316</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,371</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,524</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 579408 2015-03-31 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>4.</b></td> <td valign="top" align="left"><b>Marketable Securities</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The amortized cost, unrealized loss and fair value of the Company&#x2019;s available-for-sale marketable securities at March&#xA0;31, 2015 and June&#xA0;30, 2014 were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>March&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Loss</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,656</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>June 30, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Loss</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,446</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,445</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Commercial paper</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">499</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">499</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total marketable securities</p> </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,945</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,944</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> During the nine months ended March&#xA0;31, 2015, $8.7 million of marketable securities were purchased and $2.9 million of such securities matured. At March&#xA0;31, 2015, the marketable securities had maturities ranging from 38 days to 11 months, with a weighted average maturity of 7.1 months.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The amortized cost, unrealized loss and fair value of the Company&#x2019;s available-for-sale marketable securities at March&#xA0;31, 2015 and June&#xA0;30, 2014 were as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>March&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Loss</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,656</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>June 30, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br /> Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Unrealized<br /> Loss</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,446</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,445</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Commercial paper</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">499</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">499</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total marketable securities</p> </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,945</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,944</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 0.0170 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>7.</b></td> <td valign="top" align="left"><b>Stockholders&#x2019; Equity</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In March 2014, the Company sold 1,700,000 shares of its common stock in a registered direct offering to a single institutional investor at a price of $4.11 per share for gross proceeds of $7.0 million. Placement agent fees and other share issue costs approximated $191,000.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In December 2013, the Company entered into an at-the-market (&#x201C;ATM&#x201D;) program pursuant to which the Company may, at its option, offer and sell shares of its common stock from time to time for an aggregate offering price of up to $19.2 million, representing the then remaining balance of the Company&#x2019;s shelf registration statement. In connection with execution of the ATM program, the Company incurred transaction costs of $153,000. In addition, the Company pays the sales agent a commission of up to 3.0% of the gross proceeds from the sale of such shares. During the three and nine month periods ended March&#xA0;31, 2015, the Company did not sell any shares under this program. During the three and nine months ended March&#xA0;31, 2014, the Company sold 57,770 and 381,562 common shares, respectively, for net proceeds of $224,000 and $1.5 million, respectively, reflecting a weighted-average gross selling price of $3.98 per share.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In July 2013, the Company sold 3,494,550 shares of its common stock in an underwritten public offering at a price of $3.10 per share for gross proceeds of $10.8 million. Underwriting commissions and other share issue costs approximated $890,000.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Warrants to Purchase Common Shares</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> During each of the nine month periods ended March&#xA0;31, 2015 and 2014, there were a total of 1,176,105 outstanding and exercisable warrants to purchase common shares at a weighted-average exercise price of $3.67. At March&#xA0;31, 2015, the remaining term of these warrants ranged from 0.8 to 2.4 years, representing a weighted average period of 1.6 years.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Incentive Plan</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s 2008 Incentive Plan (the &#x201C;2008 Plan&#x201D;) provides for the issuance of stock options and other stock awards to directors, employees and consultants. At March&#xA0;31, 2015, a total of 6,341,255 shares of common stock were authorized for issuance under the 2008 Plan, of which 1,080,817 were available for grant of future awards. The total number of shares issuable under the 2008 Plan is subject to annual increases pursuant to the terms of the plan. The following table provides a reconciliation of stock option activity under the 2008 Plan for the nine months ended March&#xA0;31, 2015:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> Options</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br /> Intrinsic<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">(in years)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> (in&#xA0;thousands)</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at July&#xA0;1, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,791,001</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.08</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">831,200</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.48</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(113,807</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(17,445</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.88</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at March&#xA0;31, 2015</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,490,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.36</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.43</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,653</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding at March&#xA0;31, 2015 - vested or unvested and expected to vest</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,407,364</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.35</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.39</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,623</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercisable at March&#xA0;31, 2015</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,931,157</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,143</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Option grants for the nine months ended March&#xA0;31, 2015 consisted of 701,200 options to employees with ratable annual vesting over 4 years, 90,000 options to non-executive directors with 1-year cliff vesting and 40,000 options to a newly appointed non-executive director with ratable annual vesting over 3 years. All option grants have a 10-year contractual life. The weighted-average grant date fair value of these option grants was $3.33 per share. A total of 579,408 options vested during the nine months ended March&#xA0;31, 2015. In determining the grant date fair value of options, the Company uses the Black-Scholes option pricing model. The Company calculated the Black-Scholes value of options awarded during the nine months ended March&#xA0;31, 2015 based on the following key assumptions:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="13%"></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Option life (in years)</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="WHITE-SPACE: nowrap">5.50&#xA0;-&#xA0;6.25</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock volatility</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="WHITE-SPACE: nowrap">79%&#xA0;-&#xA0;93%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Risk-free interest rate</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="WHITE-SPACE: nowrap">1.70%&#xA0;-&#xA0;2.00%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected dividends</p> </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap" align="center">0%</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Stock-Based Compensation Expense</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s statements of comprehensive (loss) income included total compensation expense from stock-based payment awards for the three and nine months ended March&#xA0;31, 2015 and 2014, as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Compensation expense included in:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">182</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">142</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">492</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">432</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">848</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">590</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">614</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">441</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,340</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> At March&#xA0;31, 2015, there was approximately $2.3 million of unrecognized compensation expense related to unvested options under the 2008 Plan, which is expected to be recognized as expense over a weighted-average period of approximately 1.8 years.</p> </div> false --06-30 2015 30612210 0.39 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>8.</b></td> <td valign="top" align="left"><b>Income Taxes</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company recognizes deferred tax assets and liabilities for estimated future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established if, based on management&#x2019;s review of both positive and negative evidence, it is more likely than not that all or a portion of the deferred tax assets will not be realized. Because of its historical losses from operations, the Company established a valuation allowance for the net deferred tax assets. The Company recorded an income tax benefit of $44,000 for the three months ended March&#xA0;31, 2015 and an income tax expense of $144,000 for the nine months ended March&#xA0;31, 2015. The Company recorded an income tax benefit of $31,000 and $87,000 for the three and nine months ended March&#xA0;31, 2014, respectively. The current year-to-date income tax expense predominantly reflects $263,000 of federal alternative minimum tax payments based upon taxable income for the tax year ended December&#xA0;31, 2014, which was primarily attributable to receipt of the $25.0 million FDA approval milestone. The tax benefits in each period predominantly represented earned foreign research and development tax credits.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> For the three and nine months ended March&#xA0;31, 2015 and 2014, the Company had no significant unrecognized tax benefits. At March&#xA0;31, 2015 and June&#xA0;30, 2014, the Company had no accrued penalties or interest related to uncertain tax positions.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table reconciles the number of shares used to compute basic and diluted net (loss) income per share:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Three&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> <b>Nine&#xA0;Months&#xA0;Ended&#xA0;March&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Number of common shares - basic</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,412,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,672,327</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,366,919</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,841,623</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Effect of dilutive securities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Stock options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">989,990</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Warrants</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">255,301</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Number of common shares - diluted</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,412,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,672,327</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,612,210</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,841,623</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 0001314102 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>5.</b></td> <td valign="top" align="left"><b>Fair Value Measurements</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 1 &#x2013; Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 2 &#x2013; Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 3 &#x2013; Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At March&#xA0;31, 2015 and June&#xA0;30, 2014, substantially all of the Company&#x2019;s interest-bearing cash equivalent balances were concentrated in one institutional money market fund that has investments consisting primarily of certificates of deposit, commercial paper, time deposits, U.S. government agencies, treasury bills and treasury repurchase agreements. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. Certain of the Company&#x2019;s corporate debt securities were valued based on quoted prices for the specific securities in an active market and were therefore classified as Level 1. The remaining marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#x2019; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2. The following tables summarize the Company&#x2019;s assets carried at fair value measured on a recurring basis at March&#xA0;31, 2015 and June&#xA0;30, 2014 by valuation hierarchy (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>March&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total&#xA0;carrying<br /> value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level 3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,205</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,205</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Marketable securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,651</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,856</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,856</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>June 30, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total&#xA0;carrying<br /> value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level 3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,260</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,260</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Marketable securities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Corporate bonds</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">508</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Commercial paper</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,204</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,008</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>3.</b></td> <td valign="top" align="left"><b>Intangible Assets</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The reconciliation of intangible assets for the nine months ended March&#xA0;31, 2015 and for the year ended June&#xA0;30, 2014 was as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> March&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year&#xA0;Ended<br /> June&#xA0;30,&#xA0;2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Patented technologies</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross carrying amount at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,941</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,313</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,748</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross carrying amount at end of period</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38,376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated amortization at beginning of period</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(38,924</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(35,511</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization expense</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(579</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(778</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,207</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,635</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated amortization at end of period</p> </td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36,296</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(38,924</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net book value at end of period</p> </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,080</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,765</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization of intangible assets totaled $190,000 and $196,000 for the three months ended March&#xA0;31, 2015 and 2014, respectively, and $579,000 and $582,000 for the nine months ended March&#xA0;31, 2015 and 2014, respectively. The carrying value of intangible assets at March&#xA0;31, 2015 of $2.1 million (approximately $1.5 million attributable to the Durasert&#x2122; technology and $0.6 million attributable to the BioSilicon technology (including Tethadur&#x2122;)) is expected to be amortized on a straight-line basis over the remaining estimated useful life of 2.75 years, or approximately $756,000 per year.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> 0.93 0.0200 Q3 2434024 29366919 -141000 -145000 -4000 25355000 388000 11637000 235000 11621000 11348000 16000 263000 801000 4000 26156000 8677000 71000 11493000 12000 1340000 1340000 -17000 -103000 14535000 8890000 579000 7673000 144000 263000 79000 235000 66000 -5848000 235000 5645000 221000 1340000 255301 P7M3D 16000 1176105 989990 P1Y7M6D 2900000 552500 1881524 P6Y3M P11M P2Y4M24D P5Y6M P38D P9M18D P10Y 701200 P4Y 17 P5Y 2019-04 90000 P1Y 40000 P3Y 848000 492000 -145000 11493000 113807 235000 1340000 579000 -3313000 3207000 100000 0.08 100000 0.20 2012-12 0 104000 0 20000000 P90D 25100000 0.16 0.20 0.20 0.04 0.33 0.33 0.20 801000 P6Y4M21D 2.07 17445 831200 P6Y5M5D 3.88 P5Y3M11D 4.48 113807 3494550 890000 10800000 19200000 0.030 153000 1700000 191000 7000000 1 778000 2748000 -2635000 100000 -0.08 27672327 -0.08 5069844 27672327 5000 4000 -1000 1676000 -2218000 4000 -2219000 -2183000 1000 316000 1992000 -2187000 1000 441000 4211000 2269000 196000 -31000 1946000 1176105 3893739 299000 142000 0 57770 224000 3.98 1600000 9000 47000 316000 -0.17 29412365 -0.17 P2Y9M 5667054 29412365 -45000 -44000 1000 110000 -5042000 -5052000 -5042000 10000 218000 4000 328000 -4998000 6000 614000 5380000 3339000 190000 -44000 2041000 P3Y 1176105 4490949 150 432000 182000 0 0 35000 0 70000 218000 6700000 2300000 0001314102 psdv:PfizerCollaborationAgreementMember 2011-04-01 2011-06-30 0001314102 psdv:BauschAndLombMember 2015-01-01 2015-03-31 0001314102 psdv:AlimeraSciencesIncMember 2015-01-01 2015-03-31 0001314102 psdv:PfizerCollaborationAgreementMember 2015-01-01 2015-03-31 0001314102 psdv:EvaluationAgreementsMember 2015-01-01 2015-03-31 0001314102 psdv:AtTheMarketOfferingMember 2015-01-01 2015-03-31 0001314102 psdv:EnigmaTherapeuticsMember 2015-01-01 2015-03-31 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001314102 psdv:SecondPhaseThreeMemberus-gaap:MaximumMember 2015-01-01 2015-03-31 0001314102 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001314102 us-gaap:WarrantMember 2015-01-01 2015-03-31 0001314102 2015-01-01 2015-03-31 0001314102 psdv:BauschAndLombMember 2014-01-01 2014-03-31 0001314102 psdv:AlimeraSciencesIncMember 2014-01-01 2014-03-31 0001314102 psdv:PfizerCollaborationAgreementMember 2014-01-01 2014-03-31 0001314102 psdv:EvaluationAgreementsMember 2014-01-01 2014-03-31 0001314102 psdv:AtTheMarketOfferingMember 2014-01-01 2014-03-31 0001314102 psdv:EnigmaTherapeuticsMember 2014-01-01 2014-03-31 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-03-31 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-03-31 0001314102 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001314102 us-gaap:WarrantMember 2014-01-01 2014-03-31 0001314102 2014-01-01 2014-03-31 0001314102 psdv:EnigmaTherapeuticsMember 2013-01-01 2013-03-31 0001314102 us-gaap:PatentedTechnologyMember 2013-07-01 2014-06-30 0001314102 2014-03-01 2014-03-31 0001314102 psdv:AtTheMarketOfferingMember 2013-12-01 2013-12-31 0001314102 2013-07-01 2013-07-31 0001314102 psdv:TwoThousandEightIncentivePlanMember 2014-07-01 2015-03-31 0001314102 psdv:BauschAndLombMember 2014-07-01 2015-03-31 0001314102 psdv:AlimeraSciencesIncMember 2014-07-01 2015-03-31 0001314102 psdv:PfizerCollaborationAgreementMember 2014-07-01 2015-03-31 0001314102 psdv:EvaluationAgreementsMember 2014-07-01 2015-03-31 0001314102 psdv:AtTheMarketOfferingMember 2014-07-01 2015-03-31 0001314102 psdv:EnigmaTherapeuticsMember 2014-07-01 2015-03-31 0001314102 us-gaap:PatentedTechnologyMember 2014-07-01 2015-03-31 0001314102 us-gaap:AdditionalPaidInCapitalMember 2014-07-01 2015-03-31 0001314102 us-gaap:CommonStockMember 2014-07-01 2015-03-31 0001314102 us-gaap:RetainedEarningsMember 2014-07-01 2015-03-31 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-07-01 2015-03-31 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2015-03-31 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2015-03-31 0001314102 psdv:NewlyAppointedNonExecutiveDirectorMember 2014-07-01 2015-03-31 0001314102 psdv:NonExecutiveDirectorMember 2014-07-01 2015-03-31 0001314102 psdv:WatertownMember 2014-07-01 2015-03-31 0001314102 psdv:IluvienMemberus-gaap:EuropeMember 2014-07-01 2015-03-31 0001314102 us-gaap:EmployeeStockOptionMember 2014-07-01 2015-03-31 0001314102 us-gaap:MinimumMember 2014-07-01 2015-03-31 0001314102 us-gaap:MaximumMember 2014-07-01 2015-03-31 0001314102 us-gaap:EmployeeStockOptionMember 2014-07-01 2015-03-31 0001314102 us-gaap:WarrantMember 2014-07-01 2015-03-31 0001314102 2014-07-01 2015-03-31 0001314102 psdv:BauschAndLombMember 2013-07-01 2014-03-31 0001314102 psdv:AlimeraSciencesIncMember 2013-07-01 2014-03-31 0001314102 psdv:PfizerCollaborationAgreementMember 2013-07-01 2014-03-31 0001314102 psdv:EvaluationAgreementsMember 2013-07-01 2014-03-31 0001314102 psdv:AtTheMarketOfferingMember 2013-07-01 2014-03-31 0001314102 psdv:EnigmaTherapeuticsMember 2013-07-01 2014-03-31 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2013-07-01 2014-03-31 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2013-07-01 2014-03-31 0001314102 us-gaap:EmployeeStockOptionMember 2013-07-01 2014-03-31 0001314102 us-gaap:WarrantMember 2013-07-01 2014-03-31 0001314102 2013-07-01 2014-03-31 0001314102 psdv:TwoThousandEightIncentivePlanMember 2014-06-30 0001314102 us-gaap:CommercialPaperMember 2014-06-30 0001314102 us-gaap:CorporateDebtSecuritiesMember 2014-06-30 0001314102 psdv:BauschAndLombMember 2014-06-30 0001314102 us-gaap:PatentedTechnologyMember 2014-06-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0001314102 us-gaap:CommonStockMember 2014-06-30 0001314102 us-gaap:RetainedEarningsMember 2014-06-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-06-30 0001314102 us-gaap:CommercialPaperMember 2014-06-30 0001314102 us-gaap:CorporateDebtSecuritiesMember 2014-06-30 0001314102 us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember 2014-06-30 0001314102 us-gaap:FairValueInputsLevel1Member 2014-06-30 0001314102 us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2014-06-30 0001314102 us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember 2014-06-30 0001314102 us-gaap:FairValueInputsLevel2Member 2014-06-30 0001314102 2014-06-30 0001314102 us-gaap:PatentedTechnologyMember 2013-06-30 0001314102 2013-06-30 0001314102 psdv:TwoThousandEightIncentivePlanMember 2015-03-31 0001314102 us-gaap:CorporateDebtSecuritiesMember 2015-03-31 0001314102 psdv:BauschAndLombMember 2015-03-31 0001314102 psdv:EnigmaTherapeuticsMember 2015-03-31 0001314102 psdv:PhaseThreeMember 2015-03-31 0001314102 psdv:DurasertMember 2015-03-31 0001314102 psdv:BioSiliconMember 2015-03-31 0001314102 us-gaap:PatentedTechnologyMember 2015-03-31 0001314102 us-gaap:AdditionalPaidInCapitalMember 2015-03-31 0001314102 us-gaap:CommonStockMember 2015-03-31 0001314102 us-gaap:RetainedEarningsMember 2015-03-31 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-03-31 0001314102 us-gaap:CorporateDebtSecuritiesMember 2015-03-31 0001314102 us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember 2015-03-31 0001314102 us-gaap:FairValueInputsLevel1Member 2015-03-31 0001314102 2015-03-31 0001314102 psdv:AlimeraSciencesIncMember 2014-09-30 0001314102 2014-03-31 0001314102 2014-12-31 0001314102 2015-05-06 0001314102 2013-07-31 iso4217:USD shares shares iso4217:USD pure psdv:Country psdv:Investor EX-101.SCH 7 psdv-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Operations and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Net (Loss) Income per Share link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Net (Loss) Income per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Operations and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Marketable Securities - Schedule of Amortized Cost, Unrealized Loss and Fair Value of Available-for-Sale Marketable Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Marketable Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Fair Value Measurements - Assets Carried at Fair Value Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Stockholders' Equity - Stock Option Activity Under Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stockholders' Equity - Key Assumptions Used to Apply Option Pricing Model for Options Awarded (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stockholders' Equity - Compensation Expense from Stock-Based Payment Awards (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Net (Loss) Income per Share - Schedule that Reconciles the Number of Shares Used to Compute Basic and Diluted Net (Loss) Income per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Net (Loss) Income per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 psdv-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 psdv-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 psdv-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 psdv-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!$S/[L^`$``-48```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=%NVC`8A>\G[1TBWU;$ MV.ZZKB+THELOMTKK'L!+?DB$8UNVV\';SPDMFBH&0D/:N2$BL?_SX8M/XF1V MN^Y-\4PA=LY63)135I"M7=/99<5^/-Y/KED1D[:--LY2Q384V>W\_;O9X\93 M+/)N&RO6IN1O.(]U2[V.I?-D\Y.%"[U.^6M8FJW7*I/S9-F]2)B\)9=XYKHEM MY^-%QF!\;\+PY.\!+_N^Y:,)74/%@P[IJ^XS!E\;_LN%U4_G5N7A(7LHW6+1 MU=2X^JG/)U!&'T@WL25*O2G':]GKSKYR'\@?%T<^7L2908;?-PX^D4."<"@0 MCDL0C@\@'%<@'!]!.*Y!.#Z!<(@I"@B*406*4@6*4P6*5`6*506*5@6*5P6* M6`6*626*626*626*626*626*626*626*626*626*626*616*616*616*616* M616*616*616*616*6=7_,FO*I2WQ\?/?#3*..=(:QK0Q%,_\3W\[]%ARJP,U MWU/(]?;9`?Z^9#V,T]E)_+YX?@?,PU?*#3`5Y[]F'WQ.=! M%%)'NZ9]7V.]2\P5_NF!;RIS&EX2--3LR>;C2XGY;P```/__`P!02P,$%``& M``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@ M8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS? MBG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"``` M`"$`Z_8T?Q$"``#>%P``&@`(`7AL+U]R96QS+W=O/CJ>AO3GT+;C:%(I_A0J3;&\:/6H6[=P8;5,#J?GNR&Z6!C6DY[ M/=KZQ>Z=IO5ZHZ=_SU#;LS.+IZ92TU-C6!7/QS&]^OW#A]VNJ]WGH?YQ<#[^ MYQWZUS"]A-:YF`ZUT][%2LU;09^>&%XE9J7?P$GQD,6Y0SBT$<:A#<+A^YPX M,5616Q)U6NK3KT$09')"S.6Q@,Q;KQ5#$(=+81PN471*RHE3V[[^U-K.+]&9 MMQ#%;4Z(.1\+Q+SUFJ);!),U(O.;WX8A!&.D.]K`CJ9D"*)Z1VL4' MFWX'A?<\& MC.^2B7/CI+FII_YEQH%UD83(5%)U,ZW[X)CLB!\];TR`O/HV=W?+KKZ MN"]E\"\8*[1:A-&[:1B`RG0NU'81_OWPZ;K MG3;/3UH_!RB@["(LG*LN)Q.;%5!R^TY7H/#)1IN2.UR:[<16!GAN"P!7RDD\ MGC=,7=W40N+3BV2:A)/K+LA[$^2PX;5T#QC> M41WS%<_B>-[\LTG%HX"=?7NI60;[[T+E>M?\%5/[TJT2-+!K'WT7N2OP^70Z M[>[]`6);N.--E)\0_3:#N$_[&Z@VO&-&&%:*W2DGW`M;J4/VA<82-EE?8611 M&)A+@1=FE4>-<:IRJU4.RD+.\,IJ*7*.R6(W7'*5`5%)+HA,_',RZ*!SDQ"9 M-N%GN%D[-%52-S.B,CO3S*L*-3/#`G6Y27].)R9!S8E,RP8-ZEL%YD!K6ZH; M;H5E>L/N#5C`7NA2,Z.5>C]T\QF[``O5:MQJ*?F3/LBRY=;T_5.Z401QY^7L$Q%*PAK5Q*P8L\\D8+/Z)"N8L\ M\$[4?T2'4AAY&`XQ&!&@(.(,'HR\$1I&-"B+LV3^>#;0 M49522F./TA]/!RH4][+C@>OC\A=D&K&5`H<8B2SN9<@CU]=9YO@AQH\VEVQ% M=7H9\O`=AV^=%9#7DHZ]E#9D?";$1T_43T_G;(R]89K2SH[_'^-C2,VG84G\ MS&E[)V?1?(R*XPFH^[K,:9,G'M%C7='>8]^J7MT3VN:X.*.[_H27YF-3EQ7Q MD]`VQ\49.K>Z;$9_G\.$\HR+@0X=W^PM,:]')>J'\HQGM8$.[GUZH#.J0WE. M/)Y/3XX&`*I#&S[Q>#ZM&PO M=V]R:W-H965T&ULE%EMCZ-&#/Y>J?\!\3T),Q`"T69/Q\NU M)[525?7E,TM(@C8)$;"W=_^^'DR8LF]JE^; M0U&T%E@X-QO[T+:7]6+1Y(?BE#7SZE*<0;.KZE/6PM=ZOV@N=9%MNT6GXT(Z MCK\X9>791@OK>HJ-:K>G;0D,U+9;=;';V)_%.G6%O7A^ZC;HG[)X;XS/5G.HWG^I MR^UOY;F`W88XJ0B\5-6K@G[=*A$L7HQ6?^DB\$=M;8M=]G9L_ZS>?RW*_:&% M<"^!D2*VWOY(BB:''04S<[E4EO+J"`[`7^M4JM2`',!IHP5YQ6BY$_7:\KBS4(L9"4A>C M,80AXC'"]ZB19`QA1M(QPC!"B+J4Z'V""KRQ/3,&2^I;A!#,816#F`L2+D@- M`7$-GO-X#-0BJ`[319^YB)"P2S,A'*J-B=9?L<6)J99+=\GXIT0OO'"P3JA! MI9C4[N^Z`C-*J\%LE^@10I8=)2D"JHU-K2LX(U,;.+Q`4+O"S7)C( M8X@08A0&%R1,]XM!>VV,Z2#I\,8A1QFH M[C@YT03V4O/H7;$.'?48C,O2#5BRQ$3O2<'BEA"]\.#\I4==2@'27^ILI=14 MAYQ.#?LIH<8V.1*(06JSI;-D48LI0$JA7<-SBP"$\"5CGQ+`+/16'V6>ZJC3 MR2DT/;Q6;%LC@1@SX[@D&6%24T)W7W7)Z0YB3X4'#J.?D;%8[P(QV#%8.<=$ MR38UH4H6M)1H=393-JI'3F>#'96PT8=BS\;LR2S18O7>`/'2L4@&B:IF!D\' M)1]QA>J#T]W&KDGI_Q67HZB0):R`*9DZ4=14-UR.AWL MK80.J\=((&:H:(\E1TP!4-%L0Q("@(IV6:!3`E`5K0N/IICJHM/)8<\UR?&3 M-A*(P6AX+&EBHG5'P3+7S@1?G9+5@>9,*:DN.IT2]EQ"B;D5";,OS[PP9.&( M*0#"I5WK3V#3@H#I7>=:!TBIA=`-]",(.@)Z?J,1-S;Z3$K?R5=R=(P MH9C0]?V0CV(IQ?B!!].83GA*]*'NKWZN8^\NXTQ#S'VB!/,!41/C.KZ`#L4& M[K3WIW_6?:(/S0MR/"\8;]I]RB$&'W[KP.Z-](`;!S8!W#JP"6!VY\!^:'J0 M.!E`0@X3:YN4-R8!5@]1C\%)8,9?=F.B M9O66$"5,`JPEIT0O')U]E!L;!29RNS$2L/,TDHBY.7/&1#ECKB=4R[I!2K5Z M+>&EWO:G'](=FC4A/I+VF&NLF%@S^'`OOS:,IFP+@$-`',4X-!""$Z[$L4#<[RHW^$:$,.#F\M\%[C5-1 M[XNX.!X;*Z_>U)V,A(EFD.)]4236<7>YPN0)W"-U\L6@@&N<2[8O?L_J?7EN MK&.Q`Y/.?`6'&ULE%;OCYI`$/W>I/\#X?L!JRAJU,M=K]_?>=97`%U#OT@XJ^?6_>S###\O:ER)UG)A47Y^W,?F-;+A(,#DW9'LG3E MWI'%/0E=?[VL$_27L[UJ?7=4)O9?)$^^\Y)!MJ%.I@(;(9X,]%MB?H+#_LGI MQ[H"/Z63L)3N*=TJ+XAR#24"')J"&!SX:$ M3+S99!).9]&[+#Y&5!M\H)JNEU+L'>@:T%05-3U(%L!LG(TA/QB']7K)*G@T M)'>&9>5"N\-Q!?5Y7H?3:.D_0T[C!G./&'BW&&(1/D1C0X(PVB&=3_)!V8"- MLDFZ">4>?VC+C,[+C+LRQGEXL:8'.7,(<"T383"S_!@!8NH^Z/B"4\-]&3"4 MHBTT[0LA)IS5"0^\:&X#Z>B"J>&Z!MS7/?*B0<18W?GXO.[T&ET#[NE&@>5% M7<0TNL2+@LZ+?+ZY4.GHFD`,N!_(L5$Q$,38!`07=,WX;]U;;S>R`7=U1ZV" MHBYB#KHV.YUJSZ\1->"NZ'C>-XN8TW8F,";:]H;=0/6I]^Z@!G1&TPR1P2DE M.'+:-]$H.C8KYK0!04_;N11&%PI*KAI--;J?W=!6K9''>77&JADC+:L#TXO# MY^T!11!T1O.J$04;M]\]9]*+H&YZCS7`UL7%BWNI8'++/K$\5TXL=F:I$IAO M]E>[\.]&]B6_:!RRTOEY"R%HS`405GBQL8++:IZZVV$ADU;?\W@ MR8K![@@\`*="Z,.%>2:PSVKK_P```/__`P!02P,$%``&``@````A`"2>%-$- M!```0P\``!D```!X;"]W;W)K&ULG%?;;JLX%'T? M:?X!\5XPUX0HR=&IJLX<:48:C>;R3,!)4`%'V&W:OY]MMA-C0QJF>6A#N[S7 MVA]BX?__U_+!T'2[RMLQKUM*-^T&Y M^VW[\T_K,^M>^)%2X4"$EF__SXDB;G'OL1%OXSYYU32[@L3OX_-31 MO.P7-;4?$I+Z35ZU+D98=7-BL/V^*N@3*UX;V@H,TM$Z%Z"?'ZL3OT1KBCGA MFKQ[>3T]%*PY08A=55?BHP_J.DVQ^G%H69?O:LC[/8CSXA*[?QB%;ZJB8YSM MA0?A?!0ZSCGS,Q\B;==E!1G(LCL=W6_<[\'J,8Q=?[ON"_1/1<]\\-WA1W;^ MI:O*WZJ60K6A3[(#.\9>)/1'*?\$B_W1ZN>^`W]T3DGW^6LM_F3G7VEU.`IH M=P(9R<16Y<<3Y054%,)X82(C%:P&`?#3:2HY&E"1_+W_?:Y*<=RX4>HE"Q(% M`'=VE(OG2H9TG>*5"];\BZ!`A<(@H0H"OU60,+JWV$MG$1''NB8&<682S^NV7&0+L,<+,2@@CC.2Q=ETZ@'L MVV'N\R:\7V5KT`Q8!`6ZB""+*-5#:90AF+"T^U/?K[)$)'JVE`@T-1019E$0 M)+I9IH@ON5J`GF6X2Z)WEA*AC(W@[O,&;F!*D#8T&,1Y\Q"@>9D2M'$J"0B" MGO3>[\5+,OS<:LR$_\UH#)J;*6CTLD&0$A1Z),V&'SW09H6^Y(_R?6]OF42G MK"J$("4H\I:W)%@&.;-)$TZ9:%=0$A!TE1!I1S.K8%GES$T[X9F)9E`2$*0E M:(VF!,LS9U9APCP'^U%)0-!5`M&=,B5,N.>,@]"$?2:ZU4H"@F`B])DAT?YF MR`@G'#2]?QJ2JRSS2FWSZD-O7$-&JLW%E#'AH?>K$:(]&EMU?"Q#D"E#[V=3 MQI=<-)QPT<'+`INB0!F::)K<4B"=SC+1&85`?S0+H6=?*4`0ODRB-+REX$NN M"9>@\438VU.!5`V"P1$>NX#7(+PNG/(#_3WO#E7+G9KN89*)MX`F=G@)P@?! M3OVA?,<$7%[ZKT>XK%*X,Q`/P'O&Q.5!7K.NU]_M?P```/__`P!02P,$%``& M``@````A`#,1['OJ"0``:S(``!D```!X;"]W;W)K&ULG)M;;^)*%H7?1YK_@'@_@"]2H[;H=:48:C>;R3(B3H`8<8=+I_O>S MRU6V=^WM`V;Z(72^K-IXU77A.`^__SP>1C^*<[4O3X_C:#(;CXK3KGS9G]X> MQ__^E_IM-1Y5E^WI97LH3\7C^%=1C7]_^NM?'K[*\_?JO2@N(ZAPJA['[Y?+ MQV8ZK7;OQ7%;32W/Q^T%OCV_3:N/<[%]J1L=#]-X-EM,C]O]:>PJ M;,Y#:I2OK_M=(M\\'\/TS2K>[IG;]#2M_W._.956^7B90;NHN ME'M>3]=3J/3T\+('![;;1^?B]7'\+=J8=#6>/CW4'?2???%5H?^/JO?R2Y_W M+W_;GPKH;1@G.P+/9?G=2O]XL0@:3UEK58_`/\ZCE^)U^WFX_+/\,L7^[?T" MPST'1];8YN67**H=]"B4F<1S6VE7'N`"X.OHN+=3`WID^[-^_=J_7-X?Q\EB M,E_.D@CDH^>BNJB]+3D>[3ZK2WG\KQ-%OI0K$OLB\.J+1/'=11)?!%Z;(M'= M15)?!%Y]D1CJ#;0!ANN^@-?F"NZWL?!%X+4I,I^D\7RYNJ='E[X*+-.FRN!+ MF;HAKF>,V%ZV3P_G\FL$RQ`&L?K8VD4=;:!P,U7TEGR,/T!DW3G-5F?)@TU>:.Q<](6%@WH"D=A$]DHFB;*`?B* MKH6\CVX:=9H%N5S32.Q"@[YJ.PSF,^ZP_C75](L5VWYI+BYS`%_<@EQ;WK3I MKBV=+4+3@FOB4"&Y@KZ1XI)TM@S+:*XA;V2X`KU1T'.PZ(;WG!4'/><`[KET M-@^O-J>-!`62`D6!IL`@$-B![03;L2LG_=--MID0MA'H@LFY"EUD3N,V9KL( M<@H$!9("18&FP"`0V`(+V-;U^6W%<#H$=M;$CM,LZUTA6L[LOU"18T62KM/Y MG"B$4W1=(BE0%&@*#`*!8=B4AQNV8F(X(A>;.4TT<_O@)(IJS\T7LL_D@3J9 MD.U-N!\CYX$^O5%=T>::`C.T7M!GY MN4)Z-\>*:+:JNS6<3\))4)]1H"C0%!@$`NT&3"9+$B>R+V@ZQIQJXF\)5"LIFY) M_U68*R7#'K+A!O70L.D?N4@4]A1)<)D7=1V1,R):@J)@1'I4MJ)FM2A&-",& MD]"RC3OW6[:MZ+*@N29R(FR9$N$U[01*R+XA61'%B&;$8!+:M3$(V;V^GT[39:7` M9TR.G48`QQSXI$5[C?,9)SV$M61G%B+Y=QN!&H7,;<)#S@6O8Q:*P!VA8 MB6B8RAD1+4%3)B890+:B;@W3TIII#":A91M>D.4;D]I%G=`J6799A/)0/85S M1@0CDA'%B&;$8!+ZLBD%^;)#>?LC5^2R#:RX;M'2Y99Y$9[,*!+Y14N)9*T4 M(YH1@TGHSV84Y._&N+E$$XX;BR(H]OAQHT1$CKA%VA,PI1=TG:,8T8P83`*; M\5V)JU:3HR6FN<.+NBO,&1$M0?,@)L>R;$7M2F1$,V(P":V2B#5L\XE[HE9, MSOW,B[!EUZPC@FDD(XH1S8C!)/37$Y!NK\C8!:3K*]*+.CH:OB+M;66:@F*Z(KT(^W+-.B*\QJW(E'_DDZR(8D0S8C`);=HX,GCC MB5UX"3<>MB*=J#.5^V8=$2WI5F22D$-6MJ)N1=+2FFD,)J'5NX*0_7T'&U$2 MU3(OZHSEC`A&)".*$+L#^6;YA&,J(8T8P83$)_)-]<7XU)SXV?&5E$ MF1=A7ZY91T2KL?>OR!R7_H=N2TI6T7Q!IH9JF[=3M24]!4U0<+Y<+KMW##O# MYA2T7H>%V<2V(I,Y(H=\YD5=%^2,"$:D)ZXGHGG/W07%&FE&3%`FCFW>:O?X ML`-L\+B_`UQ<"3]*3W?1NK'<7 MC,*1I4$X8>F)$<&(9$1Y`L\-U6MX0I^OT*R)P22T>U>82GK"5$(^.&=>U`UB MSHA@1'K2WNY=DVRM6!/-B+E2)'1]5[1*>+1*UFS?:F)3L]/FOEG7#X(1R8AB M1#-B,`E]D1PU[+98XA(.[#)7HK\7=6YR1@0CDA'%B&;$8!+X2TEX&G;NU*W( MN9/0FRA>A/PQ(EJ".BHA\U2VHF8B*$8T(P:3T#+)5=?WH=0%([P/)6NZ[WH1 MMLKR%--(1A0CFA>B+Y*EA4S5U`>GZ5/4B[(_E*J:1C"A&-",&D]"?#3MW M)X34MKHY59T(^Z-$^$)P[G5K.B$!5+:B;JK20III#":A99M3D.4;4]6E&GC# M[@I3/_;+!?D*"\<;^ M*!%,(QE1C&A&#":AO_\K\J0]D2>EIZ(787\T!`FO<4%UD:3P("Q)3I*548SH MVV4,;A3VP%TI*.U)02GYY)5Y$7;NFG5$>(V/Z/`$TXK]3I^548SHVV4,;A0Z MORL)0>1DVQ.[K>U%G<^<$>&)<[Z"I\EI9)>LC6)$,V*?I6_7D_/I'HUW#SH? MB_-;D1>'0S7:E9_VL?;O*^^B#>BC\MX`P^K\OHJWL`SJYSK>`./KG)NX@T\P0I\VAJ`1_T_MF_% MW[?GM_VI&AV*5^B3V60)>]#9_;&`^^92?M3/AS^7%WC(O_[O._Q11P&/I,XF M('XMRTOSC7V#]L]$GOX'``#__P,`4$L#!!0`!@`(````(0`\PUP!Z@(``#D( M```9````>&PO=V]R:W-H965T MKB$7%%(U5-VMM"NM5GMY=L"`58R1[33MW^_8IMQ2=9.7$#S'QV?.#./M[0NM MK6?,!6%-8ON.9UNXR5A.FC*Q?_]ZN%G;EI"HR5'-&IS8KUC8M[O/G[8GQI]$ MA;&T@*$1B5U)V<:N*[(*4R0+'LF$<'6K(^\5?H.R-6[^,"'6OYDYV^8E)6$JH=04(JKSA_O<8$R?*4O3T<+D9*"Y M_&0%AOI-3HYF.1O,1E=MZ:^GT70NK>8"*M*5C/ MHNDDNMCT>R>:EM=H4N"YIE7/:RID,$;3XLRG<33T!\433:MK-"GP7-.L.GN# MZ30-1IC>'0>'9":"U%4V^M@_;F,%G@H*ASR-1P9B>LD/5[//"Z:Y8NC"4;#H M'3:BS*@VTXAB7N(4U[6P,G948SB`;NA7S0VQ]^-]H.;I;#V%FT.ONWT`)G>+ M2OP=\9(TPJIQ`92>LX)>XF;VFQ?)6CTC#DS"S-9_*[BB,7R2G@/@@C'Y]J)N ME_[2W_T#``#__P,`4$L#!!0`!@`(````(0`F,#`REP0``+L2```9````>&PO M=V]R:W-H965TSP%02L%JYN MNU(K555W^QR"@>@F,8K#Y=Y_W[''@.T0$OI"R.1XYGAF?.)X_O6CR+UW5HF, MEPN?#$+?8V7*MUFY7_@__GG],O4]42?E-LEYR1;^)Q/^U^6OO\S/O'H3!\9J M#SR48N$?ZOHX"P*1'EB1B`$_LA*>['A5)#7<5OM`'"N6;-6@(@]H&(Z#(LE* M'SW,JCX^^&Z7I>R%IZ>"E34ZJ5B>U,!?'+*CN'@KTC[NBJ1Z.QV_I+PX@HM- MEF?UIW+J>T4Z^[XO>95LCWK33!X*`Q^E55X*_*V[)=P0SDA.;;3]?F$@A MH^!F0$?24\IS(`"_7I')UH",)!_J>LZV]6'A1^/!:!)&!.#>AHGZ-9,N?2\] MB9H7_R*(:%?HA&HG<-5."'W:2:2=P/7JI(M!@+-1R7E)ZF0YK_C9@XX#ON*8 MR/XE,W`HLS)LS0JD0X[Y)@>IH8`64,KW912/Y\$[I#_5F!5B8/5<,=1&K.\@ M;I``^%U)0KI/A\$K3HC&V:X,.6F0 MD1'38J6$.#+[N!H*W54.#3*CHZ`JBQW=T<^.Z"B"EHHTIHX8,_C%(M\&H[!% M-8B4.:,K^ZU7-D[BZ/8^ MM-)"'9GMM\#5*)M@%+M;)@TRTF-:;!9/R2U%W83U>MNJ-C9L&F1&;Y-;ZLAM MSQPT9;>Y*U&N%[[)`H?II1^&MY:V,W)'>+OW^105%'ZOF1D:TH["JT$FIS;A MI4\)KT)W":\&F=';A%=^IYDOG\>O086V>[*Q:#3&#(YR/5+;UE%K->[(;(]J MX)[3KH:S&UI1!)F4#(O=$XZ0=N0#E;!CE1ARB0)*#8L=_2D!A9.!QFO0W91H MC#EU'(4?.\U-"9X5X.=PP:H]6[,\%U[*3_(<@$(-KU8\HUB1&7PSPMF`8U_+ MLPMU^G!]`$<'QV3/_DRJ?58*+V<[7VYD<<;UV.GY7\```#__P,`4$L#!!0`!@`(````(0`[;/D8 M0`,``%`*```9````>&PO=V]R:W-H965T(^8<4*[E1\'D>_AKJ`EZ78K_\_O^ZNY[W&!NA(UM,,K_QES_V;] M^=/R0-D#KS$6'C!T?.770O2+,.1%C5O$`]KC#GHJREHDX)7M0MXSC$HUJ&W" M)(JF88M(YVN&!7L/!ZTJ4N`[6NQ;W`E-PG"#!.CG->GYP-86[Z%K$7O8]U<% M;7N@V)*&B&=%ZGMML?BVZRA#VP;6_11?HV+@5B\G]"TI&.6T$@'0A5KHZ9JS M,`N!:;TL":Q`VNXQ7*W\VWB1QXD?KI?*H+\$'[CQW^,U/7QAI/Q..@QN0TXR M@2VE#Q+ZK91-,#@\&7VO$OC)O!)7:-^(7_3P%9-=+2#N":Q(+FQ1/M]A7H"C M0!,D$\E4T`8$P*_7$ED:X`AZ4L\#*46]\M-I,)E%:0QP;XNYN">2TO>*/1>T M_:=!\9%*DR1'$G@>2>))$%]'TP]PI$<.>`XC!@\(# MV;Q'LHSC!1`/YNBEC':]Y1;8)$EN)8OB`B,X1/RX3N?39?@(L11'S$9CX*L: M,;&-R`>$3!/DC1K!-%=C"F7P>H"#)#G(EI0X\VU>@3B*3A'3ZQ%B:03O/JY1 M#EKYUX8EZ3P:^96U&XW1A2F]SHT&2P'0F`K.NR/!4,C6S#-G9HW)5)SSZNBW/IK:Z\YY) ML*LJ>.$%HC!U$:F/R`>,&$ MO@;]%1]!AA-FBV5%_,J6?#D-->I2'$>0J4+ON:K%5N%LNA<\T!NEM9]D;B1P MR,O<[$PF3B8C:`Q%'^SZT&HQV^$<-PWW"KJ7AW8,V]/8JB\4&WFA4%>"L0/. M\Q[M\`_$=J3C7H,K&!H%,]#"](U`OPC:JS-C2P6!=<_P<``/__`P!02P,$%``&``@````A`%?\IL:"`P``T@L``!D```!X M;"]W;W)K&ULE);;;N(P$(;O5]IWB'(/(>&,@*I0 M=;?25EJM]G!M$H=83>+(-J5]^QU[0F*'JL!-:<:_)]^,QY-9WKT5N?=*A62\ M7/EA?^![M(QYPLK]RO_S^[$W\SVI2)F0G)=TY;]3Z=^MOWY9'KEXD1FER@,/ MI5SYF5+5(@ADG-&"R#ZO:`DK*1<%4?`H]H&L!"6)V53D03083(*"L-)'#PMQ MC0^>IBRF#SP^%+14Z$30G"C@EQFKY,E;$5_CKB#BY5#U8EY4X&+'C5/? M*^+%T[[D@NQRB/LM')'XY-L\G+DO6"RXY*GJ@[L`0<]CG@?S`#RMEPF#"'3: M/4'3E7\?+K;AV`_62Y.@OXP>I?6_)S-^_"98\H.5%+(-YZ1/8,?YBY8^)=H$ MFX.SW8_F!'X*+Z$I.>3J%S]^IVR?*3CN,42D`ULD[P]4QI!1<-./#$;,#80AR;T>E>F3:I>_%!ZEX\0]%H89JG$2U M$_BMG831S4Z&M1/X;9Q<(@@P&I.BGXT8.*`UY9$5V_X0(LYM+C+T1ZQJ:4-:BR. MDT&75:^E=B@FMU!H<9=BV$2'%*BQ*-`P/65CU.@=CNDM'%K+L:,&4SZ;C"=-RLWR MUEZ.1J-VV:$*H2_8B?DV;:RY['?+5L9S#%%DE9!M<=^NV]W-91SJ M79?JN!;9%+C-6%R*FYIK>$UWK47VVT\-5_>UT;S]7+HH-_57/;^<7:NS0CDU M5#V(F&],O0U;_3D*CE`X)114[.F6YKGT8G[0XU$$UZ"QXNBV"1?P*07W'?L6 M1CIC#YH%F*@JLJ?/1.Q9*;V\<5S%+FWPQF9PH? MZ4$?Q"GGZO2@I[YF&E__!P``__\#`%!+`P04``8`"````"$`U0;$MQ8$``!Y M#@``&0```'AL+W=O;'/FU.DZU=47 M=I_?JM)X)2TK:+TW[<72-$B=T;RHSWOSG[^33VO38%U:YVE):[(WWPDS/Q]^ M_VUWH^T+NQ#2&:!0L[UYZ;IF:UDLNY`J90O:D!K^*U!T7:4F9=I`_NQ0-&]6J;(Y;_91FHW;_H,E71=921D_=`N0L MGJCN>6-M+%`Z[/("' C9:<]N:SO4ULQ[0.N[Y`/PIR8\)O@UWH[8^VR+\6 M-8%JPSSA#!PI?4'JEQPA"+:TZ*2?@>^MD9-3>BV[O^CM3U*<+QU,MPN.T-@V M?X\(RZ"B(+-8N:B4T1(2@$^C*K`UH"+I6_]]*_+NLC<=;^'Z2\<&NG$DK$L* ME#2-[,HZ6OW+2?8@Q456@PA\#R*VNUB[[I.W]N>K.(,*1(PJJU].Q1M$X'L2 M>>3#XC7I2QRE77K8M?1F0-^":]:DN`KL+0B.M>65F*K]LV)#E5'D&57V)BPX MJ".##GD].+ZSLUYA5K.!$^@<3Z&$(P7G$'6C$;CKVK)J/#+&D(0#_>19X'$R M"A,G&OW_YAG](!G]C*H!!T![,KB2$PEUAO^W)10\X9],WI;U9PI],"&6"IQ$BD>#Z*"$KQ!)A#:>#0D@XH2^89!:V M@?EFD2R;=91Q`D[Q>Z^KY1H241@A9]RG+GH8$JLAB13B>ZXXBF0/]I/Y]I"L MV/.5!11P#O?GN_I4A9P@V'L4$:L1B0!(9OQ?,8-DU8PK=TW`.5#,:4MQ?*5Y MPY$S[D.1"L0JD`B`E#_>AH2-_N.%A60U?U_)GW/NM0Y5(%*!6`42`9"2WJ#< M'46/@V(M*!$1V12>I[/[QN:GK[@C._Y::9R!=$\YU)!(0V(-241$SAG/2"'G M>>UC\Y,5]FIA0:I'WT`2<^=A=R32.+&&)"(BYXX'HY#[Q^L4KMW:0M6:B'/X M"8A[IMY#G"%:>!03#R/?8_`5`'/I$6Z)W^CY=;,B[9F$I"R9D=$KWM8=.*8F M='J3>%[AI4O!`WL+=T,=C^PM7``!MZ8`N/@WZ9E\2]MS43.C)"<8:KG`.WK+ M7QWX0T>;_O)[I!U<^?N?%WC%(W"=62Z`?**T&Q]P@.FE\?`?````__\#`%!+ M`P04``8`"````"$`S^`+^FT#``#G"@``&0```'AL+W=O59L.1%J6X:D M-.W?C[+B5)*[IB]M3!X>\Y"4Q>7MBK$$"'MG>XQW#J.R#FMH+?7_F-8BTKF)8L(]PT*HB!.E)7:L"T7I8$%,BR.PQ7*_*ON\[\(,Y):[0L18_Z>DK M)ON#@'9/09$4MBA?,LP+J"C03,*I9"IH#0G`7Z&!E[).R1',%@`\2!,I7&1^C^E(%&2W$F6G@M$<&C/TSI.XJ7W!"4MSIB- MPL")N&!FD0G9#A!90,F;#8;7F,`,R0>$[!Y(NNB"8MFZ(FC[VPT;9,@@4T9H MO6_S!L3,:#M&S*Q29&-(:)+D8X1&8@B-QD)G5X7*H)4;:[V(DZF9PD9AU#3+ M9FQM0V8;;59P/!EGD/IFQ)'5WJWA#M/4K']F MN.?QW'3+W4/61Y%/T]=OBE*E]@IU[S:8[?$6US5W"GJ4.T,(TWJQJGUF$RS@ M,H0[S;)G&PO=V]R:W-H965TL^]_5H\O)2%\8P9)[2*3&=LFP:N,IJ3:A^9OW\EH\`TN$!5C@I:XF0';`)>)C6N,*ONPH*Y&`5[:W>,TPRIN@ MLK!1>:C$Z:!:2T737W^$'SBG?\&/]!3RDC^C508B@UM MD@W84OHDJ5]S"4&P-8A.F@;\8$:.=^A8B)_T]`63_4%`MR=@2/H*\]<8\PP* M"C)C=R*5,EI``O!KE$3.#"@(>FF>)Y*+0V1ZT_%D9GL.T(TMYB(A4M(TLB,7 MM/RK2,Y92HFX9Q&(.(LX[MTBT[,(/*\B;C!Q)M,[4IF=5>!Y47G/AZ5JTI0X M1@(M%XR>#)BVX)K72"X")P3!MK:J$I=J_Z_84&4I\BA5(A/6&]21PP1Y7OJS M8&$]0U>S,VLB8^GU*/*1H(ILA0Q=)AA3/G_0'2H<< M]SI2KRK>/561Y,CTNT4(9OVA5XJCUJ7LQUH'8AW8Z$"B`VD'Z&4/J7R\IY(, M>T$G>W\VU[)7G'DSI4>^;]MVG[#N$3QG0(B[!.<-A4V7,`IF`X5$$:X53#M` MSSWL35WWGMDR2*M"H)E<*;Z^(2E.QY4.Q#JPT8%$`6??$[`]<)YV8GJ^8+?M^KK=)4GN M^_$#;2M<*P[0SYOUY*8-TQ]<] MJSD>5HJC5J?N6'V[=C>^0=[HY$0'X'XCT]&'4C;5S44=JR5F>[S&1<&-C![E MK<2#AES0RX7IT95GB8:OG!#.P"$>.R$<=(!;EP"XX-1HC[\CMB<5-PJ\@Z'L M\0Q6$5-7)/4B:-T<\ELJX&K3_#W`31;#3FR/@;RC5+0O/$RD>WI3P`AN-S[KGW"? M/QYN;/L;IF0/%&O1"OLZD&(DV?RQ[I2FZQ9\OR0I90?N87%! M+P73RJC*1D!'?*"7GF=D1H!IN2@%.'!I1YI7!;Y+YJLL]-PP2"C31*'-,3+40`)R1%*XS("'T9;CN1&F;`H\G43:-QPG` MT9H;^R`<)49L:ZR2OSTHV5-YDM&>!*Y[DB2+TE$VS:]@(3ZBP>`]M72YT&J' MH&E`T_34M6`R!^:#,Q]'\/HWJ^#1D=PYE@)#MX,+`^5Y7J;Y>$&>(:=LCUEY M#)P#)@D(`M&$D"",XY#>3O)!V8&=LDNZ"V7E'QS+C-Z6&;]'QH$+G!X%G^9I MX/7*'C/4_\0/[+K>CP-#>YP(96="'C,=\IQD,1P!<"(,O76]L`.?"T\"KW?H M,9<.)^\11XP)]ETL_SH2_EW6SKP MN?8L\/IL>LR)]NR\DGXD^2]6#<:AEEX`9.H MIS5_HKH6G4$MKV!K'$U!6?M9YA=6]<,\6"L+,VBX;>"7P^&KBB,`5TK9P\)- MR_`36_X!``#__P,`4$L#!!0`!@`(````(0!$4F;6.P4``%T5```8````>&PO M=V]R:W-H965T&ULE%A=;ZLX$'U?:?\#XKT!&PA)E.3J0M7= M*^V55JO]>*;$25`#1$";]M_OV.,&>RAM>,D'>5Z;'T69M;/Z+"J([.NFS#KXVQR\]MR(;*<&E2>/^_[<*[.B MN`?WLLSNU[MC*_)5V9-4_/Y[N\+L^0 MXK$X%=V;2NHZ9;[Z<:CJ)GL\P;I?69CE[[G5GT'ZLLB;NJWWW0S2>4ATN.:E MM_0@TW:]*V`%4G:G$?N-^YVMTL!WO>U:"?1O(2ZM\=MIC_7EMZ;8_5%4`M2& M.LD*/-;UDX3^V,E+,-@;C'Y0%?BS<79BGSV?NK_JR^^B.!P[*'<$*Y(+6^W> M[D6;@Z*09L8CF2FO3T``/IVRD*T!BF2OZOM2[+KCQ@WFLRCV`P9PYU&TW4,A M4[I._MQV=?D?@IA.A4FX3@+?.@GCDY,$.@E\7Y-\Q<##U2AQ[K,NVZZ;^N)` MQP'?]IS)_F4K2"A5@2J,J`)RR#'?Y2`U%-`ME/)ER_VU]P+JYQJ2(`1NGAYB M(](/$/P*\8#>E2.H-9VC'$0XLFMZM8P$(0M5(;FNU+A@$0!A3`(?M\R[.!*\ M<4-SY0&9&"'896IBXX(U,62Y?6()ANJ9$X=D8H0LL62![\=V/#7C+`J"?KQ% M"QK^=EH23&A%]K0)0F)%:S&/2)U2,\R7X0BI^112$DQ(S0DIA$2*5!B0_D[- M:,1Z'2V=8IO2;3>7'$2H]>FQ<1&"U):+I4T\-:-1V(^UJ,EMS;CO/V]I"2:4 M%O:D"4*PA$'@Q_VTBG)JQMDR"$=N]>446A),:!$M$H2@4GQ!BVA%ESUE2RD& M=GB[5`IMDZ*]DV@,BL7]`2T['L_[V\4F1KS[\QHR]%O3'@)RHR4:@W(QUL^+ M-23A,;V(77]!"SW7HM7W!K8[0XRF%=$JCH9MM:3'WMSQ3*))&:F+:XSN>7@4 M(+Q3"\#Y/.[UMJE-LGF&)@V?UZW5\&FM&&*,'4:/4E?LR2>9N7QBHKJ0-DDT M!LNU8`-5,`6&P_F(F[-)=J[0I%S4SS4&R\4"HQBZN]'2=3SB8\2(J7_1WD,W M#_K[1A?+-.R`J)DR,\J"WG?M*D[RLGUC+9<49[^6VB4UR M=#:T]*%]GQ>.QQ@4\R=86VU0I[[\/^TA@P@ZN-&0\%6,K/,;9R MD^R=H[V;'AJ2@B4:8WBH><6>7-JML;?(![T05O:Y-W`T::#2*T":.=&8SU5Z M-WLC3V^Z-E'IO81H_#51.8J4D_11(E^"`8/-S\FMD8Y%;7*3+)^C75OJ]1ZD M>\RT=+[D83`@9B/\Q=A^Q"?9OD(3Q:CM:PS>F7=\'D7T)3HED#CV6=^EMG;$ M_V][U>##?2`D/I]HC-[-EP,!S6V`^6,O9WS2-J#01#XR<:(Q*!^/%X9S:?,P M]P$60O6OKRR6=/*X@]X37Q^!J%$V1?I@FF@,OFX''SP@6H"/'A#Q-`L/;$K1 M'$0J3J?6R>MG>5+%X=WT>A5/T1*V2K@\T"#74SA=4]>]:P`.M\[90?S,FD-1 MM7VPF=V\M`UZID(RWF4X#B*, M:%?PDG6K#/_^=7]UC9%4I"M)PSN:X5T@Y&*BY8HN!6K4/:"DM),:ILPB:)1V!+68>LP%>=X\*IB!;WC MQ;JEG;(F@C9$`;^L62_?W-KB'+N6B*=U?U7PM@>+)6N8>C6F&+7%]&'5<4&6 M#=3]$@])\>9M;@[L6U8(+GFE`K`++>AAS9-P$H+3?%8RJ$#'C@2M,GP;3_,X MPN%\9@+ZP^A&[GU&LN:;KX*5CZRCD#:LDUZ!)>=/6OI0ZJ]@\LB>Z?^,I&.I4!I#M\50@#CWG5D\R4T$M M82F?YVD\"Y\A_6(K61Q*$E>1'U'L)"'@O3-"6I5[WWA`$`P^P"GP]%B"''_P0.W](650+?KZ.(O5]YX_O&X@P7%G8^EQ1[6 MT,.RDK%=T,B\7$5^2N&@P4_B?#0M]M!2]\$+*TD-6N2.YSAC#\=*/NZGC\<=+'W4[>T%I]M*-O&`66\U)/D]S%-">AW;+[\F*?B=BQ3J)&EK!QA@%8_CU"'L:VAO%>[.U M+[F"4\Q\K.%?"X7],0I`7'&NWF[T>?O^/VC^#P``__\#`%!+`P04``8`"``` M`"$`D_<&I5H^``!WQP``%````'AL+W-H87)E9%-T&ULU)W;;AQ) MMI[O#?@=$H+:0P$DFP=1E&9Z>H--20W-M%J<)M6#[<&^*%8ER9HN5M7401(' MOI@+OX%]LP$;$/8#[(?0H_23^/O7BHB,C*PBJ78;MH'I`569&1FQSNM?*R*_ M^J;*Q61V MW5OPS]GEE_/IK.X-YE=UO;@>?;FWL_/DR^O>7_UY>+K MK[[4K7[[L^KU9+RXFG/KH!Z45U_W9MO5_NYFM;>S>U!>3&\Z6OFFZB]'Y_/% MK-=?_,O:)\]NIG5Y<7=GZT_E;T>L:&"K>CGJ7997TT1.ZMEPHE4/JN>]16?D M=-_+X;S?&U7_7/=FU4OH-5\[8K@S#+SRWC_MET^?S7J2B>KTYOI\,BJOGIP^ M_['\+?#IA_IR*)+!O>][UYWY3T^'[X:#7G4\F4VWUPQQ#.MGK.T5[/Q0_;&^ M*>\[7LYF$H^Y.F!0_BK?&$8YGEQ? M3\;5Z6+2_VFS.KWJS>IY]6:Y,(V!7.5CQQ.6,)XS*G_-)R-6KE=\TQOUQOV: M`5"0>;7Q]O1Y]?!1^?"K<75V-5G.48+Y)LHRJN?S:K*XJF?OA_.ZFD_K_O!B MV!7X/RS'"/R."?SCSX6)8=VZ"K%+NN8UH,Z]F=;]F3)[KW'TRJZ>]X:"J/V!0YA!6 MVN]/\0)CN,^ZG/399(&TW'[/R0PS-<..:%"M:RI5W*S&]:(<[M48^WB-&A!O*$7ZHT8!A7ZP6']&E"S' MY_ILR;LC(KSL/-^F9S:36P8:=\CHH]SRM)1IN!`;G-5] MC#@ZA#M:(4J?/G[Z6+[>U/!J,AK@SGYC3%W<=(B%5(75SEUK'V[O[.Q64\PF MHKVL-ZN#S9V='?U7S5VA>\O%U60V_'L]@/-XP6HXGXN>)H^W*;L9AW6O>6+O M6/>>O6>;CW?W-O>?'-AK^.?>LZ>;!P=/XZ16SZ'J+2I4L7^5/)P]C@FHDPG8 MA,\R%HOANWK4-7V#`5(V&:-!TKZMX1B9G0[1J)+CDR"S:H+X;]88?G M^2U!"F^44.C)EJ[W/D_>TQ"=8=$*)>C'$ MN3Y:9YE/%Q#!7/GD`G\QQI@/H=_)9&ZDO"5JZ$ACDL-RJ9T[.\)YWR=<XWL0]W>H%GSB5TX[O)?/Z(T*./ MH*[C?]LSUQ_Z]72!,T=V*AQ\[W.<]?Z]8]>.*__!K?<*)SX9C7KG$\(9Z1S* M3XR(A9#Y&O#,:&*^KQ2('R8WO1$.\C8=#0ZCX[K?X%MY&_%B]#D=.XQ/O-++I]R$*!AH3[B\+PB" M4Z.ZF$VNJ_`0D5QYLP<#?F]GY<03-4Q8K*%L_NS*2"/,V.*-UEW)O,2 M:@TO<7L69/9O*F4O<_P<7K'J#?ZZG'N04DY,ZUZ.271'"A6J2XEC>!,/7M\G M0+YSLN4["V-U&UO6>+QD_*0RIPJ)DL]]05B,`;A7.M(Q>N5,36K+'YE^RI^J MO[RNK\_K62>S/FHBDA-%)%C;8X](UC^2A29$MPI-[G6OT[]-U*`;ZV87_,4ZV'-G$ M9.N\IT16FD4T9]I1WI?1YE;4905M;KW_+E%V/ZZ,]>5H\GYM0GVL.R[LCMR> MX[4`>(`EE,)VK$/#EZ#?.X>AZ M,EL,_^X6">X.RPRUG-/S&NM'3&HF[-ZN<1V;HU,OWU).ZQRT`R]<7P^7.,M[ MFL#C*Y)MDGWY\N24/3>V&"!+(#N\28EP@RK8,Q/SE;<#`NG9D$1[P'%'YBQA M,`X2:P!CH0[GV,NE]&(X?I0O(`E42;12"(?C=\0&"IUN$<*3)0$"?B_/ M\KJW"*",S,&]'FF]Y'[!%*A*OZX']?YRSB\N+LC9]0*% M@=IH,3H:8!3_]H$GMJC<(@#@' M\AV/)<),%AT&ORX7<^OSX.+KGSQ=3J$MK[+9RY:RE%0< MZ!@)>[4!B]RCU2NQ6QD5W_(J8*`M>UTF;^$;/X-@" MFLU?#9H=B`![@,$=%[&9M*!^F^1\>3X?#H:]F5Z\@9&N?O['_U#TQ0M^_L?_ M?`2<*B(1"_2O/GV,-1M[5+S3`XNK6K!='0,$*UC/I$;*H.$O)I/%>()V-9)F4^(:&K-RI=AE-*!&F1)Y MF.L$:%-)"^.*AK.!V8[WP\65O6>V!`"W9+J/90 MZAICH[0D$N_TQ;$(MTVE8.T$YQ011G@J00$]FQ$S_>MRC(MBI#2EQ(=_96). M*BWI#CZ+$Y%HQ M;E3'V,200?PG3.9Y%V1)SI#"$4`J9@- M3XFN<^I1%5$LB@+/],MGK-.XXZOUB:^=\:9Q+9"BZHW`,IH0<=-H"J9AYG(\ MNM%ZQBJ=CF"/0A9=:#VPN,+&2H3'U$[F\][LIB%>;SA3Q)4T/HI0SLQ&:J#F"0;R\034TM[5ILRTJ65P\?N"?VWNQ?@!F:OJ%+&I2T#X%H,T<,DZM MT(VWVZ?;%24`04#0!M4!6H.#TJ&EE0<8&=(.\0F8$,S'MT=')V8[9O)[D"*3 M#L7CU[V?X#/.^]J3(5N'(BZ*U=SLQ#57"]\P)S@Q)$,LAA'SS6IC^.C31Q:# M`&L>UU[0@FZK8]3?\8">:.R':(P>>6D#1EKAS6:1A;9RHQ)(X$-S;?K[3N7[ MG8W"^]9-,<)UON985AL0&+),O<+7I7\Y&\V.\.N\*QR)X9]E@26UDT62W"$\ M#8(B:!+*^"S\?<:+Z]Z-3)70*"N@13G#I\%=3+"5O4WYD$`<1W6Q)-1%XBSP MZ-24SUAFT`8\:M6K1AA!^(OPZ=T9(*KIS`%[<`WU8&M&05A1TA0`Z[K7KY=6 M$D#Z)H-E'\VQ>6%0'?6\,8^A!^88+"[WIHKWD)CTP*`>L>99-9@M+[F.))A8 MS`!K)5C8T?F"J=UX=*?A@W/C+RV7@?.UR.V$R?.X,R70\V*RA#)Q`BN6M'(- M,XH>J@(AN6$=V>M^_@=>092+ZR'X0N%-7%_7_+&<_?Q?_\V(@I$![QPRZ^6[ MFIP:TV#9W73XSNNT(^RX6A>(^7LC5H7;II0L(63^\AKV'L(3KYP'`E:OOGO[ MXZL7WW_Z=WL+4<2YJC3H=Q__B>\8T(QB%N'YZQ=F$#!FN(@^U`F\-N,2_@YR MI)X0B#><#:J_+7NH.+TBY;(Q95O]..E<7IC9Y:QWK?5=J`.#-^%IPAVF5#FA M^U>S"0M'N]ITKI8+"KU_M_7#-V(%HIRZ?S6>C":7-]5TU%L@#-=M]AL_U&9! M/X-!]G*[22!:[T;?:A`;(K<%VO?^2M"$VZ.E[L-$CB@*&+(JN5GU:HG79'EY MQ7.ILA`#S\"GJG=)8&;%W$(%9^KH"3*R:3J7.R?C=4%4*=BF*:MBM+]B!U3E MWJRNA_W9A`+EG/@-,L_)B23Z$R0)/:PZ@H=!K\YAW$#KK!L5W12;>HVNAYA` M*K?_)&@=8NEB7<%7#Q8L?&C-P5B.0`71-,%$^JH-N]5G"*:FL$-:'_Z<3D8W MUY2LPS^CH1$OB8"Q`\%2F+&:O)?)F#BJ)X.51E,,\P.R)&IXH`^E];\3_F_^ M=U6W?__@V?;^P8,OO_X*QK$ZGK^FIVM7O\Q>XI/\IK/A-4O\OGY?_3`AM-+5 MB]ZU;+6-8;=_:<,NOO[T[VO?M;OSJ[ZI*RO)I`VOT0IF+XYUN-Y28$E1II"1 MIRV="/(*U;*>LE>");!`B^J:'AT$"':)_-&5('&TOV&WH]@W@;29F9<3FKC$ MS.H&N)^MW,9Q1@[KJC0CY+M0,=^B48B+1)TN;"#8W M\:6N-,GLF:V.@0&ZN:C>6U+A`1H+K7BS](@A9`.I@CHF))H15$VD@G%%)X*R MJE>O7KD+J#8P2M0GY=%ZU>[>EOD]'`TA&@1A*E,>7SS:S(9%>X6S#JIR+$MG MN$H#!\:\F@\_K!G.-4WSM`81=Q0&"VO*O9%RI1L,'J)6*_)K7A2U/?JOLVR) MS5U.L9R1S5CU6%[?&@ALOKM[S\3W(>)FKE(SN,-!C7HP,]'J@N$F[[>6T^K= MD!X$2;VZ,P=DF<9_RXS%\R>>G.@%49(]TL+$3:9;&$N+07O1908JXZYA`UXV M.,D@04_:NF8,#(3#QR_`GWG]"E9%03`:;=O4-$7J('OPI7SZW@I*3&F`:8GXBL,"#)S=;3=.HN!9)<&5Q3?UN M2+<=5D_&)7@6:5"4;F-5(]D3)6_.*2E6R7DSY.O$*XK0?$&B7#2U%+K6R%A89W1CHFFETO"5<)!B$W$(#IF),'%X@*5JO0< M=LTHY+$OKME:S9(C M1C&8P?("$`*/+63Y/-+!BID+L#B$I5IS-O'JWB$EYR7U\#$(/%)*A(:?HL-+ M$8MI/49SUB,P57CL<91-NCJ2G?4D+\J4.12+J-INSO@N0TM(QD,>JKJ[D>R" M7G@:I>?C=%%HP5RF*2P?/X1T!W'$Q$M+XVLSX=E6NW-R&C)@-CY_I%30!^N] MZPUI;V'%H=&A44DQ+63OEEN8C0^N4[QU*=1=DE:;E<%I'3X&_6S1PL3@FN1& M1LJ#Z120P+5U06LW_6J%D,9:'EGB+)_*?T":+)%`'C6;'J:(3JS7K5*>`ORH#I>37N;UM$$BXI*NEZ"?$! M35W(H6A(+VM'/HZI*[`(^D@`9>"QV@.QH(]\OFG@?X6K>!*#G>)<+?XQ<&=V MLW5^LQ7^])B\6=)[1AWU`"T5=!7YW$B@R4XE#(9D!>J3CI5LX:'DKZ>@+,%QV'W1CBF]7\[< M;)/48>4L,9X,!W-3$-05,L8(BQDJGZ&AF\0:$5,=G[?D*LR+@+%F]3IIK40C M,FH2NHQ0)[QZ>8DA9K0_](!C`XF^*O+4J"FW7Y^*:*2$.F"#2YQ?E57/5E%C&$6`1+F[8LT>_QP3^9YJ! M-$R#06-DHBJVO5BA4'L[7TB91-&9->*)+AIJ?]\O$!RY::->;6DVU;(K?'(Y,`[U<<<'^W0)/-;9N:F.>0!B6MK(&3*'I0K-5R# M>*Q!RZ1S;N0HO`\8"5<2,^#%=W/A0H(M1G,@(L MERDQV(XR8QW-F/C]*IL"LDFRR,(E+.7N<@8T$=:AWB9]S:9K-YC MX#3(0')R60L=M.`VHD^#VD%K%ZI+%!"O[W(AK9_@\ZZT1Z(KCAGI$1MYYBL$ M5/*(.#0=$6KX"1*ANQQ/ESHPRP;!S_FCCD66Y&)"?RK#!0FI+FH9_JY<6%W` M>6V+;9I%`5D](]3O+J"Q4]1MO.;10H?,SX/CNQ1;Y(<$>+<`4TE^0`\*N2>R M(B`#FE873EM5SF$24X$="E'M312\J5:H[)U5NXU#;G(L/FC&T^(?[N]N'VK1 M(Q1?^*LE15F9T6*=>FR/BG`Q0$9PM'G-2X9:9MR,`BD4Y"E5R%BPT6B?IKIX M/TDQGT6E=!>YLS09,>8T1 M.!$U&*N.GLM&M4HIDS%&N.^XG=68O/$Z@.F":5%U[(OH\3(UNA\UU9C3$([. MR@$XT-U0Y89%C^*)?TEZFJK;P6^:'/8Z?)2]A`*&A;5U9R[.U4-*Z^GVQ_^HC\/=[:>;99 MN;L4CAB@Q"%P8(03?V6(+W2PN_`>@T=JIZ5'1]4QSI5.C5GH7LPF]']F,MK< MVB5JM7%&W;E?/=EYPFX0`+:CT[>*!;CY$P#P4]>#"&-.L#O-B!BKL`3'Y6Z34T)C3C`GJ%,&=G_GM3:S4\=YB:RRAVB;I&XRU=@H M8LX5NW\BPQ3ZD$21QGO@,F*7T/KMU2%G+(/WM]2Q'-!J!QL%#!^>)O`C_"!: M'B#Y"&6$07>>I@::<&>S4-=J$3F2/\;OLM/Q=EV?:5^"Z4^H,!!26;YC=)S7 M2%(_=!JA?H:@I*(IX5<3)@1O[6%J?(.U+#!M/'#&R)CNV-Y0!>%.C+R`!JW3 MC,-[<:,HX:E:*=1Q;P:L[3?1&(4QO>KAWL'V3HJ2FA#1XHMF;MS)5.@2$&M% M#"%L,SI4I=/#VIVDE&&Y MCQ0K!2HA#=31R=>)#E5N#&L4QA&7JWAD/?01J:V."-&./"5.?-I@#LQ!\2A4 M93":W%00XE]:5L@96JN2Q&#=$B!I^FL62TN,<@J!#;[`(]]L`K8J_O%`$.\U MN;A@[[B><93^L=%2;,QI&23*&$RP'6$=HV18O](-U"(:M:!O%ELU(P6@"=W; M??*%Y,5&B,,M8>X($5*!-%NR@DZ1;#E5O]\K%S)2")`5RR$B:9OL7-E+2151 M@<@[O.M6P=IS@5J9NJMW-*9,;0>?!#J7&I):)A,-1P+R41PP6*PKRGP&K:-U M0L+-%;;%/$(6D`1+QA`@)R:7(F990!0!^>H\NR13'_VGDF`<8$6K,D(C%"\&3[ M8L=5HA6"1KI_07B.N$=O$!F:_)7E'1(!B[]:-F*2@S#@P;J"J/UIT]S@S;ZWW1H&J/CVU:Y4$L-;WUXZ#O8];*'CP]MEWET M#MX;=*].60,`TE9Q=TCR"+O)(]@+GMF6^>1][M^)VQZ_L^*3"V+ESMD;J&^$ M%XF_9&>B[&LR_HRL?(`'L108J:/@]77+#V34\%2'<*3V%8(O?H;E6#W=$T.@ M1H!BBVUZ.KPIW6$I+F\S)$P`NP)9Y$0S+!PR<#DA-EJ7-9:!9=6$!7;.1*LD M$(M!TL.`3P%_$>51&5(,+KY>+=$M4(!+@62Y#&3A4?6T:D9,<_0F(^AF3&HR7B>?(F M=':3O.3TI1_(H&Y+[/'2"O)'D'8*/P%8N*ZU9+K(KTH+RQ,]">(H`"7**[T MS`4LB831E%C?':RVDI],5BO03. MY-@RB&V4*B0<(.(+Y^&H)+GR,GE`42V:4S>!5W-`[# MM0!9Y'7&/\OA?I%0=YS7$21E)7E2E$#$:^R\*GN6X@?1"=3NS4C^L\T,"?ZE M.$(**:(@4`JC7.+@\KG\"*2RTH7X/<\BH?7,8("'3S((G,CQO-;X[3`I2ZQQ MDBRH<9*Y`D0&65HB54AE^ES+^%NGF6%.>(_NPH7)4A''8K7R.UCO*VLT?S2EZ M$/`H1,[M%>B"_$^H3^!PB7MLFX.+>E*RG.S.H.V\)X1!K5&[HXLLQE+\#S8H MXS\\V*9?MJFH6&K67;)YBO:N'JM5]VEBFQL()TB`-"G,G!U:Q#FHTWP^T29F MA-T[2A`!#B^)HK3*TWCB9X@J3Z'D305-\FG'B@75#Z+)OQ+(2G2.;'N9-F.'Y4'9X306"Q$>`K7V?U*040A&YW7?T/2E?7#_ MJ7<]_5WU'7I?HF'L+-2F5,O8\`N&XHDZTI%<5Q,Z1G`#63TTWN08NO(%H0+9 M>"$K05EU/6!*LI6^I89W&,85>Y!%[G;E6H*!FL%T[TN\=B]_9]/AWI-YE] MN+^S%Z^W[46'S"_&PTL*[&?6YF$U^PY"S;64*9;I89+K/,9UD:4+"8\G9D>1 M3^HC$8_`A4#4/60QRS/QE9YG5RPFU;W`K3=2QQ[QPOZTMK2M^]\R7C8K(D3DO%0U;C"NI M%(B+S2K`.ZO^N]W)9VK`G?:0$/^M3(T:JE)@7WD72"2S4W\PF#"' MN91[V[5$\DUN4SN'_9JQ_S;2ML5)C2P$7V*Y!S2JM^?!28X<-BA8X&WD7J.= M2`L*V0(022XB3L?:DJ-/=B&7U.8-V9#$`^WP.,:A`>B!A`8:(AS&0(<4+4MJ MPWM6<^S`@$80WB$'F,6AL;TH\".LN)E6X$7F'D+'1D18B]C"%%P2:']DS"*6 MW@TVUU9@,3:5P^!_&O=PS_$+@&]=",Q2.]&E2"!26Y;G$X`[:MB+S!)H1L02YK[VEVZGDO MFQ.OB4E@I0-S2M^TSY`X`=;8U>RA3&VJK`S)VL@5L;ZZX.+>.P6*8O6WV M3*\15U6/I-O*OS5Y_7W!S(:AE.CMUFGYV\"CGG"%\2QU%5M:%MIQ\C&)2":R M,12%2(Y1>)8M;JJ)3;8[6?`X)?,Y"5L/:$57Q7F_;#I/^2'(^6()@UF34!!V M[*@,'589:^?F+P`G\=B+M+R8.J^Z2?!D@-?W/2>4/WJXFR4]45$R3;Q+!=LJ MHFC6E/!Q'J@]^_4"M3)G>$5-/IQN?`0KN@?6?$N'B+42:&*=NZOGWGY%7?.. MHT/$&AV$U9Q"A9[%5TL0R/`B^1H[NTHIN= M#$=H/^HQO[N_NE[]R5$'YT]JW M0G+IE"?.Y5/D`^ET8"8*Q!/.*[O?=#?VGVX^VWM<_&P>&SSF^'AT\[O^UM/MD_*'^];3FWTF%C_PE'-S\IQ_N>BOGY9/*3'SHM M'MXZRAF6[%AXK@"IIXC1&-S/='CTW:QY=..A:-(M!1/NU#N+[$(UT@**8$U5=*/`Q7:W#Y(% M9P^!;3 M8RQJ/$N#MY]3U'.V8GONE!.D)"+S$4O,A.3""+:W?7C@>RS95Q_.G4BXV,/# M`Y<%C(;=U`GCL+#Q0P*GJ?^[U)Y7=DB>'#=(SO/Z?&&D>N%MX\UC=WBD9N'* MG71*,^FO']ZJ5AD;\T(GZB1A4$`1U-#R[+2_9`OQVU)2%5J^C+E9O_D*F1%S MDU,0>O"8705X4<+>>_JKH(]=+R6XM"39V[2X\LIW*\X.??[GQD,?=T(2$/@ M<@042IFV^'6G0=BL'C[-RB#H\LI7.'DT.P)Q-MTJJ9KX3+8O3CQK%<\M\12N.NC-T&A#!'+>K).!QM@XL82<9#&B>:J<4`<'`X'G. M/QQ/.=<^[8SUSCRC<:/OPOXGYT#,]GF2B'Y]> MI]E@+3DQB<8BH:2\-5"-978BX9__\6\E[[^S*>QR0M]_(PLPZHE`?UNR#X4D M5B5)`FP:#NUL,^WUY+5VA&FTB>(64]=3@#+D??Y)%4_3\OFJXY5TYRP+K[.NU&Z2+[EN*_UC#7^MNU!U^]0/-BB8HSYN"TVD0= M9L4ON?!VU\T-;3IID,[BBF$LC,MW-U;O)J,E*(6>'5]HAP'4\5YQT1GGO6&] M@FVB/UI#I/V22,MQ)NS1NV<\FW/P)F$\S`8#I4&-K;^:"M"-JX0S6SL=I,UA M`X0$/'I,`2@!PC9YI&XF"C8'L9UK"RS%^CB@D)%T?H.7ZKWTK4%7TKZSUJ;+ M'$HN9I#/MO%)#A-\@UP`C?IQ"^W9*F'E`:_LF'T!(&<38<5VW)\<^$`YF9,. MH+-N!E1:&WL^9R_:*N=@)&P'!W8F!/4$%,+>I%Y(-R"1OA:1$),31,P7J6A1 M;(K#++)%3;IJP4:S0O@:S)(H-5S8?E@T#X]1LV?4&]E#;Q;4$U;K+59.4D.! M>`XW!3VX77M"10TJ=-[JH#Q$G4ZV.4IEZW8,@#\4!!>N$];YT7_*4,9ZA;99 M0F9M5!0HAH_"$U!J]C`M_43C4_#0&72WS>[D<(2@N5V,7WP/*Y-'05X'0H*( M9J$];"F:P@'-2M24WA(R^^0H53IQQ;JA; MW9QMEVLVB4R0\UK8] MUH@YZ/-6OBC2OQ*)U8EB<(0Y,#7>F=G7@E;OM6W&;,U@ MB0%WYR(DD?UK??!XV7-G9TEJTVPA\SW^(N7^X,TJU$P)E^V$(;-9,$.6#&$) MTU$!<38PW4CYIY?LUJS0_1H+QC)XKX[DQ=\AH:QJ[*5A#IV*NA".STPSMTX,.3V!#[A1%FW'MS[>L7ARFW/ M(W_?K*B)P^]`4RU;^_0Q(BIE/&DZ5?[X)XLF/WUT>?OT<3@N[V@'-^75C:#@ MG8_6G#9G:7SZ:.6"\M'&R.FU4KGRCC#XWFV#E\_D0=4=X^YWQCTRQG:"\^-B MFWOY3J!*^]S?B]#@5%X_\:\$NLVWFW4,QRU;[XJ/(,3`!UD+!K\1UOL)U!V2 MTXBD8>4=0.$$E9VPS7[$3$@".^OCX!EE%]92J*,-RAN.P^&=Y>]O\#4=+.)T MQ2=QR@<#\+2>A/D@LO'^0#G,JZQ-Y+$%'C&6\.-Z=CEY.">#A3MQDR\&/WR\#=`@ MO&ZN;S=98G9IA0B<7CJ_X>%ATTW$G@'M$$Y1&P8)+ICM\Z82'\@[UHV%>1^A MJE_/K$VI$UU!H+S=9K]-(UR!K9@0V+9\]!9;,'1+G@>PW39KG[VVAAHF;@>U M$BJF?KEN+\"JYG\CHZW$>MUL(>8-.WSH5I?-%\"=U*.2>&+F3K3V#72L?WLO MXL7FQHGH69VQCW"(5:FU+B*QL24Z*&/N&N97-<<[NC1X%J/MP;[;UO;!X0(Y M1=S(@I&K3>W8%=E*0)V9$IK=`^OLLI>LWHI)[XVRR]"+ M8N&]Y$["C&2$*3A!]K=WOHBVIA`])W,81?=X/"5))2[(8$#'6.1_&T#P]B:& M]GHYT]@"+..[%:;M':G3&D0FT.G.UZZN::[2^(/#S[FP=/]I*R MV]O;@;AO+0E;)1O-W-MKU9)3):)\.)P\("GK)21Q*WYES>G>:4%_N+_][&EC M'5:IK+;*"]\NU)4-4IQFM/GXV6,^:YJ^M0H'.ZKDH?Y2F_O>RFJ?&B-+5Q`$-X*)4I/[BJU)B]>W>`R#[54%WJVO(D/?W;NSL'G!*5OE1M3X4-'I:9OL_FG%)JD46>QD7?B!XAYR0H:9=(LFK(R!,. MESWJ!)NN88TEPW['7A0(E&9@&R)"NB260<6][<>QQD26TYC'1G#9E`)@S!E1 MB(&V'&CA5-+4*]`]=.F5X3S*B_%$,[R2;18JWOPB0Z(KNEEF=Q$ M9ZK\A2WW0$(JSJZ@;J]A^I/-_<>[FWL'!Y%YT"-RT][G4I*^=.SX:YRMZ9XM M(*V/XMY%R*-PUD]W-I]RBIL/\BX>R*A5XV@!;[@W]/#T;%V>Y+A(CI=V"`&W M!+DR(NE`QQ6O->0[HG5R\]9>B#,2)D20D;MT$5PB90Y:_P#8Y?0/L;.)6#T= MQG0[HQ0[0==6GXH'5J%WR1(0H9RK)A?9W.CJ:EM_T`GJOX]$*"W!&VN9ZL2P M\2N8Y>U'+O7ESR\^U/8MP/+W$R7VY8\_Q-"BO'!,]4BY/=<8YB MI%/>_(IAB#V[G_S\<57!4=F"J6TG0>+*IX]L]E_.\>OSSN4WN7G3YQF;(ULZ MC27?2DR[E=1(MT&YA(U=_-G3G3V06'O71'VM@]W'S\N)/+%'-L4A]Y MS,^\N]JJ@%>$T*-W2RN1"P\@Y,DK_KJEG'58IAE^K/I=L_`N/M/LS^G9DKU2 M6F+&^)"M"!B3T!)HAJZQ;A:+$K#ZA%S'-6^Y9NM92=8_])E$*XJYU/$*^""` M+AGG9#P=PMG=LF8Q3MF\`#@-(XI"C[U?)1LGGL5+*X>.&V?6JT?V@6^;['[P M.IP$@@-N$2]LP.4+2#ZO1L%`\BYJ-U8=%^LVU-NC6]#(9.'8-!$A=`4W8`A%W2GO885&-Q&15-KC&59L!]7@: M37+VW]E*>J;/TMV[E[2D48N.<6EI^<-Q1]16!7\L4\$_)2K4BB@HPNMDQ)J[B0]V^;S<.1$79@:]"=Q3(M$$[NT%[)(" MF"YU\BQB"G)L'[+R!<*(SVVJ`NEM5I&5M.I,!T)2TK=<6\@H&-.W M6)(`O%7^REB0W?=.\WV,=(K>^LD*THNFF]FVND_8I$Y^3?F&:F.]>*^/&JZ9 MCBF)II.JDFMHT^S\YKPA%PTM`DJI"A,/P(MQM#E%?F[`N69*R#53SR5,6W$X MJEG>K:E74">?O+>42_((_3A]"%@,VEY0FHH;QRCWDBL*L;0,CY&&'(V*=MA) M/GZ>)]&$.#W6!C.%%MR#1=0'!.@($-55;QP-?]*Q+[!T;'"1M[S([ZL0I'I< M!JZMXH^UVH_MV!!XZ^V(K4\^"![Q(X&M,R8^*;9*'K!5T*G##>JN1;/P(?V!8+@K>+ M.R*MEX'?+8P.;TPLX793+YPZVA!Q]7C^EC8GNM;)@Q!_`:.KI:/L0$86ZJ&? M)BW3T#XNL'4(8-JWZ53)),8UW\Z;1=@7D/5[.K(I MWQZKT;U7IPOVO$05-==?%@/HR>@7U*=)_U/>B=?RIOD:5R$T)FWM8FM;<<,+ M:)>SBAXQ#CT<.@F>)31A73A['!^[Q!SYMVSUZG@,<9<$+(`V`>_^ MQIJMV'5RZ\V?[4S-OOH6.(FBK)EU^@#E`D481?B:AUI&=.:YG6K,4JL_HS2S M!2UCFV2G?/2T?T7&L.!AZ^P44!8^29>.EGV6NF(OL-:>7Z&']7NAH!Z:XW9# M=<@<4*M8(>1-[@%%'"_:7,'6=W81:QV`2,'`2\,-S#(7LAR.K)]@Q=D3(KZL MO'DF'H)MP1&REY86='D@3<(TE7[U96IW"#)HY%R]+]:)+"=I_0>H#85\"BR4 MC_FJ!B>?0='0[DZYQO/?(:;JW<3.N%.L,1[P"+OGN%-3<8WJA%UKHL^D)K(@ MJ<-N@O\!D%VRN1/X6?9TA$-EGZ\7$Y%"QT+IC1B"W&&UK%&2.V"(J'RN$`+: M1/O4N&Z"E'#:=W*B(;]6)&:G=X<#=D,G3T[#)L:*:F.V?,6'3Y%::^O2E\:[ MJJ6-/1MJJ7\DB%CAJ.H0AO*78?X+C)FM]R3><4L5_ALV[/3M3,MV5J317=00 M2]Y'YX)SVC(V)=@K"Y$;"'!Y0T:RV`9V)_7"K+LV8-TW_7N?YLU M;P*V0&.D7+K!KF9FXJZ(^'0XLMDVOS48A2*J/"Y%=#G15FH!?3X1=,W MXV_5D&:Q-A5%=6'5A.E#@DCY[8!*-Y%K:C9T8#A&VTL_F5ZC!S%C"3CS(8>6 ML4X&[VC.&?+NF]W,R=EF=A*23N:X M*E$E;TU-0:7,?H_N%7GMK;='6#O2-2QBRZ==CO["3OJ6J8DDB[U3^*7.W!T= M"9EH.=2?0_VJ_#T![9T9!?*5#YRD#RU$A;!Z22,@\D$!F4C5Z(A*A6`_8;9PICNS"[#]T"B:=9\L)(%_=35ZB*6HVR/UBDZ+7R[^_IRCMDHK[,],6MG&:ATW+3A=4<`^1Y7 MT"LTX:*3S`\(`T_S>AB6K]P*:FK@V< M3H3];:IVZZJ\I2W^OUX6_",8,X*5]D@0])KQ/[(/A83%J8@GS_A:_=L&<48; M<*1B:[<6)1&+?CE:*HW+S_\/X>>:80)X7^0`;XXYT\UHC6:VU(XRW1*-K1>< M:&X,NXG6+;CCQGV<>A/$V\`1S99@AM/,%)HION'$YBO%?:G.1KR+3M M<44DI]X]K+3O1>Z]#,$1]!>7OZO'K8J;V^HI?1#P(D4`^147-,1VCH M[TKFL7T#KE/GR.;ZE^^4,[RBAVW^+QWR.7R0`,,HXY8.N&[;<2MI4Q%W&L#G M'V(JAPMUN_+GLO_6F.UYI`$M36-\^63\O.6)-0#I@\=GEI7\Y;6=?=Y93R-L M)["#6)1^^"N/_/PCQ'7SX6`ET]WQ;6'E-!`H=NZNN+L]F^J_X"C9N0VVM&Z" M\;IGII*>:9RH*0^'A@7<7U_QQ<1HEM8/KPDT9(@37SG=%TOR:DX7"41B6N'K M"NFG:=C.Q>/6T>S9*HX0',%5 M_FFHVZP!]@?@._O.(3EH^&"(`:/(9@N@A*-!L,IEM">S%G14_8&S6\NGVT*3 MA>4A;^_S74IKS;-S1,G+_5S1) M;D"/RU$3.`BT[[@9[176321!IK>N?.#9CFU1+W^.0AH&*0^2-Y[$DP'@__?\U%3<>,V99J:I*%M2H M5%#.&R7NNR*VW3T2""O0O5!%J*0D.ZGQX%O?$9$.B`1+<.`V0TSP M@M/DL;/L;*NUU.B._8L=5P`+/)2-Y40DU.#T;&/1MD M7G'^AU&M'(X.;H![OL&PCH_9N3WK;EF)4\#N5LZ<3N_YM0&1ZBZ):4VCA;+, MA;)D>4FB$0^T M.=&!-FMOS.:=D><7"W@V7$,[]4#WE6%T='CU[11'EM'>S@%72B+$?#*5".R! M5=UHL32^O]+_O];&^5N3B83*98N)+UL3:^S[<3CEG*.S6:=9Z>B<\L%&%EHG MX2AX=A3TL_&].]7H?]%V+3M.Q$#P5^;((8@-RB)Q08JT6K028B6$^(!E.<(> M`GP_U2^/I[MMSR3D'(_=?J3MKJZR1?2*N)LUU@A)&:PRE!)4,Q.U-E?5]AH0 M1*U=VY5T=I+PY7&^-T7%Z44:VS3QO%JN;B8WL/*_&R!-YX@=>#F<]Q3-/-L5 M[+N[MUR8]A+4K>#$EP"M&[V%'QG^4I(EX2P%J3O.#YA0PKDNM\#JIMZF0`X5 ML0O"-[R-P$)1ACU-HAK.I(ORQ!:6M"L?9_U?G/`XG%]%(,>1=:W*^5ZU[+_D MOK`Y3"ACM:,O,V,/N;J6TZ-.E-NN`_@M"1-"?XM/-HQ/&?P0,%'G?86/.*Z8L#QV ML)UCSI-)&T+NV9>G,T"7S[KY@XT#8B?":9_O39\A4,!TJ4#ACO794'! M^3QP.$6S.$*%3RIA\%WZ!N"#,@(R<13/V<<2?(?U)'/IJ\'S\(BND&M0`019 MC@C=63XTO+4)JXC#MVKH#E1&O"#)?,4,N!?1^!LYB_N*CB(`EU//]&A:T98Y M"Q_"G@.<3@5`6Z+MT&2)XP%0_0)-B>F>J:-@]U^<"5!R.C0#IP0+BYY'+2IH M,P%SJ:"A;S3YBU$J=(&4^&^V>`3_[6B!6VAT,,_P]I"ZADQ'V9JVX,KD4I#$3S:@HE:MY"P3M,E<_?L MWUY-$%[F*?<[J]C?6QV^WTT?M_1MH>RTZ`$P!7)(Z\VO MO@;IE%+VN(U/<>9;',=5I@2LKV@2"/VN^>!49,5`:?PP9.-=]GII]&T#6IK3N+P.[,J3.GPR^8$#[Y<]ARDXLYT#ZK:U77]S\D? MMGO94I@1I'H+(V5LW:'=U/\OJ$9]PCT-:2`'S''*`2MQ-\W(W)O_RH MQ!9WR'7B[47.4EF/6FFQ9^-C6@MI(F@ M\P%ERE\]B5HI$%?N!Q(;$_H%CLHB[J2FM(7HBRY4<_A%1W%+4\Q!P.5Y#![E MW.#0]HFNUG@V`+0'VSRLD`]X\XNRHQE'"9&;R&Y99J)#B.,VBCT^\+XYEBN)G"_5/C8DLS-!F+Q M)\QM8TXFW()"L(XN\\#U&N1LQ,=26FH;(V>)TLY\ M,]_LS+Y(WWS_ZGO:%R?:NF$PTP>7?5US@F6X__$I""/[T0.HKP/37F:RV9L#\;Z[C,)MN(XO05PO7*_=I7.( MDLL&7F"!D7[/=X$FO-A+-)Q7SR.BR6R:(`S. MIB%>H3;Y8)*-%^MMLG\NL8G3-6K6=8K_.%W,BGJ[I.DZC(L#'YZB*^>*Z(F> M'F>Z94$.&?3[Z%9*6$?*IHL^Z#N;LJO1V2P;6D-K+-4R+A8/>4.%0TNF*QL4 M6N_'=V=SIWQE5=:E:?A)J/Q?@\L5G(3:]'!X6X3T?M<:> M"2=IKHMHXKI*=RX:$-%YE97=[:OH[DQA"4?=ZR)CR^Z5D;[?N3(V5$CZ?P>Z M6&+80L9P/2^?;0U-G(_`E=L;F/C%3A18\$9+7S^\;6`V$L`<%5--+_E>P[>? M(OMM8+!T(-9@&WKN"E$\+=@<*#5]<75O+>Z97H),%$6%4,M:C#L0>C^?+N0C M74RGLH4:%OQ(%OI^A#^2A5KPWT*:3].Z8/0+9/1[IJ5@D"1:P2!(I89;6P)R'SIST%5A`5]U6"0!&K!($B M5L>2,_!8.:L$@2)6"0)%K+(!N<2^"BOSBOLJ0:"(58)`$:O2!I]I!IXJ9Y4@ M4,0J07!N5K-IU>+^WF)+?XW!RU[6(OM=TQ*V26%'=*;'S^[R M!90EL^-\])M(0Q5=:<@SD8DC?'-L]L?FR+A*)E&)=2>K]IV5N_,/K2AD.Q$MQ#%E+Z!%LPJAG3@@T@)K*0$&PAP\9B5T341M)"S$;2 M0-!&TD+41@CVLLZ5>7(5[F"'?I]@RYKT^\G"L*B>>H$$>$G$E(,@;0[]V=BD MQ*.-;=K:"OGEH&_,#?QA(]822QM:'-K9T*#$RH86HC;R<9.QRPGG$FH)DCU_ M/:28)J?<(4\V1H33G?EYC:*)U:#A';E*K-ASTV'-LA0TL:2 M#%ACFSH2TWH-Y7_I>-YG+,C_6.=C`%CJNKUY79.#-7#N!4^>X+D=?`GKR>G+ MI-XG;\#'58V,RD::O=EX;Y]V_J,36>P(%%/!KN*Z=?%NS@8JQ?OWGOL4^`Y; MK-,3,3]$8>PL8W9$BVW.5.$95N`9I()$\)RBWZS0#WX2]L1DN#&BB@05V'1R8"F/)G"(`$%0CP\%SJ`PA/%0A@*I4A@``M M$`"GW)#>3?`N! M7K@9WM0`.$EE58I5E6(([=#3"A?`FQH76%!UY92\057.5^80DG0!0^$12`-U M'I$7E23G@LX"0+U'YA+'(20H,!6IA@!PE$`@1`P4U=\!Q:"H`M-H4%2"*02N M!I^Q3U`FN`JI"`/@4=(KBG'"@*L89W0#@:`J0Y)H,%2E2(I!58XLJ#!4I4@" M056&I$RH2I$4@ZH<2:A0E2()!/"(D@Q)F5"5(BD&53FRH`+O4%-"!8&@*D,2 M)H8=I\@>739-%E'I^NGTJ/53[77=N)`ZJ)HT`>]9\V3VE,P<@0LVER)3:;Q= MT<[63K7G,')_@4DFWK:XA,54)]+Q-M?87=(K7R-[\^"\PE0TV7=Z7>^M];+9 M9;I"+(Z17V;-L)X7.3BN>6E[S[>5WBP\!]L"NM;H-J)@:LXM4ILZK[82TCC9A>F>^6RQ\JM+">S$5<6JU.2$F&A"0P,,G"&D4Y@.HH:!(,O/HL<.6(Y*DK8ZO!?;.X+80[>\O=%NZ+FR<7T[V8.EGY M`,G`62"1!=/RMK)R)@V8V5)94-W;R@+U250,P5HB"VX\:"T+EC=26;@77]AH M0N%OBPN:I+)XWX\$?6^6\]R-!W^]G M5#[B<20E8ETBI>`.7A$?X3A07$K!&A_E0\$H3[`4?/'Q;0K&=R*E8`KD$8M, M^$#]=4]"[".N%P0WQ^PC(H(NG_=>'9@QV'TIN&QB5P<3_I(4-R?PC#W$2_! M@+PO7=?=BM,*BXF`8C/Y7 MK\4]MY,__5^/I[>W5O&Q:0_GUR80V=T,1W- M[RY&YF)^=V=-^T9_\5]P&?YU@FMXO/T)3_]G?Z4`CH8-S.NM!W\C($J-3<%_ M+J[-=/(F@<]NRP?8L'B4&=';YG\]X?9_````__\#`%!+`P04``8`"````"$` M^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8 M=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L M*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5Q MVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6 MF[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@ M>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT M)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU M)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P] M?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B0 M1D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q M*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[ MBV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@> M11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ M=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[ M^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]= MV684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A M5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[* MGC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*= MF5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F M%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D M,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$- MD*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%N MJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8 M[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@ MWA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[: M8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4 MX-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R M:W-H965TT\8<8);9=N,/%= M![V%OI]Z#2*MJQ3F[!H-NMN1 M$N>T/#:X%4J$X1H)R)\?2,<'M::\1JY![/'8W92TZ4!B2VHB7GI1UVG*^<.^ MI0QM:_#]',2H'+3[AY%\0TI&.=V)"![WJK15^@7P2?N/;=X0=Z^L1(]86T&*H-?9(=V%+Z**D/E80@V!M%W_<= M^,:<"N_0L1;?Z>DS)ON#@'8GX$@:FU8E5!1D)F$BE4I:0P+PUVF('`VH M"'KN/T^D$H>E&Z639.I'`="=+>;BGDA)URF/7-#FMR(%9RDE$IY%(.(L$H37 MBG@JH=Y?C@1:+1@].3`T<"3OD!S!8`["TE@,GRJ-B]5_.06+4N1.JBQ=F'8( MY]">IU6<10OO"4I:GCGK,2>U*)N!(@LH=?,!^*L;F*K%P)#=`TL77U`LW=?K MC1K2EV29_G#N6@&@??$3FN=NQHPT-BGYF&*)%&.&)F+8B4P[0YO>MB6#H)V: MBSBSDEPKCII96?*-#>0V4&B`D2,B,Q-(P?,+/0_?Y=@\DV?(7SBQ_BJ/UP`9R M&R@TP,@M-7.[K@$TFV_:5F]FO%T7I@ M`[D-%!I@Y):9N5TW)S+HO3E1'"U'&\AMH-``(T>XT(T"7I=D'V57TIZ4,TF- M2A!,T\"W*)OW*;E!29(P\7VS8W(GD25[_1QE5NT) M"%YZ%_2RZ]R%\JJR\'4PAPMTC.=R-Y*X=PF`U:1#>_P5L3UIN5/C'1SE3Z;P M5F%JN5$/@G;]AK"E`I:2_NL!EE`,]X0_`?*.4C$\R`,N:^WJ#P```/__`P!0 M2P,$%``&``@````A`+Q7;38U`P``D0D``!D```!X;"]W;W)K&ULE%9=;YLP%'V?M/^`>&_X2DB(DE0ET*W2)DW3/IX=,,$J8&0[ M3?OO=XT#Q::KTI>`;XX/Y]Q[\65S^UQ7UA-FG-!F:WLSU[9PD]&<-,>M_?O7 M_L]79-70U8H^G]B:C=0L4!U(1\=*1VE:=K1^.#67H4('O9V^.LIZ[ M6TSH:Y(QRFDA9D#G**%3SY$3.<"TV^0$',BT6PP76_O.6Z+ MI1MX`+<.F(M[(BEM*SMQ0>N_"N1=J!2)?R&!'1<2S[^6Q%&".G\)$FBW8?1L M0<_`(WF+9`=Z:R"6QN9P53(&J_]S"A8ER9UDV=K0[+"=0W6>=O/(VSA/D-+L M@HFGF##0(?L>(A,H>9,^\,IKL*8]0E8/+`V^(%EC7V\7JI(<*Y#DBG$($FGB!&)9B?XB!T)AC*.U4<+75RL,*I79:KW9B`Q`^DH MH&F#!UV?:@F&[A]I"US7T*8PRZZ/_&CN^4%HR-]KD&6X]`-_J;,D&B0*PC#R M(AV2:I!P-?="_[4E-8_P2ESO48+U_`>NT;>QPHSR;P82,Y".`IJV\"/:)%C/ M_SPRVC)6F)$V,Y"H@*I0M(JBR"AA.MJA:5U^1*L$ZUH#][4^W0D1*\Q(JQE( M5.#238O%I!3I:(>F5<[NT='X_A$BP:96XT"(%>;=OM8@;_?U&!*XH>?[GIG] M,<1_NZ_5J%.CH,;LB/>XJKB5T9,<8P&\>T-TF+!WOCPAC7CLK>'>X/'U.[?P```/__`P!02P,$%``&``@````A`(O57IN1`P``>0L` M`!@```!X;"]W;W)K?'3")-8!9VYG,_/O>BX$!IZK(2\+'\;G'YW[@W:?7 MLO!>N-)"5C&A\X!XO$IE)JI33'Y\?YI]))XVK,I8(2L>DS>NR:?]'Q]V5ZF> M]9ESXP%#I6-R-J;>^KY.S[QD>BYK7L&;7*J2&;A5)U_7BK.L6506?A@$D5\R M41'+L%53.&2>BY0_RO12\LI8$L4+9D"_/HM:=VQE.H6N9.KY4L]26=9`<12% M,&\-*?'*=/OU5$G%C@7L^Y4N6=IQ-S!Z3![I-Z)+X^UUCT+^"7_7@VM-G>?VL1/9-5!S)T-A!I!3:@&]OL[9'K%-(`L>;A"EE360`%_'JEP'H"&]FK52!%(2+[UH(\O_+(BV5)8D;$G@_]J^C^9T&41W<"Q:#OCO M.(*)'+[=4V/7(S-LOU/RZD&Q@FI=,RQ]N@7>7WL"9B#V`<$Q@6:"[6I(S,L^ MV/DO8'W:(@X6`;\]@HX128?`[(&&7@@8,UT(@E$()@N5'>R#8=S0B6L18:-Z M&=+%N_*1#/!@*`-K90%E^GM?<%%,EH-=+\;1#Q9AJPL%)X,'H_A`,HS_^[@( M!GV#N$LGKD5`F?;Y6(T128=P\P%KI@M!\%A(-`YSL`@KY/BKTDDZA"LDND<( M@L="UHX0BXC:.@@VCF.)?=]D:I28]3TR$#R6\=&181&K1D884#.V:XL9J7$+I!ZTT-N MU-PU6*D=DR,U;BNW&%23[V>S:(:S-,>OP2R\,PJR-T;6S3G@*`V<7IK+,QQQ.7RF@CF`&PO=V]R:W-H965T0"P)&`TEV1YJ55JN=V><0#$2=Q"A) M-]U_OV4[%[O2#?2\`"F?.JE35;ZQ^O):Y,8+K>J,E6N33&>F0KOE0T.0BG(K?LVA^)?,D[;C%PXB^R-**U>S83('.DH&.-0=68`'39G7(0`%/NU'1X]K\2I8Q M69C69B42]#.CUUKY;=1G=OVCR@[?LY)"MJ%.O`)[QIXX]-N!F\#9&GG'H@)_ M5\:!'I/GO/F'7?^DV>G<0+D7H(@+6Q[>0EJGD%&@F=HBC)3E$`!\&D7&6P,R MDKR*[VMV:,YKTW&G"V_F$(`;>UHW<<8I32-]KAM6_"=!A`?5D]@M"7BT),3^ M-(G;DL!W1^).Y_;"\Q\(Q9*R1);"I$DVJXI=#6@]"+R^)+R1R1*8N_1(,7W" M/LH7:.0D7SF+X()4U%#DEXWC!BOK!0J3MIBMQ,"\ZC&NHT-V'83GCO.&G6'P M(;I+U"$ZEU@:X+-_C>/->B<+9/?:H2Q8NP,-]GYK=%*YDR[51C%MWX'T`0A= MNS'"G>N0<`RQ=40T1F"2>`RQ!Q8M%\ZOY(([K+-:P-N%XV"8O4JPQ'?UE&XE)A`=/"'!T#>R;&@8>8?:\,)#$R#2 MA_VA$((\EL,B49I(6#0>%\G!2&2`7K25&$^(M&<^%BF'AX*%M_$1QL<:WG,7 M?8XU6;#8/"Z+@W59CH=E2UQ0&OZ*0.^D*?0\)E!!%(#:$TB`%3AR'H)TLP@ZQZF![\R&E MFB`"VX]:L]LKFD#K4@A>5K8M2(;J^(Z'5JU="QC4AO=FCD-X>,I\U_7P;5C1\]@J2+B7WJ2C M^=9B5%G2:["$+:;M8WN&YFPTXH@UCXGM.A_L1(3OO)_7)?=KK5[XP+`5U&NS MZS?7#E!%=RU"%2J)/_:)1CXQ>H_6UWH-^>:L:+W3DW(KUS7B?9??IJ#`\M#T MSGFB'5<5WO:(1A[\AJB\8WRFD-<_>;$I:'6B.YKGM9&R9WZUL^&HTUOEM7-+ MEG#;@!F`["%9PI4"[%8_`+?!2W*B?R75*2MK(Z='H)Q-/0BIDO=)^="PB[@7 M[%D#]T#Q\PSW?@IGWMD4P$?&FNZ!OZ#_)V'S/P```/__`P!02P,$%``&``@` M```A``3AX.[>`P``IPT``!D```!X;"]W;W)K&UL MG%?;CIM($'U?:?\!\1YP@^^R'<6,9C?21HJBW>090]M&`S2BV^.9O]\J"G!W MV[%)7FQ3G*HZ=>WVZN-;D3NOO):9*-XZ4L5E M&N>BY&OWG4OWX^;//U9G4;_((^?*`0NE7+M'I:JE[\ODR(M8>J+B);S9B[J( M%3S6!U]6-8_31JG(_6`TFOI%G)4N65C60VR(_3Y+^)-(3@4O%1FI>1XKX"^/ M624[:T4RQ%P1UR^GZD,BB@I,[+(\4^^-4=)=#W&]L'">=[>;A MRGR1);608J\\,.<3T>N8%_["!TN;59I!!)AVI^;[M?N)+2.V>F`E]K)^7[^)2K;^+\ M-\\.1P7EGD!$&-@R?7_B,H&,@ADOF*"E1.1``#Z=(L/6@(S$;\WW.4O5<>V& M4V\R&X4,X,Z.2_6('@5AKBHP$K9$0V+?O)]XXF,SF`ZSXQ*@) M\"E6\695B[,#70,^915C#[(E6,;(0LC/[<@@)-3YA$J-*J`EE.-U$P;3E?\* M*4Q:S/8:,PU-2'0-83W"!WX]20A=)WF?'()M;A/`EC`PGGT`@8F(KJU< M$`8W2-IP;@A&;M@BF,DM">:](.H0%V9A,.^Y&9['O^(9P6L7/ON(PV#1VR4R MA*$&1G:1)C`\0]/J,0]K&E2"YM(9A".+`6'@\\(RO/1$PS+J,#BP>I-,?X<4 M*MFD+H6FM!"&C:C1F6O#7HSD][]'D:P3(PVICWI[@%Z=Y)K9&8WJW%BCD8PWP]8$&[T9SD MJ_5/H+9$$VO0(]:]MJ>8X0(N2LO3FP&K0+C6J,K>[?,FUA MMBQ(,IXWIPA<(_N58F;DQD8=,+`W5NK8.E:W<'^V.X0D/:?P<@(1*;HOTW6R MX/6!1SS/I9.($]Z%&8322^F>O@V6<./!D>]?P#6YB@_\2UP?LE(Z.=^#ZLB; M07?6=-&F!R6JYE*W$PHNR,W/(_PAXG!-&7D`W@NAN@=TT/_%VOP/``#__P,` M4$L#!!0`!@`(````(0"O'@H3M@D``$XS```9````>&PO=V]R:W-H965TS0D\9=VI=7JG-UK2M,6 M#9"*T.G,?W_LV$GL]TF!,A?3]L=C8S]Y'3\)X>Z/7]O-X&>QK];E[GX8C2;# M0;%;E4_KW?_6Z?JN:WK:K<[K; M+O<_WM^^K'N::UG8&P?[(OG^^'WZ%9-X^'XX:XVZ'_K MXJ/R?A]4K^4'WZ^?_K7>%=IM?9S,$7@LRQ]&*I\,THW'T)K51^`_^\%3\;Q\ MWQS^6WZ(8OWR>M"'>Z9G9"9V^_0[*ZJ5=E1W,XIGIJ=5N=$#T/\/MFM3&MJ1 MY:_ZY\?ZZ?!Z/TSFH]G5)(FT?/!85`>V-ET.!ZOWZE!N_V]%D>O*=A*[3G0+ MUTD4?[F3N>M$_VP[.7L$5ZZQ_MDV_O((])JHO=`_NT[BZUDTFW_!C!O7B_[9 M]G+V/")=`/9XF$IP7L>CW+I9L>5@^W.W+CX%>@?KX56]+LYZC6_,> M39G8@]H6SF=UHPO&]/+==',_U/[HDJATL?]\2*;QW?BG+M"5TRQ0,T]"2=I( M3#F:?K,&=/U&89.\431-6`.Z)O1M>"-IV@@+;.V:]Y44*`^,M76M?[K"`__Z MEU=CDU$;FYHW7EB@.V]](ZZEJ)A/0PLRE)!.Z'4\_Y9'K5OD%=?0NKL6=' M4Q8I!1D%.06,`DZ!H$!2H#P0S%R//BB^\V9N6FF'@IE?DYE;C3=S"C(*<@H8 M!9P"8<%-?;Z(9Y/Z7S@02=LH#P1>Z"WF`B],*^K%33B$A=5PD#R31]`84S"JZ8\(I$!1("I0'`O?TWAJX=WSMQ MC2X=*[&FS8PC=,*I5733R4XVR6D31@&G0%`@+3@R,.4U"3S2$2+PZ+S59EH1 MKV;DV"^L9GI=E]A\E.3?R.DPM0K/K)--%D[4>9$"R8#D0!@0#D0`D4"43T(3 M3/#T5]:9)MB\JC?+-EABO(FLR#>!D@PT.1`&A`,10"00Y9/0!),&+S#!AL@P MZ=#=/;*B67WNI2O&O6B+%[?D[%CC/&@\QRV?M:V;RP$.1`"10)1/0M],+.\/7IBKC/H9$`(H$HGX1NF.CX M!3=LT@S=(%<[B\B+H_4U0PHD:XFW%F?DDBAO14TM,"`:IQ6;(T)?NTLQ>.9D[37K#ZFHB!9(YXBK`[%?Z']FCH14#PH$((!*(\DEH MB\E_%]AB8V-H"TTUD9/02`"10)1/0E=,\KO` M%1L80U?HQ6;DI4KG"B49:'(@#`@'(H!((,HGH0DFS%U@@LV`)S9C+R@Z$RC) M(DIR(`P(!R*`2"#*)Z$))J]=8(*->4$E3,ER7T1>%G0F4)(YC;M:FHPFI)QR MZ(0!X4`$$`E$^23P).Z+JE-]#CR^X=;-:%2E`<6)O%,ID,R1UA,2=W-HP8!P M(`*(!*)\$EIR67"-;0(-RP0L:6*JN=%,:BAU/?0&NLR]:$^<];T;HM[\NR<5/_"B?R3#4VX6:OQ\NRF&.!9(Y\O@!R:,.`<"`"B`2B?!*:05/L"3-ZTFL" MIUV:5=.8D@Q(#H0!X4`$$`E$^22<_&5A-;:I4]?ID9LF3N2O$`BKH,F!,"`< MB``B@2B?A":8L/CUG!;;C!ENP"1B+9S(-X%&TPPT.1`&A`,10"00Y8A=@O!) M4FC+9?$U[HFO]'/EA1/YMD!\=9K/HQIMP:!7#D0`D4"43P)+S(>E0:4U#HGMW@63N1; MTN389I/,G*:U9$)N..70"0/"@0@@$HCR2>@)C:,F;YSA24\LG=/[1`G$4B"9 M(ZTG$>DDAR8,"`A)S25GI?!DIYT"A?!3N3721-8NSJQI/6$Y)8< M^F!`.!`!1`)1/@DM,?F.[C=GE(F-A7H^W:8[H\DCH=DQ!9(YTEJ2D#O7.31A M0#@0`40"43X)/:&1],PRZ8FF4_#$BNR>5]\"#.^=IHDOF.(';UD@B&>]E\.! MYJ;G0PPGZ*J5`Q%`)!#ED]##KR79I"?)PJ?+3M0-.@62` M;#Z\H^<>FF*SDVURI^BL8$`X$`%$.F)'ETSP#I[RVP1F3;^6A&LY3<+T6LF) MNFFE0#(@.1`&A`,10"00Y9-P\GW9UR3EXQ4SM2'V^%6S$_DF0/8%30Z$`>%` M!!`)1/DD-*$O[)YA0D_8A1U;/^YO;B;9YQT3W$O30%`_TT075A9*)E-8>GFH M,`\MT$Z8DW1'@P,10"00\_V%]NZ8==%^'<$^8;XM]B]%6FPVU6!5OINO&DSU M0Q8M;;\&\;W^%@3AB^@VK9_')CR+;O4CWSH'$\ZB6_U8M^;C]@7];8:WY4OQ M[^7^9;VK!IOB60]A,KK2L6AOOP]A_SB4;_5S\(_E07^/H?[U57]OI=`/_$Y& M6OQ&PO=V]R:W-H965TMNO-R\=S[V)R?K9Z>=@\KE^^?3S_]Z_1OV[.S[:[^Y?' M^Z?-R^KC^9^K[?DOG_[YCP\_-V^_;;^O5KLS4GC9?CS_OMN]+BXOMP_?5\_W MVXO-Z^J%4KYNWI[O=_3?MV^7V]>WU?UCG^GYZ=*?3*XNG^_7+^>#PN+M&(W- MUZ_KAU6P>?CQO'K9#2)OJZ?['?F__;Y^W2JUYX=CY)[OWW[[\?JOA\WS*TE\ M63^M=W_VHN=GSP^+]-O+YNW^RQ,]]Q_>[/Y!:??_`?GG]7GS[T%?2?]>KG5OOWV?;[ MYF?\MGXLUB\KJFV*DXC`E\WF-V&:/@I$F2\A=]1'H'D[>UQ]O?_QM.LV/Y/5 M^MOW'85[3D\D'FSQ^&>PVCY0C9+,A3\72@^;)W*`_CQ[7HNF035R_T?_]\_U MX^[[Q_/IY,*;3:[(^NS+:KN+UD+Q_.SAQW:W>?[O8.-)I4'#EQI3EOF=&;7%Q[D]OI]>&,E-I[37\[2CS2[2LI MDXN9/[^^>2^@GHJH:()<[#$.JVAX]`_.>93#%,#!88ZD[QT324^%4OR#"]WO M[N70>_K.&-SO[C]]>-O\/*,1CN*S?;T7XZ6W$&*J&P[-:.R8^_HE=4BA\EG( M?#RG_-3GMC28_/[)G]Q^N/R=!H`':7.'-IYIL506HK<+V<`&H0TB&\0V2&R0 MVB"S06Z#P@:E#2H;U#9H;-#:H-/`)85GC!'UA+\C1D)&Q$C5[IT"6M"L@"@+ ME26P06B#R`:Q#1(;I#;(;)#;H+!!:8/*!K4-&ANT-N@T8`2$QAQ*SHN\&&1B%5TTL@`9`02`0D!I(`28%D0'(@!9`22`6D!M(` M:8%T.C%"0=5Z0BB$-8UT-,9S+&"&%M5OQ`9C[/5D`"("&0"$@,)`&2`LF`Y$`*("60 M"D@-I`'2`NET8E0\;:",BA<#TQ7ME0ZW?)'+#,!`AFVQ6"@OI8DY+/GFW!4, M1M,Q:J$SUW3,9;@NMG2&[X=][LU-IQ72^BNB`%&(*$(4(TH0I8@R1#FB`E&) MJ$)4(VH0M8@Z`YFQ$#L%?=?V3BR&C04M>]1\=.<-2._"B`)$(:((48PH090B MRA#EB`I$):(*48VH0=0BZ@QDQD)L$O18]#MH_]U.+B`1D]&U`@,VI6(:((48PH090BRA#E MB`I$):(*48VH0=0BZ@QDQD+L+_1^T??L"=%W.HC MK/2>[+HT^S_(:((48PH090BRA#E MB`I$):(*48VH0=0BZ@QDQD*LQO58_.5-J2?7]=R:[B2RMJ57XWC?GZ8NV4JM M`P)$(:((48PH090BRA#EB`I$):(*48VH0=0BZ@QD1DXLY_7(O=.+AM6_T8LD MTGL1H$`5`?G:YM4#%"`*$46(8D0)HA11ABA'5"`J$56(:D0-HA919R`C%F*->T(L M>G-S1ZB0UB\0!8A"1!&B&%&"*$64(>(H9Q%I02F3-+=?6W,)6X]R"*$04(8H1)8A21!FB'%&!J$14(:H1 M-8A:1)V!S+C9N\?#B?0^!"A0&=DJ1!0ABA$EB%)$&:(<48&H1%0A MJA$UB%I$G8',6-C[X'Z]/[\0'^EX)RRX)?8'-+T:SUR6B`)$(:((48PH090B MRA#EB`I$):(*48VH0=0BZ@QDAN6T+;&/6V*)>!&P!!(`"8%$0&(@"9`42`8D M!U(`*8%40&H@#9`62*<3L^K%9M.>5;RA1^R^KQ]^N]O0-$-3AJ-[3.GZ=/AL MB/@LE3VG#$B/B")\KS:SSZ^ET)1,Q\LW[YI/M?KB0K92,U&$*$:4($H198AR M1`6B$E&%J$;4(&H1=1+U56H&46S.,8BG+PWD)I^#=N?#OG_)B&.$@1SR36DC M.P;2]V[,)44HIMC92%;J6>*4"M&E'!&3=ZW[O)3ME+R M&6KEB`K.J,M;HU7)5DJ^0JT:4<,9=7EK6=ZRE9+O#"TSX.*T`4>*?@%TPG`O MSRST<0*.,98^H$`B&MZ5KR&B"#/&B!+.J->.-:&D;*5*S%`K1U1P1EV>3V%E M]QZ>47N@"K5J1(U;WAH?6[92WG>&EAG;TPY.?#PX48@/HY<*\6`5(`H118AB M1`FB%%&&*$=4("H158AJ1`VB%E%G(",6T],.3GIS<_R42"S<>&3TK9%QJ:QH MTARM[*DQ8"/5BD)$$:*8T7[UA(V4>HHH0Y0SVJ]>L)%2+Q%5B&I&^]4;-E+J M+:+.0&:8[3,9QRJ95FUJF3S%HQ>):"LYQL^?6JN6I332%\48Y$%;M_&NK>82 M2B&:'\3GM[UK?V(-:)&P&#VQ"XF/<"1QV(`CZ;N.9`<=R1V%V,X6A@*X4$J) M*0V#XP/[$VLY51DB=A'U$6XTA@*XT1[E1F>(:&Z8K?&TDZ8IGC1)9`XZ5A-9 M*J/#8\X@3DM/U;-"SJ=0A"AFQ&'1'KB?=A,V4E(IH@Q1SFB_>L%&2KU$5"&J M&>U7;]A(J;>(.@.943YPAG7\$FZ*YUD2&4/1Q%I/+:61/LS8T0E&&_6`H21R MW+FYFEM+\$@8C+W0%HQ'P?TVR6BC"DW?*S0[6&@^"NXOM)0V[XTAAQZN/J*< M]JAR.F'EJD2S^9QVUB9V9M;.3B%ME MH%2**&,II9XSVJ]>H%2)J&(II5XSVJ_>H%2+J&,I4C=C2MW1V-6]LPP1YM9J M4R(]IA)I*W]Q+"KQK645MHD&S#B]@:+CE!:T<*V?X]O?C.WUCV1TM%71S@N M2Y=XDD]4/DH9AR(H/WVW_$SI'"H_5T9!@1!UIS3`[Y@Q%-3*K-AE)*0Q&JQXSVJR:=(5^>Q?'!V]T4CN>6B`)$(:((48PH090B MRA#EB`I$):(*48VH0=0BZ@QDQH(ZNA&+HV^5Q<+1GHD'1/U>-:BEM-)0@"A$ M%"&*$26(4D09HAQ1@:A$5"&J$36(6D2=@8RPS$X[@^O-S5611-QIED`"("&0 M"$@,)`&2`LF`Y$`*("60"D@-I`'2`NET8E:].(S21R>M1QR_1Q73L]4[)-(C M,AC1RG1<;\`T)'.1NV*Y,_-N['O!D"U4KXL0Q8@21"FB#%&.J$!4(JH0U8@: M1"VB3J*^.LT`VD=)0P!/OE&FMP\@A!)IZUAEI9]U8Q"'?&)*'".--\I2BJPX MD#(C[UIB9453X*AE%Y@H(Z-`N^6D;*4*S!3B`G-&^PLLE)%9H'VCS%:JP$HA M+K!FM+_`1AF9!5I;@9:M5(&=1(X;Y1F=03AZ_ND-1^A8H[%$>L,!%/0.T#<% MZ6T);Y392CU3)-'P3/WR-4:4<$:N5Q]NE-E*R6>HE2,J.*,N;]\HLY62KU"K M1M1P1EW>OE%F*R7?&5KF2&&?)_VUH1Z/F682Z>$&%$@KVH\K7T-$$6K%B!+. MJ->.=0*:LI4J,4.M'%'!&75YZW2]9"LE7Z%6C:CAC+J\?:/,5DJ^,[3,V(KS M'GT:/[S)F,GC(8[%G4*\`5PJQ(-5@"A$%"&*$26(4D09HAQ1@:A$5"&J$36( M6D2=@HFH0E0SVJ_>L)%2;Q%U!C+#3'/Q*6$6YM8T M.2":&^5?6Y74D+$9/[)84'^%(XK`!1])W M'Y49GB&ANF*WQ MM%.F&9XR273X1ED9'1YS!G'ML#OD?*JS18AB1AP6[8&'&V4V4E(IH@Q1SFB_ M>L%&2KU$5"&J&>U7;]A(J;>(.@.94;;/K]Z9YO'0:B8/K8R&;RV]_66VJ@2]QF"`ZO:58[29N7VX]I>6_;V* M.7U)9`X8]L>4ELKJX(C!1JJ.0X5N9!W;DY5*UVL(VI0R.E1XHHQNQXU)*I$X M=!D;+%1_QAG9RG8A5T:'7"C82#U_J=">YZ]4^J'GKY71H<(;9<3/WTIT^/D[ MSNA\?K,5VN>,AT,.X7T MF$HK;=.IK!B%B")$,:($48HH0Y0C*A"5B"I$-:(&48NH,Y`9"W&^IL?BKXWR M\I1.#]&`]`@-A&V"N2+'PCJ8S M1+0:-IN2.+L[U)2.^W`"?5\]#.$2Z8UI1%R;FF-R"!^,M$\BA%)=0Y$JD-5C M1OO5$Y1*$64LI4*2,]JO7J!4B:AB*:5>,]JOWJ!4BTC\=$`?BKYFAE@//P4P M?/OX\^KMVVJY>GK:GCUL?HBO^;\1+XR.>/@-@KOI[4+D.^]?.#G>)1.?3%3HYR M/%(;/B<#>6:4TI]F0\H5I?07_I!R32G]71:DD&_#!_&L%/I5A\_.YQ0NNSP6 M%>/B]""N6OD\6WRFT#L>?4X_)^'B]'3.AZ-G0MQ5>=*F5***Y1T9T`I+C6ZX:,Z M<*70+Y*)U>TU48I;B\IHL42G&I!3./ MGL?9R*F<.V>>):4LG2D!I81.W^B2D5)V%N(E^]0C=Z_6XA7Z3"%WJ9;B!?C,(7>C:/1P96R MG%*?&Z[=K`&(/NV[$!_<137Z[.Y"?`P74^B3N#3:N%+H=6GRS34>T%O3"_%J M):K1J](+\2*T*^6:4ERC#KV122DN-7I_FNK`E4+OH"[$&Z98#KU53G7M2J&7 MRQ?B?5/,0V^4+\3[XJZ4:TIQ>4VOJ5**2RWPY_0\KAJE=_H7=\X\]&K_0KRV MBQX$E"+>UG>E7%.*RS=ZVY=27&H1J8FW?%&-WO5?B)=],85>\*>Z=GE`;WE3 M2N_!Y=@4Z7>$7N^_K&ULK)O;;N,X$H;O%]AW,'P_L24[3BPD&;2M\PF+Q>S,M=M1$J-C*[#= MG>ZWWRJ)%`^_[,2#N>ET/A:+I9\'L1CJ[O>?V]?!CVI_V-2[^Z%S-1X.JMVZ M?MSLGN^'__LC_.UV.#@<5[O'U6N]J^Z'OZK#\/>'?__K[KW>?SN\5-5Q0!YV MA_OAR_'XYHU&A_5+M5T=KNJW:D%M7ZT>FTK;UY$['L]& MV]5F-VP]>/O/^*B?GC;KRJ_7W[?5[M@ZV5>OJR/%?WC9O!VDM^WZ,^ZVJ_VW M[V^_K>OM&[GXNGG=''\U3H>#[=I+GG?U?O7UE9[[IS-=K:7OYA=PO]VL]_6A M?CI>D;M1&R@^\WPT'Y&GA[O'#3T!RS[85T_WPR^.5T[CAKA'HSTWU?M#^ M/SB\U._1?O.8;W85J4W]Q#WPM:Z_L6GRR(@JCZ!VV/3`?_:#Q^II]?WU^-_Z M/:XVSR]'ZNYK>B)^,._QEU\=UJ0HN;ERK]G3NGZE`.C?P7;#0X,46?UL?KYO M'H\O]\/)[.KZ9CQQR'SPM3HOM7:^0(5ZT35SB94/3HY$S% MJ:A(/T7%V=6-,YY/;JCQ,_6HM(F:?HIZSNW5[?7U=';[0=%@I/]T,7[B MT1S9>_R?KN)G>L&A1VEC51W_V7YP9-?S?[I63X<[:L=M,PW\U7'U<+>OWP>T MMM#3'MY6O%(Y'ON2$Z#5N)L2IV8$307V\H7=W`^I>VFP'V@:_WAPYM.[T0^: M>FMAL^BQ,2V6TH+G&;OU;1#8(+1!9(/8!HD-4AMD-LAM4-B@U,"(I.WTI4'Q M3^C+;EA?JQ MR:Y;"*)U)A`?2``D!!(!B8$D0%(@&9`<2`&DU(DA&+V5+Q",K4W!6N+2&J9U M[\R<(LO.2.KL`PF`A$`B(#&0!$@*)`.2`RF`E#HQ-*0=S04:LK6IH2#:H`/B M`PF`A$`B(#&0!$@*)`.2`RF`E#HQ!.,4"'<.5[R!/+^8<$53NY9,9FKU!>(# M"8"$0"(@,9`$2`HD`Y(#*8"4.C&TH_VLH=UYP=C:%*PE;4+"&Z6E#7P;!#8( M;1#9(+9!8H/4!ID-!-Z M!XF-*7LQQ6L#<;#!15K+!5"+58*;0Z09S M::0WZ(X=L\%"6BX!\SH>IK\T),[\U MGRA05O*)0H&T01(ABE5%I2H=GIGN$V4EW:?H*T.48\4"46E4-,7GG; MRLE3.K;4@ M9=+J7%AYGQ&$50@KI9/55BG=Z!%I?6(.'\Z5].EG#Y\_ZK=3FP=]6HJ42Y^6 M`NG3LD-*4"TP<935&DU4O8#S:5XA%0H%HGDA!VRDT&GO,;I*$*7*E?2>*73: M>XZN"D2ES=[@K$OOC0\60S:W]FP"Z:\<0+X#*$`4(HH0Q8@21"FB#%&. MJ$!4&LC4CY,P73]M-'\@)=>TI&R1GFTY@'Q$`:(0480H1I0@2A%EB')$!:+2 M0*:4G)/I4GZ@7YO"T="6,V9!;U^65)$E$!](`"0$$@&)@21`4B`9D!Q(`:34 MB2D99VBZ9-KHNR`18R_62&R1KJ0DIQ7+?D?GTDAO$),P924;+`6B M'0HALQ_[D^D+DS`^FK4FCT1Z+T)V[0NK#Y(P926?*$3W$:)8552J8A*FK*3[ M%'UEB'*L6"`JC8JF^)R"ZBO7^<7>%4FL6I`6$JG]V%(B-;A\1`&B$%&$*$:4 M($H198AR1`6BTD"F?I%V9:T.A=6WF<$817"2NED M_46TE&[TB+0^,P3[>2=C7RV0K9\XMG* M4VV:G:3Z35!V\IH8$>0\];2EBI M('+IGD98MZ:"!H6P4AI8;\E2NM';US0P!P*GZ><&PN=.`-TVVS=&@D#Z!.N0 M>CXM,/$.:HVTX[Y`>-=0*!M4WB.%3GN/T56"*%6NY/C,%#KM/4=7!:)2N8)E MC;K,Z(T/=N)L;BUK`NGY#B#?!10@"A%%B&)$":(4488H1U0@*@UDC&::$Z9^ MO*RYUU?T.KWPIF;CR916(,ZCNMGICJV_U"V5E1PZ/J(`48@H0A0C2A"EB#)$ M.:("46D@4VT[:3\_6FFC8H]6B;31BLA'%"`*$46(8D0)HA11ABA'5"`J#63J M9^?=S6B=\!7ZWML:ZN^@M!T'*5M$^8@<=TMAI2$?48`H1!0ABA$EB%)$&:(< M48&(/W'@QVX?J)6R_62AO:N]K?;/U;)Z?3T,UO5W_ASAFD\_.]Q^*[&8\,<2 MS:892ESY&85=ZN'.S.,_5/25D"LZ=^\I<><>+VT])9,Q MQ=5\H6&UOW1G'N\^L0YM0#W>2V();2>IG;X2^HKD2_,1B=7*@@3KU8ODZK6? M4+@]+7^9>E^H"S&DQ;5'MS9[.$7:%R@=4WI\$(8UZ&S2X\,O+*'#1XJVKX2. MJDC$OKCHX(E$["NA8R3RUE="!^\>'V%C!`N*8'$B@K&W["WQJ4Y`QZ;HC4*JPP>36(?.DST^G\02.D3V^(BXK\2ADKXZ='Y,ZO25T%T>CV^+H#>Z MP$/J])70#1T:97TE=)_#XZL9Z(UN9WA\T0)+Z*X%>>LKH1MJ%$'?D]*U*V]Q M(@+'6_:6^%2'+U1A!'2QATKZGH=N6]'S])70I2N/+_&@-[IIY?$]JKX2ETKZ MZM`E*U*G*1EU,YJ^RGI;/5?%:O^\V1T&K]43+9/CYIQ]WW[7U?YR%'_X_UH? MZ7LLV@C1-R_T_5U%IPQCWDX]U?51_D)!C;HO^A[^#P``__\#`%!+`P04``8` M"````"$`#+9,3;P)``".+0``&````'AL+W=O8=S!\/[$E^10CSB#66=@%%HO>W6O'41*C;2NPE$[WVT^5 M2(J'7W;BP=ZT.Q^+15:Q6"Q*NOOSYV$_^%&>ZEUU7`V]F_%P4!ZWU=/N^+(: M_N=;\L=B.*B;S?%ILZ^.Y6KXJZR'?][__MO=1W7Z7K^693,@#<=Z-7QMFK?E M:%1O7\O#IKZIWLHCM3Q7I\.FH3]/+Z/Z[51NGMI.A_W('X]GH\-F=QP*#6R$DE.YWS0T__IU]U8K;8?M5]0=-J?O[V]_;*O#&ZEX MW.UWS:]6Z7!PV"[SEV-UVCSNR>Z?WF2S5;K;/T#]8;<]577UW-R0NI&8*-I\ M.[H=D:;[NZ<=6''8<&>63S#=4_.Z&@:SF^E\ M''@D/G@LZR;9L-]7A?T+(DZJ$DD`JH=\>)1]/;Q;3Z62VF!.[,-),]J1?-=+-Q)_.%ZV=%SK2A-HAZ5=VG'VM(^VP MMB/]JA$OSO!6RM/OE;9Y%#7M4/P?-=;%28Y$%+1!%6V:S?W=J?H8T$ZE=:[? M-KSOO25K4^$D'-0%V+GXHL!B+0^L9C4DRRET:MH4/^Z]^?AN](,">2MEUCTR MMD2H)#AJ66WD@M@%B0M2%V0NR%U0&&!$;NE\0UOD_^$;5L.^45:M%=#.\AU' M*`G5)7)![(+$!:D+,A?D+B@,8#F"MCDX(J!@Z<\Y*B:XUVI(.]V("<\V="UD MO#9?MDL>`HF`Q$`2("F0#$@.I#")Y0(RPW+!9=-9FG8492C#=G<_2*';=KL$ MMF/"KK%?@S4W&N:*N;%T.S<57&M)C$4`$@&)@21`4B`9D!Q(81++4,KE5QC* MTK:A@OBTWXUE)Z3\$P&)@21`4B`9D!Q(81++=CJ.KK"=I6W;)3$6&4@$ M)`:2`$F!9$!R((5)+$.Y4,43Z8:/^\N;CCO:-@L2S+K4&P*)@,1`$B`ID`Q( M#J0PB64SE0"6S9<-96G;4$%$N<<'9^B"R`6Q"Q(7I"[(7)"[H#"`91]7%I:! M?[?,8#VVZ:UJ0D9@:Z3W^<39YI$4HE)="WES)PW'6DIE@T1K5RC52.MR!\RT M*BWDS:=VWL^UE-)>:.V$;+=RY7)FKS2ON^WW=46)CH1ZXBF@8T?6;J+^H=-* M#;GV)#*="BB24@'M3".?3FR+8BVEU">H/D64Z8ZF^IFM/M=22GUAZ;(=QA6. MZ;`>Q]`UJ/.,*(@LST@4=,X*/8ETA1U9UI(:<\1%1:R7<55 ME^DJ3E.?%[J4>R`K"40NZ7SAS1>NQX20Z59T&,IX\UM;42PGX,_;4G+BS1:. M1,(2W4S<05+9_])$LAX9F$AN3R18W$Z<@K\X-Q%['6@F/>O0U@!7Y#76XAP6 M`OFF-Q80R%+HT_<8$Y+U? M"`7BJ1-7-+$'*)&(]K.R/]7HO/8,5>6("JV*M-M^X=KU"K_(4M?,J!+IF8>> M1.8I`BA&J011BBA#E",J+&3;S+6K:;.HX*[=DJ("IB!4*[;V9%%L;0>G6`NE MD.X6`8DED4DP6`1SIU1(6*+;4UBH4VH72LH,7%G>*+8E,OTBD-T_$]V'N MJ%&,*$&4(LH0Y8@*"]FQ0$G9LOEOW6+X+'%=(1`G-!WZM^XU1G:DN%77GT@C MHR,\X)%2ZEH_AJ<*2HUYZ+CQF"HA/7RFT87A&M->#G:1?7 MX%OU1N'2^]":DJ=Z-MNJL>-1(2,>-=+VN7Z)I%"@^\6($JU*+5ZJT7GM&:K* M$15:E;M/:8/;_KJYO#=`"$B")$,:($48HH0Y0C*BQDV\P%JQD3G]@LBV#C'.=W?92W MZ?*C%C5$%"&*$26(4D09HAP1?RZHYR5L%I__B2^U#N7II0S+_;X>;*MW_K2/ M`N/^KL/BN\-UX-.'AZUIT!)02YO7?1U8_M0UI%?T^"] M\CPTN]N1?Y@L'\AL;%A/E_3]1P^?+>G;B!X^7]*G!#U\L:37[3T\X.\S^TP( M_?&2G_E@'WKL0];UM83^E/KTS9;SD5\,X M-WI+2BU]]M![8UJKOA9Z8[GDEX^HC=X_4I^^%GH^37WZ/$U/FZE/7\N:9L"O MDG&P;YN7 M\I^;T\ON6`_VY3-MJ7%[S3J)[VG%'XVL0QZKAKZ#;4N25_KNN:2W$>,;NC<^ M5U6C_N`!NB^I[_\"``#__P,`4$L#!!0`!@`(````(0#0$!,^!`8``&L:```8 M````>&PO=V]R:W-H965T&ULK%G;;JM&%'VOU']`O!]CP'?9 M/DHGXY M?4O+_(003]DQ:]Y%4-_+T\6/?5%6R=,1?;^%HR1M8XLO5O@\2ZNR+G?-`.$" M6:C=\SR8!XBT7FXS=,!A]RJV6_EWX6(3S_Q@O10`_9.Q\')L_R_.O+-L?&HQ[C(YX M8XOM^P.K4R"*,(-HS".EY1$%X*^79WQI`)'D37R>LVUS6/GQ9#">#N,0YMX3 MJYO'C(?TO?2E;LK\7VD4JE`R2*2"X%,%P7\W[&-EC\\VZ7@P&X]'D]D466W/ M0%8M0'A(FF2]K,JSAY6%NNI3PM=IN$"TMGL9HYXU%6/K8$.JTQ MP]=U.(Z7P2MP3Y7-O]'TKN!0=D8): M"UH0@*(%C:XNF18C[K3R1P9&(S/AO;0)1UV1&UUB@()`>@WNY=KFYL:8,&J\ M,2!E-!?SHU!T2G<$HS2D^7QIW%B4ULU%2300=(F1:=(G$S1*H@&@2PP`0HQ(1^!V*F%MYE*B*+KL+$-D9N-$I.']039) M6]ABH[O+1*2((#&C2'16%A*<@CZ_)!1A MZ4CH'*:0T$4F$KUX+;2)38D(L\UINU>I+>S%;<*:[#>=RU2[NLALES.,!BX? M_&@X'Z"\OGO`IKBPHR^-XR9#"D5G94V^%\N%-LVU(IT,KA(=GQB%(IK'_.C9 M%PL1RIR*$IF[8!(2+"Y6%`ONJ%=WFP^$-2G`)L;6RN8#D+61C2^+>/8E*&QJ M%,%7/H&"GGHN5A84O:@QLJFQ%6G+PA`9.R0BU/@!\#;_B0!HUSCJ3,@1?7.Q MLMKE7*5MT0\*4,RF\1]?P/SYK[>KB\QV"?^)MY)P-+B\VWSZS22RR5&)R.C) M47QSL;*PZ$6.D:(]'0N="24YME:.7>`@Q_`+QX/(ID8E(D#0\^_%R@*B%S5& M-C6V(GU17*7&F%#C[24HK$WR42*R!^AI]V)%VXU[L9^P)@78[-=:V7./'>SW MM8>BB$0J<1T,)_1@J!RQ/BPH>K%?;+-?*](F;X@,.HA[L9^P)NVJ[%?;+-?*]+;O&:[?(`HGJ\.30@?O"JY-/#!:XU+ M`ZSQ3N'2`&L<]AV:"%A+6K&J!M9REU%-"!]<43BBA?#!=8)+`ZSQ-N_2`&N\ M>;LTP%J>RJP*@+6\32`:7,G?N;/`P96#+P&7G"\:A_QNM+AS+W14Y-Q.F*-S MC)BBP`1"B))4259[5ZF5JNJN?6;!2=`"1IAL=O_]S=A` ML$U73=27)V MQ=NDRI*"571MOU%N?]K\]6%U8 M`VO*I(7;YNCRNJ%))A:5A>M[WMPMD[RR)<*R^1T,=CCD*7U@Z;FD52M!&EHD M+?#GI[SF/5J9_@YGR\[%B3?)4P'._DB!) M>VQQ8\"7>=HPS@ZM`W"N)&H^<^S&+B!M5ED.3X"R6PT]K.TM6>Y);+N;E1#H M1TXO?/3;XB=V^;O)LR]Y14%MR!-FX(FQ9PS]G*$)%KO&ZD>1@6^-E=%#3.QN+G0E?:'&0](FFU7#+A:4&/#C=8(%2Y8`ULL@$09A?J4+"((@ M6T19V_!NP!-S2.;+ALP6*_<%$I!V,;N)BWT=@WH#>P!'4^0,<$04Y8BZ1 M]*XW7$G[&J$^0B<$0HT)3==,KPT&K^U`T296-]K)&!(,Y/9CBR(&`(WWE@ES MHE^6;D\#UT&2(>Z=''5!\RN/L47A`4!C'N]K@,%B\T'\SN++8E'EV`_.::X* MC[G*`_4(O-@!\XTUC$`JQ\X2C24+/(WK$*07"2P;"X3$_,#';G(K,T12F746 ME1G1F`U!.C,\P_1WWH^Z@)*)5;;U+)!1JY:Y3!;JJ+WY51(GLPM`G80[;) MWJ22"W5RW<((%RHO*-':]_N=0D1KZL@V3*ZM>]]'"9.ZF]:;17^,%G<4-^E: M\%B*SJ1*,=>E&*(,*2::]R*^IR7`4:$7>&]2R44ZN6[A1)ZPZVIM(8*/BIO; M%9XQVLO7FU1NVA?"_AIE"(==5N-&/*B+&]L",9M\;U*I:0?T_AIE4(.%!K4[ M.P-":;7?F11VH7X&D2'*8/?'>CV\?@:YH9&/SNE0/X;ZA1,5-]7O_?B>DC/[ M/0P/@J^JG'X47:,&Y>3((#^22]H%9@$?T+\,3]Z./X?'`(^8:PX/CDI@M#(\/'A^[LN&9@6$1'U#PPKVVG=X$%4WL`KU#;>`==)JI"3R91` M1B83`OF83`=D0\RA[K`QS(%U&PO=V]R:W-H965T&ULG%E= M;Z,X%'U?:?\#XCT!VR&0JNEH0C6[(^U(J]5^/%/B)*@A1$"G,_]^K[D&^YJD MH7UI&]_CZ^-SKP_$O?_THSQZWV7=%-5I[;-YZ'ORE%?;XK1?^__\_666^%[3 M9J=M=JQ.'77^Y?J_JY.4C9>I#AU*S]0]N>[X*@R0^RS)IY=98G MB.RJNLQ:^%CO@^9I M6/K!PWTGT+^%?&VLO[WF4+W^5A?;/XJ3!+6A3JH"3U7UK*!?MVH()@>CV5^Z M"OQ9>UNYRUZ.[5_5Z^^RV!]:*'<$.U(;N]O^?)1-#HI"FCF/5*:\.@(!^.F5 MA6H-4"3[T?U^+;;M8>V+Y3R*0\$`[CW)IOU2J)2^E[\T;57^AR"F4V$2KI,( M8*_C?&J2``EU^WO,VNSAOJY>/6@:6+(Y9ZH%V1TD[C>&-(:M7MLI;%$E^:RR M=+E@$PV4Y_L#"^/[X#M(FFO,!C%P(@R&(M(>H2H!]`:.L'&7HX`27A:_IZ0F M44J.TO;"G"9,C;2;I!##:3TCBU!LC* MD&;ZR@H,S4=67CDK(V:%962+E:#QU([/5B(QS`DO:&R;E^JLQ=4CTU=-37*4 M82%=?X,82QEK@#!84@9OUT2!'668VS"(B3IEHMC1+271A`^L":>8?."FSP[-$ M7&EZIBS6(OCV4>S0M*7$B!>:ME;.M@"M'(GSE3FK5#EEM=.)H3';B@G'-#?J M+0K.*A*S"J9ID:BQ8TK*\?F)Y;QD^.91IAL.0;V%"CX M_HV*HE_3(SE2KC=U];K9O2$P:X2N_BYK9Q>\G9N&T,K8YCY+EK'3<:G.@M+- M>,R,`5-NCL/?4.:"M;NG;,,0A$M#+SO<4Q(7(C)QPHP[!O\VLPY-3R'CKK-K MD#Z&L6EH+*`3-B9,>7W(YCGZM7T8&3?^@U75(,OFAQ'UY+GVX.&.Y=]0ZH+5 M<],=F@F";";]2/<,9%>KIBS6LJAI;L#1F*DZ1G_-"4&ZI:-DX=A%JK-@>1>) M.1*T?N]R=X[.3+S`>B71S!!DJV6-T-4="Y^HS]C*&3?[TRQZMQX<27V[!7?7 M_IG`EXGAO8*2,GBC0:ZG`C29L6<:J>@>$PU"BER$[K5-2@`LB2)SDBA'YQDPK=("39VX MF_56C)76(,O=[!'*0EFTY?YO&XE`0R<'U:W11H.TD5C?4['-AK![:R64`UM4 M)@J"ODT%,9)K01!D"V*-4$$5E;&&.`:7R+I.' MZ]S1E_C1UQH-LH7`:7A[-7H;QPM>O``M9;V7J3P>&R^O7M3E+8.;BF$4+Y8W M<+'#..'MCIW]X]/50LWNMV? M![C!EW"7%\X!O*NJMO^@>F?XG\##_P```/__`P!02P,$%``&``@````A`*VI ME:42!```#`X``!@```!X;"]W;W)KZ_G[(-!%>R,_1+".7C M0YVJFN2N6T:M,Y87M2GK?G/W\EL;1J\3>L\+5E-M^8[ MY>;GW6^?-C?6O/`SI:T!##7?FN>VO026Q;,SK5(^9Q=:P\J1-57:PFUSLOBE MH6DN-U6EY=CVTJK2HC850]!,X6#'8Y'1B&77BM:M(FEHF;;@/S\7%]ZS5=D4 MNBIM7JZ76<:J"U`@`(1=J.AQZWYA00)(::UV\@`_5O0&Q_]-_B9W7YO MBOS/HJ80;BOR]KPUW>5\L;)=`G#C M0'F;%(+2-+(K;UGUGP))10.)TY'`M2,A]IQX]O(#'&['`=>.P_$^RN%U''#M MQ<#?B2)`KHP$7'L'_,F;E]UFN/9/GAQ&2Z5$9CA*VW2W:=C-@&,#0>>75!Q" M$@!QGUJ5B"'9_Y=K2+(@^2)8)!>DD4.!ONY\LK%>H::R#K)7$&@)=XBK0\(G M$$^'1$\@"QT2/X$L=4CR!+(:(!9$9@@/5-LX/,\KOH^"`*,H.`.M#-1>0=;R MD(C(A=@084.,#N9V"N,$D0@CRC,H5J_NQIA0_P+ MAF2T09,"_62Z%`'&4G`/49B%S,V,>.CDA_VR>`.)H$?8$&-#TAM$R](8-2&K MCP@18"P$MP&%44(<%^OH5P<=O4%X^0"/^]4>GHP,F@PQCXUZ_<^;F0!C&:AT M]@IS+YU0&?I:<]?VO:VJC.`=,38D(X/F/+PGISLOP-CY>_]0K5AA.E]=#QV; M4"W?M44_Q\<8GXP,FA`"\]=T)1*-I:""V7<@U:J=U=I#80]U`&IY$5IU/!/UC$E"TD0!F@D=[3`(8#1[M"7P,2+LU/`!F\4MZHG^ES:FHN5'2([AFSU?0 MMQLUS:N;EEWD^')@+4SA\N\9OKHHM%)[#N`C8VU_`P^VAN^XW0\```#__P,` M4$L#!!0`!@`(````(0#YOY9@/1@``&^-```9````>&PO=V]R:W-H965TCSS[S=1!`@"AU5V=7KPY?=T_WKQ?/WW3=)^?3\\G3_ M)O_Y\OGR]?O+[O[C/M/3U\OYU=7Z\NG^\=MYK[!Y^16-YT^?'A]VP?/#GT^[ M;V^]R,ONZ_V;U/_UR^/W5Z/V]/`KOCV__WHN> MGST];-+/WYY?[G__*M?]K]GR_L%H[_\#\D^/#R_/K\^?WBY$[K*O**_Y]O+V M4I0^O/OX*%>@FOWL9??I_?EOLTUWO3J__/!NWT#_^[C[\3KZ]]GKE^N#M*C(7,SWU7AX_BH5D/\_>WI474-:Y/Y?^[\_'C^^ M?9%_W5[,;U:SU5KLSW[?O;Y%CTKS_.SAS]>WYZ?_TU:J5H/*7*O(7ZVR6%^L MKJ\6LQ-$%EI$BIT0.5+Z6F>4OSKC[<7-:K5O]^K27*V46)F[/5--(S&0X-1QH]2^4W)O#^7 M_#+,7F4&^>>'^>+VW>4_9=0_:)L[VLQ*#U`>9 M#W(?%#XH?5#YH/9!XX/6!]T(7(I[!A])K_]/^$C)*!^9UKTS8.0TSR'&PF0) M?!#Z(/)![(/$!ZD/,A_D/BA\4/J@\D'M@\8'K0^Z$7`<(K.)XY#I&Y49&\KZ M_;G,*W9L+*_G& MQ'&%-.L)KE#6,M/)U&Y]@7E*&]WNI[%KUU';(7&DL+3SF%,W*>:$NBGK?=W, M8+O39-0I0`*0$"0"B4$2D!0D`\E!"I`2I`*I01J0%J0;$Z?AY>9Y0L,K:[?A M>S*7^=AVD^78T MO%K9+6[4#DJO?W]Y<:>47*?TQ!L@"V^`#$;#``$)02*0&"0!24$RD!RD`"E! M*I`:I`%I0;HQW&UZC;QQL/3&@;4:!@)12!01Q40)44J4$>5$ M!5%)5!'51`U12]0YR'6/V@Z-MZ;'!\:LWSW)VLZT\IU!HZ%!%!"%1!%13)00 MI40944Y4$)5$%5%-U!"U1)V#7%^HG=`)ON@W3HXO>C2?#^[9JFB.S&4C%!"% M1!%13)00I40944Y4$)5$%5%-U!"U1)V#7%^HO=`)OM!;I_&X&.^F]H&6K0J0 MJ?N*'2H!44@4$<5$"5%*E!'E1`512501U40-44O4._^ZMT5SN M1:.]QLJ_A?09Q5$!5%)5!'51`U12]0Y MR/6%VB&>X(M^0REZIGO?J;BZNE^XV_*U/U0&*Y,QL!D-"HDBHI@H(4J),J*< MJ"`JB2JBFJ@A:HDZ![GN4?O($]RCMYUC]XQWHGJH``7J&8<_5(`B6L5$"5%* ME!'E1`512501U40-44O4.O0$=#Y7QGE0/%:!@ M!A02140Q44*4$F5$.5%!5!)51#510]02=0YR?*'638XO5)1KOKJ0&_*)3S#W M2N[V7B/OAG/CW7"LE;F[!$0A4404$R5$*5%&E!,51"511503-40M4><@UW.G M;>^5$]1]8S2*#+)[EBU10!02140Q44*4$F5$.5%!5!)51#510]02=0YR?>%O M[_NW`"[4JR?'HRZR>8=;>K18#RNWK;8:H8`H)(J(8J*$*"7*B'*B@J@DJHAJ MHH:H)>HR@V8($("%(!!*#)"`I2`:2@Q0@)4@%4H,T("U( M-R9NT_L;^[_X7LR<.WZ#QM.6MI(_0Q#`?]X8Z'R+L=%\Z;UD$UHK*6&!L MT>$"$RMEC>8K^ZQ[OW!)K94I,+/J!N4662W_"@LK98U08&FMC'IEU0VJ+;): M?H&-E;)&\Y5W@V^ME5'OK+H@M^.H4,!XZ>>W+E;IRU1H)'; M35;>^R:AM3+7%%$K)DILQG&3><_&4VMEY#-JY42%S7A$OK161KZB5DW4V(QC M>6\,M=;*R'>.ENMP/Z[Q5QW.@(=Z"=!W.%"@K<3AIK8A442MF"BQ&2_865HK(U]1JR9J;,:1_-KK^JVU,O*=H^5Z5\4F_A/# M6<=D=%VI0AMTY7Z1^_;E\>&/NV>Y^4;9FR).B>CZS45!*'73M_>ZV"*;?Z[>8\LV0[$-H6_9@BTS<*^1QL2 M18.2::YX((>U$PJE1-F@9+3S@1S6+K3-4C8)PQISOO96<@UQ>G!6\6#-YHI!;2H^[HK32V MQDI6/8.5W]4":V0Z4:B17(#Z*<+B^G9V=>5U]`C)2 M)@;&\N1K_S[NV3)D?K$(^R!^V*08;4X42I`*I M!W)8N1ELC'(+THV)VS=."WDM&/+2R)M8O#W&UE@=&T:!-3*7$AHD:Y^A_>=K M;XT;&:OQ2)[=>!-0;*R.U2&Q1J8.J4']1#*_N%K?CO^'::5O(W5?':KLSZ&Y MT3Q6E\(:F;J41!51;='A*C36R*BW1)V#W*ZC@FA<*9ZXOE=Q$^\Y@T;NPLE; M(&^UT?'9IM>V"\[02(^'\WSM>3!25H/K)OJ1D;5&OG^3H7JF;5-;]/X6>7'C ME9HYI?J"^2!XN-!BL#&%EB`52#V0P\K-8&.46Y!N3-R.HN)HXX[RD_N/#KM9 MM]W))F[?2<8+R0$=KG:@\\FMT=0[)(JH'EMT6#VA5$J462E3A]RBP^J%-3+Y M2J**J+;HL'ICC8QZ2]0YR/6I3%RG^%29>YL#C<8^U6B\.0`*Y:G67LM:140Q M44*4$F5$.5%!5!)51#510]02=0YR?:'B4^/Q-7J:^.N!EH6.A8V'78^\6[NW MSM[JC!+3,UTI(`HUTCN$Y?+VZM9_EA*9;,?NG+$QLL4E%MD>/[$?T%=C]@,+ M;Q61&9ECQ>?&R!9?$)4&]66M+Y;>1JLR!L?*JHV1+:NQZ,BEMMK*;,?6*Z_X MSL@<*-[M7BKN=*Q[_>/Y^Z$XWC@^H,-7X_ZET7@*&)"]/O]>&$@L2,T`LC0Q M/2XDBC22EXF-56S18?6$4BE19J6,>F[18?6"4B519:6,>FW18?6&4BU19Z5$ MW?6U=`C'US^Y52MS;UK7R+;Z=J&1G;`#HI`H(HJ)$J*4*"/*B0JBDJ@BJHD: MHI:HNR^75]<+ M/RH0*9MA+>V/Y!B:R4!L+D[EVDAVM?U:>N%M-[.CI>9#&69P%2"E6\3ZPO_5 M>G6TB!J"S4".7%BKC72++M9S?^(^5*K;<_QHH;\@^+49>\DHHD&CT6V1O3#? MSX$V&L_81)&5,HZ)+3JLGE`J)JL ME*B[OE:AN?'=^?B,O53FWG2@T=BG&HUF;)/1HI`H(HJ)$J*4*"/*B0JBDJ@B MJHD:HI:H_],13/3'R7=0C=R%^[<6WMCKC>"%.%&JDUX;S MV\5LMO*"*Y'))C?N(W.WKI1=G28FG^S0AGP3L[?.:!;B5WZTU<@<*SXW1K;X M@J@TJ"]K)2=GN6\35\;@6%FU,;)E-18=N=166YF%^,S?!W1&YD#Q;O=2<:=C MW>L7I_4^?#5^HK[4:#P%#,A>'Z?UWLB9UH$BJL<6'59/M-%(/27*K)29>'.+ M#JL7E"J)*BMEU&N+#JLWE&J).BN%:?VTF-F2,3.#["L16Z*`*"2*B&*BA"@E MRHARHH*H)*J(:J*&J"7J'.2..Q5P\L?=7SO98ZEC5W99?:>1>EE\F#/GU]Z# M^ZVU,OTP(`J)(J*8*"%*B3*BG*@@*HDJHIJH(6J).@>YKO-#8S]9'3$&MM1H M/(R``EJ%1!%13)00I40944Y4$)5$%5%-U!"U1)V#7%^HJ(T_C&:K7_C1PU(' MA<:C1H>`[!UYJZTD3FJ'"*Q"6D5$,5%"E!)E1#E10502540U44/4$G4.^=5CV3Q.RK-"UQLM9%MRT`3=7L:Y;.Q:[>6I^T& M5]P-:N2UIK=!V!JK<6OV6EYKVN6V6T^U!1C/!3]IS7[',%ZRKGKDMJ;_:$(; MC5NSSR9W#!4YLD$OMW9J#7M"[?HEKU,[C49WC1500!02140Q44*4$F5$.5%! M5!)51#510]02=0YR?7':0GC%A;!&\K,O7&3HG][^2ME1D]`5%(%!'%1`E12I01 MY40%44E4$=5$#5%+U#G(=8^_V/W)4.$*=Z71>*@`!;0*B2*BF"@A2HDRHIRH M("J)*J*:J"%JB3H'N;XX;86[X@I7(W>/[K]?N+56=JCT6I+1H)!6$5%,E!"E M1!E13E00E40544W4$+5$G8,<]ZQ/VP'LS=T=@$&CH4(4$(5$$5%,E!"E1!E1 M3E00E40544W4$+5$G8-<7_B[G-$3C.,SV)H;'HU&&_(M44`4$D5$,5%"E!)E M1#E10502540U44/4$G4.L!\1)_\>;MUO/,>;1(/&TY:VDKWBL";#4Q>= M3[UO.QC-;[R(<6BMS*TG(HJ)$J*4*--(S@(T\KE%MEY^Y0LK98UFUUZTIK16 M1KTBJHD:HI:HTZBOO.MNM4NGNT]\Z6:M]_IVN-T99-MK2Q1HI-Z[';G6:YW0 M6IG6B8ABHH0H)/6-U^>WQDI\.6",C ME1)E1+E%A]4+:V342Z**J+;HL'ICC8QZ2]0YR'7S:=&0-:,A&LGR:/`?7EG5 M-N-[)WW<2X]M\()2:`KK7R^=^4NK2*4/U?"+B'^A&LF$#:J1>M7P"\J.5B.? M*,)7*"9L4(W2K<;RUEMH5D>K44\4X5>CF;!!-5JW&@M_R=@=JH;;$?U0T%]; M%3!"M-:!GO&:'"_H&:/CLY!6LH_60I.O?XEMN?`\$)ETR7FD6PZZAXT2HV0+ M3PWJ"Y_?>L_8,I-^K/#<&!V[\L(:F5FF-*@O_&9I'R?NUS*523]6>&V,CA7> M6"-3>&N0?G?PU@N-=R;]0.%.Q[L^+#7`:-%AT6'79IH(W&OX$DBJR4 MN?S8HL/J":52HLQ*&?7:K)Y1*B3(K95R26W18O:!42519*:->6W18O:%42]19*5%W?>V'^GXR M?3.F=XVHV)8H(`J)(J*8*"%*B3*BG*@@*HDJHIJH(6J).@>YOE!QMG'8]2>^ M4.;>\JA'WB-:+\JV50=L2\;1\]B`*"2*B&*BA"@ERHARHH*H)*J(:J*&J"7J M'-2[YW+T`?.GWOKVKE1?6`J924I^SNJGVU5I2]AL5Y+F6E.O)/#>2LE]'(<^M MI-Q.Y5E?R?7L/]GAYYG/-^HT\8FZ+:76\L;F5(K46MX^G$J16DM\>"I%:BTO M\$ZDK*1%Y=VYB929E"-?GYE*D7+D6RA3*5*.?(9C*D5:1SX*,9$RE]:15XBF M4J0?]`/-;[>9Y)'O$$[DF4D>^2K>5(JTM7RC;2IE(2G[VRK*D=;I'PT@1?S3 M/XKS4GZ;;7Z;+D4R3)6NNL`4ETI-U>FWY>:W`QU=/#DE)'Z<=*-X<=*)XL-) M%XH'IQRX7:\W*@C-AI4X]$:%E)DB4>6-"A`S16+$4MVIE.WU;*/V*,PCVY2- MVG$P138=&[5_8(IL(>3RIU+D`>-&/?)C'GEB)2E3@T6>!TJMIU+DN?3"//,>0&DRE;)?SC?KQ+//([VP3)%?PV[4#UN9 M(K]ME0EC*N5.KE0]BF2>K:2H)Y),"21%/0&>2EE*RE0>>3PL?6F+_LH@W*.4PGXTZEXFR&FK:7R M68"-.J68=9-O`4BMIWJ('!HO*5.C1`XXF4[:2HH[O9JWE`QPR2J9J+=][<]>>7G\K()+^B`6 M??;1[\]O;\]/LB0^/_NRN_^X>U$&LMGX]/S\9OY#+O'RQ_/+'_LU]8?_%P`` M`/__`P!02P,$%``&``@````A`,AR@56=!@``1AL``!D```!X;"]W;W)K&ULK)G;CN(X$(;O5]IW0+D?0A)H(`)EK5UJM9G>O MTR%`U(2@)#T]\_93C@^Q781I1GO3-)_+OUWELET)J\_?RO/H:UXW1759&]9X M8HSR2U;MB\MQ;?SS)?BT,$9-FU[VZ;FZY&OC>]X8GS>__[9ZK^K7YI3G[0@4 M+LW:.+7MU37-)COE9=J,JVM^@99#59=I"U_KH]E*GJ].4,?G^SIFG&M;LO2+XLLKIJJD,[!CF33A3[O#27 M)BAM5OL"/"!A']7Y86T\6VYB+0USL^H"]&^1OS?2_Z/F5+V'=;'_H[CD$&U8 M)[("+U7U2DSC/4'0V42]@VX%_JI'^_R0OIW;OZOW*"^.IQ:6>P8>$"HT[_1S6#S[[?HO9;/JTF,/H=WI.64_X MY+,>S^83QR*SOM,/6CMOX9/ULR`NBYDUZ_R]T_.)]9R+GO9X;DV6SD]F"ONL M&Q$^Q4QY>.\,MV3=X)-U6WXDHA;D#UU.DDATK>[.TZ3IT&67E[;I9E57[R/8 MLK#BS34E!X#E$E6>5W3.(M.&$@TRC*@\$YFU`#GP=!#H(=1#I(-9!(@$3PB)B`WG^?\2&R)#8<*^V'$C! M4D.UXQ:\BZ<#7P>!#D(=1#J(=9!(0`D$;%PE$+MN;CRIMHQ(BX"(AXB/2(!(B$B$2(Q((A/%43B4'W"4 M6*N.4F+#/I>6Q=$B+XQX?#Q$?$0"1$)$(D1B1!*9*+[#1?2`[\1:]9T1:9$1 M\1#Q$0D0"1&)$(D1262B.$HJ57P3C_^\(1U5GREQGOK3!1$/$1^1`)$0 MD0B1&)%$)HK/<.TK/M]WE%BKCE)"ZSUR8>YTX.G`UT&@@U`'D0YB'2024/PC M%87B("TOND5M3T7VNJU@1\*^O.&X`^!0 M(3>Z-Y_HEA&:3\RMZ'R6,VU?)+Q]8#[J;T1=]+GB&;0%&E`N%W+!-)&SXD+$ZI)9%R="(:J1AF95(_^2N M(N9:2!F2[RJ!AMWQ+&KDT+=7I"[R,0H8@NW)O0Y[-*P>8:D8HZ27`G4U+J0" MEC/P)W%A!;.\U1GJ9[ZS&)+O<(1\;!5@%&(4811CE"A(]9E4P++/O[;K:!T- MV<=7;&M1!*<>1SN.^NK?ZU&_KNB6])F5,^DN#\N9:P_N`9<9.&?8(<=FU`\? M\7Z0EF*?HN%C;?B9K=6E"9<9&%X-.!C=#?B7ZCI4>,L%))'1-B5#O!PG4D[?S\O1,N\/N:[_'QN M1EGU1EZF0ZIM5@*+-_W/-DDWC6_)+P"WN.W"B[4;]HX+KYTP?YZZSS!1W+"= MN?"*Y`9_WP).,2YY3<`L\/+CD.0"W MP*,`Q.-6"QQ6T.?6S.#H@3Y=BRFB"[]B7--C_F=:'XM+,SKG!UB82?<(6=/? M0>B7EF7T2]7"#QA=)`6ML'1Y0VMX MDW-1805#GBM;*D@A:8@7Z M9<$:V;%5Y"UT%19/I^:.\*H!B@,KF7HUI,BI2/SE6'.!#R7L^R688])QF\$% M?<6(X)+GR@4ZSPJ]W//:6WO`M-UD#':@;7<$S1.T"^)TA;SMQOCSF]&S'/QW M9,'/GP3+OK*:@MF0)IV``^=/&OHETR&8[%W,?C0)^"Z5YR]/E!)P%"@<<.%9B*\!`'PZU1,5P88@E_,\\PR521HMG07D3\+ M`.XDP,C(%B(8:;J^MP9!A*,P;"6I! M:Y._]<2*_N5UAI$T6.;MTC382.OSTD8&)@PCHY66XY5,]8:1"_AW%K`F&JNP MD1!JAKOA)?`\7@&F7TW@8 MIU?QLQB.RR7/;A[OS+&?\BSBU'3V:7P9I\LK//LH3J-K\55[47D]$5P4#3[2 M;U@<62V=DN:P==^-("W"7C5VH'@#GL-UP15<$>9O`5\$%-J3KW.8&ULK)S;O%5F.5;$LEZ1,9MY^&R2;(/"3M)S9&]/^V/C11`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`ID4*T/EM(R99PQ)J/';+#ER/ MYJ[!3*-8J'P1,O=#*D_C]$PST!^?)^;DT^@/FC6VE9#O(&&%%XZAC12/A_Q$C(B!AQ MZSXPD$$SM8"P!1=9Z6"M`UL'C@Y<'7@Z\'40Z"#40:2#6`>)#E(=9#K(&T`) M"$TP2D#:;W0\-H3U_9"FF'ILF(N9VM`/I0W-0]S22R`K(&L@-A`'B`O$`^(# M"8"$0"(@,9`$2`HD`Y(WB1(*:M8/A$)8TTQ'LWP=BXDYU6)1&IDT&FLC("\8#X0`(@(9`(2`PD`9("R8#D3:*$AUKZ`^$1UD5X MN%$?*M(8%T!60-9`;"`.$!>(!\0'$@`)@41`8B`)D!1(!B1O$J7A:36B-'QY M7[\1:]K^V4H45&-0DLE#IP-=!H(-0!Y$. M8ATD.DAUD.D@;P"EG6G9J;1SHZ]?GO?;[P]'FLAI.F]I_PFM59G(.\+4VW!M"I-)C3*&O>.._7>L:Z->)JS@3A`7"`>$+\DTN6`@71'=SFL M5:2-N5BH+D>U$;L<`TF`I$`R('E)"I>5H-*F\^\'58BH02V);*$E`WGU>@NM M2I/I;;&O,<>&MGA;U^>Y<6P69>`PZ*[%K57$[HEJT98E7GV>17T691`PZ*XE MK%6J6K1KB>KS+!JS*(.$07!*XW8`T_SX'9^:TY,;>O@<[D^#P(VZO,@E$;L M0:1YL)C,YPM#F\UC+M?G0<)&?1ZDTH@]R#0/YG=38Z[G@G(NU^&!VNW$-OP# MW:[9.H415;^@]$M M:GIM,M%69$NVZNO&*S9:U%/5ND)3FK'J3F..Y^I49]^:;<@GAAH*\L*J9.,E@-?5D9]D\R:A9H-VM+S MFO=0['*E?WWU>%?5XPNK>@#H]0177$]8V\A>57IG5BOJV0QFX[BWVJ26['8M MJVPFO;:(K1"S45HC;HO8B52E215/KTMAM(:D5TA M&@;HN2GF(?"G%ZH%$W>HA2D6(8BG%ZHE$W>HI2F6(]9"N9X5PA6E?HG=U%56%STM$G30?% M742>5E_'7N**^@(4#Q%%:GV3\=PP30-N]E?4EZ!XBBA3ZS,[]@G]]:F]2*22 M^GK1[\-A(*(5HC4B&Y&#R$7D(?(1!8A"1!&B&%&"*$64(
22FF%Y)Q9EZJEYHS+U;-02R`K(&H@-Q`'B`O&`^$`"("&0"$@, M)`&2`LF`Y$VB-KV>C?JEK(")2:H*R37ILB;R5J2O$%>5S3O/$:45WXEL1`XB M%Y&'R*^0=#VH2;?KH1221O@\45JQZS&B!%&**$.45ZAP78VSR#PTA]BOQ;G, M7R@CKT2RL99BTT%3)6W@.],GJ\JF^]&B-.!VLFM=)DY-NFMRI5#[(SE/&K"N M7^LR"6K275,HA3H>,4H#UHUK729)3;IK2J50^S5ETH!U\UJ7B-HS1*:EV3/> MF7RK[(T,^`/M(8I[HUSM+QDU\@&(UHAL1`XB%Y&'R$<4(`H118AB1`FB%%&& M*%>0&@N1,_E`+*H42S,6)1+1KDS,!;-3G@"N-V`%/=6!RMYC<3C0'?"[6YT#`1GT.A-*('8A4 M!XR[.V.FOT<9<[$^!Q(VZG,@E4;L0*8ZT-H".1?K<$#MV1\)(RX>_?*]B&VV!=E:K2Z(9Q.S?TW:HM;#K[MG-%O6YMP_5Z M%:&#F'=;Z_6%36>]0:W9;1/6-EQO5!$ZB'IG,W.FOSH0"Y/.:I-:LMLFK6VX MVJPB=.B\W%S8M-6K]C&1U6GVL7=N,542J#FMU7DA]FYIUJC5@?([BLJH^1@! MD2VE6-V1J%O=12D/D2^E6#V0J%L]1*D(42RE6#V1J%L]1:D,42ZE2%V-*4TN M'XFI,-?2&A5J+ALJU%PV`%J;@&Q$#B(7D8?(1Q0@"A%%B&)$":(4488H5Y`2 M"[H?J['XI3F\4%%#5"%:37#G6C)J/#-`M*X0'8H9:SZ_'<^TIP\V%Z-HMLT@ MQ0!VV$A6YR+R*D2'HKKQ?'$WU:KSN5A?=0$;R>I"1%&%Z""J,Z>3Z1@6`5RL MK[J$C61U*:*L0G3HO+J(:^ROYBMO`'*M!F_V"24)O]A+[N;N%?IM87>H"" M%3],K;R8R?3+FUEYL=;0^=S*BY&I<=K=6F*CBC707M42VTX\0SM/2VPB\0SM M(^GZVLXLS075T];L='.C>MK.T*V*ZFD[0S<>JJ?M#&7=+)$'0]\HJ66)-!.> MH0R.M2[O"UKK4,:%U-K:F3(D5M1ZAC(:5$];F:4QML3;Q^@!O8!LB7>)\0R] M3FR)-X/Q#+T<3'VL[0R]P4#UM$6;WD>@>MK.T-L%5$_;&7I7@.II.[.ZL^CS M!?0LO+.R-KY:6/2:/=J["XM>C$<>+BQZE1UYNK"R@H_J<-%_(GC;?-M%F].W M_>MY\+)[HHEA7'PI=2K_ET'YQZ5Z>OSU>*'_04`+!/I8FO[GQ(X^S*&OMH># MI^/QPG]0Q:/ZOUA\_A\```#__P,`4$L#!!0`!@`(````(0!_4;&(8!,``)UF M```9````>&PO=V]R:W-H965T?:\6AF7+&M*/E_.KV>7%_OG^\.7A^=O'R__Y3_2O]>7% M\?7N^O^_WKQ>D\'S\>/G]]?6'?WU] MO/^^?[H[7AU^[)^IY.OAY>GNE?[WY=OU\GB][ M!?_E/1J'KU\?[O?!X?ZWI_WS:R_RLG^\>Z7V'[\__#@JM:?[]\@]W;W\^MN/ M?]T?GGZ0Q"\/CP^O?YY$+R^>[OWTV_/AY>Z71[KN/^;+NWNE??H?D']ZN'\Y M'`]?7Z]([KIO*%[SYGIS34J?/GQYH"L0W7[QLO_Z\?+SW.]NYI?7GSZ<.NA_ M'_8_C\9_7QR_'W[&+P]?BH?G/?4VQ4E$X)?#X5=AFGX1B"I?0^WH%('FY>++ M_NO=;X^OW>%GLG_X]OV5PGU#5R0NS/_R9[`_WE./DLR5=R.4[@^/U`#Z]\73 M@Q@:U"-W?WR\],CQPY?7[Q\O%ZNKF]O98D[F%[_LCZ_1@Y"\O+C_[?AZ>/J_ MWNAT15ID(47HIQ*YNIW/-HM;TIBHMY3UZ*>LY]V^JR+)GEI-/V7%^89;/>%Q M)2O23UEQ>35?SE;B8B>JW:"W`6%"TH75"ZH7="XH'5!9X!K M"H^.$TA*CYX:WG-D=O>UMYDL=G!V0 M`$@()`(2`TF`I$`R(#F0`D@)I`)2`VF`M$`ZDUBAH&X](Q3"FE8Z6N5U+!;S MM1.+WLBCV6@8;6RCG3;24P-(""0"$@-)@*1`,B`YD`)(":0"4@-I@+1`.I-8 MX:&>/B,\POH4'M6I6TF,>0$D`!("B8#$0!(@*9`,2`ZD`%("J8#40!H@+9#. M)%;'TW;$ZOC^OGXEMGS3JY6H:,>@)XL5KTU``B`AD`A(#"0!D@+)@.1`"B`E MD`I(#:0!T@+I3&+%@/9U5@RF.UY8VQW?D_[$)+9#.Q<$+@A=$+D@=D'B@M0% MF0MR%Q0N*%U0N:!V0>."U@6=`:Q^IFVGU<]_<0\K9.P`2&*L/IKPO6'I;)J" MWF9!:Z*^?WA+Y_X1:B.UU$5:6I%8$Q9RG25:AVV\&V=?G6HC)9UI:45R35C( M=59H';8!9Z4V4M*5EE:DUH2%7&>-UF$;[\:Y5[?:2$EW6IJ(-4KH&/MWC!(A M8X\228Q1`B3HB3TF;IQ-8*B-U,5$(!0#270MLY^<,9EJ(R6=@5`.I-"U)J1+ M;:2D*Q"J@32ZEBGM3))6&RGISA2RHBMR#G]'>$\Z=GP5,@*,*)"(0JP:&R** ML&*,*.&*9N\L["UHRE;*8X9:.:*"*YKR-[9\R59*OD*M&E'#%0WYE3/86[92 M\IVE94=7'(W_CC1%?\2F`X!RNA4Y*C&A.6X[1(%$5G3[B@:*L&*,*&$MHW]N MEG;WIVREFIJA5HZHX(JF_,J6+]E*R5>H52-JL&*+J+,JVJ$4AVH,Y6EG^OK] MX?[7[8%NF]2W`[NE!6669+ZI/YI;@93(#"2@0&08*=P+'@$AHD@B8U#$B!*L MF"+*L&*.J."*9M2<%%K)5APUN,8:Y1NLV"+JK(IVU,0!'*.F$M;OSQ/*@SQW M_U;D:RDB3'::<%>XNX-`VBPXG14BBK22ZJY8DW'M!(521)E64MJY)N/:A;19 MTD7S[G#E;-A*ME+BE197I-:$E=QN:EB(C;R5LSMHV4J)=UJ9.B)VJ<&K(DJT4(OPCN::*=%F*,9(`H118AB1`FB%%&&*$=4("H158AJ M1`VB%E%G(3L6XOA_1BQDMH"GVI;B(CK>H_XWAJ.ST]@I*SKI:BMWJ`5LI`91 M*-%BUC\1N-W,9S-GJ$>J&NWL1K5C9335@&3(:'[K["E39;7NVW0U)PT;*?4646_"(O,49@T>8.QOC'ME+F;./ MV8D'8Z?E??Q2`FVCKB24Q+L]16E-3X)GS@8R$B83(^9MMPFX3259>">WRZOE M>F;^XUQ;-MF$7,N/-[/0-NK*2R`5D%J3<>5&VRCE%DAG$GMLB%3+&6.CS\S0 M6%/.MN*A)BXLSAECIZRF0AFPD5(/%:+#OAX"WLK9XT;*RIS)\[6S`,7*:JH- M"1NI-J0*]0N)=S5;;%ME%. M2R`5D%J3<>5&VRCE%DAG$GN@T$RP!LH;&TEA[MQ_)#(WDAJ--SN8]T:+_@4B MD5D/$442T49875W,:%P]0:D44<922CUG-*Y>L)&J5R*J$-6,QM4;-E+J+:+. M0E9,/3<+-QW3D[D=4X6XUW<*&8<#1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'4 M(NHL9,="Y*?^WPNQ>`SN3#N)G#.#L\_>*2M^;!@@"B62)X3E?MV%,%9&["YAQ/7P/*"LU'E@X>PB,F4PY3Y71NR^0%0JU/M:72V=@U:E M#*9\UH%2):** MI91ZS6A6=8DX-CM/(G-9!Q2B580H1I0@ M2A%EB')$!:(2486H1M0@:A%U%K)C(5)E[KQ;S,[,GXO%VPU1CR@$>I7U;IU# M]T[6X]D:``DED6?WY7)VNU@Y)^=(V&@W[ER+03/1A&L-+.7R"OK3^^)JX1PW MLTFON?:A)EZ4Y[Y+C9 M0O=D]LX5&[.(M)Z?1I,YNS7B"W/C',AZUHK=US-0A.HQHW'U!-531!E+J;#G MC,;5"Y0J$54LI=1K1N/J#4JUB#J6@A5;I+_,5>*-%5N8.RNV1&9,)3)7;$"A M!RA"%"-*$*6(,D0YH@)1B:A"5"-J$+6(.@O9\\Y-IKGS[EU//&GR0XB&G)[.Q,F)W"2,>\0.KM[P: MM1&?.?>,3,E,N<^5$;LO$)4*];YNKCPGZU(I@RE?M3)B7PVCB4MMI97:B,_= MX.KWA*92X!&?'VXK/=&QAH>2BD#1:@> M,QI73U`J192QE!KU.:-Q]0*E2D052RGUFM&X>H-2+:*.I6!9IP%AQ?J-95V8 MGY9U;M/"<_9T6Z^W$H<_O25;>+",:"MUR0%75"A$%"&*$26(4D09HAQ1@:A$ M5"&J$36(6D2=A:S927/\G(B=S.T;L4+&>RV(`D0AH@A1C"A!E"+*$.6("D0E MH@I1C:A!U"+J+&3'8B(C-CV1*%7LWGPE,E^+1Q0@"A%%B&)$":(4488H1U0@ M*A%5B&I$#:(646/]]P+W,4 M[&Q+=S7AWCKZ>;?.&6VGK'BW$$BT-$]OWBWO>^QVBM/M&>WL#\/F_5R\?DSM MM$_XSAEY)XWX\@))EG0RT_<'[Y;3I'8KQ?GMC%;*8R*[V]*K>0.]Z>Q%=\K* M[,V^HM.;O+.SVRE.*6>T4QYJS';VR.Y-)QVPH^7!'IF!),O5Z14#OA?;K1LZ M,G@W5W2%9_YB[D(?&SAX"\]Y`6PKK:PM@.<^*=^QE;K?!XA"1!&B&%&"*$64 M(F/=UWMIU;O;18^L M+0"@`*U"1!&B&%&"*$64(S-" MZVR50[92O1,ABA$EB%)$F416:*&I!5><:&K)5JJI%:(:48.H1=1)-!1(<>@P M=Q5_+9#]T<4\)8A?3;`/4YIP1[C#/I`VR_Z%76\V=\X5(1NHCHJTKB*Q)N.> M$A82;\R1)SXOG3+0*1LHW4SK*I)K,NZI8"'IR;FFD@V4;J5U%:DU&??4L-#P M-;5LH'0[K4O$GN+G'13%>4EL&_G6N57(2/PJ9#S[010BBA#%B!)$*:(,48ZH M0%0BJA#5B!I$+:+.0G8LQ)G4G*73FTQQQG9CT2,[N;!VQOQ.5A0/H?2ZBG-4 M2O&9.>1Z:EQ%B&)&X^H)&RFI%%&&*&F1F$^#E"\H9]"OS^)4$`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`L82R>;Y(V&$)9=^H!4,E.V_EBY>7L0Z] MO^R+5Y&QA-Y&]L6+Q5A"[Q;3*!LJV=*5;@>OE!Z8^+O!DH!*Q',+]$-)=BH9 MZC=ZJ$$Q'2JA9QM^/EA"OWY)?3`TS>F7*:D/ADKH5R.I#X9*Z!<=J0^&2NCW M@SL+W%VJ>O30[PC4]?)1S@U%[Q6;NADCF5#+67 M/LQ%)4/>HS6%<:@@7OOB:V'H)5G[]"G.`;[QZ0.-`YS:*[[R-U1"DW^PO?11 M,BH9\KY=^]O!@MW:WPT6!&N?OE.*WH.-3]^J'.#47O'1PZ&2.94,]2]]D(U* M3NV]UM.._CC(C[MO^_+NY=O#\_'B1/Z^F_P5TU\.K_1G M0>A<0W^_@/X,S)Y^HY_^4L7EQ=?#X57]#S7J6O]AF4__%0```/__`P!02P,$ M%``&``@````A`'OHZM_]`@``H@@``!D```!X;"]W;W)K&ULK%9=;YLP%'V?M/^`_%Z^DD""0JJ$JENE59JF?3P[8()5P,AVFO;? M[]H&!"2+LFDO(;XGXKALX%:8U,@P1OX6#Y3E-R0-+CQ6II2'AI,02](N" M-J)CJ]);Z"K,7X[-7"@G5 M7L""U+JB[/V!B!0,!1K;7RBFE)4@`'ZMBJK.`$/PFWZ>:":+&,U<>^XOPJ4' M>&M/A'RDBA-9Z5%(5OTR**_E,BQ^RP+/EB6T%Z$[TQQ7YLW:>?#LL@?7)CI& MO3;C`4N\67-VLJ#!0)YHL&I7+P*RS@63NO?E3[:`'XIDJUAB!#L#%BR@E*\; M?QFLG5?P/VTQNW.,-T8D'4*5#>3U&L&<_Z!1L2B-JI1*]*X+#$1/!'6(J2`P M:BCH/->7#*,C,P`HMMS*S!4%OKQ2F%:T$K7;3E6 MEO0O+S.,I$&:VZ4IL);6UZ.-#$P81D:9@G$FU;6S8&6',.$O.U)R\C0P\&$9&'JA[:+)S@]F_6*"(QBI,9&+!:M(9 M/:BWP)RUYGBI"#^0A)2EL%)V5.>HZJ\^VA_Q6U_U_"2^@Z-?GY/3N!\E%_&S M"#;,.<]V'FWUAI_R+*)$G^G3>!`EP06>71@EX:7XLKVBG)X(KH@&'\@SY@=: M"ZLD.2S=U67AYI(Q`\D:\!SN"2;A;M!_"_@6('`PN3:T<&PO=V]R:W-H M965T3X@A5Y3D:!/N:J6J.FV? M64(2M"%$P-Z^_1EC&[`GH=FJ+X>3'^._/>.Q/7A7WS_RL_:6EE567-8Z&8UU M+;TDQ3Z['-?Z7S^\;PM=J^KXLH_/Q25=ZY]II7_?_/K+ZKTH7ZI3FM8:*%RJ MM7ZJZZMM&%5R2O.X&A77]`)O#D69QS7\+(]&=2W3>-\TRL^&.1[/C#S.+CI3 ML,M'-(K#(4M2ITA>\_12,Y$R/<?L MG-6?C:BNY8D='B]%&3^?P>\/,HD3H=W\0/)YEI1%51SJ$<@9;*#8YZ6Q-$!I ML]IGX`$-NU:FA[7^1.R(S'5CLVH"]'>6OE>]_VO5J7CWRVS_6W9)(=HP3W0& MGHOBA9J&>XJ@L8%:>\T,_%%J^_00OY[K/XOW(,V.IQJF>PH>435@E$ M%&1&YI0J)<49!@#_:GE&4P,B$G\TS_=L7Y_6NC4>DHB_X?9$*[$-$RN`4^A88TFYG2^(%1EH*7%6\)3M!S-R7AIS8?;37@[>/)V M\+^!?D"M\1*>W)Z0D;F8DFGCYT#+&6\Y;UM:#XT0UE?3(SP?&N&2V\/SBR,D MD#-L"FGR\#D<&J/!4J#)*">NX\VJ+-XU6*8PR]4UIHN>V%15Y!(+3YM=]Y(+ MLHJJ/%&9M0Z.0^)4L"+>-A:9KHPWR.*$VVRQ#9$M=L*"IBR5=53@JL!3@:^" M0`6A"J(>,"`L;6P@M_^/V%`9&AOAU5:`+EBF$@AA(9HX*G!5X*G`5T&@@E`% M40](@8"E*@7B]D8CO"/B(.(BXB'B(Q(@$B(2]8GD*)P!DJ-L M7QS1,VHX^VE#V6=&K%F7ZX@XB+B(>(CXB`2(A(A$?2+Y#.>=Y/.PH]1:=I01 M5G'0[7NG`D<%K@H\%?@J"%00JB#J`X#;&HGEXPEE`7P!.AFUJZ!5 MZ6S(7-F3PM9(*$="&8`41"A6I"#>"!84@"):U%J.%B=6MQHXZ0Y(!Q$7$0\1 M'Y$`D1"1J$\D1VDU]`5/&W/958Y,V$U[LZR413MA!844=',4BH[<J MGO]`GT%K(]P)E3XG2C)$]_J4HTI+OB]$E56(4E094I)\+F?>CG"KH:1R.B/A MI"L0RZ`)SFBN>R>#FBW;%R)#G0>=D>@\%(AUC@JY2+R_T[D<:%IA]@/=*R@> M/WP(KU.[U-MR)&>ULO!WW&@XJYEV)^T*:9;5:H)Y]/5`4@NY^S9!.ZPNY*R5 MQ;I4LBBZUZ,<:5J\]B/]+QL%JW6EE.:H=T;!ETISD`VY['`CB]V4T`K(Q&@L6&T%,/L7K428&Z'!>8_:_$A9HKYQE'_;APU#N\Z=Z>46GI,NMK'%S M>!!KKER+>$+FSC[#-SG4?2#:P9MVG:+N0Z7[J:F4H9&0N=.]''!:>_<7GQKP M'\45(GFSQNZ5C7![BB+.43_Y6M3YIQZN#I>RNG8N1I[HL+/R.W1?/G$+JWBS:G%[J_QDTG13^);>-M_B MI@T7.C?L+1NN.S!_FMA/,%#\8CNQX4+@!I_:\/U\@\]L^,;$W%G8\$F#>;"P MX?L#\]W2ABH?PM4",FC=&&SVX$;_&Q_3WN#QFETH[ MIP<(_+CY&BS9G3K[4?.,?2YJN`QODO<$?_M(87L?CV"O.Q1%+7Y`UT;[UY3- M3P```/__`P!02P,$%``&``@````A`)B]EE!("@``V3```!D```!X;"]W;W)K M&ULK)O;;BHY%H;O1YIW0-QWH`I(`DK2VE#GDT:C M[IYK0BH)VD!%0';V?OM>+MOEPV\(&?5-@,_+R_9O>Y575>7N]Y_;3>]'O3^L MF]U]W[L:]GOU;M4\K7C__O#O?]U] M-/OOA]>Z/O;(P^YPWW\]'M]F@\%A]5IOEX>KYJW>4%QOUL=?K=-^;[N:I2^[9K]\W-"X?WKCY4KZ M;G^`^^UZM6\.S?/QBMP->$=QS-/!=$">'NZ>UC0")GMO7S_?][]YL\J_[@\> M[EJ!_EK7'P?M>^_PVGS$^_53L=[5I#;-$YN!QZ;YSDS3)X:H\@!J1^T,_&?? M>ZJ?E^^;XW^;CZ1>O[P>:;HG-"(VL-G3KZ`^K$A1GZE(I>UPZ5-4]$97 M%]6\%C5ONIJ7=94V6MLB?7ZMJU-1D3Y%Q>E%VGBTAOB4LL7$IVMRY=].O,DU MF],SZGC=:J`O76^[U7"NIEP"GEH#X\N$]>0B8%]$HY=.BB<7`OMR28<'?/FW MNRE8'I%NR@.?-F#.YC_B8NYUU:F/1CF)>OC$W]WV::]HS M!XH&/QY&WO!N\(-V\$K8S-'&,RT6TH)M5^8VL$%H@\@&L0T2&Z0VR&R0VZ"P M06F#2@,#DK;3EY;%/Z$O<\/TE:=!*HV#>VKM4!-QG1RE;Q\69LQL>P M,Y(A(0(2`TF`I$`R(#F0`D@)I.*D';JA-!WE'4K+(_G%EQKFQM1:$"TF=D0I M"6ISFQ&M"Z7V],92NS/JU!9$'<+BCBA'=F-)YT?9>-.IV5C:&6("JQ8(JJ,BJ;X+*?0`Y0C$%%B M*R,12V*M[2'12!UK)5*K.$`4(HH0Q8@21"FB#%&.J$!4(JH,9.K'T@A=/^T` M<7F`9XF]+2M'/AWUN@#B#ZV8OA`5Z2:8LK(W;.`R\FZL\!`**TIU6&9]>SVQ MCLZ1=$,;N>N1W58LC@]TG0REP_+G])^@J190I5S(:Y@J=]EZ@JQ)1I5R1 M=W,V6%ZES\8GP9"G8926RF[.V=TMIKI^R0$4H%6(*$(4(TH0I8@R1#FB`E&) MJ#*0J1]+LW3]M򹂰=.EY$C/I]@-`%)70P&B$%&$*$:4($H198AR1`6B M$E%E(%-*EG7I4GZB'S.W3C\<*447GDT"("&0"$@,)`&2`LF`Y$`*("602B>F M9"P'TR735M\7+L4\DZ.949M:2^YX8N])$Z9>RD@UF$JD&F&EOS)MF)I=*Y#B8;8E MKKH01G2& M[8RTCO+LJ[.1$2B4KOTV+1_;=_4B5G[27]SY.VV3RA9T!?VAM1ZSL^WD%[13 M=#9R;*5L^<38JE-MFI/*$E;]RO5)\!1)L':^\P72@V>'3@L7B'HC_KX.>X(1 M(HK0>ZS0:>\)NDH19RBA#%B!)$*:(,48ZH0%0BJ@QDZL=267W5_E_)"GOER):5(]9R%Q;\ MH?7@82$J\I?G1.@1%?6@#?$X%!5E/)Z.K2@72<]Z-+'#7"R-U+/21"'5;V@^ ME5:?7*7$4/0^.*Y2W8#EUBFD^[,:E,)*:6!=)2OI1F]?T\!<"-36V85PV1U` M=@?87@D"Z1NL0TIDK6-B(7`C[79?*+QK*)(-*N^Q0J>])^@J190I5W)NR_058F(O3/:BM7VG<\&?P>4O[6VK?;`Z]5?/.WN\8OG\ZO M9_1HG+IGL2"&=2B.S5A(PA**2O3VJZN$7HO] MYCMJS.EUV?9:9;4^]\F1RWXTHW=[L.5O8_+O'#KUR-6A.8W;-6S*=F9M3 M#^;N'E#)PED24$E(V3>.AU)?*G&-)Z(Z++_%.G1;8L;27"RA>Q&SU-D.Y MFR.]4DZW">A]6_H7@IJ.IT/VZMUSTQSE#YKR0?=/"0]_`P``__\#`%!+`P04 M``8`"````"$`0AT\L&`.``!830``&0```'AL+W=OG.OC[VZ[9W6N:D`[524@!/3WS M[^?(EBQ+K^U`U]Y,IA\=O>=81Y(EV?C3[W^]OHS^W!U/^\/;_=BXF8Y'N[?M MX7'_]NU^_)\_W-_NQJ/3>?/VN'DYO.WNQW_O3N/?/__[7Y]^'H[?3\^[W7E$ M"F^G^_'S^?R^FDQ.V^?=Z^9T?]^$FJOVTOD M7C?'[S_>?]L>7M])XNO^97_^NQ(=CUZWJ^#;V^&X^?I"U_V7,=MLA7;U#Y!_ MW6^/A]/AZ7Q#3SIZJ! M_KO?_3RU_G]T>C[\]([[QWC_MJ/6ICRQ#'P]'+XST^"1(:H\@=INE8'\.'K< M/6U^O)S+PT]_M__V?*9TS^F*V(6M'O^V=ZV*.JZ MW%K$7Z*[R:-[?&=&G=#E>DTBI<^BLJSF_,N[DQ7WS@47Z*RI>&*I!O:!."C7_5<$:(B/L?X37R\(U M*(FU4YE-\]*`13Y9S[LN8)$6@_[GRH`IDW7`,J47!RRR:LBT#G:'23ULJE%H M;\Z;SY^.AY\CFMHH0Z?W#9LHC143$^.O'C7-B.P;D#02F%#LH6F%!ZFAS16/A_Y(C)L!R)UGT0H)4T+2'"0E2Q=>#HP-6! MIP-?!X$.0AU$.HAUD.@@U4&F@UP'A0[*%E`20C.,DI#NFY48&\SZ?DQ33&ML MS-6&?JAMC%F3G#40&X@#Q`7B`?&!!$!"(!&0&$@")`62`C>2O97WM>8 MD)J3FI@T5[>ZT$+K)(V12*4-Q`'B`O&`^$`"("&0"$@,)`&2`LF`Y$`*(&6; M*&FBA8^2IN%YE%FKN>"D-3Z`V$`<("X0#X@/)``2`HF`Q$`2("F0#$@.I`!2 MMHG2\+10NZ+AF;7:\#4Q37F[`F(#<8"X0#P@/I``2`@D`A(#28"D0#(@.9`" M2-DF2L/39NJ*AF?6:L-STNKQ0&P@#A`7B`?$!Q(`"8%$0&(@"9`42`8D!U(` M*=M$:7BV)[VBY2MSM>DYTF;^6VWFEU;-U(_(0>0B\A#YB`)$(:((48PH090B MRA#EB`I$I8+4]+"]3WL?.GPK,.JM$BWD1"L_"-0:&HAL1`XB%Y&'R$<4(`H1 M18AB1`FB%%&&*$=4("H5I.:";7O:N:C/!&[8T=8'::DW3$I::F0MFDRMV=D. M36LM9"-R$+F(/$0^H@!1B"A"%"-*$*6(,D0YH@)1J2`U+6P/U$[+![G@6Z;V M$*F1)&MV:$:ID,0&X@!Q@7A`?"`!D!!(!"0&D@!)@61`F8JV=JB1;*PU.X.H1IYL![VQ;&XSNZT/5*>& M=FKD2`/13FZC*XC7D'Y/OA2JCFZGAG8F$D@#H1LVNH)$#>GW%$LA[DF[ID0: M"-VTT14D:TB_IUP*=5]3(0V$;MGH$E%[!MO#MGM&QTBG!SC-4*^WO"0GI!_8 M`P+6*ZP&K0621[(V(@>1B\A#Y",*$(6((D0QH@11BBA#E",J$)4*4G/!MK57 MY(+O@MNYJ)%)*>,!J*P)=&(H)`B^!V<6M:IK93"46]H0@B830402R-1`2)%L'26BR6 MAC;-IZ+>4`29,!J*()=&(H)"BV!Q-S,6IJ7>:$I1KR<"M=NQ3?T5W:X^`U"F M@!K1FJM)N36%9V"U$=T>&B/L=,)&7*W#'MTI"SD7B->0?F6_L1'*`9`02-20 M?N6XL1'*"9`42-:0?N6\L1'*!9"R3=2L4NJOR2HSU^[M-=(F$VW-MC:XU5`W MMH71LKE'.!S-E//FJ7;>[,J*_>WD":.A$'QA)$,(+@HAE!7[0XB$T5`(L302 M"4TXXE/J\FZY7&JS=2IJ43OW#IQ,&`WYSX61;(*"H^$LE+)B9PA*OS/U\ZA? M6FI6*FIWY$B=9+1Y;\V-AB891PBU&]2$GL>L>MO;N\!/<)&?<-!/=(&?N+%I M>A4G],)0M4*I`%$HI81Z)%&_>HQ2":)42@GU3*)^ M]1RE"D2EE")U-:?Z8=OPQH(>N4!..6KGE*/6QD)4E,A!Y"+R$/F(`D0AH@A1 MC"A!E"+*$.6("D2E@M1(>CW^U%[$3O"&>M$?AW>Z97<>%K:.$%AGT6=OCMHC MO4']HU2"*)520CV3J%\] M1ZD"42FE8/9FIWCM7'\P>]>'?LK4P%'KL15U@BKS$MF('$0N(@^1CRA`%"** M$,6($D0IH@Q1CJA`5"I('7>TJ+\F%\Q<6SK7B-VLFR6M-=5.;M9F8R7ZFHW( M0>0B\A#YB`)$(:((48PH090BRA#EB`I$I8+4]+"#LBN&2GVNI@P5CN2X6+-W M_5D2);(1.8A<1!XB'U&`*$04(8H1)8A21!FB'%&!J%20F@MV6M3.16NA\\$, M5I\S*6FI4>MQ[MH$9"-R$+F(/$0^H@!1B"A"%"-*$*6(,D0YH@)1J2`U+;2\ M4-+R02Z8N3:#U4@>=:]-G=A`'"`N$`^(#R0`$@*)@,1`$B`ID`Q(#J0`4K:) MTO2TG%:;OC4B+G_"6ZFH&>&HE9&&R)N,OC2WN\7(0,1#NYC:X@7D/Z/?E2J/MI:"`-A&[8Z`H2-:3?4RR% M>I[P2@.AFS:Z@F0-Z?>42Z'N:RJD@=`M&UTB:L^X[B#&PH,8@>0&:BV0/'6Q M$3F(7$0>(A]1@"A$%"&*$26(4D09HAQ1@:A4D)H+_2!F^$9(&UO]1L@1V[FU MEO+:8Y.UL*(5?6.%8Y0?WLAC!(?7HUF&=;S9;#E=SK2'FZ[0IOMOK[8GC(8" M\*61Z,6!&H!U1[\[M;0`0E%M*(!(&`T%$$LC$4"B!F#!AZL&E$G:KJ!-=6> MQ:^Y$6W\&R/LA[60E'9X+5KGLVYH&+<+0]^MNLRF5].[P*_?V(BV#R[P&P[Z MC1K-_MCBQD;X352_\[DYU]_92`?=9HUDO]N\L1%N"]5M9S.7?7[5/L8.=MI] M[(-IC9\#R8P_L`4A6_*W;S$-ZK\HF]>CFY^X*@>1B^J>1/WJ/DH%B$(I)6*( M).I7CU$J091**:&>2=2OGJ-4@:B44J2NYI0FKFMRRLRU'0)'[9QRU%XV`')H MQUUI22L7D8?(1Q0@"A%%B&)$":(4488H1U0@*A6DYD(_8OJUQ3V>/%DUHM6$ MZ%QK@>2JP$;D<,07"O/%XG8ZUVZ3KJC6JWAWVA)%TYR,*-'?3Q?)NIKD+ M1;4A=Y$PDNYB1(GJSIQ9LRDN`GC3#;G+4#M'5*CNYEU75XIJ/>[4[C)P"E;= M\B][4$-?1X$AS5%[2#>H?S*RN12M6T0_3F-MHHEQG15TF^8NDKH,SGTBYJN$I-*JA]*ZFKF MG/Q4-WU=L"XLEM(NEZ^XJ65L+\M-U)71K)3]=)72C)#]=)73;(S]=)73FMV*G0VI=B:?SF57264+G*>2GJPZ]J;YB+YUC!/3> M^8J]0HXE]!;YBKT0CB7T3CCUR:Z2M4DYI?;\L(``",)P``&0```'AL+W=O'AOVN_=H:KZ"6@X=YOIH>\O MP6S6[0[5J>SNFDMUACLO37LJ>_C9OLZZ2UN5^Z'1Z3ASY_/E[%36YRG3$+2? MT=&\O-2[*FIV;Z?JW#,E;74L>QA_=Z@OG=!VVGU&W:ELO[]=?MLUIPNH>*Z/ M=?]K4#J=G'9!_GINVO+Y"';_=!;E3N@>?A#UIWK7-EWSTM^!NAD;*+5Y/5O/ M0-/CP[X&"]#MD[9ZV4R?G*!P_>GL\6%PT/_JZKW3_I]TA^8];>O]'_6Y`F_# M/.$,/#?-=Q3-]XB@\8RT3H89^'<[V5!34W+GWJ&G7'&$`\'=RJC$TP"/ES\W4A8[K?7_83+WEW?UJ[CD@/GFN MNCZI4>5TLGOK^N;T?R;D<%5,B<>5P%4H43INM%OP=G#E[>"_&_(PHF&P<.7R MSN)3'2UY0[B*CNZ.$JVSGW]\OEO[J=H=KWA"N MTL";(W0@8(:N\)]/F#9CTS]$4U3VY>-#V[Q/($5A@KM+B0GO!*A+Q!'SCHRL M:X$%$85:GE#-9@IV0\QTD`T_'KVY_S#[`1&\XS);*N.8$J&0P'!%M9$-8ALD M-DAMD-D@MT&A@1FX1?H&YEB.$A&@2V2"V06*#U`:9 M#7(;%!HP'`'Y31SA0;",+S8B)K#59@J9+6/"65DSOF4RSD(Z)R0D(B0F)"$D M)20C)">DT(GA`C"#N,"]OY-I_>E,0460;-!0NL6;K\WYWS(A%P)3"CDK.TBD MD(P20F)"$D)20C)"`LL,3]T.$I0>W"&,V'*BA00A$2$Q(0DA*2$9 M(3DAA4X,0V%3,0QE2^<=+O6W;<:&ILV,>$N5!H1$A,2$)(2DA&2$Y(04.C%L MAAW1L/FVH2AM&LH(*TAPA0]M$-D@MD%B@]0&F0UR&Q0:,.S#\OAOV`Y1C6DX M)UI42Z)R?&&E>,1D/,@U;1WPS,4BED(BA1*I6I!4$J7([BR3>I2,L[HW.\NE MD%!=2-5`#%]",3/BRR$_^D.]^[YMP"A8XD9BR(,2@A46J,3T)">:)PF)&/$@ M$S6_+4Q38BDD3$F(HI203+;252]-U;D4$JH+79'A)2RZ##>-N`/*5>&/0=QT MB$">6CT$4D5'1%%,44)12E%&44Y182#39JRX]#3[P&96H,&>*=RY=1C".EZ; MX94Y#:&0@N5,2MEA'RDAH3VF**$H5>BZ]DP)">TY186!3%=A3::["G>9CVLO MAY5RALL8@@I'^L)9635ZR-OI;J4.8XIT&6=E53`Q5^2NAL/`PEGZED2"$G(D M=B?I)P:2C3F0#Q_O;!JT.+:0,QYP,J0SL,75S.'UY=Z)#/DZFN\3P*9 M"]T.9"DD0BWF_<&#".5JQY^;:9((*5BCY(0XON6F5$C=&D.FA,08O18/YC1@V:E/PP"UH!_OD"PT$MEBL8@G32TL$JS4+>3F5R M1$C,"5\$/=];685"@A*R$SOF4J(Q(R0W^QA9:(MK?9C.Q(I8=^8'B<4*:)@< M$>=;AR,]@"2Z;F3$VVE9%%.44.VI0M>U9U153E&A5)'$PO+V"W[AU;#N%XYT MOW"D)Q9!,>2=E7X)12E%&44Y186!S%C`8E6W^9,U!Z]Q==L9,C8WQ[<.,*'# MI=3Q-Z(H%@B\(C/&\:VB/A%2H%*3(GL9Z3$3#=4@9S9$2J[8Q0"*D8B2B*.>(%C^?.K6HN$6WTB"%KOQ!2 M?644Y0*9(6J5VH60TCO4"SS3Q5C>Z]E_>R=PV6E`WPD$TE8\A50TV29'7$C? M"2A*E"JQ]:0*7=>>454Y18529>\$+I;77_`+J\8-OW"D^X4C;2<8^C&JKIBB MA**4HHRBG*+"0&8L8(6KV_S7THW7UVHYVF*>00:"]6IQ65OGDI`+J681(;%0 M9*QB:VN]3U!*=42.-D1M1D@^VI&]_117.S+=BE6T[M8/4HP7WYRI/N%(SW% M"(I%0R654)12E%&44U08R(P%N_#^2Z<8.&*0'8TA,R+7]C&&-X3QB=4T4DA- M-7FN$G,I<:R?DZ<*0HV^Z=CQF`HAU7VFT(WN)Y75H$3S!0>F.[".`=Y0B_#^"5W@A?!O#:B_+0 M\0,\=]$[05!>P(#'>.C,P<;A@R-K.N#I/]@X=@>>#D&;,4_"LQYH,W9GZP?;T?[] M(!SCD1_`VRUJ1[0.X.T-Y0E,U1A/_0#>Y(#\3)H'WT)=RM?J7V7[6I^[R;%Z M@0">#^>(EGU-Q7[T//.?FQZ^@AH6@0-\]5;!\[\YOOU_:9I>_,`.Y'=TCW\" M``#__P,`4$L#!!0`!@`(````(0#:M0."IP\``!=2```9````>&PO=V]R:W-H M965TQ>5D]4\F7S?9IN:?_ M;K]>[EZVJ^7#H=+3XZ5_=75S^;1-Z__=!]/SLZ3Y(OSYO MMLO/CW3=?WG3Y;W2/OP'Y)_6]]O-;O-E?T%REWU#\9IGE[-+4OKX_F%-5R"Z M_6R[^O+A_),7=)/;\\N/[P\=]-_UZN?.^/ML]VWS,]ZN'XKU\XIZF^(D(O!Y ML_DN3-,'@:CR)=2.#A%HMF^I1DKGPKX72_>:1&D#_GCVMQ="@'EG^=?C\N7[8?_MP/KFYN+Z]FGAD?O9Y MM=M':R%Y?G;_8[??//VO-_*D5"_B2Q'Z'!`Y4G$B*]*GK#B]\*97-\+WD6I3 M68T^=;6I?WW[[M#H(Q5)]G"U]"DK>M.+6^]J-KD][O%&5KS5%4]J*-UE!W_T M^;:&SF1%^GQ;0ST:07U`*63:YPE]ZJD@BC]TQ9-ZU5-A%'^HYOH7I]55L12# M5KL]I;TJ)![](2O>G.B3HMCW$8?3\T\:!YZ*J/CCA.9>]K?;X>Y=+/?+C^^W MFY]G-"52='8O2S'!>H'04O=M/WCUG3QV(],=+%0^"9D/YU2?[M$=S3Y_?J0; M]_WEGS1CW$N;.[3Q;(NYLA#3@Y!=N"!T0>2"V`6)"U(79"[(75"XH'1!Y8+: M!8T+6A=T!KBD\.@8T8WP3\1(R(@8J=Z]4X"#YH1LKBQ4E84+0A=$+HA=D+@@ M=4'F@MP%A0M*%U0NJ%W0N*!U06<`*R`TO5@!&5[DU+TAK#^QV+B39Q8]$8^W8V&T=0VFFLC?6L`"8%$0&(@"9`42`8D!U(`*8%4 M0&H@#9`62&<2*SS4TV\(C[`^A$=UZITDQGT!9`$D!!(!B8$D0%(@&9`<2`&D M!%(!J8$T0%H@G4FLCJ?-B-7Q_;I^(;:7QVHC=0T M%P&)@21`4B`9D!Q(`:0$4@&I@31`6B!=3PY=:$6,'B<'(J:>M4]^ZA`R=LPD M,=8+33@B$+7>AM(C;.-[[^P5/]1&.FJ2\(XZUH2%7&>)UF$;WW?V@ZDV4LXR M+:U(K@D+N$IMI*0K+:U(K0D+N&R4'''B<*&0,%T4*B"6UO].WL>S/[BD*V4I<4H5:,*.&*AKSO M/!2G;*7D,]3*$15T;*7D.TO+#KAX`L9L MQ&'7ILW8#JS&E&Y5 MR['(_CESNT(3'9ZY0CP%+Q"%B")$,:($48HH0Y0C*A"5B"I$-:(&48NHLY`= M"_$X_898R*=OOB_N1(:5PN-;,Z/OS(QS944[9#U_NJO&@HW4*`H118AB1N/J M"1LI]111ABAG-*Y>L)%2+Q%5B&I&X^H-&RGU%E%G(3O,XK'\#6'NG^*M>;-' M%&P=/W_B[%7FM'*+L6#N>3'(:./=.L,EE$+^[2&![-WZ5\Z$%@D+W1+727Q" M0Y(!&VA(^FI#LJ,-R0>U)S>@L$:,9]F@4N8HWC$9A[FS:>F1/.LX0F8ODGIB9CL\YVDC=62'74RA" M%#/BL!@7?'B43-A(2:6(,D0YHW'U@HV4>HFH0E0S&E=OV$BIMX@Z"]E1%MD0 M,\J_]#`NSM+"8-1 MP5@+CMLDVD8Y35]SFAUUFFO!<:>EM'EM#CEV$CF M9YFR,6^['M':K`;7W).(#PX6C'B\P:8CE%:3J\,^T+]^=^WL>R*E0QZ&II3# M'1TK(_:?,.)ZX#]]U7^F=([YSY41^R\4,NN!_U):32E#H:]N8.\GN]?4[ M6CGD-C0*F?6@#>U);>B&M(PV6$//'\[F<7+GC\T+W:J#:7HC,7"0L?>%"AG3 M`R/N0J-A_90OC29<+T04L90:V3&CLUH M7+U!J191QU*D;L=:)-?,:>;X,B[.VIWMGD+&?()H@2A$%"&*$26(4D09HAQ1 M@:A$5"&J$36(6D2=A>Q8N(DW8\I_)2R8@_-[9!X&(UH@"A%%B&)$":(4488H M1U0@*A%5B&I$#:(646K#R?*;*7D,]3*$15^>*+.5DN\L+3O@ M(JN#`>>'CI.^&T2900BW1&:X`2UD1?-$&5&DY%DK1I1P1;-WG`QHRE:J=S+4 MRA$57-&4=[+K)5LI^0JU:D0-5S3EW1-EME+RG:5EQU8D=\S8OK*;E;D@WB_= M^1+Q`^!<(9ZL%HA"1!&B&%&"*$64(["VLWV2*SYQGKF'!'.?6E%TZBVJ!1NI410BBA#%C,;5$S92ZBFB#%'. M:%R]8".E7B*J$-6,QM4;-E+J+:+.0E:8*27WEC`?S.UE4B+K&`=.E*41[8S& M@SQ@`UFL4!K1'")>2?*F_HUS>!T)BU$G\8`3=[0E`S;0D/35AF1'&Y(/.'$; M4E@*T(122KQR&F2)N"[J$YK16`K0C/:D9G26B-$,>S2^+DX M:]Y<&1V=<]A(W5DAH@A1S&A\'"9LI-131!FBG-&X>L%&2KU$5"&J&8VK-VRD MU%M$G87L*+OYJ^/+_`235A)9K.)\TR4'76::\%QIX6V44Y+2>A#3*775\[6K1+EHQ=: M:[UQFU9YH"5>"\&Q1S?FQQXS(C5F;D=^*<-#!P,P8?3(GC#7* MZ%@3"C92UU\J-'+]E2H_=OVU,CKFO%%&?/VM1,>OO^.*@]=OCT(WS_C*S(4) M19$G$'D&XP&%T6`#Y-CJZ]&DJOHVE/4,%+&4LHH9C:LG*)4BREA*J>>,QM4+ ME"H152REU&M&X^H-2K6(.I8B=3NF(EUGSBROQ+3/[ID/.N+E(#>F$AD/G4CID7G7 M]817_@4=@8EJ%#D]Q<-F-Y1&ZOF#OM$*^P.2T0(XERLG:I`GI[A-';X1SCFM=8^E-=&$-TYX*^5%8X_T726B-'#]E!Z M+4]XVI<31/K?'4L2F8-)([XZHV%R"N^-:+U1W1%*=0-%RB%;Q8S&U1.42A%E M+*7:D#,:5R]0JD14L912KQF-JS:'^&&B6W'^IK'^U:1/O@B`P^_HUY0.:ZO+_:`;M)_0KR\-Z'R:!I^H MH0,.ID%W2`>[#JZ#[C`)N?PFZ`[?\7&Y3RVE[P8,>/!%6X<:2SG00*0SL0YE M-`.1G,02RD\&(M6()91M)#]#)?/)=2!6,*Q#BU@@UB,LH24I$*L+EM`"0WT\ M5$('4-2VH5ZFJ#H1+*Z@4@ZVFHQLJ&6HU)?ZI9$AMX4_I>@9'(?FY M&ZPSIY+Y8`F=D`;A8-OH4(Q*AMI&YR=4,M2VB-3$N0GV`9V>!N+X!$OHR)3Z M>BBF=&Y&)4,MH#?,`O&R&*K1^V*!>/4+2^CMKT"\R(4E]"X7S1M#)7./[CGZ MVB;6H6^GDI^A$OJN*?D9*J%OCI*?H9)J1E6&IH-Z%H@7`=%_,PO:PU.2,[/0 M^Y^!>+MSH(;G4C9@T5T.N2@7@9$L6R&5W]4$$^"\2+D5BCF`7T1O,` MIP:+MUV'2CPJ&=):O`O:H6Z\FP7BG5*4FL^"^6#!8A;0&^18@=XQ#L0;Q$,E M'I4,.8EF-%:&"N)9(-Y%1:UD%M`KY0.7?I;O9?EU52ZW7]?/ MN[/'U1=:':\.1Z;;_H?]^O_LY?YMV1N M"S9IR(UV^_=F755[. MTRE),`BK1-U8J,@>D,SXY44I'9.-AT??./!!`R:19)%)5Y%M"(Y1BG(+1F`6 M'3:*Z\8;$>+5;Z@3\EUL@([R_)H:"$*)(.@!F+J!2'JDD@/2??BZ`RA)H08# M-B`MLH)^>P-X@W\.=,J9T^BP=W&G/NXY6\FC.+AWJ`=CV[99.^YBQ/P%?5D\ M/'6KIMH>NI)`^*&?6F!8Q"K7&M3MGN_>?)T@;DOZ6RN5[-(QZ4$$4$E\CQW3 MG935^.Y^.2=\E!>3-(]GNBRF[.J&3<:O)3VY^GD^`$T?X-_$$X!WN7_^.?\" M``#__P,`4$L#!!0`!@`(````(0!D4<_'E@```*H````0````>&PO8V%L8T-H M86EN+GAM;#R.P0H"(11%]T'_(&_?.#.+B%`'"OJ"^@!Q7J.@3_%)U-]GFS87 M#A?.O6IYIRA>6#EDTC`-(P@DE]=`FX;'_78X@>!F:;4Q$VKX(,-B]COE;'17 M;P.);B#6X%LK9RG9>4R6AUR0>O/,-=G6L6Z22T6[LD=L*!T/J!.EP,9\66.H9])4NA+-FB!*1#VE#E;W MEE_@V*-!I%PM;5-`V&C&/\HD82'"_#1Y"6U2J.&U2>4]O4VR'I:;Q&N9*96\ M\6E.9W_9-.>S7^/)ZJ0MZ0Z4>!7V#J6@=7:\77^PWL#B-O&V][EJM3Z4\8\]9#&OL"\ZK4IW_!]B=5AL8=J!Q,X7=S M]U'J.;YD8W-'\VGSL3@\C,H.E=#(W=SO#J('^E-851CIS:CM0[*1.;XHOD&O MU5\O/KL\;5^TZ8>S=Q:%NU]=_!\``/__`P!02P$"+0`4``8`"````"$`1,S^ M[/@!``#5&```$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM M;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+`````````````````#$$ M``!?&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`%,+F(&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%?\IL:"`P``T@L``!D````` M````````````@3(``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`/^(H[>*`P``8`L``!D`````````````````*SX` M`'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`)/W!J5:/@``=\<``!0````` M````````````34T``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@` M```A`%3E;_]'"P``@V$```T`````````````````V8L``'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0"L]B78<`,` M`!L+```9`````````````````!">``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`+Q7;38U`P``D0D``!D````````````````` MMZ$``'AL+W=OFY$#``!Y"P``&``````````````````CI0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+,_B="!!```CA```!D````````` M````````ZJ@``'AL+W=O&PO=V]R:W-H M965TQ``!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`+]L3VH&$P``R&H``!D`````````````````I+L``'AL M+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'3"J*Y8!```B!```!@````````` M````````H^H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`/F_EF`]&```;XT``!D`````````````````G/D``'AL+W=O M&PO=V]R:W-H965TH``,``*@(```9`````````````````.08 M`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A``Q^ MC&4"#0``"D,``!D`````````````````&QP!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,QQ)TY,!@``DAD``!D` M````````````````'T`!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,%UGF_+"```C"<``!D````````````````` MN%\!`'AL+W=O&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`-!E<9P&`P``&PH``!``````````````````QGL! G`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````#``,`#Y#````H`!```` ` end ZIP 13 0001193125-15-179302-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-179302-xbrl.zip M4$L#!!0````(`,AUJ$:UQBL7)HT``'36!@`1`!P`<'-D=BTR,#$U,#,S,2YX M;6Q55`D``W@$355X!$U5=7@+``$$)0X```0Y`0``W%U;;^-(=GX/D/^@^"%( M@)3-8MT;T[W@=='`[-AQ]\Q.\F*P)=IF5B:]).6Q]]?G%"79XD42)9$TO9@! MNELDI?K._9PZ=?C3GYX?YI.G,,VB)/Y\AL^-LTD83Y-9%-]]/EMD*,BF470V MR?(@G@7S)`X_G[V$V=F?OOSKO_ST;PA-KJ\G;A+'X7P>ODQ^GX;S,`WR6*>X\GD/L\?/UU<_/'''^=I.EM_ MS?DT>;B8(+3^B=^6J_LTF?!STSRG&Y>NDT4\^S3A&Q\Y:1CD`SBEXDUGT^N]5/9Y#K,PO0IG)VOOO3Y1SJ?`$WC[//9!CS]\7F2WEW` M3Y"+:$6=L^6=G_35^8[[YU'\-TV^U_OU!Z7[_R#%W5@I=5%<7=\:90DUL=BU MF.4=K]^=14W?#+?BB]__\O.WZ7WX$*`J`I"4NR!X?'WR-LA^%,^M+L#SF"(# M(X+7C\S"MQ\J5I2%T_.[Y.D"+C3<_IC-GDH+>\RBIV@6%-*BN6R0MYOA5_.7 MQS!K7$]QI>$7]")F>7E-*^CL8GFQ=&O4>"M?WAJM;\WRQ[09I[ZBEX'+RYB" M3.?I2_,SJXOZ,5)Y;)&FH+G;GEM=;8`=/D_OFQ_25QH>B(-HFC4_45QJP!3% M3V&6-S^SO-:`*(NF6P@731M^(P[O0.-G6R5=7:3)/+Q8W?;ZU.*A^8E9GEYH M2;F`.\(TFKX^`$9A_S-)C"K/+?)TQ]+@ZAF8C\FD,"#S3UFA9M?A[:30YD_Z M6S^?9='#XUSK7/%9D$XUHG9VHWCB/@UO/Y]I34)KC3E_SF9'F)7V%NMB"6ME M!SY]NP_2\`KH$DZF29R'S_FU7E.8S&^N/,XQ(1PAS+"!_MN`+[KY]MV],6ZT M+^L*7 M@,!*??+B/,I?P"L\)/&W/)G^K;@INUSDA;\$'WH@2&8P@Y=`M@-EN-1R+=]! MMB--1*E%D+(\!PG7M91!?=/D`D`Q^#6#G7TQ%<4FX>RGBW8HEHBUW'SZ2S0' M;84XX"IXT7[].IR&$?B_7Q^3V)\%UN-CFCP%\P-QZ^5L9>XF>,1JV(E)E>]C MA3SL8$1=B9&-'8),X=N<">99Q+O!@/O&!.0%"0S@ZR%H.A)AJA6N"Q%VI<<] MRT:`QD54>1S9U+>1H!ZGC/N2 M[3`.;R,(;SH$N`^5YV"+V[Y`TB,$4-D862#62`K7QH1:U!>61D7@![YL*.:6 MI9?Q.4%V;\4S_8?W]T4$/`5N9U;N!&GZ`A+^6S!?=,K.DM"2&E@)W\1=D%+B M"(ZH_@W;<&W$),<^V"&N'%.#-6],>?8%2\98(;4'X=E0V[_"YP'<\==0AZWA MS(*0/[@+O>:V`=2_V3(4,>"OV!1*&?(9,],0S#S*C`GN$NH(@;C-)*(.1%V22M=UJ+_#Y)M4$<&5`0 M76ZL1;?%\LLXKR!\#2&/F7T$IIJBY*7VK'TK0Z^"]#+]ENN4I;#I5V%:/'PR MV.-"C[;@%8`_!V/5R.5MF/9S>ZR";4)0S:IRO1O`+K`?E.FTQO1VL/;S?8RN MR>1[%;S)+;FKVZ[#IS!>A+\D\;(VDW?)W#W19TN$&$)/QB0M2?76]>_BXC'A M]1Z`SUGT*8[FG\_R=!$>S4-2*U#\'`4_HGF41V'FC)8QX%M,$\L28^H+W^I4 M>F!'%[!TJF.J;;'!1DJS>37*'XK4!Y(AP`.N-(RG0((Q"ANN"9LUG2X>%G-M M$2_S^S#5&PQI>!_&&83O7^-I\A#^G&39+V%^>0NY[?A81L#Q257FV8&@:A31 M)>X,,IG@QSP$C M$+R80E)1`EA?>1E9H/P_F5T$T^QH[P6.4'UP9 M&P(LT=&"24G%^S2OO]$27:7);9AEQ=U^.&)!UE4PR9N,T18(.W..\5I=KN5W M5[K1"*^;S8O6^([>O&#'[%QL:._X&&8"("$K>Q,;*RY#\1X>Y\E+&%Z'18SP M$3R(+EA6\JR]*+;I7IP[\&>4CSKE5Y#RDRT:6`>PT\STAJYA\\3RF6/;#G*% MY2#*B0/JIPP`RY7EN93!C3=";P`S7JG251;=RK(LDQCXX"H$L[MRK%\!;!IF M^C@1METGF2+%&RA-@A=[,&T!^S9 M`ON,NS:":!"#!;>E(PTIL?"7.8#))*L$3WN!U*J9CQ!->L^/89R% M0*-E'E%\RVBC*4AAE5055N_%42U79'D:3<'/-6O&J'T9.&_,JB6+MGB:RU)K MDBUWV'651]>Q1BL"%!)@8E3SAOU(RN#]"!88_JP["L`1!/%=!'[01N')6IHX\.M8F$:]0ZBM"_M+D/XMS+4,?-/V;]RE.3#HDK-R M96X'@*8*5L'V\2&#V!OC,AO4\%N8/D73L-@$ MMO6Q%[T%`AZW.)@"+D8WO(TXRGP<_DK2`;MVE8:@#[\L_XC#-[J/'JS"=PK^#N_!KO#Y\="K@ M1PAS-Y'6@1K"-;!G@9^1VNUXEH\4EN![&),&]QAW?6=9&S'.#4Y638B'0^FW M/_68[I?C^U/Q:?VI7I;#$O1]<;P(YM9#DN;1/PI27MY6`Y;AC+UO,-N5)EAW M6VAC8+G(LC@(AA*NR:F-7?AFIEVR6&58AZ/9U(;F[#N>-?GWU^QM0.,H,5&. M9SL(4V*#-.BV;.$O/=9`A/>S:TG,MT[TA^B!:49N0]X=(;L8+;U$.T#W*GIU0V<`N#FIL'==JU!K?%C&]TTZRACCZ\ MT@.GJXB[YS1>'C"M=W&^@UP+PLEQ!JPM6G+#7]'6NE#V(=Y1CMSHHML,G(^G MB"!$%+Y.B.,TW62^:RM&D(,A]J>WEZ!B="I@Q>GR7Q^ M2BB@<3]C:G!#C[_96B"KET4(`&+8D\C@^JRN\'T$V;"#?`M3S\*.]`SGK09N MJE42O`U!#UTT;T>2326DT2*@;0IWL&2*,>(AFVM_2"F!OUD4XCCXSZ',H<19 MCE8H-[;M[*GI<2MU\R"VHJR%0:OSUO8-WZ<^0Y:#343A:Y!E2P/9Q(50SC:X M%+;&S(L&$K/<*W7$YNKVC&?#.1:F4#?L!'-=#]?')^SP-DG#HP^%`*D@&3/X M2;F>4"91MC!!("R.J&>:2/K"0[XA;(N`Z6?26A:#RD6`DS&W)N$RJ-`[$-GQ M,C48H7"1$?.VM-H$-U2!8#!:-&WS'EH=:-R`LG1A_J[8G+!?WFY9C4XH=J4N M'_6-V6_+?:JXZ)?1/2/?$_W1QK'MI44_@9B*4VVLX%YZ<#)J$!<8AX"A3`0"U&KSRW)?4FW46%HI_Q/I!>L<`Q= M,*<3ZO6C+AM!W9]US\3HM4:7,2`,EK@+M[&'&+V%3Q_$1>L.9JH,154OT5'/ M,>K7.$^C.(NFIVW9MS`^>Y(N5RIE0:R#7*D)+GR,;$$=1(2BEO(@"*+6JTL@ MO'($K#>*#.T:K+N[M)C_^P$9@XN]E6X90ANNF< M8=QVL^34K=1C]A'?AS+:0TE%6U.F81^QFZX26M.3#@?,F:O9IZ:2C,GWFWW: M-TBS%<@!9I_V#71,LT][QCJNV:=UL#V.P33'-_NT;V:/S3OGG^ MOK-/=S*WBU-9.\Y]FG`\!ZQ]FG@PC; MT+-/!V"9GGV*#5HV$>\__'0('=1565X#/OSPTR&X7`P_%4)GNV,8?CH$>[5@ M,[/&WT&&GP[!4HA>,%45@(,./ST%9:LCF,49Q/(9]'>?/;I`'*LJV"T-F%\V-FG0QA=;92(W)5O[-/4\8$JYH.* MRI3IP>:##B"<@$^Q\F"8]YL/.H24JK,O1&P1TG[G@[9'=^1\4#[F^:"MT1\] M'Y1_I/F@0]@N'0034O:P[SL?=`#4.HI2905_Q_F@IP"V?&ZZ6`F$B5!@Q@5# M"F`BYKI8'^-50(+EB$0]I:(22+W[?-`!6*WK]K3*ZK',!QW"EXU\/N@`)`#A M9UA48^MWG0\Z`&I=:A6\?"3MD&.X0Q_9.XDD;4Y;%:_&;GO4ZJ@C>J-Q_BV] M@F[QI<4FP[N/5!VBG%#,*2F[P`%&J@Z`K!BIVE0&:YC>.58,>OYHO;+5B*"7 M@[`#F)_E6YY;'Q(>[N#K`-B;E._0>6#C#C1U94L1VC0_MSX1M MWXW1E^\YZ)"^MF.NY]O!G_2X=LQ6?I(4V9-AR).2IYYTMDJ&3J;;M0L?]'** MH0?R)*T>G"YZ1-AQL^]:T<74RR'K;K$3K5VO>G/\;,QVA"CTAF,UH@&A[T"$ MDX/L_C6DNP&A;2W'LO"H2-LI(`.;CN$(L7Q#$STQ,NJ=$/W;3-R!S>QJ!W^X M0:GX=5`J;FBSZGVB9`/>?B>EXM=)J;BYX6B82:EUW#U.2L6ODU+;G0+I95+J M?L3=I4+HY/M%K1@FJYH)5Q!",5 MB]Y)00XA12^S-_N9Y[5)RH'G>9'UZ()S8R/%^9"#'D^=(K6?"QU.D7JENU"X M=#ZWYRE2ZW-!ZX.^;C1?Y(>DXZ:@2V)U\1H[/;#:)\)"GFWZB%*'@(A*#XC& ME85=`3_-M0E49U^049HXMP5'&:P.NX+L_BI-GJ)9.+-??LUTE'H)RPOTN41K MFD=/2V-1'%1KBT#);FG2R8":&PPF$`DIRV'":3C+-*OHZWH.W(J^)TQX MV$JDNJ#4`W/+LA1FOD"4>6#+?,*0DHZ+?-LW/4L:5#`;!(5"W,`E)"DF>:/. M@8AVZPNH730=N;;(O=I2H*B$!R`8,TT2R.3>G*CW/)TO0*3\-'G0]FB1KUZ7 M6/U&"#P6AX00!TA#DXW5$[BYR\&HFHZ-J$M\"!@5Q;>*XKK& M^!;B'=@E.IS:JX+YF._1^]88:\1:F];":=?#VV7=\/5\F/;R>1HD*?BN('WY MFH%*_]F@Y"[8X-39*L=)C'Q2X[2HU^R)"F=IKQ;R,=:WE\K9T!NOU M`-88I1`L<.45;^VP5!S06A3?*#Y&*5%+(2FW^36LO;937_5&HW:J.LU1IJQ- M)]H&HE(;2.*D3)%54^P8L>JTO]QVL77YE8-PR4LPSU]&["B+_2%2WDDKK[IZ MM*_X<)1ZI[F$93G26:^W45-#NA.VFP59`M1KE.SF3MEBUF26R[$Q*JZY&9$_A,G5=WC'J<`I7 M[>JVU5>*9?-Y,@W6U<-:M?X]/`GCQ+=-"R-!E*E?BFD@BV`;"8L2[',J+$LM MS:WBE;=#M@)3*8O>WH93<*O>\_1>;TQJ3(@&I=]'.J?>68G7-&7D/*E8R,TBE+_:Y;SE1S,+Q>>6U^0!BD4\UY%X#/ MD\)PCSA`!'$6)A>5R&,'B(H]V^C=N[RM]G&-47QU[[FL]%_M!-%F^,M5F$;) MK*H$8X2O2VH85U_*>@BJIC(*)$DK\5B-U1D4.C&I\GVLD(<=C*@K,;(Q4,(4 MOLV98)Y%O.5F!9*B:K::5E\=\P2)X30ZL!=W.)869Q;++FESR:UVMOTH#N+I MA]S9UJ/*L3)8+GZ MZU4:/D2+AS$20+\6E>^P^`TP6BG-,N3_F$JC6[(KQO`TE#M41I^(*+\&JNN^ MH8Z(`K&!,M1V36D"4JES@P-)@SDHD#5[B.(HRS5YGL9<(N1Z;!8O6\\],-IN M.ZUF9]?V8XZ:\3F@P2PB!5+-[T]`V:9?<8R48/6DOWGQ&P,O=J6"(W60NI2\ M++ZV0/#_[#UK;]M(DM\/F/_0\#H#!R`=DB(E,48.D&1YSPR=U]65!B MR^8.16KYL*/[]5=5W7SI94FQ9,LF9G;'HL3NKNKJ>E=7"=0?#F97HNON:PKV M$OQ4EOC-IKI01\*\`=[>DIT`2Y9I&EU5ZQB::O8M76UK#5/M-K6^=J'I6J_; M$I>^ZGJKJ6N61,"6<)4P4V:;6.4(2A6_@2D81-SW2S=()^#<0E=/39 M23`B,+T>'4S,`_O`-V3FTH;PK$4P1&X9#;[8,X2WN[>;ZU#'/#PO*-?T'W1' M0)N*)AO`5G>3>UJIF\_9\@[33U\,3JUFI0CH"7%JY#@5O38;K8:]6YSN-,Q# MMW7HEDV7.,#O=Q?V(6($.K1FW/W;1'[VB!.`<769B4/W,;E*Q=6K,^;A[K6[[5;+[JE6LV\!W"`V M;:NCJ>?=UOFYV6GTS(MBQ^VMX'Z:),3-[_=80-_K7O`AA>(,?:_*2YQW(\[W M-"NN3KP!!'3];42"E1EZL]'3\X[5L%L]M6OT@(,9E@5_`0'V@6( M>]S$W_WDS/7N?[]-S@`"_$0V*XN3J<\_'5U79Y? M__@._'$P. M[]T&GXZ2<)*_;L++\K'/1PF]CC\?X!_-4_SSPR![^"%Q5XRX=)BL34^6M[)J MT`^517^@72X]F&0[_KGS[>^77]3N]'?T*-\9A$D2CO,Y[>6O/-7S9YNZRAB3:`&)M3>A ML*.58-$:JD3^"")FWEC]KER[I/&,?Q2GGNEPVN/0]]RC.83#.0#R"\@BJM)7 M1>C,<[[B`[+`-27;J\'''*^OH,-\6G2L0:P`T0P)WI$Q^NFHO?S<%S\IP#:? MYN?K+'DC%@[L[A9F#8'?_:W7Z_%DG77Q`>4@!>]2]0=/+Q#)]7 MX5$V)5CZ<1@$'%OSQDD\)\^>E,X7O'N\%I>5'R/<3WJMJ;?7>C$('R)G\NE( M_/>75_L,D-J6L5M(GY[R7R2=ESH7A\_U=!;N@[/O=O0P!0EL_AT?N.&>#+@[CU_,1>>.+>D:B[4!OJTJMC8Q[M;@TY5&2W\6 MKK]KN"S#K)G[ABRB`2S"#=.!S_?(E[:?],6R]U>&QT?BI(.(#7TGCC\==283 MGZL>.H3%'1%JP!_`^N-'[$-.ZC*T/M\79,/,@-G+N7S?&82B?JMT&_@N4PKL MGG%NZA=]U3";7=74.I9J]ULMD!=MJ]OK=,[U1IU2\(PI!<;3I!3(+!Z*8I?( M+`Q@H,YMQ(G.ZD2#7XIQ9[CN^+"8R)E!YK,G!+RDK(P_`C@JE'TQ+!,C7[V7J%9 M,=O;":;,%\?"94F(!T&^B;\@-2R&Y\P5]ZHH;$RE/W2$8F`$P`VBQ('E3*+0 M38<)###$4CO727BLP#JQ*`'32BZO_OCSLO]%H3>S.4#6I&.8V(&!1N*F`\>' M(2(>3S!#A83&E(U"@2:WN-P%\U;R=&=:JQL>?[B'+X+X\3("8(9#H@)IB$&6`(+4,^C$13A=*+8?3$2WSNPB"P?7(,>.\=+AE_$\`N`A`C#S;X!%;I MB*3Z6?[*!$WNPD1G^Q\Y48O.>P*;E3P"C7IC&_A0)#&\8=VFX-(!] M\3WXA,"!LH"I3B>T'SET2$O#<#S&(E"\@UD<.0EJ#A^@VLE6I[!!BG0=!C`? M`.G@ST\UU&'&6L2EJC;7?H9$@8:2J)!P6`@RD1DZ4=+$ZK?1:7 M!F64XBWV5&^^P[%IL&QD^'_/QS2LF)=Q@.GGB,-TPETB&Y@*!D&Z3&AQ.;YC M4#O%9L<+T(1H":8Y8G`=BZD.UR`V/QEZ2$'&[B#VZX>"4W507X_AQ6%E1Q+WQ((UB+CD(3IT- M"?P*GHT=U'F1$7$1V18L&/D1![*`,1!@\>.X?##@&[G6TPT$W<_="3JP(;:1 M<[J!P^XQ\^V@M(#UTP+7UP)NEIUZH/(1#HVT&,*IO)6WLPBY04KK.1R5&=E! MN9J:C8<-9.UP2#=?W_K`Q5#(.E3[%^=G3)S@B#LC9,EIKI#,J0\Y"[D-\-[Z MDEB#(=))=FP!K\!?@9_$*7`E8(#`C2.&R@#H`B-&['F(2K."DD$(3``.H#LK:$6'3B$#].28V("!A@+:A+P5D5!N=TD]/X M`@D.$UB?G.*R\H15VYV$B8-<\[@%<&@:8?S8;-'?0)62\R=W\'LV!BO\+J/+ M);G#-(!0QR0S!?+S2830T*"-Z;DV1D]L*YM,"%80WY69X,W-YCIT4FCOU%[[ M.H)S'=7FVG)4@=J$Z9!(67I5W49Z$_ACE$-)2A]H!*`I=J3!!C^ADQ7)':B7/KS/7"^F<8EY@,8G[!:P,E``H1(:L/2>P\-XWIJ] M*@;_C9*R4.>K@'J:86+LN"@?0":!)0?03<1MU0CEL7':*/.8&?65S&Z"*:6R M[DSY!;SELH8S/@+HA$T\2O,QRO@<"0F(6(1I@6"FL+EE4YBLWDEF=S@HR#UQ M9QF(^#!2R?8-D8J^XE4V[/+#Y25S0:57>3QT1-LD.(RI.R65%U[/0`!K2<&Y MT?H()\(N1%2C22/'NF1#F<7#D@B@BZ7="J/<.4"+09BP`>>HZ\->((TI.0^> MI-$$+0M8MR'H*W!J3\K[]_6Z-[-;EZ,*[A_@T"!* M/:PE19E`[@`?$#\!;%=G8S":DFWW0YCZKEBYPVQ-=Y/*R,XD$L25@*N$5 M"=@N`6`.(]^%,\XS%;[DY)"T439_.*VV1(89$:))%/$DC>0D0&1:X5>`43+Z MPZ,]"=%N@`&E>U]UO5NTZ=#:5@=8@%^UEO!UD&##R!MPMTQC*-ANL7]T&`GN M(PSVLL:8>S2*-<1S:.>H*1$M#^ELSK`%P2L603V)/*2)L+(70]J+'/<%$<(@ M&0G%SI@O0#YID*6CZI#!!V-F&\@YJ@IDC`UQ\1$=QB@W_C+3=)3"7I2@%U9G MCM53Y..C;,%N"-\CP2]8,YP*.`1.UG17,/R,[2+!SS!>6!OJUVD"TBG!XP5L M0VJLJ/S2RG&!$4<;4QP:5][2E7N(!G"Z8\<::DG(`@5H@QQ[:'"[L(' M^$VDR._+QXIV!.C3D;XGXXX7EDKB`G)"=BVSJ"K/BR5WHSDJS_!0$87$*R#2H6`;S1LC&IH'P2E>G@4&. MFX_8((]/(YW9N0V"%`/[L>2]JEHY%+>6\E@<6'[O^"GL\%)11"8_^M+XOU+8 M)P2K-)SPS".W&XI^X<"@,J(3O"'C3`LVD=;M"&"`UA5A'\XSL'`D7.,_:5B8 MX=@Z;18Z%VIOY*]<^AHFA6\E!)UEZ0*T[P=$HC9-[HFE7.LTK)EL(' MBK]4B*1YVL@=Z`M=86%Q@Z-4S$@#QA2`Y>7*A[X)N[7WNTX:E[%&?^'_V!6( MFMH/L(*0TPAO!:)H@",U6#+K9L1D'L8M1VY1(*Q&/1@SJ%04.G)NM91-E;'S M%Y>^,PK#?N-@.(-U/F./%.:$,"^RV-[IX\M`9DL1E'*,`Z?-)X4Q_O3`*,-Y M48(R;SS!6S)IYMRA`&8F=Y),$>E]_A/71\9EG$767+S+7,BZS)21O#;F:+[F M(5,88.2A#8P'O%%<6D`V#@5P@%E[(HYTZ,=_)YY?$7)#.16.1:S[,3+('<&& MWLX\P:@:-?3F(UK8QLJ1T,*.VYI>N)SU4I!^@1J&^L06;N=3EJ6JB>"R[,.Z M(4*,AEAG\HB^>=S0#/G+)9K-H=/J;D55/_!NQPX:!Y$SX2E8U[,Y6@>+N5W( MIW(4?-8=O=`#)@/QZ@#,/<%,,T%39"(!/\Z"C4BQAI*G(HE8G+0]*WE)>D/Z M/19L(+ORQAZ^4?$3BA]6?=A%M&G&.]6-P)*8?O=\9;GBV/5"^($'0B1[KAO& MF?">D-Z?)RL5C*PLKF!$O%(=5DQP2E_U=,)C&6Q$&RFJ9A[D^0LE+_2(DVUT MK&M%.,T3W*M(3VB_6^P*5+)4BB(Y8RYI`@RE4R/R=&OX!&D,`,\S?!&BMPJ-%<)[([, MWI*E+Y+FEN4+%&%>N=/SIQL]![B(2KH`AD1D/![0+6+UR_:C[(AR'L\9D(&H M/$$`TX3R]`'T\Z+OM1K(Q^GF0_Z$&)CE0:"D2$F(N)\1<@GR"C^;T5JD7;^^ M"TDJ**43#1^$H"=X1#?E1.6<'91E_SUH M0V$:"_L4!XG1P[@P4Q&.T:WH0.1/EV9)Y>YR#`OE]^[!P%F:,X5T2^.0AQ>B:6Z@'V;+B3'R2%)/!M$+G M*/@GK,&3L?L'#)R5@4ZRB,7$YZ7@1[&EE23W',Q,4BWZ49R9761Z6F7[L#EG M'ZYEB@H-=75``/BY69[*GIT*!MDB)O`2LY+:!W)1XGS1V0;U8K.%9F,P08BZ ML)4H.:!N407=[?6U7=TPM?/S<[6IVYIJZ@U;;3>MOMH[;[;;6NO";G7K6K-G MK#6SGZ;6K$1=TF56H;"ZR&P'&=-"U"-O1NW@C]/OIUBI@5%TY+V22V#*#)(8 MI[0K]@/#]4GX`%+T,\A%,$U!P4BP>@/-.5#109J$Z>T=ZTPBC_S.=I;-@:H] M\!R5[-<(Y/\#%@2)[!$GR2JE(E0P*K4Z*)Y1\N([R8(BBCDS'*$IQZ?+,;S8KA1X M%X4I,3:D$<4;#L-&22KQE@25(U(/CH$SDE#UP#RY#X>2I<%2!QBC!I5!>OJ' M,(QW\%;)3K).EL8\JQX3M(KC=/!/6;HB%5H&]`QDP@G9MYB)(3I>8(\@D0WD M.]X8R60(*F:`<7[,S$-O$J9R`-T4*8.``$>(6S;@8,K?\U@D0F&>@CY="%=>QIEZ`O(P9.K M,([?,]'!'AU@,`B15:T*;2\)ND[L#:G2\\0G]'HY>J6.X%$=YX28%,AD.$.> MFZ5"P7LP1O5-Z<)_D#U^F".:_+`@I=@/%5B)]!OB3ZAW%,DYS*4.4J4T*>'Q MS]R=6<[43%Z:R/(6=:YB&0IS)6,MGE6!RNK!""S475P!EO#W#@@O6P)!/@3* M;RM^G_7;RU[D_TJ]>PQA),481:(C^I%`B$QECI)(;U2`UU,9*WF^A2RD&)`# M`DC-)JC+1^ORT4V-H:)Y1R+3XD%`#S$:*(YY3L6"5-&%2K:%9`PPBC@OE,%4 M.G=+>$K=VZ/N[;&%HF(;O];;PVINWMMC13N0IWI>3[W7J>N.)K,=/)J+.GB4 M0Y$TH^^(%+P=C-?IN M/`G+ M4&7)\4N!;;K">M[_M7/B>*[?U6NNU_R*%:+&2B;PG8(W(J%GOXW_'F'/6XPP M+S`*IS7:%+M:ZMYD:(VR9U$[[+:MV+9V2&"_"4IY+6K::@[]@RY2VG/_X3=! M/S7*7@%S-BQ+:6C/TQ6LII1?=+D>5L.Q5]4'L<9BC<4:BZ\)BW60Z\WX=+8- M&OKS.$_VM9'Q]=4HK>;BZ_SJXLJ%U<7%62QN):1;N6BBY+P]AS''Z9^UCO@ MMW_+ZW*X+,HM5<,-^-#!6Y%*=66EMBC8S.6WF2(ST6_%B67ET(*,AKJB9\41 MJ2MZGJ:BIZG5%3WUU'5YP\;E*75%S\8HJRMZ7O3^U94>=45/O<][XRYUL.,M M!#NN)_*FK.)RDZU\#,^9PV(JIJTIMOGF"CH:2MMN**W&FP-<5]IM7;$,\ZT! MOJ<=?RVIH:MY7Y8:>M#,3U?T5E/1M3=7P?AF`;5 MIE5CL<9BC<77A,7:%_'B?!%KD_J^5!ZEV6PIFO4\]M[>@-2:MM(V7S60AF(V M3$5[)LO]=>WD*U157UGB4XW'&H\U'E\?'A]):!Q$V"`ECC\==283GZO8J#4: MWF';,37@#[X7\"/V(6>]<]U'EG;5J#;?^#Z\XV[J\^O1A>-%?SI^RCMQS*EE MR94GFJ)Z//Y,%\US]SKXAO<3X>W[V!,@OL%5[Z!YF=GLVUW-4#OGFJ::IJVK M[8ZAJSW+:G6-"]ML6O:RAAT'E0FZIZO:L3_/>.Q$WO_QY4VL'=IW-G1@>ZD# MHI.P$1`%GIZ4L[$D`6KSC'>_"S*@6_MB_.V27D$X4.`NZ4B/?2#N\SZ,=QZ/ M<)`I.Z%.F6$:PZOQ^SIOM,X;?8:\T;99YXW64]=)=+.)1KJY,M-HB1R@]>PS M^>B-[BK+QIOQS)^TQ__];0^!V^\4;>T`F28C'4N7L&0^$@YM$] MF3LE'$_29:@TWC0JJRA)@TVQUWAB[-61EA<7:9FUB?:3^23N'-[[(3]>RP2``I%:\=+PL!J!U M!)XWDS'B9!YFOP0MJB5S0I%Z/.QH?OU653@XR_L/:HH[?5,G-X3 MJW=7>%1X5'@\/3P>XL7JO]3'.H&;]/*=6->$_6*F/9[*TXB@603': MT`=6M%#U^:H^_Z#1J.KS57V^RD6?4KF9JL]7,"N8MRWM^Y'M$ZW/=W2K=72W MSI[-8D]Y@TAAZC6WTH[385+U^0IF!?,YN$^G79]OZ;GC=XZ)-O6OOI^!H MCXMVFYUC6K*JKS]J_^A[6G,VXXF/':;G;"[2QD>E-H^LX*ZB#,`*X-%R[/=Q/+X/PG!;K7;,@64YSJ4Q:#D#PW&LOM'MMARC/^@.6U:K MZ=B>>Q*M=EI;:K63<""%#]07/6SBB1:41"QZZDSBA/KN1,!JV@PH=YMJ/!I3 MEYTU[1*H:4[QWH*S1+RPKH_./4MA+);*SC^IZJ"CSN6]_%Q>N_6R9=AU]>R#%!B]8K-W1N\Z6[]<]5XT]C!.P:Y&&^08>^0LM2UB4AB(@9>._\C2; M[>68T$MK<2YLW3;M39GF[7$5'EEZV]GRQLT);E&WVQJ'^CMGX.!3X=E-@NPHN=*O9/N78XL+26_;&+6M?S/@JI%`A MQ7%C4844A^I8/1%`'$]VZ\)NZ=;FIV(.V>':8E"D3,]A*TV%165ZSBH8^L`S M;13'7Q&\ MGGT,:]TYKIM;EO!+EO+Q-5M@XLF[9\GX)H-7?I]C7)#B`3**$&"&?":^V](1 MKW9S:-I.NV.TS-[0<#S3,3JNYQJ]OM?I>UZK9UT.3^*(%YXOVLH9KUX\`T=C MH?DL]&60A\>R+D/F?S6`ZG$(4`IC"U8V%M34&-*9N<+;+_M'S5>?J MP@LKH87!A--13CP!FK[=FN>^[GJ-E9-%$]!;!1Y6]$CIM+H-MUF)GU%];#4L MX0GC*+NB]B'2EMP`[2[&W:DPR!;'0-5V]\VC1.W:;W9.T^.0X(]!^M68))QK MY(?R--/PRNEC(+;9:#'S2^M4Y'D,/?@BB8 MY;/-@ZP\"L1;\SP!3(VY'X##EM*YW)4`S.RT/,?MN(9EN5W#,>V.T;&&`Z/5 M:[NVV_.Z?6<``9CUT\_-1KM;0_'.T"#0/^;!/_NQG^,XGQ9S_GJ7C+C]RZ[G M-8U^NS4PG+YC&YW^L&5 MV0STPFWW'ZWO#GG'9ZUB&XWBVT?4&/:/=[WO=IC.TK%8;P'1@O*;YT\_S M&Q1]1NT$&@+HQ\"K@/^4,/3";Q:S41SN!6K`\/5-_P\![!(XZS(9'JQH'(0Y MMM2\*=NB#+[Y80[!ZS")9\B;>4:L^?MDP!(LE4RO>4*L^?K9C$[3-;O#5ML8 MN)>>`6)E&UZGVS7LGNU=MIR.V>^H?(;*9^RAAWSKB;M?UN4S3KF;^GE. MK>[G6;UFIO58O%'$$/CYTRT$N=^[HZ?Z^4&VFT`?/9<33@)ES[G5:&<84RR_ M2K^G;U8ZQ]ND7O]"J*-8LZ+S+K3+H96-J:*T[>UHI5J<9VG&(G3?-\N8[O&* M%D=WNDV]ZQS=I4TO/YG4Z=IZVSZ[A9MZIV/J[N:5X\>Z\!U1_#PVB_[-,&>? M';?R,W6SW=+-YI;+6=7"#V;AKFOI1]8.\8CH?8)UVR=UX$5A46%18?&4L*AR M$0>7BW@VJ^_*Y=%;K;;>=`^ZY>'+%]EL=?6.<]*+M'3'=O3FGB+WTZ+D";JJ M)W8T3N%1X5'A\?3PN./6AJ]5[?G]<['UBN9ZJ;CGP]Q!MMC66=AAQW4&@X[1 M=>V>X;2'EM$9>$.CX[K=_M#S>AVK=Q+5H]MJ=U@=0Q6%A_,DQO,/J<8>Z80H MBDO%>5AXGTG::GDTYJ*SH=5L=K3KD$6;]$A4E:*J4G0?E:)/5"&N*UQ\XK#L M:WVOIM[IU*IL[L=*BS[DLQ$H_7@B_9;"*Y%VG\!ZM:JCPT?'ORE-]Z`IHW?' M$S;E*]\.OH%7%Z2K7U\G@<\5XIY`W$<^8T$D=]MKW_?`OTC`'R]\JU&<<$ M.KP'T%=#5HW<=R1K:AOL+$IRJVHTO"3RESQ<5'PC8FSG011YZ-4[MM[NFGJS MN>5>HZ^_\$T;JS::6^X:N04:[^NY@X;Y/&IAWV,E+-]]D^:7ZI6.;>K6^15# M.HUM-Z4]1E$]1IC/U`R'.%H-QS[D]6U*-KWE M;GE=)^@/GEC]NL*CPJ/"X^GA4?G.9YGR?)ZGK!G:'4_Q@O`XT?)(?H;78`1> M],W(8GKHT+WJ9ENW6P=]AGASKWH_%QKMS*O>TVUU6_>J+>55G[GU57A4>%1X M/#T\*J]:9:1I2EFS1`=VCS0C;>E=@--T]U/2LVW?N7G0(<%+:>1+$ MX^*8NSS73C_V6<;+UJZOT+DV2&/',MM?/M_TO\QY\H4Z.*9/][(=6-[0Z[BF MX7F#@>%8PTO#<]L]PW.&[<%EM^68;?N+^<7^Z6>[8=NOT,MV,^RL=HP=!B%/ M>O#$-$X6>VF]ZOSTL^?[',!@F/XF@.I-8Y<@7.:LP6P>Q@O.;WAR%_C\<51^ MB&6BG;"6?HHS%M9_[\5I]B'._N2P;#^>1L'?@&="YC!.Y%?XG/EJV/%O5[@_<#W42H#[Q)50S[Z4R6PVWSSS&J9ZB%Z\[E17.H5\ MDI4^]`@_F`U:[.B[CC6-N':8&C^P:*P!.P:IZ(=[#6H3]!7]^-14W[%1_V48 MVK=1$NJC>+S0#&,3XC^#6`^NB5NY#J[`/5[WQGP?!(I%"]SQ`RD8@VR!]H)/ M5/I*JFP21"SRL:=P"B@@92[QLM0AFY"6YJ,T&`)%=1A?AQ5D49UP;!ZD?QBFH#`04?TOYXSBYA:7(#L@5 M*@'R>!9DB$B8"O&=C.%5#IR=W=),"3@I@N42/I5]F%,80TRF5?836$BV8H:B0"_>U&4PQL?^3Q.,@VF!CT^`YXW_E5R MP`2HP4(8!:_^$)37?LGK[3;MIKC9H*%=1?1*/`\B>6$AR`<3[H@N"`D#+1%0 M]K#6Y@F?`[>,$0@<(\4^]"/2"$!D_$:N6M#Z>^LFSJDS<@4]#/`X_#J](%$$ M6BO4V/BO/,UH2)UF#=(,Y3:.PH60(7&W'M[4F"<);>+77\EN648R$'&?IRD# M3ZE$*SA6*-`U15?PWZ,TKY8YCU,RLCK,FN9AH1KB4IDBJ#,8^!;D`=N!7X`P MI6]Q8?%,R++/TEMM@KW!"W@0%#+DR"/CP&"Z/"(]S0)D?S$$:X?V+NCR]][SK9:V58$MU5`D5 M2V')PXQ]Q5[G:3Z;EY8$!@,O!CQN9'E!`VJ<#@0&!0;D@P7CJO&F55V["&K' MKQ*2!&(2>#87BA?'YT*:M#!@HR`D[?`.7JV_6^DM01'T<6`*!/3Q`3`3C01' M1BZ(7^=M%-U'T/V.QH&Y'P.\#G;"[WB4$W+Q#:P4`0V9:N.<6)54(;U&M"#R M"YI7C%5C*U(DW[4*ZVT"BD&>"5;$T_C+:^@0D>3@`+-D#E0_^9W'$0Q1:(`+>;!'88\FA^"`4,T M9PF('DP.3/V5"]4_(<.)4\+K(812Y'04LU_]^OF/J\&'@O\'8D;PST;PN@_\ M[(._`89HS&=L5>?U?QLLJSS0U\`2OC#7B$U2J?*SY'R2+5!E"8+SGYR!#DB6 MJ+.,*M#F1KFZ.MO!`J8)FP$B2,[]/!6V6#XCM'6-4OYM$L,H#PB%.,U`O_U- MR`+B@U$`A<']VR@.X^E"FX._A=Y?NAY*\A&0^::+PARGCP("VH//4>U$&>B2 M^UN(^$N]FY.*BX%2(J5!P#P&!S)LG$]OZ4T(LB!DJ@4EDL(:FP)7D_H]$)4B MN5M?[S*06*S0&/&FDPI"DQU$?X%>Q:!)UV:!G\1&`&L%3Q`0#C&;*"HDF:R$ MIA`9,*8PPB@,1/%B3?7HR#>L$G7IQB'7V"VI2QH%_,@O*4\KGV\)#N)"8'@I M5C0&B(EV08\**'5D%_H3])DN/L[C<#'C22K_+'0-\M1;(JO4@:2*XWN.8(SC MM%1;Y7CH27X$%D=HD-1I_MC&=<=]\T[[8_#QTU7/^]7P?KUZ_^&?6MF1I]0% MQ#@P`GZK/^G@2X6I!3-@4Z#`_\*J`6)BJ/A+)&\]`I9'.H.BLKE6'?6]9JQ)S MRL`O3A!QSPQL1K%-PQ'P>DL]"5[`OS?5A=2X0GQ&J MZK#2X9,@23,PF>$$F0V>:PLZ`IPDD=+Y)AAT#2E'F8(EBU0X22#)@!H!)KG7 M0JP!#)0YJ M^@S#%P!G#@-D;_7:P"#K>%/]N!H-0WH:C^C&$)=HF+0T^+9F0"&5.&3")SPA MLX>6J`":(?"6G^J%HJYI)4EU@E=C<8C]'\J7C.M+O)% M@!J?Z/*XT5TVN2$#TI8X$S?[&Z`Q[@((V82$IG*3A/B!?&4Q"//21<)0*(*UTC=@", MA!3C)CGP6SY'ZL::Z39+#)&.!DYE#>TR1DDE2HCW!!K@48@S(-BCMKT3.WP5QGH;D+T32(J(\`[U(SHA92E%`%QES`Y6@KW+?(VQ> M,;ED9/)_\C%$B#KF]]!&X[2@(="W@7%%Z@QPS7V6UZR6D#)\?;V<05PDLV-% M-"=Y0%)\R2Q57'@K8U54@Y7R%*J3R"ST9)`5"))9O8*?2EP1?I#QT"T+A3N` MYA@BO1(/$+L#_L`=Y12Z"KY!D.4(?!6MJ^P./D<^GG*Y2ASD(:?+]18:%K$[ MS0-*8`#:XP>H(1,+U"OX#0V%G#C#D2#_T)P^0QY&I4<6(4"/! M1$/P=T4TJ;VQ\F,D_D0U,:-UD8HX4A/XI(KUKU/4P0LCPB9WXY MAX'HP"3-D(^2'-5(N7$4H(J]QWU(CD0MY0=6,[]=I&`+4&>)T6`4&N\J$QF< MPGDN$Y4%_0KJ89*G\NIJYIV>+"P,K2T1AM7'_*A/L5<94-7J)SD9I">M.FS9@GM+`TGP"%`J$M@![S6&R09#&J MWHK10"6S.4QP(+3JHSX)1GFQZ5,Z7V(',YB-D%=I]>`89IC50,S4\8&&Y9VK;X@

NHI337I/=1Z0ECI(&S)3Q:,AT+4$A@N.HI]2*IA5N3 M17(?,YCXGC8*,.V)*>@XY#YM@,L@K"XZ=P`EZ$/RHP*YF4@6I@+CX73ESCE( M#2U`8U,*"LODX3V7\3TR[92CY25E*]/AA`JQ4RAX?`K:"'2+8%)4O3'X8;<) M);T.C@=DJ@3<0!+*:L\,R(H[KU(D\"FQFX>ZB"2AVENKCMB`I711[P3)D15]@*?5-?F]$Z=%( MAJ=`?A\\>/(#2H<`7\1MV0QY("W+)I:CL1&P"8`C8TB:BZ6WNMB$QK?O,(>1 M%>ZOT/VB=*HJQ(#)_MLV&VU MR]R3C.^7R7)1J21\/KN/EQ,DM*V.X5.1AD&?4)@T2NNAOI0[T1`8R)T,"KSB M#!4IB'K=(9,D3XO$UZKG=2#,C^\L[>+'$7SVB]H+<#+]`^&U*\R2+F1]#@*.O%#@^U'^^3Q'ZB*;QHU*.^``1K.KTTH"'/RCJ(X0 MDE;T+Q/^O=8#(Q?C!A(A(9"P7'P"8^UKK6;K[4IH=O-9DQ.LA&#]].`([5F^(8BM3S&GOWU6]7-2^=H)%$2I0;B0-*0U=W5U=U5U55/ M%5(V"7(7'"G5V>+V`6BP%O"/C'+-<4Q#)PIU#2B3(I*MKCB#,35A?F.0V"G" MN@L/$<8!P3,)"Q9F'J*")6QW+QP\Q6X;$]A`1X29Y.1;'BA5#"NN8H-+)QOV M*+_-P6@?&CWFP#D8Y+9&.=DI"Y!Z(M0)!9V-";-YR_7,/#C47*M-18?="#/[ MIDXD=X'2:TLOI@N8KEIFL6/\Q>@Q;PD7:(+WAG0'Z=3)LW'?$SQ),2"EW%Q@ MC*LJ_UCSC,M[P>:5.7&1BI_')B'/TCC"S8L1C6$&IC18\:D8.9L]QM4I`;-T MW%V.-2%PO&9,&T&J;+NA7JNJ*W0D=&.*PEPW615X-+\EW&PH@+T<\;T0$4[2 M/FQ1GYA..>X]_PER]S[\6"A.>7H(G/S]\C+_$-'CJS(UZND9HKH486X!+7QORN*8:O)0A/_EFB7F8HGLDCBW(02/)GW<[!GF MEX=^XRT!6CST\H\JTD)5=(_7&>=UQD]09]S<4,-Z*6,]?T<]7<5MWG0C35]4 M9=R#%#,V-A8S_H*G0-6-W^DI4'T?X'%`'Z[J&2\?#EOFBUT,TS[XX9GQC(O] MX@QNKN%=X@%=E-2^.&;M"L?,Y_D8NPL'6KL&H+7^*I.SEG:Z;/HUC=YRLN=X MGWF?&]@'3K/JU8VK_O.:R^>C+_8=@>QD2]GJQ3,J:+CK2+5K&:EF7\M(5?,, M0!C;J@%^;U^%=G[1(ZOQ>R)0*JIK5L-^PY9L4]3K^"$0[:T]A7F MW7/(NBV=?O-K&0(MK^[*N/1]+(P"+TE^N75F MLX"(/MZCLP0*$1$Q_)#,2"6T3:1WWO(6L-A+]>ZZ_=S:*_6+0*M??O^OD-6Y8;7_74<`!\1 MC:1]\GYU<7_FZ86]97>4%Q4PP[EXI6%'IU?%MA;&9@T^N:.:EQE6HRL-!T%= MX.9^81?5G(^MO/!_Z7)XQ0W^_+=]@?V;7UOVGA]@_9])[$'R?TT4,` MY='R`4G]VO[]A^'R];3B#!U+ET7'&0Q$31GV1$'WH4ON M4R<<_UYB(P\HZG)5J1K^F!?7_A)[>*WHT(JS;EF2]O`A"6I?-4W''(J2I0Y% MK:_IHMV7'7$@N[+4ERW'=H;K0A+XA2^[`94EZ?LMKWCKBE?QNE9=%P=DDLY? M7FD,KO/E^RE*<2V92N9JA=$W47YAE[WZ:!0$>O2F6%7DO[2&>Y)V8+N-B1?0 M'Q#1D<&N>WZ,['#K:Y56A".W?^RQMOV`78T/XR+J($_-TP2Z7W#2/LUF,*Y&E5P;: M"(>/K^&S\KIH'ZD'C MQ8^^4L_-\]PZ1_6B9GHL.+QXAD65"*@VH"KOY#<[0?R4U3'TU@7.[#C6M_JN M`_VA%>/#N6SX:H1?(9RZT88/6DS MG(N8W?E%Y*< MCYR/Y\3'<[P@WS6+!F_6#YY&X\*I'SY0]-;0#XDPI376!8*EU=K[TT]=(L)N.N MX*P%D>W0#E=MSA-X],:,"/N*.9`XQDD<3075$L;>P^DH/.,736[Q1O=)<$\B219+0FU6$[O;2HMA77Y M3?/('Y[&UX99X?%8/!Z+QV.=XO%KO75H:3P63^.[G'@LGL;'O<*QG>^<\'=1MQMQ-U&IWB7" M+B0Y'SD?SXF/!RLY2%]?RD;:F">THKY@[^5">[W%0GOH_Z9>;R=)LBFKNO?9 M3_X>QH2\Q_Z2)/WLI>1W/_2GV?0`-0=G64SJ%0>UIH-'8,,"\U.8C\75^4Y7G<\\3'6^NF#5 MT\F`#I.S3:V<8_3..:7XO0]9FAV]G6>9NWGF'IJ[8T'NF!)T7I($5B45$_S\ M%*NN3J<1YM8E.#N"'PJ>$),'/\%=8BR,_9B,4GAX0E@*FL7^B*81OM&ZLBS,2,Q:%B;PQ$.,*8>S.!H1,J9] M>6-V):"1YRQWA4^!-Z)[G.`]X/\GA+`]&1#\!OLP MIA:_D6T9AWLF2<1GE8X.LN(2X.X],!+$19T7%WJM#!R$\QTF&^0!R#T2D=F_ M\/;;:NWV_^%\^;WZZO[C!YS3A]B;8CYZDGDP<4#DZZ,/@EEO8^H]=UAN*,I@ M1$^H#I,R.LD);'(K!3474YIEG@(G@3P0H9]0KK"[#P\@OWB/60IM*8K9#+L# MHM%5"DGKP.LQF4%#,.XB21_^A?#KU(/S$7ZZ]P(O'!4YL2LS8G$!/9)@DJ^= MF)[4T%GH!PIQ%WD.QV4(BPG_0%/AR3?0@](\0Y\EVP(["P[.3XH?@LJ$LP*D M00]@5*C@T\4CZRH5=F@&%P*<#HRC=1(SFI$//V"Z;I(O*X_R%=91W@W*(2"A M=J7OB_$N+%;&^YQ.`2Z03U:W!G6`\_(("@>=T`KV`'<"/QJ_B'Y0ZSI0&OM` M(TJ98-!-C0E'!D1B>-9/"K[5NU!U`$ALB[RP:O?4S8YI2CDAU9([NJ&4$DE[ MTH&93V8XO4\D`.%&:0Q).K_'*8J&TX13A"`-VJKV6;WXK-[]_9L'SBHV/SK3:T6RMH^NKSTFV_="S M#O<:*GU?P91)8;^8@4WFCZI=9^$45+NR5,T,D%AS#LI2UZJ.P3^+%I!BM523 M7!37'(8+1Z%E2Z\]"K\U)PU@O^XD#!:2/6+,'-F=*`5T^ MY4`S-,@`5@0K8[^@NK>6CTVHYOEY1#PX)O,C];7'8;[Z`T#NEJPG/Q(OIV5K3T*J^X4&: M]XZQD3*B:[#7VG[Z68VNZ?X2LAT M%D3/A:$,YD:2!2FN+ERA-VMQ>#KU;<3HJ)K<472]IO\LZ#YLY\G2QRBF\$'8 M_[+OA4).&'=PV&C8,1L07@:CW)(ZEFSF9`H@H5P=0HL1GIYDB$Z6C[)+9X#V M$-7XC-JMR"/60=HT4EC1-/P1S)/[_TG4HL!-JBD MV*9G0(*USG"(Z`Z6[Z/E]*&_!'@]\@/?*ZRY^O0):*T](;K9?`=SH2BG?VMD M.(Y]Q'/7=O`0V\J>N6O*ZW/7]-,ED/&F>=K<&63D?"B.J_P*MO`S[U5//?'NG\TI;=!E=S(-7R#-F7,J1V3!CPT M#+MU-KFB:E>RVC;4DSUWUGV^CI3<7]&UR=3W5NTKEBIW%$EJW5+;-[6TJ_'M MY2+Z?*U:3N$\:=^6\U:6U8XEF;NNOR.#7>P[7*6[^U#Y5G-.?;X.3688Q1/B MMU&7>2N;^R#,M&Q?4;L65V$NHL\7F,I[4=`/G(OGR46^F^R\FW`_^.5;B`M^ M\$T%HIJ".-G;3=/1;*EC:Z=!B]ORN9T]W.II@"V/-'=&5U//>7R[3EO'T!L> MUP7J@Q<&I<'YR/G(^7AY?.2Z\U6Z/+?3E`510``,,A:B6,C"_#/+W"/?,+D; M\_6G+^NG">EI6G>6SMHDV'?N]*YRFHB)IG5GN6E/ M.]>=3]THUU4X'SD?KX^/EX2+W`C>(P-:8-!"R>O!=H`"`BGYS*\[$4R)YL.4 MT$QI5(-=HK"NL<<09TJP(?3WHNB*Q4$*:,4S&.AW@M)ACPCZ1"M<)*%"Z MLHAO"J/`GTQ*F@CTI"U1\@0$Y']&&,@(8?HI_.E*ZJNZ/-]A-0=3`Q).$!28 M1CD['[TG!*&3I;QO%;Z``-TD%#L)^[\,8(J02V-$Z9UX?HPK*R,E+MQ"(U\] MY,$;M:NJ-6A3P:E`JW33[FB25;(@=[V/*R!8G&\@LLV,4ZS>,4$@J!RS[K'> M8:`RW^6\T7DLT0RQI?"'7N"-_A;_&#U&"+K+GKUA"'I(>QJ-2="M0XP)(R\8 M90%%[EPF4+0*)$IP,`3)6A[MMM)]C\4#!.!V.@=S]3BDH(ZFLQD*[5W9(?C;A3"PNP$4VX5];5.%W`9IG`OE7P M86$?*:U2O:M+U?(3JX]&5V'^(:1RK-D^Q[FEQ3:$IP@.$C\H:FN<^:R:]OKJ5KB0=?\+/<7H'1=3( MV$>LT7#<7,')+68VGY3#F)\<8+Y=MGFS`//TM!)I'3.A7NN,KH`P641=:RT7 MCPI/75:?*4"<9S%Y!&ZB_?\VB)+D!\1!CJ9HTL*'(!O3^#2TJ4?U.2!L#A@V M.T4V%IG1.&,EYW*8YIOO2N_*JKHO6R#<,WQ[H.,EN26:4+VTP@'C9B@W0T\` M?6SN8(:^V@I]_>^\Z:,V?5%@G0?!5S4VXJM^P5.@ZL;O]!2HO@_P.*`/5Q"K MRX?#PLE_\"B`9]OA@/M[KY`H,DA)8M1_?/F#R1()JA M3^GHBWW'V%K94K9Z\8PPUG8=J78M(]7L:QFI:IY!7'@[E9G-V]JO)"2Q%]!= MS1MC'!FK"?^TX]7L8<1JM]6@MFXU[)W#8Y\FA?J$0[9:"'>^;[:/W3"J_04F MQ7#`2RHY(ZJG::\ M4+/CLHTSL*U;IEY>6&XFYR/G(^?CY?&1YUR_$)+JK,7NH5FR,<&<7LQ.CJ-O M_M1+2?`LO%&ZJC#U@P#O?VF":Q;&9!0]A/Y_R7AU1'),\CS9J,+;+-)BLW!, M8J""\W=K,A@GI'8CVA& M^/PPY*Z5)TPOB]G8?\*O/_^8)>*#Y\U^HF'OCU$`/4T&_\G\]/E#E!+73T9! ME&0Q^0)<[@7PS#L@(?P\)OY/SI2$8[PA&P;>`TVXAF<^D\DOMR0*[CX-#$-6 M54,495V6Q'])DJ3>_?'%O5-,[0[Y+ZFJ?"?="O[XEUM_?*>;DB7+UEU/=WNV MXTBB:QH#47,U5;3B*!FB*K$^K^M&\$MR;%9#QY$(Z_6:/K%.%\+T5RZB M#I/0#]GTGL0?)ZX?9/#K'Y@TG]2!;'<>4!;Z["V:B)_<"F,R`O$/$AIRO3!< MQW%L61^:HJ8/8+*&JB[:5M\5A[VA,G`L23/UWIUZI]V^4R5#5A19JI;'*TZ?)\KSE.>A,#R MTB7I^RW3#NINE>)UK4IA",@D+4VW>_Q@L=/F_D5[CE)<2X;)D@#"1))-!"]) M`6HX):M2+!+8(B8$CA]0.;QO"*Y!TH3>$`>^=X])VCZA`#5```%8IE2UF60I MK&CZ!N+0D/]D)!P1FM%%GFAN5_KHI0R(Y9X0Q!:IJ3)^#NOAAUXX\KU@+B-S'3*XI21^C<6>K+L.^5.*EP),%H$BN>XW]"9#`3D/_ MTJ_0Q75=HH2Q':#@)TP'7--DEA10)R3TF!:'0P%""8Z90).C-.`/ M3/N;[Q8;0%T=C(&S<8(0,_`ZK)R,:9T>9J1Y.!!4'Q.4>C]Y1"Y/.A6,"D@< MG%4TAJF>C4?GY!"-5V80\``>D* M/3+RLH0"V?@(Z.,G:13[(P3PB1($L:%9?Q&<=%X%=3YX*YE50BZ1 M=*YGY>QVE]8+Q;.!D;+T1"83)"038`GT\XVF4<"C:GI9ON'6:89SE&^^J[1] MH"U7Q%\'I=-=L>Y?&`>\BDUAE]Y8)GZ^V2>'DJ9.@BZ"@@RB%#PSQHZ8RDO7 M@)A&(D5=JO4H'_T-@A*1<33%A9D&.(!)`)02L,P,E2%,380)&;/`E@#6>\A$ M%L-;IMDT9V:>%)KD*R*;(;20]XTJ`7FKY1"A=;HRZ:C@79>,".IX*X:6+UVT M&VKX0WBMZ52JMRZ#K,6@,QQ1]!=N&< M85RJS0UN(2@5'K27FWF+G('O"8;'C^&I&#<]&!(HJR&ROXQG!!JUB$:VA0,= M: -FS5D=F(SV!XH-SA.@K7HP=4(B&!F?$GL*G!+,PY%>J3#KL]"LZF)OZ9 MU7.S5*D0S>4F<6\;C>(,DZ3AA`KHH17%-92.NN=B1.+4\\-B`=%S`;;:>2EA M_ZWV(VRR`>:MA3]&L%%G`?DX66E:.&`-,^OJ"ZZIPQL2FCT<&K;1%_M]I0>& M!%CQEML;BGW%`AO)<*2!I:PS)%JU1K9/]7Z=6EDAM+%=#Z49]*@@AYL+J8V, MVQ^S2Q&(CDH9^L\RBEYW3PUA&F_-IIJ>S'.``!7,'D^XYPGW)TBXUXW7)]PK MITL]YTTWTC3//-XJ=SQO@_IJ_L?>M?:V;2SM[R_0_R`8YT,*B"Z7R^LY;0#J M5A@G3MPD;9%/!BVN;;84J4-2CM5?_\[LDA))7:R[*(D-FE@6N=QY.#NWG9E= MJ>9^^O6EEMOG(5NEXOY@B-4L7Q=AU\7V]7O>SWNN\V/WGA];E?JTY<7V'R=N M(KA[@S#(O$5)>(4S*C:9N`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`^<9T,MB++?E7XJIBYX&7EPHUP7J>+>(*0FY)XHZ;9P3?/`BEHB* M]WCRS,H4,.IU_>*YBO>I1%_#"LWK`CI/%V1[5HJR^D!D_2F4G_N!+T>2VS.C M_VG<",&"75+^-PH3+H.&D8>=4]Z-`L?]:X2-][!V&(2BZ`C!Q4G:F@;O`V') MXMA#YG*2M(-(?B'SGA0H2+'Y2<+;C\P7I=Z"4NTG MO/,0;UZ1?5YH00Q]!UL7Q2/L@!*GXB(5%C^(WC:Q-_!\)\K6-_PF;RG-RA"X MH"QUY@J*TD#?O01-HGCT"):$AS+F)?1'`Y:1\ACQ5EH@C"(GB/&98)J\\T%* ME2;P8RUR:I%3BYS=BARZ2.3\@&U_<](E:X27LR7BT1#[G6&GN3$L^22!RV!) M!V&Z8G_X/[&"O63,K0=NVV@@\K]QA(<0/))G M<,O$H(VA$X&X\8:8@MCX'H[\5*SQ82O@+JW:*+Q7NQVXX/,0FND#CYB_ON=6(O)B'T&)PL_'5!?@R M<2B\Q(F?F_QO&`'9!5B8/Q?Y1S"`$%N3NJ#K)3VNT]Y?B[I%P=2Q8VU*"._A M]YBG8[HR1-O`K&>4],`<[L_C/'.S!,_:=W@?P^_867L*@(@#`#_P06`A)2,$ M!7N?P2_'&6<_CK#MHF@BB0H8^V@+U%.TX)E"]Z9=UQ`P!JL!7?1$M*)T&>]: MU>0[[2SB[V_H#%G4;,#ZQ0FD5\3-QN_77ZX;3]A9.Q!='Y\8O`N&G04C[A*, M&["`?`%^]JL?L+/=<(319'#OG:>(B9C#=7;4HC]NIE&'[$E`WUCT.G3Q8GPE MO!F=RP:B":";-B/'WFW-!J(K6MG!W)%9UFG2]KJ_U3E\W71QOAY4L9^4Z-I7 M=ZYY2[B\7I=(E50#\DT46%[,Y68L+.+,+P<]E]GL:20MZY7*HV-.IKY$?]34 M_,XTF#">L6%HKGDC_A:OC4-87"Q.9=<@=#%^!O+"]_[!K],Q"G8_ZNQFJ>%D M.PV$\N:MBX0:2(D(5#CZ_"Y[2/(`RE`(L(:`02P@NF9".],$#N*9-VN]E<%[^-!O:;]%QNKG!, MO,B5T)H83[$'3)&P)LX$[$&8NBOZKG)'*OLZCV'J#/$Y\G=UG1E1:<0T?8,H M`T'5^2,71=Q(6%"B#:P/CIAH08@O,36I0&^X.!'V"L0*]GSP7-$U%?2G>`'8 M9O$!5T'TD\N`IX6'EO6'G?+9V&.^R^'(OV'@:`0S=0-!H$?8P3="1=./40X' M_6?$'1N7OF1M$Q]Q;7(?;2@X3"BEE%@/;#?4-0XRD(\N(3JK(UBJP@3$'GGA M`!A%M$P6;SG%C[]8`3!'"YOA.O!3$GFOHENHTW_.VH]RC8BG->2GQ'73DQ.Y MXET6*%U$I[!`TY[):4!LPC.9QKL)IXBYVH3]@#"PT0+W] M#UN\'%/SM>]$$1\4N6,VXLZ9W,&&@Z.(VR&"V9W-["`TWJ<$3_="WO%X0CB* MX>;XQVI$[^OV@R?F7&_;?M!4Z_:#]:/K7FSE?E5$7=JP:H$>6#&;H>Z0MY9K_93.AVOZW;ZHZD/S&_44"KN#)2^ M?)?Z$#]>&HQ?IOD:T\F$Z&F5$)IZCWF,T6N9#Z5RT5`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`>J[_F>.'0H?,2S%3.(TT.0LK/%`CR7:0`+]CENL,#EQP=H6;HVQ52ZN;ZA91$/EY- MX?Z?71>RK5<;\]'+B[M;+CJGG[LH$E.;+"N$.C M%'!6+0!\OHD9RRM])BQTY^#1V'A^)^L_!S#QIRR#==\+CF6RYGR MURB,Q6&B6,?<<`;A"$_Y3AH/[,D+^+&Z8'D/6>2%[L$9<\/0NDJ:NFFM=&]% MLD.V()::34O==M]CID0I##OI,J1L!9F+_5([7`` M2G&<>2$P)2^)Y]0D??>2Y\:C%W@):_C>"UR'W@H,`J,[*+\DK&1L/#BQ!U^] M,%Z)Y$6-B,5#)HY$87'B#;C+,XK9X\@7XUR7X\QS2Z(2/*$&[OP7L0!/6>;U M3O!!YQ\>PPA&P=*GY#EBQ9JII153F+G>S,W1'S=A(#ZV9EC3!VFFDCUH?F76 MG*?`0$N><\W1GR0W"-5;(!TG(H@'C;R("+CC7\HU:0P\WT?PWCG#812^PTC4*R4A)Z4SBIR81=FQ+`I1E/],4[C'@G[Y6G]CF)87 M?O%\KP]?YVY^YP5]?X1U0LAN+'EVW%&4?]*//S:`7W!KH<]3Q\/&`YOPHLMY MK,AA,$Z1QP#5@>/Q#;5$DJ&)O@(#!Y^V?6,[%DL M+%[W)RQ`,FXD*TP<]H#U;[-%RRM4(A=+E[\\.Q%K`2.Z*)!8$'-98$<1UDEC M*+XUGEYRYXSQ5_9W)W(GY='PH-%@B'?%W92=_@@QHN][R?@SO.A;!U[X:+!Y M!?0(A!^_:PAT7#56E.JCB:F;JN:J4F*HEF22J@IF4JO*^EM0Z-: MV[8Z:O>>W-.K]_*U1:>X'0Z&/<+_V8O_[H$8OL$R(UB3^P5?W11\#<&7%5G> M$_Q+8!#@N\S[=R?LCW"4'BP0Q[_C#E_`2,NG5.19^P@\5S/'Z$^^S)I6=]]18'/W%X4 M#A!$T!*(QJ?'KA.AD(YA/(ZA+=+YMF>(&$>+\RQQ\[$W`P,,)NL=W9)LI=T" M&&A/,GMM56J97:JK1"6V">OQ7H?GRT6EJJRH4];8";5%`/_DL0GFVJ#) MG"?V<31X8-&G1WY]_&F4Q"!#474"MWG]O0`URRVV;5M$ZQF2JG452>U13;+, M=D?JM7I*US9EU=!:`),,"%E4URUB32%:BYXB%)_P)#@$,&+/L.P`XYN@'P[8 MAS".T[W:=KI5^Q5W:O&0/5B8@?MUNF]K3[9M/[+DT^-7YW4'F'EQJ"K$N/_] M2RDB_CV(&+BO8&_^"H;D!YYT7$'&T0$`M4#^:L04`?C@]3&+!WCG M"XM>\"S+S^R%!>!\5)!F`F(&5';QI2^DH-P,IP](Q*S#Q+\W@=WOHQ"&R_O, MXX_8[QX,S2I+9=!F8$$6@%R;OI*>RCAU^D*JR$06YR&EI,=G MYUXD;HZNJK2Q8B*55"W*G25$%*F%U1`6$>F*'-(JTDK`&2=Z@="%\Y\G/KE$ MN'.\PR[7%;4'18-=IW,$WF3:19H^AV/'3\85M@W`23/EXO(K3GJ.^7M:#`D4 MJK/F[HI,F8)02=E)D1F)5EQLV82+9*1!EOAK:/?_-_(B-L_FK>**(Z`93=TH MVA@K4?,&`'<1OOYD?.<[00+F71=^.\1+*HF"(,LQ6$A029FPY$@6P9HF M$>H1HEI%85N8?5E]O##AN(LK*FTZ@T=&E)(:F3_]4K!PFE,/+]YU/30!'1\5 MSTW0=H9>XO@\4/10CKY^QI.&8R]AJ;GIJF';EM#R ML]BM1$T1@>[C(^N#C=I]%:UW,1C_*<"3K$'BX#_=Z7G6512D(FQ8U";KT/16 M;*3#'ED4,?<8!M^JNH0@!/*,$;N8JLB^8!9IA%0794B)* MD8.YRUH(__(BJ"+Y&+XV=*.X>MKUB"5U29M( M:LF-\QV?I,=<6/G^`4F=W15< MD5(R&V1X@X@BQ1TVC&`6(@VL@CRL`@L75W!^QC/N"K(U.#_-"S56D7E%G8[W;4;E,I'?80X)90[B?<1>Q@;>3Y)&= M@P)23=>7"/4Y9*S$)\*K.DT^`8$'ORL%C;>CLQ03B<(^8R[?J#G^CLFJL-#9 MY?,F(46Z?P6A"5(4-*;M#KS`P\1(S$>IL)D'ZT/32[OV;Y"QZC;NG3.>N\/Y MP7,>,-NMJH%!#,67]HVV(G*53+XJ`J'-<>WGSUY0.(S=%X$4>@6.CR>"AX'( M+K)S&$W))2+$T(FLI0!L2->Z*[WM^'ZJ,ZNVV($C M+-.R+'F=Q9ZC9PZ3Y&`K+:+/60T$&D^1TT\^8.7#KM;^BDP`XNV.?#-N]4Z) M"=:<=X[RO(&4"8I/CR>S!ZACFJPL3^7"ZO14*-<:I)MNZJ;Q2A2#`A_L)_>: MX,-Y^C4!FU%3M()3M?OLZ\I`JNF*M1](E0FD*)]-DVA[SFB?OV,U6S_QL$[Y MRE<6#<@V0%N:0CG0EFIN6"P"3(G1K3O]&[TM6:M[(?<-8V\B-C,9(D*F>P-I M->,/0>(Z@-PN,?\6S'VYNIO1$R/'WT;%O4GQ2BI/125_IWQ3;Q5UBBW)UHRV9*L]H]NR M0&$;@`='A,C?=K!(RI3MJ-HS=4U^Y>_I)AT[;=._*^C6-(16A!8$D"&3W11[ M+D9A1S#SO_X0<7$Q^C8R?">LB<:/6N;,'=&6$U]9S6`;;D;N4="@!S6?V)-4V M-,FR=%VR.EUJV@8U+1$G%^$1(Q5S*Y!8JMAB<J]L4GQS8)B9;$WM]/Y`AT(STQ.`$`0?561CFJ2P6PCVW'X(D;(LV02D M+,.45["Q9O-;B*E9FD:[4DM'@::J%'ZR54G1X4];U=HJ;:,ASL.@1"Y*L3?: M$7%$L\8$@`V(JCXF`3WM@^)R;\1Y9H1,%8UHG1:P`3"$VK5:DFET+(ET3%.5 M.RJ(&&L2PI.O93/EBKDTY&BT@X#OSG`T;O^_O:MM;A1'PG_E:KXS$4@(V,I. M%2]F;^HVD[E-YK;VTQ03XX0KQ_BPG4SVUY\DL`,8VP*#+&RJKNIV')#=_;1> MNOM1=Q`1V>@E@-`/3XHMO[CP'=M#`N4CUF0W2C7CDI-`-`XW:9>^P*Q1F+6U MU`?ER;I:N@4\B)218Y*C!YF\BHD] MD\BG>Y9IJ;KAZ)NX.QE74U0MDV[_+Z[A&GP)7]F?CMHD4RDA('ZL49^&Z#O0 M\HT1\?:9>E3V3NC9KS^;;?)(0 M@;,(G#CAE>TLC.\ZOND0D_9POB9Q/*$)/+(9S)>58Q[/)RCJJ;$.*/&&+);O M)[OC)!(V.W1R(M6U1@;BFHYI&):KZ'BDD\EAJXJET_K'CN%YR(8N\O$FK*KI M3+68OGV>L6:D8_+%WV;!?#Z-PO%75AV'?%5ZV>?M2[BD(:PV M=ITM!?,<*@Q,MEW7,!3LZ*:"7!4I-*ZI:#91L.N2`P;6TH,RHH<*%;_3GD^K MK^[/XAWK4R\SG5&LEX#&T*"4-WDB1PT%;$N`79R4P2>ZSNVYBODK.@KR'(-Q0865'3- MQCXB3I,/M)PO#.&:SE$MA5BWL&-[P06)Z[B%S)7(6]9.PRC-8NEU4G25&\O9 M1:G-O`XLI'-$#"M:1?C`]Y&O*[9+G&9$AE%LQP2*`ST+J0[`IN%L/*HZQ3<; M\UBS!`M-]+.U9D/TCNE'->Z5K5)*V3$$"!-8&%'UDJ>WFXXX#M!=`Q(GW$=8 M08:G*J:JZ8HU@I;F.\#S?9B_1X)N--5K@>G;NH9JDD\6!^@M:_]APW`I_8Z- M?Y&0HW9[Z%09__=YF'S?#JYLDUD(>-`T7%W1@4OF@>MAQ7)4K*BC$31TT[!YKDZ-'-A6P,AO3U&5H4>9.:]B5(T)2'!4U#HCU@6ZZ]_F@0[!&`[ MA'ZCM[A!--!$RSM!Q;0ZJ[V`+$3PHVFVN!?4U%B[4R=7E:%'ARN-73N`-VJ; MAZL&JFAY[A07RK.:-F1;01]1F].&7UDGY`**VK4U833`QHE12"L5J!`8CU"%,[1*9WU7GDYKL2>4BN_L$V%UF;_T831*QXC7TW<[DKJMMI@%5.Y#\Y]<(+P$@O7YH M:?E$:#TI\[&]+9NAD:V%_4A,B@X:+19DY=B*+K>O)Y[`'K^&6&`/P$UDKYF4 M>3;4FF&2Z]?8;(UH:C$5O3VYU4%I;CK,4:%V22-B8T`-ZW0Y9(O$(]M1-!V0 M/=(:8<5!OJ,8:(21CGT389B5+C-*"\:I-X9MD?DW!CZI:=3$4F79&+CEK=H8 M^`36:`&`(_:%];7MS[/%DKAD*54]K5X;)RT`O!ZJ):NF+0Y+%\ZK?WDW)'F( M]51,#(%(-C,C'I!OD)$D?SJ=4)Z+4;H_V$>._.DT2+NO:#B['M0929X-G-'1 M6+'LNG0["Z3';.'LZ;3+0?Z$N2U&J2%/J9R<1RO1U?&H4UGW[AS[F0=PK>MH++C#);PO-ZTG2"WUDLG_XI`-LF:C;8I([C&S+NEJRGQ;G#*@Q M9ZK%X;^C7K79I`Z:/1M7[N3U;[5S3+DVN@5HK,L9_]7UYJ)W60)`G+*,ROZP MM>[Y5Q49_#9+PF`:_1V.?PNB6;T"`.*$QZP97%YZ/EE:9[`+$YD&9;!1;#;# M>8VEP][V,BJ*UL#0-+7H\'2H@U*7ELS2XBV];N^"Y.$19Q+!9NJ>[XW+#XDSMIP.K&* MW7@[[?`M3C:U/),X^WNW7%KL>('Y*HG1"8904>)&9<2:-Q86ABW9#\B`:O6> MUVE;86$BTB).&K9*BXSPKL+'R^L#W?%,S5*@8^@*TFQ/L6VL*B/+\#2,'%IW M..LM:^WK/[D_VW%T%]WC!>5J+A2%E4VFFKH$REE"AG6I#LFMVJM,L#@]#RK&E^U;*. M/D.(4TG7U5FSIN?'5V=M.SY7/R=:6?B?LUX8K%=^I2L:U0X-<-0=:LXA0]3? MTPW#.)95U1[5B%<-K?/I$$NB:L786D-.:BF+Q%3&.)KKM;93?7`G5OE50ZL/ M?K3,;5[J04E%K12\%:HJN&F\):K2]1+7JT33O>2\59HJN@5S%JAB*Z0EE]2\ MI8>VI>:M/,3@1D83L5L)6(JL%]:[L$$75-#%)SZ7X9B$$\ M'8X;DAP8PY08CZI!K!\D.0@D!HG%W3R(>P6=8P]U<'.?,!_%J=V[HZ2))J&E MM).[]I>5:]G8\'=+X$HW;?7-%XU(Z^U35A3&!M![S(KJ=,$`-1:,_K"BCFDC MSKG*4%:44J.EA\R\*!'J,JBZY&1&B1`?ES-X)R5&"9"8!8$;N4X2\:)$Z(GR MHG10"LL)XT6UP`P2H"2+Z4@OZD@D,TC$$F%6&8)X9I`(FU]7]1=,#1*!(CE/ ME3B.^_QJM@7V"CJMDM_,"U]#)I0`P6BA(*T$7/M$*!$(42(4LJRB+`*(4")D M(Z<*#&0A0ATC,%\>DRXG6"W.MY,0H01@2[8_'9J@>HL70(02(")-JT`H"1'J M&'DYHU6,"%5$]`1$J&,$Y2)",4'+SNTIB%`"3!C3]ATE:B87$8IE$N^3B+82 M)!;P$,V#V=*/:2N!;_.Z=4WWQU(AL3]='9D*P+1TM.'[BJGZKN+;*AK9JFN. M@)NNK:SM,<K( MJ>^EL(YNK,@["YB:<+ED8ONZ:*LF5NN*TDU/LVP/**8!#`7Y%E+(MF$3>W(U MT]!T%_BC=WN"F:+V5L7*I&'?=(0T;#`R'!DW6KYE_R+_CL;TDTD4)O]8/#P1 M_?_ZX6FYG/]R=?7Z^OIQ$3Y\?(Q?KMS/_R++&Z`U1XG;K5U?O;_V/M0B?&0_ M^_KGCV0ZCGX)?\ZGQ)%=WH3TG/R/57_3I^FK]2S*9KPI"7\_?O>GT=]-. MOQXYI-&.P*H"D`)4,L;FT\V#X6R<>PPKM"CL^K/U5^4&O[[*L*L+Y-Y5KG=` M.L%JP2*+O\?//SI$3B>P<2!''H,*5,4BQ_;BWB%G3\GS27#W0-S;!]IHXN$B MX1M6T#,!,O-_>@?DZ"68KHKX+2X3P-1[[QV`]O+^*4RY=NOJ^1>)7Q9_ZAU^ MHUGT^!P0#)-@'JZ6T<.E3;]"$%5*^-),Y]V2:(*^^3N-NM(%DX'(E>:^5$AI MJJ"_D!Y(^UX6J/M38E*"G/4]ODVR@&%NU;T+B2+&7Y^"17C_1,X]![#D_LH_ MZ`I?M**L7\N%64LAWRRE=1R9D7;>J@[4$-@7([+-80_ M`WKZNR3?N'.P^ZF=79?AI9P:,L1>$1]RZ!3(#;'7'L,WQ%[/!,@A]MIW`(?8 M:Z_Q&V*O/85OB+V>+Z1#[/5L0!VB::>(ILEL"$,TK>-HFFS@RQ5-DT8[NYK. M2CDUI#F*0C[X8(?P'6BJ+"5^>RH1.F\WP7_CQ)T&B])2]94HCNAD?!\^/,WB M:?SXUBVP!M^\[(QA7.PT+]NJ!4^\:J7:@:HV!$":6+>J<2U;Y+%N\0.&?-;- M.??98QUIAWB?Q>POV8HQHHD2\C22T[SIE>HOP7.>''+_&M\_Q:M%,!N/:)U0 MXK#2;WH)Z;/=GCEY$.PR1[F%X)"D[#]T0Y:RS_@-:P>&L*=Z$8DM.J*>EBRXGA'^$RB&;A>)UFO%0@ M38PE/?7P+JX/#ZOGU90\.][55>72L!W(6V>,Z<#>.B-4(33A3Q4#4X62'HGN MH^4TI.7*Q]%+-%X1Z-Y]SR_AZ_3-GL_CB#HJ7VAET?"!T7.\*`D?EG%RF7@B M`V$HZ:ZZ%\\!08(@O;P.37I[74X$-ROL;V'\F`3SI^BA@.*?Y,_),GZ]N(1D M"AWQ+S'$^3H$.D:23L8]=0@^3U"Y$"`[#V"`P&R MWP`.!,B^XC>D^\\8TR'=?SZH#H&U4P36I+:$(;#6<6!-.O3E"JQ)H!Y0+/.&/)3EUI-3A7:L/ MY?&'R4-$[V40C9T33-@TD:3.0`.8DCD-DX7TZ?>'S@&N(8<@&1[#9<(^H37< M$.P12,.U/SF!&>[R28W.<$&O)X`A3=7D=I`^SU["Q9*^M$TG/D-?:(V(Q+[0 M?D3.UNW!%H`F.V9#@/J!E!]$R7^"Z2ITWC;_^4\R)LU8O?U.\U5%]#8/?9[- M5\L%>T)MZS;'8#9`TM"@"#/I%5;D_].NL/)OCVU@IXF9XF>W5^\RES/?$029 MR]GO",QL+M=,Y,?JY%E/D3+#(9[)8'R`GBN\B,FK;?.^30C0X=_U` M:R`+]0BD@2PD)S`#64AJ=`:R4$\`DS^])5-&22`R`S7E?!*1IS*;RS43^;&2 M*W8*C`RR7S&3! M(?_#7>;2Y>A_7LRE&S5Q7LVB5.!H$9/CG_']VYWWG3S^?4$K&RPVTK$6"KD+ M\_2]+RNZ4"WC]Z60_.$Y#!:K)/R4C?<+&>_Z:OWAYO6KZO?9L%XXBY^CV:Z! MTQ^V:\SMEZ^ODG4?5]4^7Y.=5N#[%1#Y4AS\M>M(>B''.^Z\6JV M3-ZV7Z>;2O9'CF'20VV<5(^S_NN.@=(]BOS'_P%02P,$%`````@`R'6H1OMH MH/]!YP*'.^`<)]G=7C?8;>&\ M%4&3V'"\;7%?"EJB$][2DH^4G/A^_0TIR9)L4:)L*91R!8IF;?-EGN%P.#,< MDI]^>EE0:X49)Y[[N7=R=-RSL&M[#G$?/_>^//2'#QM MR<2Z]%P74XK7UN\VII@A'UM3].*YWF)M72!J!Q3YT)IU2]RO,\3Q/RSQ?\>" MKWX_G]Q:IT#Y^?F(,2=N\LCV%@.KWX^[^S4D[,SZ_NCT].A] MZI>)%[@.?)_ZZH+AL&,'2#JS3H]//O2/X;\?IB,/#[Y MUM_LOT-A*`DUWEF3H\E1"N-?K0?/Y5!ZL43NVAI2:DU$+6Y-,,=LA9VCJ%$: MP;6`HR[_W$LA?)DQ>N2QQP%T\VX0%^Q]^XT5%CY[X213X?E=7/QD\/O=[8/] MA!>H3USN(]?.5!2-Y54]^?CQXT#^&I;FY(S+5FX]6W))@T!+64)\ZL?%^N*K M_LEI_]W)T0MW>C^*#C\QC^()GEN2AC-_O<2?>YPLEA3WHN^>&)Y_[BVYLQ*< M_W#\+JS_W:5G!POL`E3GRO6)O[YQYQY;2*I[EFCWR^0F0_Z2DQ5QD)0>/Q+% M@2@X*&QK<"BE$ZCYQX,/XB;Z&,VOB0OC0Q`=>YR(+BXHXIS,"7:J$J[9ZFM" M&".&*P]`A:;])^P3&]'Z0=V`1EO@(?4QYA00_`3=H%2'%)R`)1J_=0.\P+QIVOJ/?,;UR$,V_X!4';; M.IC<2\)MZO&`X=%2K'(@L!SX M6V+#R&/H_<*C%,V\D)SA(\.2W;QFP'OV5R/B&[%"/)(9Q4/.L<\GV/9`55$B M>Q*3/OO[_E@K]]0@RIJ'4:_Y&O'<(?85^P@Z?,!VP*`SS(6IY`04C^;#A<=\ M\E\,0L7]+RX8AU1\NO6XF%?7B+!?$0U$P14B5+0"1#X@FMOL_EQY32(;YFW- M\J+?18VX-BR]PTA\#O6+E-<+Q!C8(D-_NXPS"0@9.D=3'^V.NI_L:^3&T M;19@Y^IE*51P6C*S/^P/6;N'&E$]^)[]-6O9U"N[NATTBDE^,UK*M=(&4Q2^ M^N+"SV.*:H56V$^C"'_!:Y@0M9\%R$7<9H+92,).:`67QPS[7: M,<(AF:*7VI>DTI9K1`'\6Q`_7`"$Y>OZ($(8;,':457NJ4:4]]@7QDS(V#%F MTN>,UX#I$_)C`QCSZ1.^#Q8SS"+/-)IG0LX"'XN5SP;R+PF%3TYNN_NSZ'7) M;)J_8\^'P2:(TK6D`YSXQ,2Z>K%I`'I)3-:0Z,CUB$C^#8OX)A@B*W!#'W&( ML6;.-D!@/>&)>R",3[U-J&H38N#WR!>^^3SQSJORI%+;3<-)>=HK/&0,/#?Y M0S)P4_SBGU-0YO7AK-)ITPS8]E8;!:[360L`3X4S5J-9-5"`A@3<@ MAL7=&`59MT#H=-8TX*%M>P'\!5])=`A2%T5%;@F:$2I%L5&ULR\!+65,W3)R M&!E-,VG7*1=E&Y47_2Y;`[YNF:C:BE>6]%&<%HV&&IU&_3 M;+A"S`4">.Q&-X!8W84Q<'7/W[*.(J!VDLHF,MDR@*$&=F6,.?Q6]%A'1E+8 M\V"KZT;IT4PTDC0`%<"G3,]4I)-Y+#OV4<I-?F$IK-A3-!5(NV9,B:H%!EPPD:!/\(H M72$JK19?I!6L8;F3GJZ">KVZ1E"I#3`5EH(:IA!XKO09"H=@NY@)6B_Q'(,$ M.Q/@W@7\)?Z]Y]J%@E]8Q2R&%7:#DO554;@%=%=@_'9Y$]2#Z4A\?`O+H+,= M](?54`&AI)()'"ES14%TNH1A"D&_[<8BRLG.KV882_$\;8D5F9>Q6$QX40T3 M"*396FAHI4N8H'#,(L56NF3FE31$\1*,YR@'*O8X=:Q&G9IF$'E+S/RU2/`3 MVV1"12R%2:76Y8553&"88.XS8H.KEF_=EBZP%1HP@T]L3F(GCF:E?%,P#8A- MU+A**YK`H[V2%:U=J1C9D&5)1\R.&X1_[@3(LN<;HQ(#'BS"R%P?#)5%7'_. MO,6.9QIWYJF<0LMC0+(\8_OA^+AG/33-P19=&B( M2W`6!,X2N&]G6(MCM`GB#MF8NB$MA72G47?(V-P'=>%V2,*%#MF@^W`AK]0& M_&DW-9O&\KV=,9",]_$;A*Q*-DA0=\@JU4.MVKI*('?(*M6;RKG1W@1OAQQ. M?06>W0U.P';(Q=0#JTQ%291UAS27'F:=L&P"OT,J3'/(J^99);S81[>U,54R M>Y>963)W+RLSDP&S+0,E>79%-4SL3?P,4UJ([<@55^^(V[A2H>]-W%L!1K.R M$5S8Q0Q1<:K%61"7<#\\FAL%2U2`2FJ90)*HEO#4N'",`M"_R8GJ6-9"+%I"0WC.52O5O.*+6E M=B&,5US*"0*[9*@6Q^-D*;MT;4 M7Q<;(5N%C(8E-)S+='QB:V7OY`9A1<@5XS!=VCQZ!:\OP\D\(Z"3V5&OS+B" MI:>3VSFY_D$:<*/\[>1VD";+RJ"$8G$Q`K82^S33NY MRZUT;K<248NLV4[FI&D!+PT[=S)37@^ZYDZ"(GV^Y4JO($J2%?S8`>IDRJDF MRAQY4)P2:/NH5HB(Z#H>AT2@.IGCN"\3=4/LG4R!W(Z$9!,\E3LCG3R84(1U M.^IRV#$$8]D&U=X3,TOK[H-A)FZ6"5__B:\WQS-Y$[9(]APSO"#!1I2V;YLI MK6?DGIP,5;M/9FE`4;Q^U8:;=,88YIT#L@NZE^-+'/Y5);!4:<+,;2,P'^WP MT3$%ADP1$S1>S>UV2XN)$?P=H@N5)>'M%B-`[OW=XIO<@A('TC:HEJG1CO& M92OU7IO[V_7:@29[Q%D;S%8U0YDWHF_09&#"8>=\+1[7N7&C=%L0Y?#],7&. M(B>HKD[5.:31%O$A#!37S`?=1EO$AT2UU<@'W4;_S$A3WAL4OOC&I][0!O,C M_XE/!?5Z=5N!2GGSB2XT=0.UK-'0O(VQ(_<>;S@/0,N!=9@Z>B0#3M);%S]C M\?;L]K`Z"JM[)X^UU^-U M9SBEYQ$I4OI:GAA0'[LJF_R=O,CJ%<2KP(]0Y+K_W\C87LY7)W--ZN=9>8A9 MD7_23>FJ&%[4.6#2I525^KE2EAK0R7LWZV=3=E>^D\F1]3-%%7SI9'YTTU,K M-X>HD^G4]7/J;>=>U\^O@[(7NIGJ_)I,U$J$Z>3IPM?@XD["1C=/2M7&*:WD MG,/.4KUNKF[ROG("&.8*&`*$"]V-N7A$-SPC$%\S:/@IW83D)'G]PJ,4S;P0 MP/"1X>A=^?;1O&V5@Y+W7!LTD"4\*UK=K1)B\R1@*KA"AHA6`)3RLW,B]B7,I,5W7(5T)-2E9 MD_,OBRZ\HJ'@-?"#VS5R2D=-=7J@JV/.U&X7LI*WNTOKF7WAIMJ`96)#ATM^ M)P/8C;"LID>BVJ3D6[@6;=:3.W!@X7/H+86O-2'&"%@%_G899^1.!"8&WK'T M#XVL,I+D)H@UI*O537O&-:M-7/M-9]-9=+I222BUX]TQ'W+9?_GNC3_Y5 M9<6;5?31VSGQK2,I0S[[0S4EJ4C3C]J\@)+BN8.H[7P-H5'!B*)3OS64K^"4 MY0U2/V;>'',NY>\::T)053)RV'NQI-X:PYR51JGV:)37,W;A;E7!*JED5L>6 M8/93<7FBI,*)N8G4QYT>*`SL+0R3AGI?$O4P&'I:^8,BYV7X%JH0^Y M2V0J23W:4EU_@6Z82/UH&ZV_X#58M,$B3*D7&\)3;[A#9@PIW^3BR-VABO,T.-&7B*A",D=!3[WD>NH`VU56VD1TAWBY+RH MAE/1AE&+:L^!3=M9%3G62>O5BTP"Z#9\R$,MRG&P>,G:+[2'33-@?]X""3[W-VZR;ZS[YO3A. MB$?S5.YDJ^A+90FN\%`(V*/\(1FV*?1[#@O/UW81OIW=\A8(GHJ)WC(!25Z( MX"*I=R:.*28[NI&3F^SK@H>`F7B(>LJ0L\G*[\#@-(.RC2.:LU_%6SHLA:2V MD;>[1RQV`W&MGPQ[@FCC>.P&AD39UH^`-MEMY/DFG-5Z-A>$MEI/^Q5B+E#+ M8T.Z:V262>ZG@2!BACB&#_\#4$L#!!0````(`,AUJ$94`DH=;QX``,CP`0`5 M`!P`<'-D=BTR,#$U,#,S,5]D968N>&UL550)``-X!$U5>`1-575X"P`!!"4. M```$.0$``.T]:V_C.)+?%]C_X,L"ASO@TNFDI_=V&M-[<%YSP>9UCGMF][X, M%(FVN2U+/E)RXOGU5Y1D2[)%BI))D[(-#'HO+MY;3_7WI\_7%Q\^*'PRR", M`P^^+WQU19"33.P!1%]Z%Q_//Y]^A/_^,CS__.7CG^&__RVV#F<+@L>3J/=O M[K]#8V@)/3[U!A\&'PHH_FOO)0PHM)[.GZ_M^;\!ZT=X`443FR/N0#>IG MZ/:`H`']>E+`\/V5^!]",CZ#:3Z=+1N>_/$/O;3QEW>*2QW>/BV;GY_]_>'^ MQ9V@J7.*`QHY@5OJR`:KZGK^XX\_GB6_%EL#'%ZT:EX$Z_-9^F/:FN(O-)GS M/G03FDJ@T^.V8'^=+IN=LJ].SR]./YU_>*?>R5_9A#^1T$<#-.HE$'^)%C/T M]83BZ+NV`4DFD" M]4F/C?MM<%<"?T;Q''M.PFM1QK=GK.&9<*RS;2$=0,_?7B)@3C;'T^@6![": MV/&?0YKLF"O?H12/,/*:`BXYZBY1>'8(:KP`#8:.)BC"KN.K1^H.Q-\4]?T( MD0"6?HZVP&)S+.7@ODR`')/0]T!6WOQ?#%S;#[PG(`]A0@M^0@%`BE)(MD"E MV3S*T;QRZ.36#]_H7>!A@MQH"U0VQ]H:W&M,73^D,4%/,W8D`L-2H,^E0S%] M&CT3."Q`KK"O^YZ7\+/C;R.IMIQ.(;[WV(651S#[5>C[SFN8@M,?$Y20FRI& MN.5\"C&^8R?$&+_ZJ$\IBN@`N2&(*A\G,[%-7_Z]/:Z-9]*(I>)EE!M>(3X/ M#OF.(@AKUIR&)\.\(F(I&WP)0)7WVUWU(V;ZZ=3#Y MQ?%CUG#N8)^-`D"^.'[EL.VILDL@-=-6,;_(3Z$0KQ5)'Y##_D[E2\*O5PXA MH(OTH_4VWE,P8!`2L*`2>=P>9S73*Z1'WW5)C+R;]QD3P47.+/_0'F7I&11B M]1*%[O>R9J.6=V4GT(I3\LW3+#DK75!%X:MO`?S\[#M*41/.HQ7#OZ$%;(YX MFLQ-OU'D#"79A4SR$'O)O0Y)^2?MO#O&:6US:X-!*(::IP_9) MN"W;2;1+L%4S=]G\,(%AL[OK](X``C/E>Q M;MY=/P:YQ#9K"G1F>F0@_XJ8-Q04D3F8H6.4XJB8LAH`5..>>`3`Z#!#:95#:55R`'@6I@0_$T1I%4S1`RD^E&N.^Z80S_ M!UN)30AUS,!B"5*?$Q(XOG_2RP8NHK+JA8/HS,/3LZS-&>N@$1Z8 MBN5XA,&IAT9.[$?-H-OLOAM8PRGHY:U!37OKA#29X72*F)>P(9BEKAIAG,`0 MQ(U?T>F*,LT@K1H@@]=;98RRA-$2S+#54)`$9])OV5`J4OG2B<_*,^N$1C(_ MSU*XROEV)H'<3*LA$SOIY+[SBORO M)\W[GYG`;A6->G:P=Q=<.3,<.;X8(V$?,UC\,\X<3<.0`U[":$D2?3&,.D#` M<[!7T0LB<^RR<`D./19Z&J=LG[@KN(30/*T)6C(%/`P2BTO(!9OM#$.;1J7N M*(USF<2'N=3:!.1Y2#\,6$`FT[`JX:YNVTFH?[LP`O0M;4"A4.$T-@'W2D=98V/:?\<\#A+W M,8H%J&_H#C[6@IXW-`IOXAFH@S5M9`;.=8\D%]:-AL;@34^[ZYBEM:8:1WH* M%K(-Z( MA-,Z+6$Y-*;`9($!OMZ\YDA>=!_)!C9XCO]'4QMWPTFL M#UTP'LPCG$04A#ANZ%I%Q-8UG"4^'S]F&*5^XR\LU(6\KR<12?P/V9=A$*'W MZ,9/1OAZ0M&8?;!T?\L29%.5RA?97A$MAQW709&C:*^`ED-QS;;.$3,E@54A M)F>.Y_C^T'%\6RC-.?*?]Q-YH8648__GCF.OWX.>T^H_S="J,OXJI%C)!U%Y MAE=K,TU5%$.AM\T*#CN'9ML2#(T\"YOY,>R;W_H^L`-Q7ER,`A>QK*M*%Z6X MK9&H5WZ=@Q'M$8B3?S.$3]1Q$XJ*HWD-1VF&*8?FC/58>A?\CVVAN>-GTU?= M4%]E#5>M2,N1C,1.8A+.Q,'B4A,EE+[SXSDP*Y^ERPU,T.7!>"HD3+F- M$LHLKQ1>L71CPBX@S&8DG"/O-B3/)/1B-ZJBETPWI?`]@ZC+,B-9^31V!1S. MZ)L`!*@O`E#83PN$Z=@;OE1Q6R60Y*<'+\[!;:9F?C)V`OQ[>E*!$,UN%U[& M%.:AM"J8(=]/#83,ELGNA[,\3)<=K.-JH#A-E<#Q/`$%<@A-J@5A=1L34BG; MRT\DTVL%8;_*I@9A9L=?!@H51NCY[3L-O:$<@P'3F@1LDO]N##IQ\+W00LE> M'X0+QX\6`[`XQ!*GNJ$2&%Y8%0%/1NIP6AJ)7J9NW9]1.";.;,)21H4[@=_> M:`R_"(],UL1&>R4<,"0L(=@=X=NW6>JHJ.*$FAXF:#J$"9Y& M!5M-0,_JMN8\4"WM5.9PJ3'0C4=R-V)!==KH"BDYC7$/@T/2%)*RSVP.%#7& M=-..LCE(U!J]:D/6YK"1-*IU9XW-L2)I)#EJGF&,[A*%?&,TWT8BU0TS/,+_84\VK73H;TISU%NN"=R##]P8:<,5&. MG,@%5[&>58XCXWM8+CUN:TRMR(R3L`5K?7RKLVHM<)4C]^,>(+?IC^I"OJX\ M?CROFTW9N8+MN.')W1"DFVQI[YZK\/P6\5D+OW;A)D"M?[2425P*N^<+]A>; M.;#6AUK2Y/CD,,^?4N@*W9NE/+6FOD2;<[&V?H_%3#F$I#S;LDK#`+D(#$E6 MQN<115T=IHU#U1PNNW1BZC+?SGTX?>6S>E4S-0E]E6+KZ2U`A$[P+/>DW069^[4:/^NX*8FW0DW=?$+KQ&(P3G@#=`/US0``2S\UDJ@856M_`&:A22Z M1E,071%CG6`,YF`X8O$Y.)YF479DI90!ML*D"O":'B;V3*X]+LUR\>[AMU=)T_*B?9N!QA]$66A%0%AA-R7P909O M?IH\C?XGAD5$Q%\`^XUPQ&ZZ`"\^C48414E8Y!)^07,^E!KH2 MXP7LQ4-V`R?Q^#V`\5MBV/X(F#5CXSX+<3,63;DUN;:C:J>8!TH[;<6L*=G3 M3&&GY,PHW/1[B/T(SWQTC7S,7@IBY=L+YM`U@O69XB![6^@%^7YRX+-XQY0Y M!CC'E8:)NI?>JFC-,DB$ZL%:(S5IN,D;5(4#C[OCUIB\BI[M!^MXZN8V*Y!I M4BSW0Z"$5;3J;N*HS(&;ASOLC2MN2P>^8;O"_L+>8,\.TH585]I6,P M1]S>8//63"_PH>3X&PI#5^>-MW%#YKE]TA[!?4TJWXI\T@:N]1GG6Y%!UE*Q M/C%]*RILH:U:G\:^W2[9K>O,^G1Y;7MM1QX7ZW/VMR)P[44%2U/YMT):P@-J M/)U?%P$D`B+F\[]T+GZ5D6]SYNSV&"L(3MJ<\;@]@:2B<<8OTNJ6"#J1&#'.$]TQ@;)KCF=-A');(N+2;'?L\T MR/J4W1QU0PJDW#7!I@F"7;@/*WEMT)[+!'MVFZ+-)4,S]RGNV*.E8\QT.DI1 M1)G>%[C8QYDZM_Z[D9L44[!9LHN\%1!5!XAK.IF(;]^RE43WS%F^#D_AW8XB MX!S<6@QD&;Z7BP?GGR%)7GT51/F;C*`J@Y:(X:9QPCY4M!BH&EX`V1.PE"/QPOA!?%N,V-E&QT)\B+64!) M1&O1DXSR`QA5C5LI,8ILC]VUQUV*@V1SAU[AI$NW8YGCWEK9, MJ1085]TTGJ$H_])68[53DA$V=;EN^BWM*?MBW%G)*WR!PQ?L8U`>!54OUMLH MF?DZ)@Y%1'!UEIE\DN[]>Q M+_UX=^Z*_7'WMK%4#M3/*]8^;+X`I\"756E'=]S!+87SIM?"N&O[Z+1KZ[2K M>CPG)U*VKY%W%=+H6T"0X[._V`W,?N"M'MF!AG,'^VR444C87="J88VX_I9P MW:9PY=`4P@])[+*,W25#!`V==YYW<.MQC50)YD-=7.CF.)=ZVX59357OVGXF ML+D*IU-VUXT]QP:"39B*4]W6#-1DQG+VT35ZC7)"UD`OZF,"BT2,LR1T^C1B M0(&<8\^-18L"N_.=M[*]+<5,Z/23[[_7V!ER9A8.9:[,JO._-QO#5BSE_'UU M_?DVP4QK'#M21AGC<58D1HU)W`7/%5;XE^I-QGW M4G%=NJV$>K5OMU9>[K%K=VLR2AM&77#TZ:2&K-',+"):P: MS1@MIY6%E]?=C"%9>E*28RP6VQB!,JVQ)X:RU,;,M;+T,?IAV'=!'E3O+`[T M%4IC'G5LK;*VAZZ?542MP%KVESH;:\!L;B3XV?5VN.A;92-,D+PE5D M;#B":JC7@4\``8.1746<,D&: M""K84^R<`=@97]!A&#E^\742]-3[L-2>$] M;EZMU1T#893.;".E#[4+SP1^^^-E+U.7O3@2]A&]^8O^;!9B]E8#L.G-.ZCB M[$W>:TR0"\/P#U;IOFH@;0:;;FAB-A:K$TDC',5+Y9)M\I!4*G\U/4Q>W7L: M)3N5G8GL&>DJ_56JBQ$N;^9>B&0-+Q=)B4ZY:X*;/8Q@4*DU%FSKRT7>))/!B2J9 M_/,+G"',\!*^":!T"F,T>JU'X'4=@9OW&2:%NL4B`BD9OU,ZFGI4Z.?AQ-F$^7:U&KGZ?+U"JD'?T,?7D7&+1-URG:I98Q32"G=YGP M$#WEKF.F[E-LS;.7_'CM1/FEK9U0LQZ*3IV9&8Z_)$ZK\JY3?7R*IK*2.ZE0 M4TK\]H$G94MIF>I(L\93F2KIPL"L"KA4-%#BM=KTV;#D8-H?`XF8$8PI2V[( MG*$@UUSX'H19E3NK[5!&Z+R$%7G7,5F9,:F,>41OR4]0QPQ$_8N M\%A0G+UAP_U`NI?<309H/3-:#K!LV%X$T0X$M^%:3K*P6#:6)9Q9,7P M+1Q.PI@Z@7?#5)N[@&UA/$=,=/(=[S+=C*P%3/`T*AP3HKU2V58)57]-LB,B M^A1'-`(:@3Q9%<>X"H,D:QZ6^!Z/*J5ND^ZZX%W3=#?F;P"[U%!*\1B&SS%Q M)Z`:9$[?1(P70&)E3=]9>A;EW=MM.Y12/-8HE\U3J4S(]S-XR:E=+M+JIH\@ M(6B55W=A*E%8+DVV,C&H5+9*BXYM/L%4*J?6"'7L2,"58Y^J.&BI6E==TD6PWI]&AJ-+;Q9-S>AV:=JTADSTG MYJ&HY/H3W7.:'HH^KS4!/B?GH>C]>NZ"Y70\%&M!PWVQG(B'8D(8NZJ1D_I0 M#!&]=S7RB.VA&"K+4376ULF)>B@&CG:B672MIOEN')R61* M6Y++4A/>6!`&>^M2YXVG;,BE0^DB0%BD#Q66-)2 MJ::UTB!9UV;+\:V\17R(-4RVL`@+$:N[("(8I+&;F-G"&D%Z)NP4/VVBDYK5 MJMF+.T_'J=7@=MJN9^_X/JX+EH%&.41DNH,-+@U)%WGY-B0CA"/0SU:^2TU\ M6S53%REVK&+4%(]""+Q\6&JB&W^^CE-/Z]F\.4_'J67@;):=O8MG!I(N\G,:YDH2\&7+AXS!D7Q63]9:YQ#N1J^WAV4_J:Q7'TM/O)VT- M".\M@>JB3&^,\J[-,(4`6KE/N+[)LAF*>(DE2O:%6B`Z2><*X]0$I9N"T4E: M"S.E=D+F!A!85\6Q$#1;;4RNRZ;Y0)VIJ&=_C9YNY"FHK=!C*$NL324&-6%) MBTNKF"O7L"UIC\4==IR\7&'4'G@="&VW/`ZNH$0;;>9P*TQHB><=7F&*W3L! M#Z]\@\;DD\.K_+#S^-?A%8LPXL`XO'(3IGR?AU>HPISW\_#J7E@29#I6A]"? MM7G@-2-VG2)RX.4D[`B.'GH5BEWG+!]XL0H]R:3'XA4&,LV.92QT7%IJ6LS" MEBN=?T.+/J7Q-,7P&V605?U05/98G8DU!:8VCC7'K-I+=Q5ECGV)(RC M8V;C+E3Z8\+C+@S3PWO8:_LPVU>A4;9IG:DLDJT@0AEE`$7L2 M,WV*=ITA4SH#GVKF1G$S:^5.7U#'[X]#1:KZV>O)E79_"K MGL4$I7Y&`2*.WP^\OC>%_4$C]IK''&6K)XQVR?4U@=5=`#L5=B1P)]M@]]D* M""*+HAX682"LV2ONLQ=8_&:F#-,`400G[018_1K-D1_.&&@R>T2FI]E(L1HI M)AU9$XFPLHE\CPHT[5>5B M&RJ1[LKS(5*';\E7+G/*=2%2TAAS22VXBS$5#<>[Q$YI%W$Q8[BG*`R==T3[ MGH=3B.Z"44BF"2XG!F&[8H^U1TF(!IB370+`P1@%+A;"NEM5\AY1BM`]HZ[T%-9V45,TJSW'' M.-/QD\^,5OE;G=>;R8K-^YLU6RK)*6>%"+H:P0FY,1.+UV@64ASQP%]K90;2 MQ!;X&85CXLPFV'5\H2G/;]]IZ`TY(5:';!$B@4N+WUZ)K/D51B=1^":HQK?> M9-7&G3;.+G,F,B/ M*+H/*4VM^&=$$@_'WBYEGI`X8EX1[#+?%_9C M]EYLU;@F?0&5`#V',#(3P?XB@1O/478@8T1OWET_AFE9UD&*9.;CR5!<*S:0 MTL1('@*@X,F#?^,05A.!+HG0GX9QP#.X2+(4-_Y;+/*]L*NQ4']C5OCTU@FF/O8`ZET&1 MKM\%+Z.L6E(DC^#P[X(WL0W*:R=A%WV&*E4=A9M%?'C8[-]Y#"-$A^$M#IS` MQ8Z_\FH!+[$JPRLW;1C0W3ME^-!=A3[H<&&:/E0($^1NG"',>PEZY7>;P+X+ M(H`4`Q>F[N[N@YML*:M8XRZ8(QIE'Z_1:]0/O`>'?$<1`S6],E38HH%WA4@$ M(G-(G*1\8C<61@^.]JWFZOI:#BVU^R\L@O$P#>6;X*6*-BW%IM7&EE;RZDO#;1]]%YEHEI.8D%6JN60;RC>G0*R MAF-_.F,PL)(B\,?_`U!+`P04````"`#(=:A&&E\VR0I;```4_00`%0`<`'!S M9'8M,C`Q-3`S,S%?;&%B+GAM;%54"0`#>`1-57@$355U>`L``00E#@``!#D! M``#MO7MSW#B6)_K_1NQWP*W=V'%%2*XD\UTQ/1ORJZYV94LKR]4SUW&C@F(B M4^QBDMDD4[;JTR\>?),``28(,+T[T]VV)?+@G,/S^^'@=?"O__W[W@?/,(J] M,/C;3];KR4\`!FZX\8+=WW[Z\OGRZO/;Z^N?_ON__>?_]*__S^4EN+\'[\(@ M@+X/7\"_N]"'D9-`\.!\#X-P_P)NG$?HQ^#&"_Y\=&)X`?#_;D`8@']_9BW]3G7Z%2Q>V_;K6>DW]^$Q MV*"?EW[T-H).@IX&&Z3-K\">6//+"?K/ZL&:_SI9H/_\?^6GP\-+Y.V>$O#* M_1D]C)Y$;TS!_>O[UR7S_AOX'`8Q>GI_<((7<.7[X!Z_%8-[&,/H&6Y>IT+] MU%R`G!G$?_NI9.'WQ\A_'4:[7U`STU^R!W_ZS_\)T(=__1Y[E1>^3;/'K5_^ M_>/-9_<)[IU++X@3)W`K+V)A;:]:Z_7Z%_);^G3L_1H3*3>A2[PDH"!@/H'_ M=9D]=HE_=&G9EU/K]?=X\]._X0;_-0I]>`^W@.CP:_)R@'_[*?;V!Q_^E/[L M*8+;=BW\*/H%O_]+`'?H6VYP"VO<@K7`+?R7],09^E@2 M)T!)0R2VB5`L-G0K`GT5#;J-P+Q1-6?NAL%-^,8>?^"K8W"9/,+J'+O2> MG4FFWPW,D6<,I=E7[S0.5-")8"?22+>;+@>(0 M;YYQJ,\GTS30\4_^2#'X%CWIN8Z?U]L#MBLAW%E,9Q.K"I22,//]H`KK*ADFY&28IUL4 M)HZOP:*%J$4:.W<^>&K].\<)!K%_%X5;&..U-,?_``4)@/62?A9@:"(>6JO2 M<)6$5EDBP"+'00A*#"6L4#%P"T(6;^9G,=(-PBS<7&`/F<`ZQZPZA$]YNQ2$>:<0P?/M$?0W/TFX<*<`_POTC MC/J'2_K^N$!-E9*9WUSW@#/X2MLQ-^L[A!\:*.;X@>>`$<&Y&N.20"[YT`B$ M-QLO(1G#G>-MKH.WSL%#@Q=63#">U@G/=A4DDKYYMB\CEP2P*-1U@%28(<"I ML,RN679`HBZ192[;,FU(XH=:!3<<5XP()?S.C?N.><3(D?=RNIA.6G%S6>#& M=(^ESM`ZC(BAUV*&&L83IS?J](\9;/WC&"=XJ2-^"!DJ?GYR(D@V1N,>%'6? M9%7D'O[SZ,5>`C_#Z-ES(=U&>0_=`:'9)M[V7=;L`N78@50]0_4!)05-4,R:/$[;ZG(3NGZD; MW5*#9BE*#[:K+*?ATQ@G2JQ5X'H^_`238D;@(7SKQ$]W4?CL;>#FSKCO71K[$^ M(%,(/+Z`5U@G1)4_@UPM4.AE?@^Y<2?;+4Z.ZF0_<[*+G;SUPV\Q MP%0%PMRS3J[,KZ.A3,4H9]*DRJ^G9F_.+H(0*_<0.8B=7 MJ2B0R;K`&8#N375*S+':S,'6&)K_46B:73;-Y"2/$&0*^/*,-S)6\8EPN"$C MK3?UD5:ZUX^56(J]K',\(:21\*!];MLYBE+!S%F0;)^JH1Q_`,.YLQ79-C:C M*;A4\%:2:G%W]4=E#-W7N_#YEPWT*"#17^HX1#_ZXPKU;!O@%Q8GZVV+Z#QWES-#`@=QNHI$>9!]&B?<7P^^X9S%6YWLZ^XTN98296"C*QX%4J M^&=#_85:@^TV@Q_#8`,.5!RND[-WHC]A0HY3(FH\1F1*PFC_(1JZE:Y#R'/F MD7B-1DO!SL/'&.,8-B9D!%\RAL&Z)A+'T&>S=@`6(@&5.0;HG69G$W>/MIB8N9*E7EV]Y(3K+=@&H!H;R-/W.LS/G7>;> M<\/]'ODGQM-P`.][>79\LH0>'A-<.!.7,T6Y0MFOY%U\T#1SZ`$Y-,8Z`=?Q M7;S-W?1V(Y4@K>0?RK[9&7+7FY=V`5??/>;H;\`6SX?G>&9(')I9+?GL]Q7+ M,[4':"P>LOMYZ$R8202""OFJ\[.<(8O=>`&\3N!^(,HJQ)\//^4Z2^RZ6\V4 MIF+@*U8"$"W.D\)Z.I'+5ZJ=>"8LUX"H0DJK?J;Q\-I=>, M\TVABTR7O>+RR`7`4L%7*G=4S-#77![B!BA-RM`] M8,F1.R[6*@R.KL.WE4?TAZMTN>PIHO%JARUYD^EG6"'S4>?WA#F M'MYJ&FDNI#O*(U:>T1[0LC4!5RO++L?SP)4.Q>BXEQ$E5DXK.(^&G7FE#!L& M&P]L(TPX2CC'!H3>SUK`H9+!40L96;6T8!(&46E[*C$8!((!J;@.KR MQ:C`=8]GTB(OJ)_=D7AQ#/#*M1$_);;,2_3Q\(7K`Z6B329GZDPF&1NI`E+> MD(-GF<9WQ$$X:(5`6'68FJV\R<,3_$C\=KO=0BR<<]Z<^;#V;;PL301#:3J9 MK>UENHDW`2BHV[7&\8Z5R?'<_'O/DAC#XC0BWM9>E(7;M?U-FY=FHCG,I9ZWEVE#83 M>KD-H\L8B:WNF3*-#(-%>>S?HC".OP01='SO M+[C!Y:?>0/21(.=BB)/EC@/!8LJ*'_Q:+M<"`+\`Y2+LI&50-`UPVQ?@D;2N M_CX)B=-PFOU&#LQ];$NW+^KN&2E)R&%*D$,D?#TRBJ$G!W$=CKA'7U]Y>QQT M459)?$5@:EEBI)"))T79P!LG]DRM1`_A@@4'WE731XKNMG`6Q'##:^-":L2$\\D&V2T?Q?P<,P<6^>PRRW0UN/3"SY[O(3TYH*P_HQV1-05$ M%QG6R_5ZD<+1"T%,9>B&XDG*6ZGRJ0BC$#S)$%O"$#W08T1^@;LV>Y6`#J]U M(SSC/]X7*][H)T7J7*28^;)QVS?I*4DW@/NI*4KPUFR]F%"8DUT$F-Y=X>T$ M8(L')L^X0L.-=<2?VKL:!L)!"$L7$%W8)UTX+KB^`DX!,^H`H M/I";PMX'W*6L`:R?=7!]`B#Z>;@%5,$!;?^<.%&BV?IYI_6/<.<%N`[`P#[H MG#L9P'J;:[W)N14ISBK/N8A[:3Q43"\)O`[<"#HQ?`?IGU)AP!!AG)C;]9*H M0+N>=/)S>J%GU@AXE34S4`'SKE7'X3Q!EAX_T3OIJ*WD6NZSP2\_T+MAS/&A M*33WRJC&DTHIZ$D6^7%'4ZF34->IRM+6L8YIJ,GWD4H[1];<3.@CO<.(S&7D MU\/=?@O0]WKR#@C-+I[IV,'K`!=>#"C:07D!2%LR,?LRL#L( M&Y6,16.4=7U;3V#/.V\?S/ MVS`@^Z3C&T:E2/GW#5)9IW+"H6JOYTT2>X8%?KN"'F)*"9ZW86UQ`/J%DYR MBG`D@^I,NKD\2J&]4AQ$Y(^4?GK8+D4];-O'PCH5",LP3N$Z(W,F%06+&H#% M0>X'^#UY@S3XDS68EY"@#K*,$ MO#3].5IL=X_\I(2, M#=T]ACZKR5P6WB,8`P[GBVZ$CQ[+'4-`:=^90G,8?,87?W:.`*O/:<9DI7&9 M(9)=P"X,`!$R@E'?">;84N;H1$QK(-5!T;3<<-S?.=%M]#G!Y6S(KIGLDK#N MK\=\TPPV6.J(WT6W6,Z;:+D`2#`((T!%IY57\_OFC&-(C=EE5,74[(.3GH`: M":ZZ`I6!-*Y_#&./*!)?'9.G,,+5:+J_=N,-,UBKJR%#X=,VC%&!H)!H'%>G MF=B"IYB:Z'!--(`K5A`R\-3JEU'@Z#J.C^(82I\VB1^J@LS`8<7&S@6@X@R> MZ5)AWXR69$"/NC##C-&C6BJ,FNLR2I[@^IC#)C>/&8+&B*W*"EQ2*_E"T?ZE M6@,?G>_>_KB_VNTB4NTS*PQ]%WDN8Q>3E`3]>YEDU!->I5BOI^ML1U,19%F, M[6D;P,D:R:NY@P-N1OO^IN%\T!RZIWE2V@;(&RE*I)-FC.QU&LX/#<(1C06# M^Y[Z0+^T^TG:F:-(P6Z++?NB'5#Y%9/)6$D/F=ZP!:1%1E:2.9+NOK>5[#X_ MY!MIK.-OB45N[U]WC6%`<8]>UA\S`QRY0X=V?KE>%2Q$RJ"C%QF8]+"I!1K_ M]?5D8A4S:!=@,;F83,A_F_,`%\!>7\PL^V*ZF)-U(/1/>[VZF,]7U;R:_+)\ M*LI)<*$>]PE,+20$Y9_DB?]Q#""83LA/9A<`O7^`+MZ*Y[<>'#,`4/:!SK8/ MH3H7_SOT=D\)W%P]PP@?K,*^)?TH8^I;_GV#>7BGR<)I!IHU M`-(6*'!IVCGPM+A(#J[8_F8&;M!^X01?L(W2[&OA.&]H3=?8*DAW,U.I[,BSRZD M`2H.O,(7;_Q\`3Z1F]WP#2T7X"I)(N_Q2"NV)2%>Q!NL9'QG'155+E@T7?#* MQ[;C.BI(JN'NO2M`:ST]UR=F,!8=\*D%^`X^)D7ANXZ=(;QWM.*,HXC$6&^6 M'ZY+Y0$LL'(UF.'M(\KLM*MVO@F##=\Z?5@2",0JFKJ<8@1/]"*$#W"#>E,? M(?O]]P,^]_0&!G#K,7<^=[RE$U-\523J[NI2-Q7@50H>)6*':C: M5R>P5!I+H)49Z?BH\8">^-M[`9FQ39#AON<\>KZ7F!V6B@5I!6T"GNJ/MQBZ MKW?A\R\;Z%&HH;_4$89^E&OAQ:[C_P=THO?!YAVB@-KGY3ZJ`4N\]H7W5"SF M^=)W!B`B"V!A`$D#6)Q>W*@SS.YCV-#X$`DQ#(I.-YCH>=[!+40J;>Z15F_1 MGU[R"5G*O52+^XK&/H>GAS`'SQ99&I>)`U@>H`+12"D7:::O46>D73&299&N MSD0D[LH]2:MA1#WRF'?ICOQ(V M[>%>&#R"".??MLAXV%R\RU[#-[.SK23UL#=\E:(*N\8.`\X-@ASS1P`*B82I M_KPY:/3((JSU8LY"QWC2I).L&SM&1'.D-B>80J8%!3!2ZA^3>>WQK=DS60Q^=&&[NG!=ZTI=?TN)$H3I1=)*FPI,_TW6V M?;!T[AT%;;E)D+9)[F&/TZV%EZ1=D#5LO!2&3G_9@_M+&Q,H`5F%.T[_#DHV M6[U+-RQ=!9OW0>(E+]?!-HSVM,9U.TF(OZ=[397:T(1-+>R8B M&'B%9+T;J-3;:%5LQ$5)J6!0DFR,MP:RV3[=9BV[I63@F>^2$G;7\"M?F2IT MO8'>I?,!_:Q>H8[_K*:U+Z8"PMW>>K%Q3,?J M5V>89?Q-#0_&D$2SDS4NLEEJ3=B20Y=)1X*"G5:THX%NE'P.- MT&I'0-4%^N+_+CNESM@&T?Z:%SWS,ILO5NF%*ID`S24%3M';*NMM:*OV MR4;8PD;H&2^W!GHQ,FY::F+._KT3X=N]X^RH4L=L//-QC?/L+!V$DXCY?)TN MWF:BBB-XQF?%U5AG9UE113 M&.)>9\'WAQ'<$'*ZW;[_[C[A^Q7O<5'`X*T3/^'[-M`?[_]Y])X='V_P87UD M&1$ZT26AES"MSZ>+=(]K0>M9`^">5(X,`!9.;V+!?RDU8PB%@SFBUK]MPPAZ MNP#`S"&D'@+]>XP=XV:.(7^!?,=H0W`/"%1`+>M>(SC?'_SP!<)T"]]->F0> M92#\4TO=[^E$=)>(P")#Z+M[% M:11WHB%9`9N03TPB[#.,GCT79K,Q>+MLL8/VRB<:H+_=;N^A&^X"7+F1+OZ2 M;;4W7@"O$[AG=K:*6S&`7D6JBU^DLY?O#W]\:=OL#:Z^.='F MHOH:5@A\Q1H!HI*I+-ND8VUCCM7-4XJ!W<9J*K_@:#GP4Q@\PQA/&N`O'S_@ MLG?EWV-;/H7)?\"DL/*4R._5WMAXL8\1PNG!KL2/P)2MEHG?M6W/+4WT>9%M;MV&$2@I^X/1JH+O(<:U MX%M6ACLK1TWO\_HA.9A+(EJ(F?U=C;(U+ME]>\#*<&OTLI\WP8%U)<2W@RWL M=9VN2$EZ*LUP75Y%]A'XT]?'48NW,]A:`=CJ!"6[KM\'WF[O/#PAUCO`8^*Y M[?6I^<_JWHG-4D0T-M9+?`<1V9--18&D)$OS]FPUQE@E8\JR3.[95F.9S;+L MQMM[9*N(Z0W=71C*MW9S'3+\01]ZT/HM0E;D^-?!!G[_G_"E]N'8SVDZ^M/: MN/CMXY:5[>"F9^5308!(`DB4_N-`"BRR92W2<42(&T[962&V\=KB7?Q60<&7 M]")!P9U[^$SPM`J+MNO2C=TO.(2U]HG6:D20X%6#$E[2A:T/G@^CMTX"=V'$ M[DFJ3VE%3Z5IX0"RYI95@0L1`S(YIL!Q@C&VE#'Z8K\U@*K!WK1:5W3?PYV' M][,&R2=GWW8TNO4QK?%=;5OBL/&RFB85<@`69"K"3S''EC-'7XRWAU$UR%L, M-S(5]L\C4J;K3$+U(9V37I66Q<-C8F4G#H@`\X<+3K##%K9#VY16:]!4YK&: M]IJ+;CPY'09H0/(NW#L>J^)N^[/:8[VF@,S:QZH2\KD@\)6*,AKZ)YEE2YNE M%PF,`&L"HLT+:B9UX\3;XWV15T%P=/RK?1@EWE_IGJ'K`(T4=MZC#Z_B&#:V M\_<0H'WZ5T8[T9J+:VNU7*9SPIE\X)`&@%-J`6]P]_(V@$,:T3UE/)P#K*H# M:`.@W`*XW8*B#4`;,3&[/)P3",-4;,[6B?%9HQ?H1.;FFOM`NYB`EO:9D7[Z MB,NL\]=@RX_H[)5+[4ILD)UFIPS(ZZ:75GO;8`O:H*V_;0F42C=;MU1-[_KL M^$>Z%7<70;*IF;=HRGY:>[_)5$4P#*;V9+&>IYUD+@P4TH:-;'9_J,@PRY!A M'1V=(NOL?M;IZ=8Z,57T87QW*('X!\>+?D?-I#UAZ7C11^C@@OB;V^`>']Z/ MO&"':ZTP#^R<+$XW29R@JW"2M9HNTI)XN#5`FDL3R?*Y.Y"U"&[Q10QIFZ2P M4#S\>1LFVVCSD#5R#_%I2YN;[&'=I(7_%!!.3I"G.MX0@SXX:.2A)I"HJ/$S M)]%3M!-?V+:]*K'F,PEV.O^0WWV.@WV?!3OJXZ,\V!]Q@YKG*;1XY%26)$V> M!T'V\,ZIY,CVSDAYL4(C)W!BX6L34R"YOF]>\K_^OQZ,D-^>7F[@,W+_=X]U M.%SP98W3)F(:22R$31NXOP"Y0/`52S,TNS*$J78?4W5-PLB%:GEZ1L)51C%8 MW(/6=2&O10_Q*A4FV:;#4?Y0$&E]&5V=EO9<4MU([RCC!V(HMEF_& M@JBN"GW\=PQC2KJ0W7*USM8"6.%FO%J?0D/KN$J3K;WI6E]"@=@%)_-5^W*M MKH/#$66UN,NTN.MFO#=,8*FIAOA>D.EDUDP"J<`+0$0"R_!2FS(["9#^US'$ M:_)WD>A//*A[E1K]\R@6YP2"LQ5A#%>-!5^V-+[L<>#+ MEHL[-/*8M0RRJOBR1XBO7G;2\E7>+O"VGHNW#=_B$Z'@]C&&T3.>"4@-SS!F MCQ=CMAS&[+%@K)P;-(>#W,V:'L(H>0?W88#'B(D7[.ZB,-SBB]^)Y3+(:WCT3JW?;)0[:LWIVHL>B?9:C*9I^LX[^`!!AN\>_EX"`-< MA`"$QX04-0^WY)\;3-'A@51(/$3A+G+V%^@7'DK_8OK\(=V?2%5)Z];H7N?1 MZSM*?;A-0!L%E58!:19O4TT;!FG+6663K.VTB)*)I1^]#B/$B83B)G`DM0>- MN44>50Q4+/H&'=IKX?]\I%%'8D]8[+&W=9_;"\()V)D;1V MPB46I^BO.46@1BY)*\TMZQ>@U%)EA[M:0EA3;P1PAQO*+_CEYE!#>V=!-KB7 MS*^<<'`2@+HEW`6QB4&M/SXG3I08]:*2VJ`*`)^@H'&*,;^XQTVU`$FA!N[V'$;_J'^X:BQEQ)>9D7JJC_`R+*SWZ(P M[I&2T=?&D8<1780'%.M)=M%,UP"4R!T$]8<3AYD]+)YAB\E[P'6BZ`4/E5`G M<0R2@0>4%9-/&4GV,'K.-?I\QHP5D`HFDH6[1L8X-QV79PF].@[FN9&^C6FU M7HD-_;I&AGNGS7GT"6!"1-\9O?N(H5XPZ<8DS_GJ^I)1Q8+5--8E= M7LNU6-)0GJ?`#9E>[Q_2(0)XEG3("-#-`X(@T)F>'1GF/T'F20G^2^-`--)$ M.!U,@&YZ*,@L>@BR4-U:F[8PRW1Q_XWM;HU8LG0D(0])W^'!D;E"8_KXI)8?DX8L@9 M!P.T*R?3==EBV"^O1USQY]B-HEZ%0T:_RG!R]`M"GN-,$V#_#?'/31C'M\%G MQX>WVSM39K0O` M?7WW\)VI4DOMNJ5.1:91K(F%9`5D`JX9(;JXQTW%WAT/TF2/ M9EK3J2C>#)]$'<#P!OQZ/+*/I(K[S0@VPW#SS?.Q>O5TNB@$T5$32$Z& M3JS**"8QR;),1Z&9?!*[S778H@WCA80&](2MTA/:T-PG["NHEG:HD@W(U_[Q MV8/MM[>W/*![^V^E=<$P6B_FBUEZ5_7#$P37-U]^OW[_"0_\-D($3O9!-+9^0(]";R"E(OQWB%8BB@M7K M#MFBQCYZ0#/$)V&6Z[1'IZUDLU$X!D&A$BAT`H]$*9`^3]2Z`!7%Z`:L"U#5 M#63*F5E#'HVWR0)TZF:/.C%U:?JO!+=M,D70@.AR0C'TES%'BI]1OD!*?70, M(UA/:R>CA@KB6[IFRT6%2')1QD<`2DRS>YBF%Z_,8&MBK=T7(\#)#6X)+V*Q M3_KRWC"'E[(:XN5IK?F:@9E,GM%3N\IL;`>/@(V&$-06AAP4-1PS(B1Q]V+S MWS&/)ME"8BM[UHDGHQNJ%=K9A:D1[),6"DD!7!G>`YWGG<+3PKPWM*.J50V9 MY&=5P102-Z;I764VVGUMU(LF;A@VL<1VS$B0U%4BGON*62S)UTU'V="2"R;C M]>'5F5G#TQAF-/B!UP$>\Q7A2_,?=XY7+\W)>LH$1FC3XE6Z%K6Y`R("8!F& M4=#'$%J0T8F?P`&]B^NNC&QBKQ%!K9%?,MUHL*>;!=[``&Z]SH2K]K2)X*^J M(+&A>64U^H9L&\BK5-K/AO%PBFWE#@$A`<#,ML=!;!/?UZKFR\UJYJ56@5>I MG:WF:0=^.YI:":#%&X:((().#-]!^N=U<.6ZN`@'XJ<77+W_*MB0@O[IA<);12DK9*]+NDM"EG#Y6LG MC;&4+F?9:451ZI5#R2N.ZT9'N,G8S71W?SIT:MQPHH?'Q2#WT(7>W2J*;&DO;+%N*-HLY4^:+L&9E-1L)&TJ\@UN(/+ZY;QY*$WE#^U9#KCJB5T@OI\M%6CDT1VXF M$5P'(),)[I4?.>O<@:C00,N@@1V;%!5::=,;1U*#(D.'Y23@5>QA[/;".'*& M0JUG&!Q9!^.ZWS/:_]>4$>ZZYK,9?X10`A.1/)81P$D&UU'%M,Q<=\R(2GZG MV^:4<8`L[_3?.@$5E/5E/N/@K\NBTB3$LS`[B!3J] M_H2>I/>DAKGE::%SG$?[Q;#SUW$!MBO"^,MO`8B'!RU MUXS"M:J+<)]AK>QZOED%:2$78,'C&>N>9/"L`"0V,BJ,=!E&FD-?>W#R,=?B M''7C4#+0\]^&^WT8?'YRD/.N$M3:XS'!8^&'\*WC^_0.L_I<5#\91L:J$@J* MWC)@VZO%M#1ZI4T`V@:@C8!R*^`A!+B=])[`8::H^2/:P=Q@CP7Q! M+WM.0O=/GHGZ1L(]`%X=&\MZ2A\W_=V)(J=9J:V'@%&R4J:=Z$R,M5XO9[*4 ME#4R0CKJ9[\D%PUJOP(>ZN<$0D(\T\;#/W40RY%/Q3UFQA^L"@3=&TN[W]0Z M"NE41V:I1C&"WJ6*CZY6KV8N*^L8@P@%:'8:(><8,YIXAK3!)]PIU MGM9G/*X57>TZ"`]U9W,K/P:1B4J/P%\,?+"]&T0J;,N00UY--ZR:Q0T_R*I@ MX7C`+$+B=_`QN0HVN-!C\O(9NL>(S$IV3FP+"S""HBZMQ(_>S*=6'5?Q!<#B MR40N;0`4+8Q@7GL8)]CJG*`?HZ)AWHY:(4<:QC%>-2-*?G2B/R%)?QOJ!INW M,$H<+WB(G$V^-,$W6NGA1 M"MNR&]D\EF*XW,9I!MER!NG'8CV&C M31N)@A/+QN@W-EY*0ZUY]?Q[)!4T1$.1C26F:TQ@ZP:B[@[>0"?&71^>/-Z1 M2>:X.#&"5]WC>QC`;X[_`*,]X_OWD:01?3W4DTB\%FG=*-H*2)L!Y78NRD>S M2%/X7C#2&,"MF4'MX&ZQJ5OPYIN(RKC@W'NF"\ZDEPGFJZ7%PY_QI9%A++;;+#XW,/(60J3< M9AB<;^G1Y.X`R!XT`[BT=?&CV?:J":T+D(HQWK'U,J?4E64'RL>7]]7BB0&+ MLOWC`(!X?U1_P2@@>BQ-+YH#GQP88^IQ3K*0'BIKHL3HX;'NJ./#1?T=3#>> MBXO:7.TB2.8=/B=.E/P'=**/89#4SWJ)O*%[XS=?'<&8F:\FL]6"[O1.!8)< M(B`B`98)B%"].[M5&F@9-)"_=5NEE7;92B>WT@WWZ$^7_F/C)$8VPTF`+M^W M+>`;,UTH50LEN#!Z1O^(^844V,]K[4`92DC4_)G.JD#"HY=,FMEJ"8JLHWUG MZ"/I87I[*5(7!9S[1(S=(*%^.,#-Y:F=SS!Z#+58:DF8.H9R$9V8J^8//!^I M3!_H:;7WWV'D>C'\RL91DCM/:9F'JA`]&_T0Y@V9CK5$`%H/=_H=)>) MI..C\X\PPGL@XMLM:X\Q>WN;Z-L:$Q)!E82[MVYN MB]P@]MNJ[-?5KTN&=;F7EW'@2!'+O=%*_/UQH5;N!JC%>CI92N/6Z':]@7P@ MB]T1[.F3#G%)_!J^+:O8^EZHQ%\UXKVA%:5,-83[DZ4UF66X;#D2,?"*4C<& M%5E8/_01C^+0AT#D5:'$]X:2(6];(_<0`]0+=A^=!/_HA>Y/;!N+R+RN>P@L MH9MH"9^9-;4L.A1NC2X09?+!/FT`'$@+K_6.B0>SGI?W-@@N0>D\\&RK-_&TH%WG5SEOV.X$^]QLG$]6_"@^/6!UB\R?014 MH;6T;IK[!#='9!G*HJ_V891X?^%:E6&<7(`O000=G_S@)HSI+JP/CA>!WQW_ M2-]X=CP?*W.Y#:/+SPZ2,[J#H4+!W94EF#^BV:95\8%^0WR"OY%$U+2\;!BU M38TD%FLF*VX67HIE+!R\PN(-W:TVA.T$S)]@`HZ%H3MBJ(\-!6&`>M,SR-[9 M(=T%488'!\OI_PZ]W5,"-U?/,')V,.O*17,GUNMCR.D9NHE6Q)O9TZQ2:WM> M]RV5#QS:0)[HC2"G5V([)Y'(Y(.T@3RU'TE.K\1^6@V1]95'E<=WP)B;Q_-\ M929'^.[MCWONB?7J,UI[_%+#,IEJWK&3]\%7*L%8_MW;"EO4"GW];TNX5+O9 MNK&*>E,B%@UZ7=PS[>#M]G\=G0CYWG^YB\*ME^#"HVAX?+O=QC`AH'N#?@.? MO?`8^R_7`=G=OKD*-E\"YW#P/;A!OZ6OTBVQ+R@5PBE`XR2J`07T]^@:K1.^ MM,JRYXLL)Z`0*!3$0\E<14`;`JF2@&H)'O$O,A5!IB-`2H)<2_P$J.@)<$I, M-=6=6HSV(UB]/P)-9L;Y);HRG=%^#IOY.4C-< M'=`'?W;:HUWP5>T]DYA>@OA93";6*AMG9I*S780@DPVP*R&!FM9CD3?-SWB[&^%+6J%MA%G6[A41IP-8TU$ M]2<\D8/2A+3&4O,F+LZ#&N.[V;KX$=C%,NU%J!#,D868$92Z/=4V$OHEBW"^ M_,:)/;)=\`X?X4GS%)-P8,=9&1,,5Q@!!DSPC7@H]7WV-G#SYN5+##?7P0#R,6P%9,WA@_0JWA$9Y/X.\,5"T M9OSP_=".H:?ML%.V?O@M!A@N8)M[PLG%&SVEWQ\%%5CW\^6X8?\V#!(O..+! M=&??>9K04=)!FZ82^VRSW8`]J.$"%&V7>G(S=6QT.FR1.0Q?/0L.)8>U\<9Y MT`8/1?THA.GG$=$)K6&L((O@"3)/&QSM)-835V)4D3=V!EF$,L>T9A%>[HEQ M9Q$"*!"@@"Y?CAOVIV<1HD)'20>G=8KS];PW-9Q#%C&(PZI9Q*MCYJ1R/M'& M(.=!("?F$S(>'Q&QY!723\TG>(+,$PA'._'+9*8S,=(H+A@8?SZAS#&M^428 M>V+<^80`"@0HH,N7XX;]Z?F$J-!1TL$IW>/27JQFO:GA'/*)01S&GI4H\3K`C-R,]O,6^FUL+:_8U M8Z'/#(&*D*<`IQ97AEFZ24XUTJW9J60[XB?XS7^Y.AQ"+TC@YA,I_.8>,9C? M>1%TD9C634!R[^K>D"BJF/`FM96%.&A*HP6)!KEL\(F6/*32029^V+U%S$V) MP]AMC<5N_L;$88RW&<9?0CGCM6Q'E`5SOA]1RG=&#CXI'"Z MXX--<=][N`4!PB_QCE?QSOAVI,A&?25AD/*MFF2"-GD;H;%&DO[C2W!PO`T: M*Z(!8/)RASY?@NOYX`OL=++K'195AHF*3::!2B)X2A5 M!"0S[S.BF9Y3A_FSY6PQ7>=44AK6;U)Q^E,C)19EY#"V61I%YMG9!VN:%X]@ M(D9BZF64DRWY(B:=YMT:TA1RH61.72\9"#YY&LD MG-+8JW4QG`41%8J&,26IN%AZ*E9_1JK2S#PQ386"BM12J20SV:E*4^ET6J44 M%UYZ:/^^>;$3L@\U/C[Z]#XV@R3"&U=) MT12X^1!&=U&X.39Z7N'7M/-(MTZ"<;=>S.?+M'82E0INMR"7"S+!X`.>+J*B M-9.):ELMX[9V4(IJ@^V2P8A0W-Q@)S/8APY9^F%9K(<\Q/%9T(>@KY02R'40 M)UYRQ.!T?+I:&D;MT^S\-TS11KLZHK.HZ/_7=ITQ*B)!+M,,5:BPSS)GGQ@] MJ#"RQ@Q>Q4@ODXG^ELYMXEJ4$%=(-$X2?`PV^('C+*74<(>PAQ`8OPWW!R<@ MBX'Q0_@^0+9Q/R;W/5,TP5-*-*V=SJ?+29TL,L$@E4P6T6/P$`(JW`QKJ#/7 M&H&Y8B2BSN9*]5IGC_MCLAT@LSUYWA>Y19F6@V^$"(,- MN"-["*ZOK\%'N/$VQPB@+KV]9*56KA$!=8-Q.CT[".]0^;#U0D'FLZ;Y)5-$ MM%RR-4.-,3DEDV:61/K9Q"*.06V28XI^AM42C=RP;T\A&H_L#S[$;`");+*- M"A-#Q@(%+XR+#^I@8W)`Q6JYO-LUUYQ M]C038F;Q[41;RHMNN4608Y&N=0)F()77!=J-'T7<=RRQL9\WB0/I!::UO9RQ M\&!\'4V1>7;5O`P<1E?1.L.-BQ+C=11NJXMYG$//;4^:0$B/`K%DI/AYGN4128:I]BJG8T<4.S%5AL M%RF9CZBVCJ/DM$[)VG=LB'UONYY"QGE1.?AYTMK;M&Y MC%K4@;2!]%^X"5"T`7`C>JQM3OWB$;XQ.#+<`HH[4NM6*\QK`-)S5=V&C!9M#9.[1S@F\OXC\JV"3W37TYABCMN+X M`1>%:_T<(N]IAZ^`4L*7LZZM95H[H2R6G&\/\CNS'E/1FG=:JS?4:AB**QJD MEX/=;D$F&GPEPHTP@'*C;05&ZZ$)"906O"'J+R/3;"7E\!;PT/_L*3?>0W>&,AYVB8658*Q,O^H[-L8X2A2PL5UHR/MD_4L'D!VF_GKCO%%SBV6DL0C&NWDC M^`2#V'N&Q2+UAS""WBZ@('-?'B(GB'%%2-*_D7_YM+?;_.,8)[A3^P23V^V# M\YWW5=4WIAM7RBT0#G%KF>>V),0KFE0W?%R`5!^0*01*&I$4KJ03*)2Z`+@2 M.,KHD&(&P6_8R81',@^ZF0>3DL>80W$KR#],^N*<'3!8^,KOC:BI=!7TZM'F1F?M9/LXN8K%;3"H(-U"S4`C,BBQM%%B[``$T4MU$+@P;F%-9 MP9"U^(_;N7->R!B-7U2-]:CV)?YV/42W@EAV7O:(QD@F:NAR8NRE?!4&6?H- MZEBK5V%5"XS$3G>>=DT!\Q],#=)^"T`]W+ZUUOCL?U]AA MLG20R/2RG3"9*%#(,E0,6ZUQ=KMQY!9O@[6P18.NW$ER'6(&,2]X2TU\%6S( M0ISC=VU4X;VA%3=,-42C:[&>93?(9]+(#'HFS_AX49F-=E\;]6&H,PRK,.([ MQA"22#=XN^V\UD;H%;U88NHAOL"R6$US,-%L#F4]YF]H46\DO93ER8G@""YE MD0F_&H3X[C")H8?PROWGT8O@1R?Z$Y)+OC]#]QB1[2$=WY?_K@%4<162N--Y M.JG!*PE!*AD4HD$AVRS.%)J=UFO+38QS.>"07N>FN-S4FAH;P!U*V#::S;5F MY8OJ"(WNVXP?`]T((;6-=[K]-0H"JER5A]*-_+8\T7!@"S!)14RM9")UQN:C M3/X%O7/R@N2<[WDW+!K!JBHW-`$[GJLE^XG_A91P?6172 MN;*K703)1FOV_6T";^F>_^U6272.$?TY7]"I8"H4)9XEJ<#)Q&H^VZ7:0JMD M844JR,6:O.=-M;GVB>9JF106AV,^/RSH)S5L@;GW`3T".=Q0?T8[$]04$`Z3 MQ<1*:R?0"J-$!J!"AD4"&_,GV6+5;3$)YY,LH:.31OW7!US_=02H9<"BP&B; M\49R;^3L3\X>7GWWF&/\\B,Z\^=2NQ(UNK);C/'K`+\/OF()IF:3>QMABQJA M+9=M"95*MEHWU60\OPOWCE?O#1@/&8AIVK)X0=-I/@]5!`2583BN^QA2CVR. M(;ICNQHV;=%=,MA(?"-9,(H@O;O[SHEN(W(.=O.[XQ_A'8S(%#GKHXF]K!,/ M0AI)$.;WP!I`%#&!K`>+MJ?$R-/R#CG[%0 MHQB3"MT*]L0=91Z31)?XZI@\A1$:B-5OVA!\R1@&ZYI(4/MLQL`>E0D*H6/` MVVF&MN,LIH8Z7$/-X(T5EFR/! M4Q\#N5CRF`::Q%$U_+HP5'+*6/!S>TSBQ`DV7K"3^+KEMPPCJ:2*>$D>:\)* M#U,XE:2.!U.]3>4"*^2;:A)=+<'9!;&ZC\SCC.2F0E^9/FD,3Z1Y\4.OUIR5 MYA%!%R/JDGI8U@Z9__IZ,K&*4=0%F%],)A/\WV;*=X$/'<"TWR(KT:-$6B4\ MV>@J7&@(40?'VZ3'F:Z"3:G."[^XELB;>A'7I8YPG"XL>YHC$$O-KFXBP58N M.&2XVI9RH^VRT=F%3A1B]+PM%3J"IV3G1U10Y,D^26Y)0M1UI.$&0]CT8 M?;04W1)@+Z?+>;I10R@P\4%O_+,X/T^0'B;0O8-K>*]4*>I#A:)NJQ1%JG:@ MG]%3%J1!$V='='G&YL=+FOJGD6+^S,GIK%'L/NGM7.74]Q'7&O>2E]NMP*D3 MV;=-DAQ?-=&KGZSU9+JH,1O!<"8>XU7?.10A(E-I>0M[F;%5&IYDUH[I-$Y/#FME7P&GF1[K?79\U#E('\F1 MD&!H_->AEOC(R+:LMI$@EH\#5^>QG#[C0J5^:$FJXM0/(SR=(Q_FK-&BB!.- M(QFG=K<']9XIU+8I(QZCBW4]J:!8)>.?5"S(Y8X`G*>; M2R"9O9N/;$!X,'[IMW!P,E''](XAK&V.;G(;?8;1L^=R]]2W/:H748WVA=>6 ME\MIO@!!Q-`Y^%14;':__/ MD*82XF5+)I,9%R9F-_"KL8^'EC'LZ^\*O1;0,%RB:NIKZR5X9LT+=K=!GC7B M=C]Z@;<_[HN*?E=;]!4_.M_Q3Z]\/_R&1X>WVVV,9^?N(OCLAPNX58\3493O#R M+W'*JQ6N'2^0G*F'\*AUOK"+&>#RNDQU M689<86-L9*[(3+ML9G79Q?A=%R)Q6!N<\[UB`DSWZ"/PIGF+WVN$2=ZH>+GJ M>;:CG+QK=`*WI_:VB/:Z8KL1%N5`KAIH+&JY=S24G]`=N9*7%:QG$[L2NT9G M57M;8(M9H#6"V3:23+TG,C@890H,Z*^V&E9M"HE&DB(1A!3N=3AD=FOA]A<";8T&6'#.C MS&(Y$<.7X2M_E!O=A)NLT:/`'Z<'$_28(2PFD>V]%Y!UWMOM9^@CG79W$=XK MN@^/G-12>4-:D:E:>_'J0O/5/$,U40*4M+@`F1Z7FT(14-;D`E1T(=?\46T` M4><"4(5,,8-9Q](S#G'B[0FGQ*EG#E@>=E7R!$')LS'8AA&(T@\1%5J;)9^A M,%PEKD&^E$'28RZ^9;_63S`2=\]-LTO9LU>'`7"8.+X`@"457V#%'[#L#$Q& MSQ/5`Z(E[@VNNJ4*=-STW'C,0/3*WG>\Q*.A:A0;O\;Y-%OLLBV_CB&F>3I5^;L5VQ_4O3FQ50OAC;_V>I+6VDCE@`@),K?M4($U M5MD:+,CLAD(%%K7L'XR(5%PF`F5R$.4PF_3@^?'11UE*$$,C]QYT`RC?,\CV MBY&>*M6&L@J+7ZL/Z>RE*BV+3]>MK5D-#U2"H?[I!"OLLA5>X(9[HQ=[M,=+ MI8-J&FLBL#^[3W!SQ/MQKUPW.L+-C4=W_B/N>,#CG@?X/7GCLVM92@C0"`AQ MK823H-D\2^@RX9AH4_&@)!]\)2T`W`0@;1C*]X9R@LUR0KI6;'3`(Q_0951* MNLPP8H/$VWC^,4']>U$AZ?UWUS]NX`87@W@;[@_'))VFR.9EL\N!B#W=H:.B M$3/(5Z"Y^$3^PK);V*&D0JD<&\B4H$E920W\4KZRD=_%E3**>1K1[M$FU0SO M40-,I1#(##93]>7.F_'$X'M[HA7=^?3KBS9EDRQR]K>]+ MC)R4A.F(`;9X$-?*>H6+`?V,ZVN%^X[+XO632"^4M5.*_+P8?*OZ@/P1;BB=LBML[9]:43FCL];1ETF8@7(\J/S3I<$*DY8;R$^[%Y1"7 M1!MPY[R0(_!7WYQH,Y(YY($0/B@YCBB=_.!X$;GFFMZSBQ+?TCZ(C]")\3U; MM\$]'FCCFGXX/9;=+J2B#2-$J$!QB45PNX7\L`;9U?)4"3)0*^]!RO3`14-S M3YB$5BP]U.`69(J$,KB97EMCDU*OZ2R`=%`QG;C&28J=8)C;%C M?R<88`/!,&=`7<219G%7RH.5V;NQ M\(56/S9(95@_ZN8.(*88[JQ\.IP\%\RYL*UTO"H[6.X04[!E>=2E:C/X69L/'8Z;+LX M[<2/9)C?L,)O7M[Z3BPX-=-\PPSSU-40/T!C35LF8BA7H+$!D3B:\=1I5C9' M2,)6&L`L*Q09`&QUC9)*89_QI/+F[@FA^P$]V'YG".])W;7"VM40C)7U8FG- MU[18&!4$B"1`1`U;IKD-Z\HLLDQ8Q"\:IL(LNV361[CQ-L_Z^AH\1)[C M&RU`+0"AO%@8QQ]&^D5Z`.GE'3R$,?/>@_I3.ON_:M/"O<'2GB]R/!`)(!5A MJ(<[Q0X"@.LH@L\H$G#N'B=.L$&=F@\3>HLY<",$#*,7%S!"J=*7M3C!3-3O M<._R&PQWD7-X\ES'I]?V,3\>ZWFM2&`H(;$P-4TQ419B^-)%16;94F;IPT1' MH%71P?.$$9RT3F.Q/F3[PSH1TJJ!,-6NEOG^,L9,KR&$*#"KF)%-S7++JT60 M?<^D-J1P0ZT"$[8[QH.1TJH2:U&)_,_O,,;+YG1SO245`#V;,(['?GJ+GRI> MSSI07%X1A:@(O0)7(U\U0*I06AM1T8J^4T5.A MA7ENTN_%].!?0&Y-.**,W_>V9,Z74A)E*//$I!)S#592YO6S2IW*YWVRA29\ MZ!/?.OK.>_8V,-C@0Y;7:84$ M0*<3?=R(=3NS5%"QJPD7ICMX2%KXR@O`"W2BN/7JZM$GA,(`5I(ABGV,'R9E M_#WTD1C?HW_OC7F>?WZ[`N2>1K58)P[BX2%L'8Q:ZDGSR`J3J_D") MI8+/4=K7_9Q+NP![MJ_..M'D\L+@&2?[>_VHQ.L%AHDW5>`'(UYJE<3^Z+5E MDGBINC\N\?;Y'"SB9?OJ1R+>*B_H)M[2]SI[XKWWXC\_1!!>!P@*,$XTY[N\ MYL^5=#DVR217P\^<8D4!UA1DJOYPJ:ZR;T$KK2!IEUOL,"]S6-3EL+.D70%6 M&(QTNS[9CTFY^C)=7O,_%.7*I57+Q70^-TBY/TR2J^Q;=%#N#Y;I"K""7LH] MURSWINO>N-,%GP--WLC>JH;'E;8B`AS#S7.:'6?K<=SHN:T!/R6L=6/^0KN^ MJM/;BM+3\O'5,7D*(UP^777<,MLY![9B*2^3,:@;,#;G#.UE:XR_`WOM!TX MF!O-G2'1U6V0J&VQ')+O,KT(I(EFYTU\I_FYR.UBX%1[)VVQ]"$:N%V-;T-`Y\H+8<\G86OGNR>X&SV'W9*<5$D40%JK&JA=% M=;228A<@5XW.XYW9[DG%KJ9WSNQV$=PY":S[IN(Y?!?-1\1@3V!J70!<6<@X M/PX*<27[*\4^UUDEATV3:#>@NJ=GMG,.Z2!+>9F]S;.!B9!J=&;YGQK'U@:^ M;?X9(=T-@58E>2#WHYPYN?T=>KNG!&ZNGF'D[&#Z&XB+A2H_=2C9^GD2(<\D M&12K6]1MI\=,3Y`JFOT6DD*QYW80<>H,EY#MU%S9.H+3-7M\U=O1\;H9T!IHSD/KDYYAO?PBC+?22(\+>M4#Q(<4MG5$>W:*^3*ZV M5,_#)8V`-TQUHC7U:T#F*#=#IL>GNW?&F%E()1N^1&(XF*K,:EE?X1R9C2R$ MY6;\%H6Q\OV+G);.B-E:U!>&WFRQ&F`V@&I4D!K^"=+J/`?^)[N7-67Z&ZT. M.8A74+KS&([<+U:I`$FPVG"NMV<$&>V^+O?=,-S`<4'<58U5_'/H5YI+AJ%GLBYXC;=\>$W+E M"NJPJSLU!D(*N[TSHF*F$<*;D>8J2Y'DI%O2:TS[OLQ[FK_MJ^JW]^1/\.CX M9[O]7Q3;*@F3_Z7.G!H'W?'5;.<\J5!N8Q+^0]UU%NT4..".+WI=!.(*3>S7 MQ[GM<[.R;*?(59\3)TI&[*RY@+/>P)T7!#]>[S#<%KGVCW+FO8&!+7*BK9]G MSZ%D:Y8U55B(NKT_,;%%3G='H^Y;S`2VR57]"W_$SDB=0^?2#GW\03LLW?L. M93[G.>X[9-O'VGMC#[3QJX\F9[3OL(=Y$B4.%D,/J'[X?8>#?Q_9?8>CGILR MPS@J-QWV_=[G.(+!US4B\X)-?N%%B']4 M#+!^2_4&2,6BHGD2DA_7^@3FM/IYKCAH^F!=!]%+[35WFX-+LLD&WU$;@6/P M7'PK6/I6^,?&NPB3?*5R!'!:6/R8W<6@JR+"S?]0G8':+;0`.K%BM-+J%9DGON@O`\%TGOW]/X_X1F:&L0]E!#QKT_Y%G2=$NM,1-$+:O&.5&UI&TR^XE1$'XA&EE-WG8YXE:7.+T6CA:PD-SHFJQ<8L.Y], M4X[%/Z%*HP9=I`MJY79[A_X9A5LO<1X]WTM>/L'D)HQ1\3>)5]`J::"T)DO5LN5]<*:@>%(V!VRVB%$PK9>^@!@%M$=P&`+=) MGR.MZN5KG1XBU'O'BY4BK$PPKQH*P22JP*O&\M/.]-%,=B=[/=.\BDC#F5`/ M[0E:WI9NID?TB>LZC*>P)S]W,#S40KTE25/HJA3.8<(`9RU7WSWF[@_N.SH# MGJ>(^%3$+)O33U?F"CG@*Y9D:KE2G76VK'7:\"$2?A7(=#K%*(I^@^$N<@Y/ MGNOX(@AJ/&\"/74EQ/D7_1]%3EG$.$!SFE&VA%':L<(*LE: MH[]V@J-XT`0J\M:%(V<]7Z_39"H3`KYB,8#(,8V(G@;9<@9I1T,CG%IA4#7> M:/S?;M\Z\=,'/_P67SW&9.]PUZ=K>\4$)EKT$"\::ENS.CK"+<`"`9&(*#:5 M:1HI)YMI]S=3.WXXX=B*))9S#&/J@QLY_ET8>V0*5AA;[%?-8(RICT3U MP[RR63D(<\$@DSPFS"DRNXD]:;,-8+`S?!E8Y#O-,"8_X^F8I]#?H"B@XS5Q M4'+>-8-*MD(R?<.\!99ER?\"TF'ZB("IRO(F,GM8;@";W6',`&>'XXRB\P'? M&]SU[>E#)O!&6A;?7+^<-OJ[KT2$:?3TL*,^X&+;H1T+E:!I#?K"7C/170<< M\_LT'M0:Y?76A8ET.IMF"S9MW'F5))'W>$S(I>M)".Z<"'T4@W763[24E$1_ M,X+RYB?:,1_:CB1,'']("Q;8@@?<"EUERR,/$F%FZ8F%^BI%M3I@'#35F1>/ M(QD^-0]<+F;65)J^1I`+JS'<;AI.T?/KN.##3V]'F-/65?H4)E`:4I67C,*J MK(G$$:CID@,M+'.$0.IO:@N8Q$TUAZVVT.3CJ^&B\6#LG1>[?A@?(_@`OR=O M4/M_2GWYMO>-(Z]%*1F:GW6!L)"/QG:H!4":&!4B3W8!$YSC`R,GAKMQR7*4 MFEW:N,GK.#[B4//BV`N#C\YW;W_<%QLH:U_Z)%': M=VCWTU,P.*>SI359I?NSR59!+VT*N+@ML@$[!@YN#?TD:P[L:7NE;;>ZMV;K M<$M!6R!K"I"VR,[K&)#60-$<2-LK;>,VL2=;AVOL9L3$%^+18FZ3]FD,4FS1 M/L')QK(5K"_:(>("J MB6MJ>T!NN^E>+QDR;MJO.!]+59S>Y"#,@&P?CH@-R3U("LB0(\<\%[*5$U^8 MFDRL[D0FO2",/I)5!.7&NS&64^43/LF-$.+=$2^`\`[O&0'X\7#P24?L^-FV MV>M@&T9[1V2/JN#;.L$LII+$ELU5MB6N)+G8+@U*PLTO7PQAO-TP?E-,$"/H MNM@56^P*KVC*[(*A7%!7D"OA01-X??`2?,#\.MAXS][FR#W$U_ZL1BRV*B!Q MSFV5+L43.3C4"DE&S_`IL,N6MTL7>K@A5L8*VPVC0,;?O>3I'OH$M_&3=W@( MWP>)E[QPBVK+2C&))KYJ$NMAV=[4LC`\TT3%&2Z*/:C9=D^SC6%1+*BY*!7P M7W_\QM!]O0N??]E`CT(7_:6.6/2C/QXB!]]9\OEE_QC6OWSS]QI0UFA4?+/' M:I76ATO?!U2`7KB65*T'VM>@%9I?XIE[V=?N/Q5\9./(?[<6!,C$S42>,V7AP7\IH9&OH4/3^$Q=H+->UPF\3K` M"\W>,\1W0GR$+9>K"[^FG5"Z=1(M&F=/IXL9914D%3$%%0M()4D44:E@0BVZ M:4.UE59F9286$+D@%PRP9/"5RM:<4@]C,B$2U/I*QD@]+"$.QX(J!-UC9(B+ M&KC=EA9/>9,_K<_J'*ZV*2!>V66=;?C"EHCOA@J"*_#S:96NLFJ+`D@42"3908_2@RS&X8ER+!'CF&Z\-$1:&6$\#PQ M(HR@+C+<0_2#.Q@X?N+!^"K87`?H0\,XN7+=Z,C<%W"*1/-8$U%3/&R7TTD' M'B\`;9'\,&^3=`I9JR!M=E305>\G`N_T37#(/1%&:#B1.B+"4YQTQ^01@3)* M'#1VQ21P2`O1C)$%9*`DP!3"CE3[7#*MM!=C2D8@P,2T^UQ2[;+]C=0[QFB?[R%F$);\PY.OZ-MVT]8BCSNNX> M24(WX:LZK-5\2KNJ/'K"0CS*CU+YP"T:`#YJ07,O-ICM5L7VDGB0RP>E!@!N MP4#/-YC]A#G*9G_+?-'\]N3#&^LO>R`[[TAEW3<4%=4NQFKH($%+0J)&0%$B M>@J&[&RZ6"UL#EU]RVYZ<]*;WA@Q;)Z\U'N%362-^^^:S#8B6E/O&6F*NV@& MTH&YFF^*^V2HA,>#POY6RHD/X1V*I"),H4 M)TKJ*1KCEK68SVN*?)2 M<"7O;(GWE-68JM'1PNR\'[G_SA`GJ;.V2D"CNKQY((M%KEPV3C*B]R/+^4@1 M?:`OEH3?.%L!ZX_H)X5*^Z)5B%9E_*<2AIURY0#]!`LLC19TH?<$,VQQ,S1A MLS7P2S!L&FMD):1*`S2%NMV^\_PC^FDCS6!-]DM*T;F:(J>:^&&JI95N7FAT M#T4>VDS(+T#:LJ%5F2&]03`XJ'E=%=4'-6]1'6-4AZ*78,,V7-LR53\P5Q:R M>GAP1+S5'!?QRSE(BS'/7$S=Q.NMK;)R5?VHRWC1AV$]4\WYLZ%Y&:SWT M#7T!F/,].&:56R>SQ7*P9LT,VY$]_"$3>]Y&^C?Z%_H+KK>(_O&_`5!+ M`P04````"`#(=:A&[[/T%]$N``#H:0,`%0`<`'!S9'8M,C`Q-3`S,S%?<')E M+GAM;%54"0`#>`1-57@$355U>`L``00E#@``!#D!``#M?>N/X[:6Y_Q,D,W"]LH5;W:ZM3JGM^.GJ[N[-?_S[/__33__C[=O1X^/H.HXB%(9H,_J[CT)$O!2-IMYK',7+ MS>B!H`1%J9?"<*-['/WQ["7HWT;T_X,1_.KOEX_WHXMW'T>C19JN?GS__MNW M;^\(";9COO/CY?O1V[?;^7[-*/MQ])=W%Q?OOBO]Y3%>1P'\OO2K*X*RB0.@ MZ/W[_]`/_[Z_3C]S]^^`O\[_^76\>K#<'S13KZW_Z_0F-H"3T^C1[? M/;XK,?D_1T]QE$#KY::]D]`BLDA<4O,L'#7-V1P!IE/S\IL3A MZS,)W\5D_AZF^?1^V_#-/__3*&O\XVN"*QV^?=HV__C^[Y_OG_P%6GIO<92D M7N17.M+!>%T__O###^_97[/6"?XQ8:/GMMME;^JNW'R_> M?OKX[C4)WOP[G?`G$H?H$8NFL5DR:A^,Z+C?GV\JY"_2O`+#CRV>M)\ M+;ZG#=]+QWK?EM)'Z/G[$RQW1.>8S&YQ!-\'>^%#G&`ZQ57H)0F>813H$JXX MZC%9>/`(TOX`&D.G"Y1BWPO-,W4'1]H2C<,4D0@^_0MJP<7A6,;)?5H`'(LX M#.#TN_FO-:S:<11,`!Y"CR'X$XJ`4I11TH(5O7F,LWGE)8O;,/Z6W$4!)LA/ M6[!R.%9KV&;DZKE=`;Y MO<<^?'D$LU_%8>@]QQDYXSE!#.[$,,,-YS/(\1V](>;X.43C)$%I\HC\&(ZJ M$+.9Z*:O_KTYK]HS=C#A$_+7!"9#"165@G6()K/Q M,B8I_A/!HDK2KQ$(AR']Z3Y.Z+ZZ]3#YU0O7M.&+AT,Z"A#YY(7<89NC^3-0IN7E?T""ZOS.H?FK.L/(-!KI[2V/^C*MF87;NJ$W3*$_O-9,7N M2A]$4?C5UPC^_!!Z1EF3SM,IAW]#&]@K<)-1\T"P#YOB M/!/H:5V=T=(H0E=1A^[#5EN^D6Q(O6<-+:G9Y\#;TD&'$ MM-C%K6NA6`43)=H"_KY3,BN6::[S.ZSM8IHC>?#^1?XQ!^ M"KCC-H?HN&1VC>]#G,+'QEX8;A@=H,07(M;-JQ^NX5RBFS4C.E<]MBHC5VU^R4 M-.T7-"8$-#?VA^+#3=%K>AG"86Z.3YU)NP9@7UOME'&5R7K`\)0J8P;7M?J4 MW3/_@I(T_^D[AB"[TSUS,+;10N"4123T<38E'?6%'62(=47BJT)I?C)W2 MV37,.ZM`04+2P3*43V.52=,+0F6RKAD>^WZ\AO^"KD0GA%676T7NL?>,0[84 M.SUVFA+04V!,KY%V9'0-TJ%23MMVNE[4I^P-\Z;7A.[$W5_`N=&B8_E$,DOW MVHK0@M&QPJ(U;]?T7*T)#?VYA=WD MA?]`'KF)@FOX4AS2A$WUJ#Q/@%GZ7<(`4MSTVG?0KJE%9M#P>C1DRX@7);W<\^J8PK(0L]N?NJC#V[R.&*B6V8PGJQ3&DU+57LQL;).QZ+\%H>( M7,'*FL=$C&NUU;%H>T1S3(^X*/WB+7EKD=NL>^IRF\W39ODD2IM'_.U`\,^#^[X:'YVW>+]B<:UO_04.=Z+"C,1+G;MC2T7,V=VCF(`6 MP@+W/W[X\&8$#,P0W)+!?<:KD$!&70H*#&(M:4\<$Z#@YS<7;T;K!)B+5YEC M\+3@V9-O"GPN!GPD=UN!TZ198/7]@!7G7BKP^C7>_*O^/9:#?6:#O8OXU*PS56%F=>\LS@72=O MYYZWRC1&%*;)]C?[JF/^Z]^W7K]M.MPC\A%^8=;A+RC-3Y4]M5*O;W,5N#U7 MN2]3C8V]QI;HWO.XUI(N:&^)^O5R'<)Z%Z96TOA(6!N3V=1[%?.D-8H53G>Q MQ`\>#NZB*V^%4V_?_%+7V@KE>5(?G]!R'IX-N@3>!T$C>W36[,I*&^M4*H&Z MW]8&U32SF?J>X3\TV.#%"YDW.J7I8AL0.%@$DX`+M;Y6N!([UD6\2'K8XB`7 M`J6?8+^9#5JO;R M5>YNF3?Y&=03_>.0#'7T^R#_\*H$R(&7];#!`5/8I"I&N84-"A^V-JI:<8;7 MTA+%*U`;\[SCK:U%10]1Z6F'HWB%2+JA2?7,)@E'W8J*N^)[5MK%!@^/"`X* M[*M<*/Q@!V^*,)02C81I"6K#(@MF$?B_FJ[6B#'YE!M^:64.IJAR=% MR:DGLI*V=*0B#QW1ER*W55''28W]Q=40)G5@Y$>_JR%,ZOC4*:&N!B^I(U01 M,5V-4%*'0T<.<35&2?=<;AN-%*=>>`I(")3@,B"*)O<=7A=N14=HXR55T0N4 M7+[>%5!2#"HH\'+YNE?`2TG%+]!R^>I765TB7)K(`/T_RW4MS&6H9!915T-- M3>`F\62Y&GEJ%C:>\]750%3#&[5M+*K;)YHTFN)X\:BG!YRL=8&;FX*8H9TI M<%87Z#41S$YJNVK(_ONAMX68YJ;Q01LE4:!O`91;F5+-@!+%0A4H.2^]*J`D M7T=-!-7^'TLZ'KU#]9%S^5VX*98VQ4G]TMPA^,E-ZZ">P,"-,"ED!#<=%?I" M?#6@N,#'3>E`#Q]A>DD!DYNR@1Y,*C$J!6)NR@F:"TLW0ZN`STUK5UL=NHQ0 M$_%!1\SJ9PYL]3U+N]DI0,N$,+(#=J\4CV5PPXM4>EK.M\F2KL?K=`%KX\_B M,XHY.>C1"P[NDF2M3GW>NA>4BXNG*76Q'^.LN2D4.]OG2W%KU'3J"Q_2#2+I MT!?ZZ[=)72^GHX)/2.]7/3U<#V8U@]_A*>5ZD*M)W+:GHNMAKR8QXU?H<31` MMBEP2DJ#Z_&R!L"3'6^NFJ@,@79XMKEJH3($F.!@Z]HP9='LDEGDQB'0&[&' M!'V2W`2,*':VPA>*$/%"^AA8 ML,01JU5+#Z(\5%W$4$TO&YP4WHWLL5T:.+B&Y5,\1'N)9G'E7>R;5Z`;+AJX MM&4+D!7Y(\B`N`?'B]GTIQO(U(L@+ MJ9ZS/;(%K"AVML$7B%3%P20@O]KF)*C\_<(.G2"X9\Y1:D,#R/LM!9 M?S,E7I0`LM1`$07LIS"SF`3_N; MM-7L@X-F5FB--UY(G]B1*1U[C6S0^1M,7V$AS]&6]?$9D,LO-6:KA M%;JC](C3`^)J5I?V,'WF56:9U1O#II.GSE9>=NP(;-.N>UO;0+0SA+ON7:VQ M,5:C__>O(M>S(S3`D6B7KF=$-$&IK,6V2WGH?]ZD!CX*]J%VZ0].K:9./4SM M*K`YM2J%WIQF]==^R#"*T)R&@#F#TIX%O5VM-:?6CU@0<[W$F@9(^JI:NSIL M3H&W[YEROOB)CLQEP/;J>HD4#3BE87;MBJ3T_]!7]E]6Q0=12(7KD;B-X*KS M#;A>#[$1:$IX=9TO;@>O6K_V7O5RF) M#MS_EN?\;J&ET2!.S MY7[,0:,:J?U?8!U"*@Y/.EY!58NIN8SO:N&X2%A3;P=KGK;[W5__(D_;+8_^ MOT9YJ3D+04P*]0(_([H>!`%,ZOUMA&@)RFS*.9+VLGD&, M"^@7`/C9UGA$L+`2G*)<&,DDOT?DQ_.(C2)['KGS:2U7?Y.N@L-VO:A5=[I5 M]II0;BGE*SN-Z8*.(UC]U_$2U$OB/@X$0H%#0;J$;], MQ#7`KF0R^Z;@A5QJ9&/77=.*J,DTC`G'DE=P$>AYF>#H\DQD$2)"DU* M/;\@\AR[L;JNUW>N/X?TA&S7LXU;`2?5QEQ/059#KGNOB^O1Z$U%C$H^ M39.@\^S^O(EZ'K?92L2H@M3`#W]J(*F82ZOKJFJ1/!N!OF*!Y2+"5XVV`'T8 M$"KOR!TL1\#%8KC+E97F*]S;=]$N('[LIX`3>PU9[H7I9"HK@27+ MF*3X3[:L)K-K])Q>X\2/UU'Z0-`2KY?F#K9+-,>PT;/GP)58.>AD M)70"5LXX"NA_Z$']XH7LC$ZO/$(VL'AD,3MJ?9WDRI*[BT\;/\1>BSW!$#9X MO$9P`?F8;1(!#Y4F5H)V9C.XM":SFU=_`7L8/<+--(GXT(IB>72&&-Z@Z*!Z M/TJH>BU@8+^5)4HKV_$N&OOLX@.2-E2JW,8([Z[Z>^P]XY#=]6*^6HS9+Q1` M&D*P17A$2Z_A-B/J(;!*@A?*U__O"IQK7GG#MHC'+(*+`:^NVR@?O/;_KNK#MHC'/1M*0T&ZC>_[;^[ZJ!# MDH'DU1L?@"TV4!3L#E%FU:U__4:QOQ'9,Y]N0AX\DN8_?(U6H./P=;2M(,R5 MJ$V,V#%7.Y\T((JNXD27!TY_&ZL,M+.M=]@'(`GBU:`0K#"UOKW@JK)B8*'4 MV1DT!C"RSF!X'Z&`E>3=+HK)K.0U9;$TS'7*/*?"!==L(.,\?/92^OTWDYG" M>M+M;65%EK4*&45>N*7H+IK%9)DYRFO84>QMTPG?I9^V$KY5XPUL%<5\$E&H MQT*ZZAURO4;AL5`5G<*MHJ<'?#5B&)P/O3X6U/J5.G4BMD^I4J>^2V/O68SF M;K=F0=T#N(J>7==CN4V#>^"8=+W*>#,`E7S3[0J.NPJ=*=-]NVSU_A=E;.ZZ MW2W0AB:X=N^P]7_=MD-6P[CD^A-M9H!LZ[-W_8$V,RCKQ6$V>]#MW%:N7HRQ MZP_!=8GI03QZJP?C3B:/_XB05A]+:V!8.9&\Q>:1497+7\W'W*P0SBDI]^W@ MU':RMJJ2@8[6I\2UV^SIC?-9I(W\Y>W>W#A9`4H3TOI0ZV8ORY_?XFP; M`-ON;?J3%4XU/2:BBDE-"@&NX@335^1ZCIMNR.;N6F\;/;D#]Y.;#M4ND.5% M%1`YZ:S0C/X>.\*J59P*+#J.@ST MV#6S:)A@&"=K@@J]%A8-?6\PH:::TF?;%8TLH:A7&TN0+S(.\1+F?O(Q`@$\ M`?2Y;\[(VUJIT40(=0HRB0Y`@\WG%;\I/9,L?T-'=Q0C.3H"[T84\"S(MQXF MO(I&;4:R4E5G375HZ<>H-#%3BR-45*O9\9"JF1<.O?>D#$I]?ZG$^4H*F9W-`%J.13:,(_ MAOEM+&5!TI-D0O*RUY)7Y+A-+=*%!*O-(8"[^;HTZ^5N( MI19&]LKV>7E0`>4[EM_0"`U/U$P9J.Q:04LK>:=H3@^O7U`\)]YJ@7TOE.X# M<7NKF;]E>E0>L3QH;V0%3`FF[P20%/L8Q)CT%J2&^-O751:PQUL)-3UL8#J% M"2:SDJ8EP9/?UFIJ6S,]<^?Z$BO8KC[*5B.3[I!1$]Q<+;9?)SL7OE,53:U5 M#KI+*!UJ8ZZFD3>&AJ]*NYH-K@Q3W5WK:@ZW,D`"D=C5U[&4<1&J]ZZ^?J6, M3%-#MZLIT-KVJK)C3"!&._O63BNP)'K<%C!')'9B5U5=91-Y4:>BZK=UO2R%.C"'QF#77ZY7 MQT9D+G?]G?H#W\W!776XC]P\8#A^HC(6>Z$6[BBXAQM'U#25UW532*W2]),=#SEY4YSU<5E%"R[U=Q6'H/<>97#R>P^64 M(=4^K--0,&5>H&Z;T594`4QH2/V:$"0LJ:W6UX@[U$*PJHB2*%I[8?Z!/\-9 M`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`4S"\.YV_U!0\!1]>J[##7K^5T7[9\>PWKL;%MT?+@"??U?#@ M]N`JN;V=KF[1]@SLPG?B:B*($<#%CP0[EA32?G&@QT9OS^?M$WCB\WG[W_C,E5 MZ"6))$!.9P13*4&B"6]C@O`\RG02?\..R##?4&H?L(L9>O9=?R'LW5'=CYEU MG?-4G`!?O"62UAW7':5GG'Y!HG#YFDX]XZ-TII6> MZ-1G33".#6Y_B>/@&PY#$*+WJ2P$RYJT);TQK+QW`3=/!)?/%/F+*`[C^49: M*T#8W$J5?W^!@C4-*Y&M*$Y6>8,!;.I^#>2MLD:H?="ZKDOKW*:*0.8R1:O0 MR!7S6#,S[]GA)[H_7`V+['HI@IS:+I(Q6XPW47!V^`EUOF;!AS]D>$9H3D=\ M<'V/UUFQF@4D5D%T"[E.[!.NABX>?]]73U(=GR%OYY_C@+ MF\R:42DI+53%7,U9:J5J5VI[:FB"KFLW^EJQXCX^U#6=C0WH'$M+L0']\<#V MIV:J=;>KJ$(FCI]PB/U8\N[Y01LC,U^OB9<@(JEFM-?"3`W!),5+)GVQ\"VM M[])@@)X9T*T[3@='U>"H.@-'U2.BZ.)H7CX>,MWLHSZ#TM$&I]7@^!DAWJ\ MJT4Y!G/N*9D@!W/N8,YM;,[EO?Q=H)O?JRBXBI/T:T20%]*?:!4G.!-V+X1# MPQL%:,PENZ;C.Z"FI*7F(6:%/E[I(R@J;>J\ANW'I<*\], MB:DN?VA]GBN]^\59S6-IM?UL<',5+Y>TBHL7/G@K1*2!O/RV=J@F*YKAB:[1 M>9T1NCKURJV8/K^ML47_7/&+Y258N1ZSJ5 MYF%6?7Q:^;084.0\\:YXZ[MN46^)'5?.<]V:WN@JJ[AQ5/68=C;U_@>K=HFD MJG[CN_[&&;V_(3Q?4$<]K?0[1]MI5>D5=;=C M!&$O-4B-;M4V5JC,7IF04UEI8Z>D`JN=G4SCL0^7#?^D$%"OUM?4:Z8^0D%R M"_?$=NU-9@JTZO:V\D(FK7@G,4@6?[=&G705EUOTU:`VF`U/PVRH+@L,YD(N M@`>'2:4L>'DOGP42A^\6"NYGUR/#ZM"HRE2N1WVU-G)9!.N5 M1PB&W9CNMPDFT2-%C#[Z>>DEV$X\9E8):4N:2C2HJ'[\=L]MX_VSMXG9 M+/QC4F0=:SV<)7YX=K!60UDI#+"E]7*S^^?_Q2"`$G^QN4]K$=?.+C0YN"B#QR4!<3#Q2XO=*(UAMU8 M?1H:(MGQG(;VZ;V"BVX.&D:6MBQ=7@H=K3HF5*7Z2O!CC7CFNM&Y$6A:D61N MF:=-B6\5..N_@:L%>(\*9TD?;E:"M_\AN2:D\4J2LJ*$ZZSUT#2@/&%A"YYS M?EY3X+4_)=Q_,55/%^7N<34IW?6@!!7EM\6B/),@ET:J'W=5\O1WU_VCG:!W M<8B>FRY1L4(NOHGY:K#KNU3=%#`D6[8&S7*6I3T_\=CWR1H%-Z\K%"65PC[5 M/^BY@@6NB'S,*VB)?2_,Q^9[#A4Z6'&`9A25A(D:QZ>PO47J'T@\0TG"5N`M M4F1!U,D&'S?+51AO$'I$+/U4^6O4][/!S21=(**[L&HZ6L*5K.- M*$>JB7M-QPYO3_Q]2F/_CT4<`J=)5B[`0%ZW2/J=$\2L!>Q=1_@>,#`M0L(- M&Q(WMB(W$D*CD;,@TBCX`O`4ORE1*`_>TAW%2/C3.)TN\O22R0P6,(WH%SYV M)&YL!?5O'@EJXA:J;8P@1K7A.&([XVD!YTV29S>-Y[`F:3&6+30/!/O<.#'- M$4Q3O9=O<)D"$T5-#XH: M0(!VNBZ2*3V%RW^G1\B7./T'2A^1'\\C6JVG1E M%SHR$59QIAMILJJ-6Q*W'VICV*J-(3AAOZ!OX6:\6L68/ET+R_3F%?GK%+^@ M:TR0#\.(+U;EOF8HU:.M:VK6="SZH$N2XG2]%2[I)H\)5_BKZ6&STLEDQG8J MO1.]R$<\^56IBQ4>0B^BKW=(Q*E*$YLT2N-N]QI9H;.4?+S]LI-928@2D5[; M;Z@A<\HU9-@WO-RPIT;4ZJD<]K#"`5<6*VFLEYNB27ZR,0&-_=^O<#)3=4;Z MN*31*:QA]%S/P/,^`S>O*TQ*3V_)`#(R_DFMH/NZXDKM!SXI/+;23V8Z&*_3 M!77A"_54\_.<,EJEZ/]?H*_(\=;9=">%7:9O)HSRY"X_/%@M8].P268Z?<3V M[&7LC]=>6M0@.`J:]52>Z$)H.9>U[,,]&<+TF.\4BV_5?T#?V)^%)H];9!E]3G%*E\BX*J/.7 M/JHLUNKY;7M!]6\X7;!H(GHP+_!J&M]$*:Q_Z6&F.XJ1_3/]%D\7\3KQHN"& M7L!W$5W6^`710U%L=%7I9N5+P`236>D"D*T?;ELCJ/[&/.-I,EFG20H8P1[; M%:2[BB-V_L$'OLO?DL8/Y-6A7&LHH']/X84W\!5SZN6F2'6TE MDNCS$J\T9CP1%4MI.I11/O:0R^?A"@KJ_:SFQ#>+1"F"Z<3A(+MXIPLW`^FX MX2250GJ=R-VNY^GPO$J56K=GBL=A`IRZO%!L13PQEQB6^+94RXQ=N!N\V M+#-^T:101O_14/`J\@Y:QZM>-$2'4T[8V4-%$QJ!SK>%Z6*`B2<_;N'Y-,`C MLSQM8?IN@,F8F]S]BC'F@@DJV"L:?5U/5NP(W9(+QO7\Q6X05`@J=#W;L2-@ MI=&[KJ=$FL54*:;;]=*D'4"JFW;F:A73#B&69*"Z6L2T0S0;1PZT*W!ZEECK M97<6`/\P`*P&<&/'YP[KCX,FIHFUW#E;`#LH89K`*D5-%/@.*EIS?-6B/`JL M!ZU-TZ!@-H.B^!"#JG?\#W&8G%%\CT%//,+WD"5\%)^B@3X)I]]S/'R,]IF3 MQ5<8]%#-;V`F,[/X`(-R:NM$4DBH*C[3H.(>89](L[&*.)Q!!5;_%AW6LRH^ MR*`Z]^"#"$ID%5_I3!7P%FF,W.]V6'*K@-A1'XE25B'_L7A.M(KKP;;2Y#AI M+%-=/MK9(:>6H%?XBR45R8I-ZJ;*TQH[Y;IS!9)N"L72Y,1*J*9NEM3Q]F^? M:CV7;LPQX/$"O_H*TQ!ZY^J5?#:3?%K0RJ*>=C)#_JY`YF/>UT_JWEAH.>A0 MJ.^T"_65!)[&\JAB(;>6X_>RU,@Y%NUJ82`IA0;<12G!48)]9K&2%L7K9L*3 M6D^'[&16)M/+2SC/B:.ED>A^[-E/?!_7>?A!H)\BLCS"!E>FY!37\FU,9@BG M]$7;.X4RF89G.D7$AK)]NGR4XG:JEV5'N(GG.W'T.KV;#^<9T-*8Y_>+4\?+ M@BRC.ON`;$>SVURU+:0SC4C07#J[Z$A.;$+)*:[F+`2!1>&OD`__G,;T5^4( M_6W"U%'N^.;TN(E^IY>=\O1N8FOA^&Y)U"F>Z=HL']LD8)#`7NX3H9V\:A)! MHGA!(_O"+!$GB3/'4&(#:5TR3A)K:0#L46#6H*!W!;M+CNS=QA2:#_4'.IE" MT19B,LSX[`4A:FT]MJZ'90VU5[NLO>IH\+3I@(BA!F4W6)J(S1@JQ=G)9^(8 M1%H5E5ME,DKJD73X'*837H<:=:9J*`KD\&9%ZW[(D(Z8[30X2ZR[B*EH5NUN M^!A=.&K;USWX\ ME`>T\HDTW59#84$K7TG;Z374*>SQK521L9L4.AQD;(L1+4/91,N2M^KG&8HI M'J\&4Z.0TZ'.HKUR668BR5J59QR^X#'S`(<:CI8EPOW`[Z&F8S^E/V&D_E#= MT?)A=U"\X'@U'OM4(.=O:#-.DO4RP^=K0M?P>+4*-QEB5`ZF#ZC'`0IO8Y+# MR"`%4H8".M8*Z.P]%,QEJ]K&"I75QYWY5%;:V*#RK@/'N%\,IT7I3SO2:4^R;CJ))6I?D)G M5N.O,2WU&((X0==%?NT<W`^RZ#+%*C2%AQRR89( M:96#,WRASM7A(?^FG]_G=F-)S.Q^M;@2 MDW.YZDTQ^CU<]R=T=$%67H!4E+%<-Z`IW$5EV&H.?M<7IM*]5W%0J%PQKCO$ MM%%3%/O.QW76P6VNL*O/SK'6,MSLF7"RU3GU7E$R#@*<4747S6*R M9+/:,-%*@>T%(#76%QD/:QRH/0- M1*V-U/#^C$.4I'&$ROXNHJCV\`;KU8D?H$M525-JZL-A+]&9'<2 M`7(Y9")CA:AUCRC?+8('!&=)BN%DB8*M\V+L^V0M+`_?9D3[0IATGQ^*!)Q- M=1["JC).M1>!ZT*J(EYZQ^-Y:-W*BTQX_KH>/&(&)[73_GAA'O9$:5`TECC- MS)910"M3X&B.(A_W2;06TZ@LHNJ-84,PN4=)@M`]\A):YZ`4NCE9(6KLB.;T M;RAYA#7\+:L<(N"UR4@V.*Z2$XR!ZGHG9DTG(T)[=8Z["+:!%[)_4ZS@/L+"J>;DD72UPA/RU_20O4:K.!$J>_NM[%`ZI]OQ%Q3/B;=: M8-\+I7Y2<7L[SVKE1L$R/1)/M;B]D;WZ&XQ.TOB;Y$&L_28VY9=&=QG?@2C; MNJZ[7=2NC@IN^\>#ZVJK/D2-)!#7M5EU&!N(#JYKM3IR1O7)&.$=A\GN8WH`1'FE=WN MRNG"HT;*&"2V$"731?[42)Z"F1=\H][;=4H]N=BG<1XXA)\"[K@V["DW'J%E M2),M#36F$V%S*Y'2>\3DV&JRL-_+B"8"'Y:P/>:%5,J/HVQ)C-.4X.=U2L]M M6!I>&.95_WBJBO88QZ/\-X^P%T,:D[T;P,:ZV:O%N]VU^4+(R"W5&16L(]U1 M>L3I`7'L=-+C4S"&U<#0FK.L?*]I(M-*080IGN.^2P4ZX-4>O*XK@HHWST[& MU+\.7-<&.T&PN)9<;PI4Y4OG^(861JJPDW#!W\@G*+(4;) MS:L?KF%:FA6:R?9Y.&8.Y![,&:Y6\D2!A4"=_(/S?QFO(Y$,;69L&Q)12\HO M-_P!)#Z/+F<\003K?+K&AN\/-E^\)9(Z]6J[]4&[/BG+P#:6OGA17)JQ*6YO MUR/?Z-3&)%N\W$/>F7K;:Q*;(=X>:II##6'D6N^X5-7U3UZ&H+5Z[[ MG57O0VX>U.'9[;I9H0E<>X?@N=D-U,)CS-RCKA^8W<@=!H]-^1UX1M$`/?T^ MEB(,CFT^^A*G*)G&MSCR(A][XP)=YB$/, MPO?ENIND@PVYGH,BGVY.0ZO7=RWNY;W&X_)X\F!_]LQ5',)GC;,:#J5(P\)( M.X5Y+V&]_6$GX42=//XJU1G!2NH%F7L1_I-]\BM8AK!V@VS;1,%#:3E,9IRO M5W.RF!G;:LRG270JN:$Z"^L<#X8[F"V:8Q!5LOC%GAP(O\1Q\`V'898E**"P M9EOHC6&G;$(]^'S>5'K:W-"-OE\U^5T!FF'#$??JA8-L]/9+3.ANT:JTD)77V`X M>\RA:4\N=4ODAYE]5P/^RR/4CLW7TN[+5";2P_K91IC??8>Z8OQL$Q_QEY ME-9@$CW2HY_DJ46)IBYN8HY3VLN&T3W'O9][)9,';T/1H&73LZ)V)?QZHHTW M)57JU=8>S<8IDM.8;(GTPKJ#4-;#Y@Y7X*02<=+TDP];61DL>Q=\1\O:3BS^ M`=2:=W?M`">T;75@.<>=>OBP)&W;DVLV(Z@NGZ?:R$YU0540!5M/N;_5B&;N MUZA6P%+&8=AK$GCLW8,GL^-,/W:C?#F:GL\N>GSR2QDM(,JEL-+3C:8,T7C@ MON!1?CZY3#95[;-O7+Q+W1B;%I/T_"8PL,)EZ6IH.HL;OC>,E MM/5'HN$\;&$Y2L:95\!T8EDD74[HV1,YZ^>H,"C57;><='(.KYQH?H<6;/9C MX[:N]Z\+V#EN[H-<5ZN6ME.NH2,$4HWX?NRY-F4MAYW$A\.B'>V$]Y.Y['UU MCY.IB2S;(O?+0%1KJ6N:B?1&.Y6SJS%:SIN#K!2,L6$`1-57@$355U>`L``00E#@``!#D!``#M'6MOXS;R>X'^!YX_ MW&V!.HXWN]MNL&GAS>,07%[G.&WOOA2,1-M$:5$EJ23NK[\9BK)E258DV]E5 M<`*"75F<&?GV:"/#"EN0R..OV]_0YA@2=]'DR..G>WW<'M\?EY MY^>?OOWFT]^Z73(_>4PP10TC(_HD`SF;DUMORF;T>W)/-?.) M#,AOGX<7Y.U>GY"I,>%AK_?X^+BGE)\0V?/DK$>ZW:2"7V)6#LF'O;=O]]ZE M2H8R"GQXGWIUK!@U`$U\8.*0O-WOO^_NP]^/H_[[P_T/\/??-+0,YXI/IH:\ M\;X#8(`$C`,RW!ONI:3Z.[F5@0;H64B#.1D(08:(IF+_GB&HK+`$- M!OJHDY+O\6!/JDD/JNCW?KN\B)72^?8;$L,>/MTKP5POM"J":_KON?K][ MT%_%,O.0Z4(T6U*,%VK_886U4/,'[E/K#6C&_8,5^`"L$\V*Y?>-ZF%5/0#J M`A13W$NC/H^7PT$8WRS0TJI^WXL+4]`>.*91\U5PS;R]B7SHN4(4ZB"G!B]2 M"EK;.E176JQ"G_%B-"@HQF!/WK08!4N*<7CPP+0IQHK+BB4+*/=T,9HM0JQ^ M#DMSKQ@'"M9@F%"M08&2+(ZA:L+,%9TQ'5*/5?-`Z.-F+#!G4LU.V)A&`M3Q M9T0%'W/F=P@U1O'[R+`5@"A8@OR$5#[1()#&]E;V-[X)0QZ,I?L)+[!)'BHI MV`C``]/*?B1FK+RK&@6CN? M0G,-`>'WB@CEUCL`DRT($1P'`Y\%.#[#DY:"X^CID\]4X)A#;J>,&=T:<3LC MWE#HN\V4&0ZZJ6U1B_V,6=]M8E;R9H6Q[UHS5S#S.03$,S80AJD`1'A@Q?;, M@Y4;\'TU`RY`-)%C&Y8J-@4XJ("\N9!:?T?BFEM;5K#E[13\?RJ%#_.,TS\C M&+H&@7\-[4&M:#;6:+&=ZY$H]X$/-7T`7>#62.\/5_\_2,Q!:_L*MC^F>GHF MY*,^#WRNF&>*[9L'*[?A#QNU8ZB$V%I:TZTSW94T3(_D8IQ<:O"*FDBQZ_%U MB/D'X$RG3%D+K=RT/V*TR[4GI`9$^+'$M,'O9ZJY->=-2KNM0>L;]%@*0>^E MLN/F0"D:3&S!4ODC]F0^"^CY*EFZ#KUR%_B8=8$+[F'KMO9/52,#,I@H%E?? MND!]%SC'J>F$WPLVT!I"U4U-7X5.JE-];SJC7/U"1<26ZM7U7**<0KE=WV;MBL2(I48N&<67[3BPH64'GLV9ZQLZ MQW8";1'>J(CY%YS>;SBW'E#?`TZI"D"!^H8IFRZM M9^SUV.5V_2%KURMF5G/D)&2*6)JM55]DBC["N*I:-JXZM7*KYY)TN>DZ>1,3 M:I>[&C1OK^4I+\I"N7OE$H"%<_C6Q5YJ,E_#3ZK0*37VVUSJ;\W$OC7WEY_A MUW"$[6HH=Y%<3B\[VV]]XTM,^VMX0UV:Y?;/Y?Z*4@"M#[S$Y*&&S9^C46[C M7$:O9"+1FOKYS:D+52[7SZ%/MJOGU^/TVOG`]RV#5.3WKVY)I-SBN<1>E95^ M[/P7=:6WP)(W)Q`A\G9_716?<`OJ-JV36DY?KJ97EO,CP:['@YE4AO_%H$?7YBY0C`K\ MA6$8=/.+R3X`/H#"D0I8X9:*0K)9-_F259<[6RY_69Q@ZI*$/>Q8%@P2Y/![ MLN21()-V@$KE+A`CX;0+K':1UW69K-:!MW+@2KU4=<1RYZF8G6Q[JQT8>]'L MTYG`>#@XIDIQY@],%@;8&Z(9%$Q&[1PBZPB[(5KJ)`>5LYK=9'1S51-J"F#M MP>X%`VYJU#I2=4=R&<,D89@:=E8+LKY2&:_<'9[/8&;&FER"L[5U95OGDX^5 MQH>J:.66KI:K;`>'%[&S?7,=VBR$9X""F=\%4'PC:`5SEV*76SV7O5QC=?N: MQ'60I!)B:R%836O_K>S_+S:'T32:6?WJ.^!F)`=A*.:QQF\4]V#XO)0^$V=2 MQ2_UX)$J/SD#_F+4R_VGTB9'>`TLD!0/!)D@1A++1N)7CA%B.2'0M[@"31PS MK9=MY65XYA1&92N.&Z#/E)Q9P,]X"\\-G6-P9[6=BRBVIE?N2;G\Z1I/2E>: MA!ED#-7&"%U;,7$UQX[31B'U,FEN=VS%Z>FS\.5V+\B6+G?4MO'&+BQ:LB&V MDH5KXY=;/)2*" M&!(CE-@^;G7/F>97AC?W,7_PP!2=L-BBE3SY!:HM]^%<(K?G#AD8V+O1#S$.P&/.IK/0@&=7OR. M*@_QRV]3[(5*@HE0_;V$;$(@A[UZ?:-M"!G].:X2"E/%QD<=O#BQFUQ/]SM@ M[#W-1`)BN,%:CI=T"!+2WQ-PDTZON9*OFK&"X(!0(/C)@LPKD5O0>R8JB@RP M!2)?((57(FVVF5<0&E`*A%[9@E4@^Z=>^FI%^+5Z]>(G$%TJ0X+">R#7W,1* MXLM>+Z1G"96@X*]N@M?%5]W^V^Y!?^])^X[%.APL-5V/@P2O+@>E-[BNX\'6 M7WAE;(\)HQ>TNDM:]=51>-%K):VD,:]B1%3+1U1+_\,VG&S&Q68L%%Y#6]4K M$@2L]'UM1\C>`+R%'^";NF[PW(VZI>P4X24_NDLB&S!2<#]O-4[2B(M?6RDE M<^EO)382''S8JO+L]<&5:E\@V:>MZL]?1%R)@Q2:>][*'7+W&E=B8HD5/W:7 M!.JSD+DFN1(#"0X^;%=YYL+E:K4G2/9I3?WN!F;+P%''K48?PP"'5YBZ;/&Q M;47N1C\,(GY_!BX.@^Q-[(=3S%?`ZO`R[L=JNCC@$^0!T1T.0F0F7\4\DH3&KG M4.L:49,]Q2-%`PWL`"IN]])I,=?#;"VB'RF7.WQ!&06'T9#>>APZ08:S\$N& M&9BTB&M!8@GCV^$/?3FC/"@2,&:N3+Y="`),4.$VB%\")S!!1VV=,9:6I0SJ MY0SFL_M=V-K,I=#_%51#XIH3(+!N=:1\R*LKKZ MEM5%!;25YFW?;:B''0B@3(*:9,KGA.%O0I,'X M-."3&85X3=&0`:*G<^RO!VF4((`PPYO6XQ#;'9`I/2T82UC+NX@`Q=8JHS7-743@F_AKS' MN8@>.,M/M3/OF]1UG@<0K4+@<<+B__'N-`B3H8D/5U.ESP&^"ON@#/;[=L)% MR':B,'"?YT/J(WE,A7#;S[/BUT)=Z0LM\-=KY96X_Y7B-S!,;:F7>$T2.;GK M(PE<;L$AS7\859CR&,L$)^AA+VP&6D!4S][3(YS-'\NX"&H<"/)"H6 MH\81[-SMXV1Z165?M-[MDJF[U3CN:#;0X%U/`#$]PX#M+I3!F4\'8:CD0_)I MREA753%>P13XBCV*.7`L<8'-O[+=HVUNO3F>Y#2X3!*Z9)K]5&$N#;(MH=:`EC)IE?(M429%M)=KGD["[Y#"87<=J#XXD: M^SQB:G;Z%/)8:R?4I'N1>FA-FV2FKD_-+[H5%38H_[UDKRC+7UC:).[5A`8N MZPGQ4_(YVL^1!G9U+E5?#;R1>7D;&KIYA"X/HRB;TQZEELB[ABR5?:[8Z(;#B_ M(?YKB.O3HB6IH.OQ^NLP<_IX#NF5*"&5UPGPIDN\']P&P)<\6,T'#<:&J60W MD1#R$2N/DT'V4O$M\T\-X*5)_6F)-@H'B:H(#9+132^'$/H5BK2FO$$2W.*% M"'[)\+`.H$F#1'R(/Y7V7=M",FZ5EG-S&DTR9RY'A;SJP01`["4M6@.Q7*(\ MK8=-*31("R,%4S3,WW&/P_3:G$GL8._"W*K2&Z8-1,I#\?/],Z+E'"XY3E>S\^D M!#:FT*3M&XD0&1,N-M-E-O]7`U\9:^IO=-]E5O%7B.V4D8_Y#CA7\A4[VT^] M^(`N//X/4$L!`AX#%`````@`R'6H1K7&*Q&UL550%``-X!$U5=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`R'6H1OMH`1-575X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`,AUJ$94`DH=;QX``,CP`0`5`!@```````$```"D M@;^=``!P`L``00E#@`` M!#D!``!02P$"'@,4````"`#(=:A&&E\VR0I;```4_00`%0`8```````!```` MI(%]O```<'-D=BTR,#$U,#,S,5]L86(N>&UL550%``-X!$U5=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`R'6H1N^S]!?1+@``Z&D#`!4`&````````0`` M`*2!UA`1-575X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`,AUJ$8,Z">>;!````::```1`!@```````$` M``"D@?9&`0!P`1-575X"P`!!"4.```$ :.0$``%!+!08`````!@`&`!H"``"M5P$````` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity - Key Assumptions Used to Apply Option Pricing Model for Options Awarded (Detail)
9 Months Ended
Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock volatility, minimum 79.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
Stock volatility, maximum 93.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
Risk-free interest rate, Minimum 1.70%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
Risk-free interest rate, Maximum 2.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
Expected dividends 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Option life (in years) 5 years 6 months
Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Option life (in years) 6 years 3 months

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets - Reconciliation of Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]          
Amortization expense $ (190)us-gaap_AmortizationOfIntangibleAssets $ (196)us-gaap_AmortizationOfIntangibleAssets $ (579)us-gaap_AmortizationOfIntangibleAssets $ (582)us-gaap_AmortizationOfIntangibleAssets  
Net book value at end of period 2,080us-gaap_FiniteLivedIntangibleAssetsNet   2,080us-gaap_FiniteLivedIntangibleAssetsNet   2,765us-gaap_FiniteLivedIntangibleAssetsNet
Patented Technologies [Member]          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying amount at beginning of period     41,689us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
38,941us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
38,941us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Foreign currency translation adjustments     (3,313)us-gaap_FiniteLivedIntangibleAssetsTranslationAdjustments
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  2,748us-gaap_FiniteLivedIntangibleAssetsTranslationAdjustments
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Gross carrying amount at end of period 38,376us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  38,376us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  41,689us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Accumulated amortization at beginning of period     (38,924)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
(35,511)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
(35,511)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Amortization expense     (579)us-gaap_AmortizationOfIntangibleAssets
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  (778)us-gaap_AmortizationOfIntangibleAssets
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Foreign currency translation adjustments     3,207psdv_FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  (2,635)psdv_FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Accumulated amortization at end of period (36,296)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  (36,296)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  (38,924)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
Net book value at end of period $ 2,080us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  $ 2,080us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
  $ 2,765us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentedTechnologyMember
XML 17 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
Net (Loss) Income per Share - Schedule that Reconciles the Number of Shares Used to Compute Basic and Diluted Net (Loss) Income per Share (Detail)
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Earnings Per Share [Abstract]        
Number of common shares - basic 29,412,365us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,672,327us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 29,366,919us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 26,841,623us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Effect of dilutive securities:        
Stock Options     989,990psdv_IncrementalCommonSharesAttributableToCallOptions  
Warrants     255,301psdv_IncrementalCommonSharesAttributableToWarrants  
Number of common shares - diluted 29,412,365us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,672,327us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 30,612,210us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 26,841,623us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets
9 Months Ended
Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
3. Intangible Assets

The reconciliation of intangible assets for the nine months ended March 31, 2015 and for the year ended June 30, 2014 was as follows (in thousands):

 

     Nine Months Ended
March 31, 2015
     Year Ended
June 30, 2014
 

Patented technologies

     

Gross carrying amount at beginning of period

   $ 41,689       $ 38,941   

Foreign currency translation adjustments

     (3,313      2,748   
  

 

 

    

 

 

 

Gross carrying amount at end of period

  38,376      41,689   
  

 

 

    

 

 

 

Accumulated amortization at beginning of period

  (38,924   (35,511

Amortization expense

  (579   (778

Foreign currency translation adjustments

  3,207      (2,635
  

 

 

    

 

 

 

Accumulated amortization at end of period

  (36,296   (38,924
  

 

 

    

 

 

 

Net book value at end of period

$ 2,080    $ 2,765   
  

 

 

    

 

 

 

The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization of intangible assets totaled $190,000 and $196,000 for the three months ended March 31, 2015 and 2014, respectively, and $579,000 and $582,000 for the nine months ended March 31, 2015 and 2014, respectively. The carrying value of intangible assets at March 31, 2015 of $2.1 million (approximately $1.5 million attributable to the Durasert™ technology and $0.6 million attributable to the BioSilicon technology (including Tethadur™)) is expected to be amortized on a straight-line basis over the remaining estimated useful life of 2.75 years, or approximately $756,000 per year.

 

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC M,V,S8S1E8S(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D%C8W)U961?17AP96YS97,\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O M&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A M:7)?5F%L=65?365A#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D%C8W)U961?17AP96YS97-?5&%B;&5S M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=&%N9VEB;&5?07-S971S7U)E8V]N8VEL:6%T:3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN=&%N9VEB;&5?07-S971S7T%D9&ET M:6]N86Q?23PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DUA#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DUA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D9A:7)?5F%L=65?365A#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS97-? M4V-H961U;&5?;V9?03PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYE=%],;W-S7TEN8V]M95]P97)?4VAA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7V8S-C,Y,&)E7V,S.&1?-#5A8E]A,V(V7V(P.6,S8S-C-&5C,@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F,S8S.3!B95]C,SAD7S0U86)?83-B M-E]B,#EC,V,S8S1E8S(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^36%R(#,Q M+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^,C`Q-3QS<&%N/CPO'0^ M43,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!& M:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M06-C96QE2!#;VUM;VX@4W1O8VLL(%-H87)E M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'!E M;G-E'0^)FYB M'0^)FYB'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P M,"PP,#`\F5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XV,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B M,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V M,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#`T,BD\ M2!TF5D(&=A:6X@*&QO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H55-$("0I/&)R/DEN(%1H;W5S86YD'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T M7V8S-C,Y,&)E7V,S.&1?-#5A8E]A,V(V7V(P.6,S8S-C-&5C,@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F,S8S.3!B95]C,SAD7S0U86)?83-B M-E]B,#EC,V,S8S1E8S(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M,S4\2!F:6YA;F-I;F<@86-T:79I M=&EE&-H86YG92!R871E(&-H86YG97,@;VX@ M8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B M,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V M,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*(%1H92!A8V-O;7!A;GEI;F<@8V]N9&5N#(P,4,[0V]M<&%N>28C>#(P,40[*2!A M#(P,4,[4T5#)B-X,C`Q1#LI+@T*(%1H97-E(&9I;F%N8VEA;"!S M=&%T96UE;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@ M=&AE#0H@0V]M<&%N>28C>#(P,3D[65A2!A8V-E<'1E9"!A8V-O=6YT M:6YG('!R:6YC:7!L97,-"B`H)B-X,C`Q0SM'04%0)B-X,C`Q1#LI(')E<75I M'!E;G-E$$P.S,Q+"`R,#$U(&%R92!N;W0-"B!N96-E2!I M;F1I8V%T:79E(&]F('1H92!R97-U;'1S('1H870@;6%Y(&)E(&5X<&5C=&5D M(&9O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!# M;VUP86YY(&ES(&$@;&5A9&5R(&EN('1H92!D979E;&]P;65N="!O9B!S=7-T M86EN960M64@9&ES96%S97,N($ET65A28C>#(P,3D[#(P,4,[1$U%)B-X,C`Q1#LI M(&-O;6UE;F-E9"!I;B!T:&4@52Y3+B!I;B!T:&4@9FES8V%L(#(P,34@=&AI M28C>#(P,3D[28C>#(P,3D[28C>#(P,3D[6QE M/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXF(WA! M13L\+W-U<#XL('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@87!P6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*($EN(')E8V5N="!M965T:6YG#(P,4,[1D1!)B-X,C`Q M1#LI(&]N(&$@0T*('!A=&@@9F]R($UE9&ED=7(@=&AA="!S M:&]U;&0@86QL;W<@82!N97<@9')U9R!A<'!L:6-A=&EO;@T*("@F(W@R,#%# M.TY$028C>#(P,40[*2!T;R!B92!F:6QE9"!I;B!T:&4@9FER"UM;VYT:"!P2!E;F1P M;VEN="!P97)M:71T960@9F]R('1H92!S96-O;F0@=')I86PL('1H90T*($-O M;7!A;GD@97AP96-T2!P871H('=I M;&P@86QL;W<@:70@=&\@9FEL90T*('1H92!-961I9'5R($Y$02!W:71H(&]N M;'D@82!S979E2!P2!D97-I9VYE9"P-"B!P2!I M;G-E#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X M03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@24Q55DE%3BP@ M=&AE($-O;7!A;GDF(W@R,#$Y.W,@;6]S="!R96-E;G1L>2!A<'!R;W9E9"!P M2!B87-I7-I8VEA;G,@:6X@=&AE#0H@52Y3+B!)="!I2!T2!A=F%I;&%B;&4@:6X@=&AE(%5N:71E9"!+:6YG9&]M(&%N9"!' M97)M86YY('-I;F-E($IU;F4-"B`R,#$S+B!)3%56245.(&AA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($1I2!A;F0@6%L=&EE2!M:6QE6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E. M1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS('!R92UC;&EN:6-A M;"!R97-E87)C:"!I2!H87,@82!H:7-T;W)Y M(&]F(&]P97)A=&EN9R!L;W-S97,@86YD(&AA2!F0T*('-E8W5R:71I97,N(%1H92!#;VUP M86YY(&)E;&EE=F5S('1H870@:71S(&-A65A<@T*(#(P,3&-H86YG92!F;W(@=&AE#0H@=')A;G-F97(@;V8@<')O;6ES M960@9V]O9',@;W(@2!D969E2!P97)M:71T:6YG(&5A3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E M8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X M9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R"<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@ M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS M1#0E(&%L:6=N/3-$;&5F=#X\8CXR+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX] M,T1T;W`@86QI9VX],T1L969T/CQB/DQI8V5N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z M(&YO'0M M2!F;W(@ M=&AE(&1E=F5L;W!M96YT(&]F(&QI8V5N2!E87)N960@82`D,C4N,"!M:6QL M:6]N(&UI;&5S=&]N92!F2UB>2UC;W5N=')Y(&)A0T*(')E8V]V97(@,C`E(&]F('!R979I;W5S;'D@:6YC=7)R960@ M86YD('5N87!P;&EE9"!N970@;&]S2!I6%L='D-"B!C;VYS:61E2!I#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#%P>"`G5&EM97,@3F5W(%)O;6%N)SL@5TE$3U=3.B`Q.R!-05)' M24XM5$]0.B`Q,G!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E. M1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[ M(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!7 M3U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P M<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@ M,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[ M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@5&AE($-O;7!A M;GDF(W@R,#$Y.W,@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,@96YD960@;VX- M"B!$96-E;6)E$$P.S,Q+"`R,#`Y(&%N9"P@86-C;W)D:6YG;'DL(&%L M;"!A;6]U;G1S(')E8V5I=F5D#0H@=&AE&5D(&%N9"!D971E#L@0T],3U(Z(')G8B@P+#`L M,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@ M34%21TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D'0M2P-"B!A;F0@)#(U+C$@;6EL;&EO;B!A;F0@)#DU+#`P,"!F;W(@=&AE M(&YI;F4@;6]N=&AS(&5N9&5D#0H@36%R8V@F(WA!,#LS,2P@,C`Q-2!A;F0@ M,C`Q-"P@#L@0T],3U(Z(')G8B@P+#`L M,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@ M34%21TE.+51/4#H@,3AP=#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO#(P M,4,[4F5S=&%T960@4&9I>F5R($%G#(P,40[*2!T;R!F;V-U M#(P,4,[3&%T86YO<')O6UE;G0@;V8@)#(N,R!M:6QL:6]N(&%N M9`T*('1H92!#;VUP86YY(&%G65A2P@870@:71S(&]P M=&EO;BP@8V]N9'5C="!0:&%S92!)22!C;&EN:6-A;"!T&5R8VES92!O<'1I;VX@9F]R(&%N(&5X8VQU MF5R(&1O97,@;F]T(&5X97)C:7-E M(&ET#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%2 M1TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D'0MF5D(&%S#0H@8V]L;&%B;W)A=&EV92!R97-E M87)C:"!A;F0@9&5V96QO<&UE;G0@'!E8W1E M9`T*('!E2!R96-O$$P.S,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E M;'DL(&%N9"!N;R!R979E;G5E(&%N9`T*("0V-2PP,#`@9F]R('1H92!N:6YE M(&UO;G1H$$P.S,Q+"`R,#$U(&%N9"`R,#$T+`T* M(')E2X@07,@;V8@36%R8V@F(WA!,#LS,2P@,C`Q-2P@=&AE M($-O;7!A;GD@8V]N=&EN=65S('1O#0H@979A;'5A=&4@=&AE($QA=&%N;W!R M;W-T(%!R;V1U8W0@86YD+"!C;VYS97%U96YT;'DL('1H92!#;VUP86YY#0H@ M8V%N;F]T(&-U2!E$$P.S,P+"`R M,#$T('=A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z M(&YOF5R(&]W;F5D(&%P<')O>&EM M871E;'D@-BXS)2!O9B!T:&4@0V]M<&%N>28C>#(P,3D[$$P.S,Q+"`R,#$U+CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-% M.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE M=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@,3AP=#L@3$545$52 M+5-004-)3D#L@+7=E8FMI="UT M97AT+7-T#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z M(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/ M4#H@-G!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@ M-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@4'5R&-L=7-I=F4@;&EC96YS92!T;R!M86ME#0H@86YD('-E;&P@ M4F5T:7-E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!! M0T4Z(&YO"<^#0H@4F]Y86QT>2!I;F-O;64@9G)O M;2!"875S8V@F(WA!,#LF86UP.R!,;VUB('1O=&%L960@)#(Q."PP,#`@86YD M#0H@)#,Q-BPP,#`@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F M(WA!,#LS,2P@,C`Q-2!A;F0@,C`Q-"P-"B!R97-P96-T:79E;'DL(&%N9"`D M.#`Q+#`P,"!A;F0@)#$N,"!M:6QL:6]N(&9O$$P.S,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T M:79E;'DN($%C8V]U;G1S#0H@$$P M.R9A;7`[($QO;6(@=&]T86QE9"`D,C(S+#`P,"!A=`T*($UA"<^#0H@/&(^16YI9VUA(%1H97)A M<&5U=&EC'0M&-L=7-I=F4L('=O#(P,40[*2!F;W(-"B!T:&4@9&5V96QO<&UE;G0@;V8@0G)A8VAY M4VEL+"!T:&4@0V]M<&%N>28C>#(P,3D[7!E2!A;B!A;FYU86P@;&EC96YS92!M M86EN=&5N86YC92!F964-"B!O9B`D,3`P+#`P,"!B>2!T:&4@96YD(&]F(&5A M8V@@8V%L96YD87(@>65A2!I6%L=&EE2P@86YY(&%M M;W5N=',@=&\@=VAI8V@@=&AE($-O;7!A;GD@:7,@96YT:71L960@=6YD97(@ M=&AE#0H@86=R965M96YT(&%R92!R96-O9VYI>F5D(&%S(')E=F5N=64@;VX@ M=&AE(&5A$$P.S,Q+"`R,#$U M(&%N9"`R,#$T(&%N9"`D,3`P+#`P,"!A;F0@)#$P,BPP,#`@;V8@$$P.S,Q+"`R,#$U(&%N9"`R,#$T+`T*(')E2X@07,@;V8@ M36%R8V@F(WA!,#LS,2P@,C`Q-2P@;F\@9&5F97)R960@6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO'0M'0M2!D$$P.S,Q+"`R,#$U(&%N9"`R M,#$T+"!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^ M#0H@)B-X03`[/"]P/@T*(#PO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M#L@ M+7=E8FMI="UT97AT+7-T'0M#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%2 M1TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E. M1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(F(WA!,#M%;F1E9#QB6QE/3-$ M)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR+#"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S."PY,C0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@S-2PU,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UEF%T:6]N(&5X<&5N6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@S-BPR.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S."PY,C0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@ M0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA M;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@,3)P=#L@3$545$52+5-004-) M3D'0MF%T:6]N(&]F(&EN=&%N9VEB M;&4@87-S971S('1O=&%L960@)#$Y,"PP,#`@86YD("0Q.38L,#`P(&9O<@T* M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(WA!,#LS,2P@,C`Q-2!A M;F0@,C`Q-"P@$$P.S,Q M+`T*(#(P,34@86YD(#(P,30L(')E2X@5&AE(&-A&EM871E;'D@)#$N-0T* M(&UI;&QI;VX@871T#(Q,C([ M('1E8VAN;VQO9WD@86YD("0P+C8-"B!M:6QL:6]N(&%T=')I8G5T86)L92!T M;R!T:&4@0FEO4VEL:6-O;B!T96-H;F]L;V=Y("AI;F-L=61I;F<-"B!4971H M861U#(Q,C([*2D@:7,@97AP96-T960@=&\@8F4@86UOF5D(&]N M(&$@#L@0T],3U(Z M(')G8B@P+#`L,"D[($9/3E0Z(#%P>"`G5&EM97,@3F5W(%)O;6%N)SL@5TE$ M3U=3.B`Q.R!-05)'24XM5$]0.B`Q.'!X.R!,151415(M4U!!0TE.1SH@;F]R M;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P M,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXT+CPO8CX\+W1D/@T*(#QT9"!V86QI M9VX],T1T;W`@86QI9VX],T1L969T/CQB/DUA#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]7 M4SH@,3L@34%21TE.+51/4#H@-G!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z M(#!P>"<^#0H@5&AE(&%M;W)T:7IE9"!C;W-T+"!U;G)E86QI>F5D(&QO28C>#(P,3D[$$P.S,P+"`R,#$T('=E#L@0T],3U(Z M(')G8B@P+#`L,"D[($9/3E0Z(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[(%=) M1$]74SH@,3L@34%21TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R M;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@$$P.S,Q+"`R,#$U/"]B/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]LF5D/&)R("\^#0H@0V]S=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/D9A:7(F(WA!,#M686QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT97AT+7-T M6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.U9A;'5E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T M)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XT.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT M.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@#L@+7=E8FMI="UT M97AT+7-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S M.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y M8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P M,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXU+CPO8CX\+W1D/@T*(#QT9"!V86QI M9VX],T1T;W`@86QI9VX],T1L969T/CQB/D9A:7(@5F%L=64@365A6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO2!A8V-O=6YT'1E;G0@=&\@=VAI8V@@:6YP=71S('5S960@ M:6X@;65A2!C871E9V]R:7IE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!! M0T4Z(&YO#L@+7=E8FMI="UT M97AT+7-T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M#L@ M+7=E8FMI="UT97AT+7-T'0M$$P.SPO<#X-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M4U!! M0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@/'1D('9A;&EG M;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1'1O<"!A;&EG;CTS1&QE9G0^3&5V96P@,B`F(W@R,#$S.R!);G!U=',@87)E M(&1I2!O8G-E#L@0T],3U(Z(')G8B@P+#`L,"D[($9/ M3E0Z(#9P="`G5&EM97,@3F5W(%)O;6%N)SL@5TE$3U=3.B`Q.R!-05)'24XM M5$]0.B`P<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4 M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@)B-X M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE. M1SH@,'!X.R!7241/5U,Z(#$[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1% M6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P M>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P M,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,R4@86QI9VX],T1L M969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F M=#Y,979E;"`S("8C>#(P,3,[($EN<'5T2!L:71T;&4@;W(@;F\@ M;6%R:V5T#0H@86-T:79I='D@86YD(')E<75I6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@1FEN86YC:6%L(&EN$$P.S,P M+"`R,#$T+"!S=6)S=&%N=&EA;&QY(&%L;"!O9B!T:&4@0V]M<&%N>28C>#(P M,3D[2!O9B!C97)T:69I8V%T97,@;V8@9&5P;W-I="P@ M8V]M;65R8VEA;"!P87!E0T* M(')E<'5R8VAA6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO28C>#(P,3D[28C>#(P,3D[0T* M('1H:7)D+7!A28C>#(P,3D[2`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@ M#L@+7=E8FMI="UT97AT+7-T M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI M="UT97AT+7-T6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.W!R:6-E$$P.VEN/&)R("\^#0H@86-T:79E(&UA$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/E-I9VYI9FEC86YT)B-X03`[;W1H97(\8G(@+SX-"B!O8G-E$$P.VEN<'5T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#(P-3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C@L-C4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C@L-C4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@+7=E8FMI="UT97AT+7-T M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI M="UT97AT+7-T6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.W!R:6-E$$P.VEN M/&)R("\^#0H@86-T:79E(&UA$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I M9VYI9FEC86YT)B-X03`[;W1H97(\8G(@+SX-"B!O8G-E$$P.VEN<'5T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+#(V,#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M-#0T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.3,V M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4P.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C4P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$V+#$Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'!E;G-E'0^/&1I=CX-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO$$P M.S,P+"`R,#$T("AI;B!T:&]U#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]7 M4SH@,3L@34%21TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M4U!!0TE. M1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M6QE/3-$)T9/ M3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CDU,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ("=4:6UE"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\8G(@8VQA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B M,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V M,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT97AT+7-T'0M6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@26X@1&5C96UB97(@,C`Q,RP@=&AE($-O;7!A;GD@ M96YT97)E9"!I;G1O(&%N(&%T+71H92UM87)K970-"B`H)B-X,C`Q0SM!5$TF M(W@R,#%$.RD@<')O9W)A;2!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N M>2!M87DL(&%T#0H@:71S(&]P=&EO;BP@;V9F97(@86YD('-E;&P@7,@=&AE('-A;&5S(&%G96YT(&$@8V]M;6ES#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P M<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@ M,3)P=#L@3$545$52+5-004-)3D'0M6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"<^ M#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@/&(^5V%R M'0M&5R8VES86)L90T*('=A65A#L@0T],3U(Z M(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=) M1$]74SH@,3L@34%21TE.+51/4#H@,3AP=#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T'0M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT97AT+7-T M6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L$$P.W1H;W5S86YD$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-SDQ+#`P M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@S M,2PR,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,#<\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-RPT-#4\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N.#@\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.S,Q+"`R,#$U M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-#,\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,L-C4S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4 M:6UE'!E8W1E9"!T;R!V97-T M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,SD\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,L-C(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3,Q M+#$U-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)- M.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%2 M1TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D'0M$$P.S,Q+"`R,#$U#0H@8V]N2!U$$P.S,Q+"`R,#$U#0H@8F%S960@;VX@=&AE(&9O;&QO=VEN M9R!K97D@87-S=6UP=&EO;G,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M M4U!!0TE.1SH@,'!X.R!7241/5U,Z(#$[($Q%5%1%4BU34$%#24Y'.B!N;W)M M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED M=&@Z(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#8X)2!A;&EG;CTS1&-E;G1E65A6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C4N-3`F(WA!,#LM M)B-X03`[-BXR-3PO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1&-E;G1E$$P.RTF(WA!,#LR+C`P)3PO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4 M:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@3$545$52+5-004-)3D#L@ M+7=E8FMI="UT97AT+7-T#L@+7=E8FMI="UT M97AT+7-T'0M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,34\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,34\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4 M:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ("=4:6UE6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,W,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y.3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX-#@\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0T,3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDV,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-& M3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L M,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@ M34%21TE.+51/4#H@,3)P=#L@3$545$52+5-004-)3D'0M'!E8W1E9"!T;R!B92!R M96-O9VYI>F5D(&%S(&5X<&5N2`Q+C@@>65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E M8FMI="UT97AT+7-T&5S/"]B/CPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!! M0T4Z(&YO2!R96-O9VYI M>F5S(&1E9F5R"!AF5D(&EN('1H92!F:6YA;F-I86P@ M"!R871E M'!E8W1E9"!T;R!R979E"!A M$$P.S,Q+"`R,#$U+@T*(%1H92!# M;VUP86YY(')E8V]R9&5D(&%N(&EN8V]M92!T87@@8F5N969I="!O9B`D,S$L M,#`P(&%N9"`D.#&%B;&4@:6YC;VUE(&9O$$P.S,Q+"`R,#$T+"!W:&EC:"!W87,@<')I;6%R:6QY(&%T=')I M8G5T86)L92!T;R!R96-E:7!T#0H@;V8@=&AE("0R-2XP(&UI;&QI;VX@1D1! M(&%P<')O=F%L(&UI;&5S=&]N92X@5&AE('1A>"!B96YE9FET6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M M4U!!0T4Z(&YO"<^#0H@1F]R('1H92!T:')E92!A M;F0@;FEN92!M;VYT:',@96YD960@36%R8V@F(WA!,#LS,2P@,C`Q-2!A;F0@ M,C`Q-"P-"B!T:&4@0V]M<&%N>2!H860@;F\@F5D('1A>"!B96YE9FET$$P.S,Q+"`R,#$U M(&%N9"!*=6YE)B-X03`[,S`L(#(P,30L('1H92!#;VUP86YY(&AA9"!N;PT* M(&%C8W)U960@<&5N86QT:65S(&]R(&EN=&5R97-T(')E;&%T960@=&\@=6YC M97)T86EN('1A>`T*('!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B M95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C M,V,T96,R+U=O'0O:'1M;#L@8VAA"<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F M=#X\8CXY+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L M969T/CQB/D-O;6UI=&UE;G1S(&%N9`T*($-O;G1I;F=E;F-I97,\+V(^/"]T M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@'0M65A2!I&-EF5D("0Q-3`L,#`P(&ER M#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2 M;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@,3)P=#L@3$545$52+5-0 M04-)3D'0M M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P M,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXQ,"X\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\8CY.970@*$QO#L@ M0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA M;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@-G!T.R!,151415(M4U!!0TE. M1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M=&5X="US=')O M:V4M=VED=&@Z(#!P>"<^#0H@0F%S:6,@;F5T("AL;W-S*2!I;F-O;64@<&5R M('-H87)E(&ES(&-O;7!U=&5D(&)Y(&1I=FED:6YG('1H92!N970-"B`H;&]S M2!S=&]C:R!M971H;V0L('5N M;&5S#L@3$545$52+5-004-) M3D#L@+7=E8FMI="UT97AT+7-T M'0M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO M"<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/@T*(#QB M/E1H$$P M.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D)B-X03`[36%R M8V@F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,7!T)SX- M"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.2PT,3(L,S8U/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(W+#8W,BPS,C<\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY.#DL.3DP/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR-34L,S`Q/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,P+#8Q,BPR,3`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251% M+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-0 M04-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I M;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/4#H@,3)P=#L@ M3$545$52+5-004-)3D'0M6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@ M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!! M0TE.1SH@,'!X.R!7241/5U,Z(#$[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[ M(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z M(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#DR)2!A;&EG;CTS1&-E;G1E$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.TUO M;G1H$$P.T5N9&5D)B-X03`[36%R8V@F(WA!,#LS,2P\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#0Y,"PY M-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#@Q M+#4R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`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`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4L,#8Y+#@T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#0S-"PP M,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO65A#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT97AT+7-T M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M2!T$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S+#,Q,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Q+#8X.3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UEF%T:6]N(&%T M(&)E9VEN;FEN9R!O9B!P97)I;V0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S@L M.3(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S4L-3$Q/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT'!E;G-E/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UEF%T:6]N(&%T(&5N9"!O9B!P97)I;V0\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XH,S8L,CDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S@L M.3(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[($)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P#L@5TE$3U=3.B`Q.R!,151415(M4U!!0TE. M1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D%M;W)T M:7IE9#QB$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/E5N6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[ M(%=/4D0M4U!!0TE.1SH@,'!X.R!7241/5U,Z(#$[($Q%5%1%4BU34$%#24Y' M.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O M:V4M=VED=&@Z(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]LF5D/&)R M("\^#0H@0V]S=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D9A:7(F(WA! M,#M686QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B@Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4 M:6UE6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0M28C>#(P,3D[2`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@#L@+7=E8FMI="UT97AT+7-T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT M97AT+7-T6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.W!R:6-E$$P M.VEN/&)R("\^#0H@86-T:79E(&UA$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/E-I9VYI9FEC86YT)B-X03`[;W1H97(\8G(@+SX-"B!O8G-E$$P.VEN<'5T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#(P-3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C@L-C4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L M-C4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@+7=E8FMI="UT97AT+7-T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT M97AT+7-T6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/"]T$$P.W!R:6-E$$P.VEN/&)R M("\^#0H@86-T:79E(&UA$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I9VYI M9FEC86YT)B-X03`[;W1H97(\8G(@+SX-"B!O8G-E$$P.VEN<'5T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+#(V,#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-#0T M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.3,V/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4P.#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C4P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T M)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$V+#$Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'!E;G-E'0^/&1I=CX-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[ M(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T], M3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[ M(%=)1$]74SH@,3L@34%21TE.+51/4#H@-G!T.R!,151415(M4U!!0TE.1SH@ M;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M=&5X="US=')O:V4M M=VED=&@Z(#!P>"<^#0H@06-C'!E;G-E$$P.S,Q+"`R,#$U#0H@86YD($IU M;F4F(WA!,#LS,"P@,C`Q-"`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@#L@+7=E8FMI="UT97AT+7-T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT M97AT+7-T6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(X-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XR-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0Q.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS,38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Y/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SX- M"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2`H5&%B;&5S M*3QB2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\2!U;F1E M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z M(&YO#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI="UT97AT M+7-T6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@8V]L$$P.W1H;W5S86YD$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-SDQ M+#`P,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4 M:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C@S,2PR,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,#<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-RPT-#4\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N.#@\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.S,Q+"`R M,#$U/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-#,\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C,L-C4S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE'!E8W1E9"!T;R!V M97-T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,SD\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C,L-C(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M.3,Q+#$U-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\2!!2!C M86QC=6QA=&5D('1H92!";&%C:RU38VAO;&5S('9A;'5E(&]F(&]P=&EO;G,@ M87=A#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z M(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/ M4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@ M,'!X.R`M=V5B:VET+71E>'0M$$P M.SPO<#X-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4 M+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M$$P.S8N M,C4\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE'!E;G-E(&9R;VT@4W1O8VLM0F%S960@ M4&%Y;65N="!!=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA'0M#L@+7=E8FMI="UT97AT+7-T M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE#L@+7=E8FMI M="UT97AT+7-T6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,34\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,34\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C,W,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(Y.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XX-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0T,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CDV,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\8G(@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E M8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X M9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO#L@0T], M3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[ M(%=)1$]74SH@,3L@34%21TE.+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@ M;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E M>'0M$$P.TUO;G1H$$P.T5N9&5D)B-X03`[36%R8V@F(WA!,#LS,2P\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/@T* M(#QB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.TUA6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y+#0Q,BPS M-C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@&-L=61E M9"!F#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z M(#$R<'0@)U1I;65S($YE=R!2;VUA;B<[(%=)1$]74SH@,3L@34%21TE.+51/ M4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@ M,'!X.R`M=V5B:VET+71E>'0M$$P M.SPO<#X-"B`\=&%B;&4@#L@5TE$3U=3.B`Q.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4 M+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.TUO;G1H$$P.T5N M9&5D)B-X03`[36%R8V@F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DYI;F4F(WA!,#M-;VYT:',F M(WA!,#M%;F1E9"8C>$$P.TUA6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.#DS+#$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@X,2PU,C0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U M,BPU,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T M)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C4L-C8W+#`U-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU M+#`V.2PX-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,#8Y+#@T-#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\8G(@8VQA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B M,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V M,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%L=&EE6%L='D@8V]N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!09FEZ97(\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%L='D@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M,3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5R($-O;&QA8F]R871I;VX@06=R965M96YT M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%L=&EE2!C M;VYS:61E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!N970@;&]S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!N970@;&]S2!C;VYS:61E6%L='D@:6YC;VUE/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3@L,#`P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6EN9R!A;6]U;G0@870@96YD(&]F('!E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B M,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V M,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E M;G-E('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C M,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T M96,R+U=O'0O:'1M;#L@8VAAF5D($-OF5D($-O'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-R!M;VYT:',@ M,R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA7,\&EM=6T@6TUE;6)E'0^,3$@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B M,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V M,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S M8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5? M8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'!E;G-E6%B;&5S(&%N9"!!8V-R M=6%L3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E8S(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X9%\T M-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM M96YT($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A&5C=71I=F4@1&ER96-T;W(@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^,3`@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&EM=6T@86=G'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A7,\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA2`M(%-T;V-K($]P=&EO M;B!!8W1I=FET>2!5;F1E&-E M<'0@4VAA6UE;G0@07=A&5R M8VES92!0&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q-3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-B!Y96%R7,\'!E M8W1E9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV M('EE87)S(#0@;6]N=&AS(#(Q(&1A>7,\7,\3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U M86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O M'0O:'1M M;#L@8VAA2!/<'1I;VX@4')I8VEN9R!-;V1E;"!F M;W(@3W!T:6]N6UE;G0@ M07=A2P@;6%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB M87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A6UE;G0@07=A65A'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA2`M($-O;7!E M;G-A=&EO;B!%>'!E;G-E(&9R;VT@4W1O8VLM0F%S960@4&%Y;65N="!!=V%R M9',@*$1E=&%I;"D@*%531"`D*3QB2!3:&%R92UB87-E9"!087EM M96YT($%W87)D+"!#;VUP96YS871I;VX@0V]S="!;3&EN92!)=&5M6UE;G0@ M07=A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B7V$S8C9? M8C`Y8S-C,V,T96,R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F,S8S.3!B95]C,SAD7S0U M86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B7V$S8C9?8C`Y8S-C,V,T96,R+U=O M'0O:'1M M;#L@8VAA&-L=61E9"!F'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F&-L=61E9"!F'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F,S8S.3!B95]C,SAD7S0U86)?83-B-E]B,#EC,V,S8S1E8S(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C,V,SDP8F5?8S,X9%\T-6%B M7V$S8C9?8C`Y8S-C,V,T96,R+U=O&UL#0I# M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I# M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements - Assets Carried at Fair Value Measured on Recurring Basis (Detail) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Jun. 30, 2014
Assets:    
Cash equivalents $ 17,205us-gaap_CashEquivalentsAtCarryingValue $ 14,260us-gaap_CashEquivalentsAtCarryingValue
Marketable securities   2,944us-gaap_AvailableForSaleSecuritiesCurrent
Cash equivalents and marketable securities 25,856us-gaap_AssetsFairValueDisclosureRecurring 17,204us-gaap_AssetsFairValueDisclosureRecurring
Corporate Bonds [Member]    
Assets:    
Marketable securities 8,651us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_InvestmentTypeAxis
= us-gaap_CorporateDebtSecuritiesMember
2,444us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_InvestmentTypeAxis
= us-gaap_CorporateDebtSecuritiesMember
Commercial Paper [Member]    
Assets:    
Marketable securities   500us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_InvestmentTypeAxis
= us-gaap_CommercialPaperMember
Quoted Prices in Active Markets (Level 1) [Member]    
Assets:    
Cash equivalents 17,205us-gaap_CashEquivalentsAtCarryingValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
14,260us-gaap_CashEquivalentsAtCarryingValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
Cash equivalents and marketable securities 25,856us-gaap_AssetsFairValueDisclosureRecurring
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
16,196us-gaap_AssetsFairValueDisclosureRecurring
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Bonds [Member]    
Assets:    
Marketable securities 8,651us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
/ us-gaap_InvestmentTypeAxis
= us-gaap_CorporateDebtSecuritiesMember
1,936us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
/ us-gaap_InvestmentTypeAxis
= us-gaap_CorporateDebtSecuritiesMember
Significant Other Observable Inputs (Level 2) [Member]    
Assets:    
Cash equivalents and marketable securities   1,008us-gaap_AssetsFairValueDisclosureRecurring
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel2Member
Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds [Member]    
Assets:    
Marketable securities   508us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel2Member
/ us-gaap_InvestmentTypeAxis
= us-gaap_CorporateDebtSecuritiesMember
Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member]    
Assets:    
Marketable securities   $ 500us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel2Member
/ us-gaap_InvestmentTypeAxis
= us-gaap_CommercialPaperMember
XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Marketable Securities - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Schedule of Available-for-sale Securities [Line Items]    
Marketable securities purchased $ 8,677us-gaap_PaymentsToAcquireMarketableSecurities $ 2,714us-gaap_PaymentsToAcquireMarketableSecurities
Marketable securities matured and sold $ 2,900psdv_ProceedsFromMaturityOfMarketableSecurities $ 3,350psdv_ProceedsFromMaturityOfMarketableSecurities
Weighted average maturity 7 months 3 days  
Minimum [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Marketable securities maturity period 38 days  
Maximum [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Marketable securities maturity period 11 months  
XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Jun. 30, 2014
Payables and Accruals [Abstract]    
Personnel costs $ 618us-gaap_EmployeeRelatedLiabilitiesCurrent $ 952us-gaap_EmployeeRelatedLiabilitiesCurrent
Professional fees 286us-gaap_AccruedProfessionalFeesCurrent 249us-gaap_AccruedProfessionalFeesCurrent
Clinical 418psdv_AccruedClinicalExpenseCurrent 316psdv_AccruedClinicalExpenseCurrent
Other 49us-gaap_OtherAccruedLiabilitiesCurrent 7us-gaap_OtherAccruedLiabilitiesCurrent
Accrued expenses $ 1,371us-gaap_AccruedLiabilitiesCurrent $ 1,524us-gaap_AccruedLiabilitiesCurrent
XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity - Additional Information (Detail) (USD $)
1 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended
Mar. 31, 2014
Investor
Jul. 31, 2013
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2013
Mar. 31, 2015
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock issued to investors 1,700,000us-gaap_StockIssuedDuringPeriodSharesNewIssues 3,494,550us-gaap_StockIssuedDuringPeriodSharesNewIssues          
Common stock price per share $ 4.11us-gaap_SharePrice $ 3.10us-gaap_SharePrice   $ 4.11us-gaap_SharePrice     $ 4.11us-gaap_SharePrice
Net proceeds from issuance of common stock $ 7,000,000us-gaap_ProceedsFromIssuanceOfCommonStock $ 10,800,000us-gaap_ProceedsFromIssuanceOfCommonStock          
Share issuance costs 191,000us-gaap_PaymentsOfStockIssuanceCosts 890,000us-gaap_PaymentsOfStockIssuanceCosts          
Number of institutional investors in direct offering 1psdv_NumberOfInstitutionalInvestors            
Number of warrants     1,176,105psdv_WarrantsToPurchaseCommonSharesOutstandingAndExercisable 1,176,105psdv_WarrantsToPurchaseCommonSharesOutstandingAndExercisable      
Weighted Average Exercise Price $ 3.67psdv_WarrantsWeightedAverageExercisePrice   $ 3.67psdv_WarrantsWeightedAverageExercisePrice $ 3.67psdv_WarrantsWeightedAverageExercisePrice   3.67psdv_WarrantsWeightedAverageExercisePrice $ 3.67psdv_WarrantsWeightedAverageExercisePrice
Outstanding warrants remaining contract life, weighted average period     1 year 7 months 6 days        
Weighted-average grant date fair value, per share     $ 3.33us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue        
Options vested during the period     579,408us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares        
Unrecognized compensation expense     2,300,000us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized     2,300,000us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized  
Unrecognized compensation expense weighted average period     1 year 9 months 18 days        
Non-Executive Directors [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options granted with annual vesting     90,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_TitleOfIndividualAxis
= psdv_NonExecutiveDirectorMember
       
Vesting period of granted options     1 year        
Newly Appointed Non-executive Director [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options granted with annual vesting     40,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_TitleOfIndividualAxis
= psdv_NewlyAppointedNonExecutiveDirectorMember
       
Vesting period of granted options     3 years        
Options [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options granted with annual vesting     701,200us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_AwardTypeAxis
= us-gaap_EmployeeStockOptionMember
       
Vesting period of granted options     4 years        
Contractual life of option grants     10 years        
At-the-Market Offering [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock issued to investors     0us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
381,562us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
  0us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
57,770us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
Net proceeds from issuance of common stock       1,500,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
    224,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
Common stock shares maximum aggregate offering price         19,200,000psdv_CommonStockSharesMaximumAggregateOfferingPrice
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
   
Agreement transaction costs         $ 153,000psdv_AgreementTransactionCosts
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
   
Stock issuances, sales agent commission maximum percentage         3.00%psdv_StockIssuanceCostsSalesAgentCommissionMaximumPercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
   
Weighted-average gross selling price       $ 3.98psdv_CommonStockWeightedAverageIssuePricePerShare
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
    $ 3.98psdv_CommonStockWeightedAverageIssuePricePerShare
/ us-gaap_TypeOfArrangementAxis
= psdv_AtTheMarketOfferingMember
Minimum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Outstanding warrants remaining contract life     9 months 18 days        
Maximum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Outstanding warrants remaining contract life     2 years 4 months 24 days        
2008 Incentive Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of common stock, authorized for issuance     6,341,255us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
    6,341,255us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
 
Shares available for grant     1,080,817us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
    1,080,817us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
 
Options granted with annual vesting     831,200us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
       
XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
License and Collaboration Agreements
9 Months Ended
Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License and Collaboration Agreements
2. License and Collaboration Agreements

Alimera

Under the collaboration agreement with Alimera, as amended in March 2008 (the “Alimera Agreement”), the Company licensed to Alimera the rights to develop, market and sell certain product candidates, including ILUVIEN, and Alimera assumed all financial responsibility for the development of licensed products. In September 2014, the Company earned a $25.0 million milestone from Alimera as a result of the FDA approval of ILUVIEN, which was recorded as revenue in the quarter ended September 30, 2014 and received in October 2014. In addition, the Company is entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera, measured on a quarter-by-quarter and country-by-country basis. Alimera may recover 20% of previously incurred and unapplied net losses (as defined) for commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company’s net profit share to 16% in each country until those net losses are recouped. In the event that Alimera sublicenses commercialization in any country, the Company is entitled to 20% of royalties and 33% of non-royalty consideration received by Alimera, less certain permitted deductions. The Company is also entitled to reimbursement of certain patent maintenance costs with respect to the patents licensed to Alimera.

 

The Company’s performance obligations ended on December 31, 2009 and, accordingly, all amounts received thereafter under the Alimera Agreement are recognized as revenue upon receipt or at such earlier date, if applicable, on which any such amounts are both fixed and determinable and reasonably assured of collectability.

Revenue under the Alimera Agreement totaled $70,000 and $47,000 for the three months ended March 31, 2015 and 2014, respectively, and $25.1 million and $95,000 for the nine months ended March 31, 2015 and 2014, respectively.

Pfizer

In June 2011, the Company and Pfizer entered into an Amended and Restated Collaborative Research and License Agreement (the “Restated Pfizer Agreement”) to focus solely on the development of a sustained-release bioerodible micro-insert designed to deliver latanoprost for human ophthalmic disease or conditions other than uveitis (the “Latanoprost Product”). Pfizer made an upfront payment of $2.3 million and the Company agreed to use commercially reasonable efforts to fund the development for at least one year, including assumption of an investigator-sponsored Phase I/II dose-escalation study. The Company may, at its option, conduct Phase II clinical trials, which have not been initiated, for the purpose of demonstrating Proof-of-Concept (“POC”). If the Company were to issue a final report demonstrating POC, Pfizer would have a 90-day exercise option for an exclusive, worldwide license to develop and commercialize the Latanoprost Product in return for a $20.0 million payment and potential double-digit sales-based royalties and prescribed development, regulatory and sales performance milestone payments. If the Company elects to cease development of the Latanoprost Product prior to POC, Pfizer could exercise its option for the same worldwide license upon payment of a lesser option fee, with comparable reductions in any future milestones and royalties. If Pfizer does not exercise its option when available, the Restated Pfizer Agreement will automatically terminate, with any remaining deferred revenue balance recorded as revenue at that time, provided, however, that the Company would retain the right to develop and commercialize the Latanoprost Product.

As a result of the material modification of the Pfizer arrangement, the estimated selling price of the combined deliverables under the Restated Pfizer Agreement of $6.7 million is being recognized as collaborative research and development revenue over the expected performance period using the proportional performance method. The Company recorded no revenue and $9,000 for the three months ended March 31, 2015 and 2014, respectively, and no revenue and $65,000 for the nine months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, the Company continues to evaluate the Latanoprost Product and, consequently, the Company cannot currently estimate the remaining performance period. As a result, total deferred revenue of approximately $5.6 million at each of March 31, 2015 and June 30, 2014 was classified as noncurrent. Costs associated with developing the Latanoprost Product are reflected in operating expenses in the period in which they are incurred.

Pfizer owned approximately 6.3% of the Company’s outstanding common stock at March 31, 2015.

Bausch & Lomb

Pursuant to a licensing and development agreement, as amended, Bausch & Lomb has a worldwide exclusive license to make and sell Retisert in return for royalties based on sales. Bausch & Lomb was also licensed to make and sell Vitrasert, an implant for sustained treatment of CMV retinitis, but discontinued sales in the second quarter of fiscal 2013 following patent expiration.

Royalty income from Bausch & Lomb totaled $218,000 and $316,000 for the three months ended March 31, 2015 and 2014, respectively, and $801,000 and $1.0 million for the nine months ended March 31, 2015 and 2014, respectively. Accounts receivable from Bausch & Lomb totaled $223,000 at March 31, 2015 and $302,000 at June 30, 2014.

Enigma Therapeutics

The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with Enigma Therapeutics Limited (“Enigma”) for the development of BrachySil, the Company’s BioSilicon™ product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and milestone payments based on aggregate product sales. Enigma is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any patent maintenance costs, sales-based royalties and sublicensee sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. The Company has no consequential performance obligations under the Enigma license agreement and, accordingly, any amounts to which the Company is entitled under the agreement are recognized as revenue on the earlier of receipt or when collectability is reasonably assured. There was no revenue related to the Enigma agreement in the three month periods ended March 31, 2015 and 2014 and $100,000 and $102,000 of revenues for the nine month periods ended March 31, 2015 and 2014, respectively. As of March 31, 2015, no deferred revenue was recorded for this agreement.

Evaluation Agreements

The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third party drug candidates in the treatment of various diseases. Consideration received is generally recognized as revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the evaluation agreement. Revenues under evaluation agreements totaled $35,000 and $1.6 million for the three months ended March 31, 2015 and 2014, respectively, and $104,000 and $1.9 million for the nine months ended March 31, 2015 and 2014, respectively.

 

XML 25 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity - Stock Option Activity Under Plan (Detail) (2008 Incentive Plan [Member], USD $)
In Thousands, except Share data, unless otherwise specified
9 Months Ended
Mar. 31, 2015
2008 Incentive Plan [Member]
 
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Options Outstanding, Beginning balance 3,791,001us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Number of Options, Granted 831,200us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Number of Options, Exercised (113,807)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Number of Options, Forfeited (17,445)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Number of Options Outstanding, Ending balance 4,490,949us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Number of Options, Outstanding at March 31, 2015 - vested or unvested and expected to vest 4,407,364us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Number of Options, Exercisable at March 31, 2015 2,931,157us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price Outstanding, beginning balance $ 3.08us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price, Granted $ 4.48us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price, Exercised $ 2.07us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price, Forfeited $ 3.88us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price Outstanding, ending balance $ 3.36us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price, Outstanding at March 31, 2015 - vested or unvested and expected to vest $ 3.35us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Exercise Price, Exercisable at March 31, 2015 $ 3.04us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Weighted Average Remaining Contractual Life Outstanding, Ending balance 6 years 5 months 5 days
Weighted Average Remaining Contractual Life, Outstanding at March 31, 2015 - vested or unvested and expected to vest 6 years 4 months 21 days
Weighted Average Remaining Contractual Life, Exercisable at March 31, 2015 5 years 3 months 11 days
Aggregate Intrinsic Value Outstanding, Ending balance $ 3,653us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Aggregate Intrinsic Value, Outstanding at March 31, 2015 - vested or unvested and expected to vest 3,623us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
Aggregate Intrinsic Value, Exercisable at March 31, 2015 $ 3,143us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
/ us-gaap_PlanNameAxis
= psdv_TwoThousandEightIncentivePlanMember
XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Jun. 30, 2014
Current assets:    
Cash and cash equivalents $ 23,007us-gaap_CashAndCashEquivalentsAtCarryingValue $ 15,334us-gaap_CashAndCashEquivalentsAtCarryingValue
Marketable securities 8,651us-gaap_MarketableSecuritiesCurrent 2,944us-gaap_MarketableSecuritiesCurrent
Accounts and other receivables 430us-gaap_AccountsAndOtherReceivablesNetCurrent 517us-gaap_AccountsAndOtherReceivablesNetCurrent
Prepaid expenses and other current assets 989us-gaap_PrepaidExpenseAndOtherAssetsCurrent 547us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Total current assets 33,077us-gaap_AssetsCurrent 19,342us-gaap_AssetsCurrent
Property and equipment, net 280us-gaap_PropertyPlantAndEquipmentNet 297us-gaap_PropertyPlantAndEquipmentNet
Intangible assets, net 2,080us-gaap_FiniteLivedIntangibleAssetsNet 2,765us-gaap_FiniteLivedIntangibleAssetsNet
Other assets 115us-gaap_OtherAssets 117us-gaap_OtherAssets
Restricted cash 150us-gaap_RestrictedCashAndCashEquivalentsNoncurrent 150us-gaap_RestrictedCashAndCashEquivalentsNoncurrent
Total assets 35,702us-gaap_Assets 22,671us-gaap_Assets
Current liabilities:    
Accounts payable 812us-gaap_AccountsPayableCurrent 464us-gaap_AccountsPayableCurrent
Accrued expenses 1,371us-gaap_AccruedLiabilitiesCurrent 1,524us-gaap_AccruedLiabilitiesCurrent
Deferred revenue 35us-gaap_DeferredRevenueCurrent 138us-gaap_DeferredRevenueCurrent
Total current liabilities 2,218us-gaap_LiabilitiesCurrent 2,126us-gaap_LiabilitiesCurrent
Deferred revenue 5,584us-gaap_DeferredRevenueNoncurrent 5,584us-gaap_DeferredRevenueNoncurrent
Deferred rent 53us-gaap_DeferredRentCreditNoncurrent 37us-gaap_DeferredRentCreditNoncurrent
Total liabilities 7,855us-gaap_Liabilities 7,747us-gaap_Liabilities
Commitments and contingencies      
Stockholders' equity:    
Preferred stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding      
Common stock, $.001 par value, 60,000,000 shares authorized, 29,412,365 and 29,298,558 shares issued and outstanding at March 31, 2015 and June 30, 2014, respectively 29us-gaap_CommonStockValue 29us-gaap_CommonStockValue
Additional paid-in capital 292,439us-gaap_AdditionalPaidInCapital 290,864us-gaap_AdditionalPaidInCapital
Accumulated deficit (265,520)us-gaap_RetainedEarningsAccumulatedDeficit (277,013)us-gaap_RetainedEarningsAccumulatedDeficit
Accumulated other comprehensive income 899us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax 1,044us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Total stockholders' equity 27,847us-gaap_StockholdersEquity 14,924us-gaap_StockholdersEquity
Total liabilities and stockholders' equity $ 35,702us-gaap_LiabilitiesAndStockholdersEquity $ 22,671us-gaap_LiabilitiesAndStockholdersEquity
XML 27 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities:    
Net income (loss) $ 11,493us-gaap_NetIncomeLoss $ (9,388)us-gaap_NetIncomeLoss
Adjustments to reconcile net income (loss) to cash flows from operating activities:    
Amortization of intangible assets 579us-gaap_AmortizationOfIntangibleAssets 582us-gaap_AmortizationOfIntangibleAssets
Depreciation of property and equipment 79us-gaap_Depreciation 103us-gaap_Depreciation
Stock-based compensation expense 1,340us-gaap_ShareBasedCompensation 963us-gaap_ShareBasedCompensation
Amortization of bond premium on marketable securities 66us-gaap_AmortizationOfDebtDiscountPremium 26us-gaap_AmortizationOfDebtDiscountPremium
Gain on sale of property and equipment   (76)us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Changes in operating assets and liabilities:    
Accounts receivable and other current assets (388)us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets 1,016us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
Accounts payable and accrued expenses 221us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities (833)us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
Deferred revenue (103)us-gaap_IncreaseDecreaseInDeferredRevenue (290)us-gaap_IncreaseDecreaseInDeferredRevenue
Deferred rent 16psdv_IncreaseDecreaseInDeferredRent 11psdv_IncreaseDecreaseInDeferredRent
Net cash provided by (used in) operating activities 13,303us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (7,886)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:    
Purchases of marketable securities (8,677)us-gaap_PaymentsToAcquireMarketableSecurities (2,714)us-gaap_PaymentsToAcquireMarketableSecurities
Maturities of marketable securities 2,900psdv_ProceedsFromMaturityOfMarketableSecurities 3,350psdv_ProceedsFromMaturityOfMarketableSecurities
Purchases of property and equipment (71)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (75)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Proceeds from sale of property and equipment   76us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment
Change in restricted cash   (150)us-gaap_IncreaseDecreaseInRestrictedCash
Net cash (used in) provided by investing activities (5,848)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations 487us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Proceeds from issuance of stock, net of issuance costs   18,149psdv_ProceedsFromIssuanceOfCommonStockNetOfShareIssueCosts
Exercise of stock options 235us-gaap_ProceedsFromStockOptionsExercised 909us-gaap_ProceedsFromStockOptionsExercised
Net cash provided by financing activities 235us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 19,058us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Effect of foreign exchange rate changes on cash and cash equivalents (17)us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents (3)us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents
Net increase in cash and cash equivalents 7,673us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 11,656us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 15,334us-gaap_CashAndCashEquivalentsAtCarryingValue 6,899us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period 23,007us-gaap_CashAndCashEquivalentsAtCarryingValue 18,555us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 263us-gaap_IncomeTaxesPaid  
Supplemental disclosure of non-cash investing and financing activities:    
Purchase of property and equipment   141psdv_NoncashOrPartNoncashUnpaidPropertyPlantEquipmentAndOtherAssets
Stock issuance costs   $ 86psdv_NoncashOrPartNoncashUnpaidStockIssuanceCosts
XML 28 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Jun. 30, 2014
Income Tax Disclosure [Abstract]            
Income tax expense (benefit) $ (44,000)us-gaap_IncomeTaxExpenseBenefit $ (31,000)us-gaap_IncomeTaxExpenseBenefit $ 144,000us-gaap_IncomeTaxExpenseBenefit $ (87,000)us-gaap_IncomeTaxExpenseBenefit    
Federal alternative minimum tax liability     263,000us-gaap_CurrentFederalTaxExpenseBenefit      
Milestone payment received upon an FDA approval of ILUVIEN         25,000,000psdv_MilestonePaymentReceivedUponFdaApproval  
Unrecognized tax benefits 0us-gaap_UnrecognizedTaxBenefits 0us-gaap_UnrecognizedTaxBenefits 0us-gaap_UnrecognizedTaxBenefits 0us-gaap_UnrecognizedTaxBenefits    
Accrued penalties or interest related to uncertain tax positions $ 0us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued   $ 0us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued     $ 0us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
XML 29 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Net (Loss) Income per Share (Tables)
9 Months Ended
Mar. 31, 2015
Earnings Per Share [Abstract]  
Schedule that Reconciles the Number of Shares Used to Compute Basic and Diluted Net (Loss) Income Per Share

The following table reconciles the number of shares used to compute basic and diluted net (loss) income per share:

 

     Three Months Ended March 31,      Nine Months Ended March 31,  
     2015      2014      2015      2014  

Number of common shares - basic

     29,412,365         27,672,327         29,366,919         26,841,623   

Effect of dilutive securities:

           

Stock options

     —           —           989,990         —     

Warrants

     —           —           255,301         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Number of common shares - diluted

  29,412,365      27,672,327      30,612,210      26,841,623   
  

 

 

    

 

 

    

 

 

    

 

 

 

Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares

Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:

 

     Three Months Ended March 31,      Nine Months Ended March 31,  
     2015      2014      2015      2014  

Options outstanding

     4,490,949         3,893,739         1,881,524         3,893,739   

Warrants outstanding

     1,176,105         1,176,105         552,500         1,176,105   
  

 

 

    

 

 

    

 

 

    

 

 

 
  5,667,054      5,069,844      2,434,024      5,069,844   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 30 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies - Additional Information (Detail) (USD $)
9 Months Ended
Mar. 31, 2015
Operating Leased Assets [Line Items]  
Irrevocable standby letter of credit 150,000us-gaap_SecurityDeposit
Watertown [Member]  
Operating Leased Assets [Line Items]  
Lease renewal, Period 5 years
Initial lease term expiration date 2019-04
XML 31 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
License and Collaboration Agreements - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Jun. 30, 2011
Mar. 31, 2013
Dec. 31, 2014
Jun. 30, 2014
Sep. 30, 2014
Collaborative Agreements And Contracts [Line Items]                  
Milestone payment received upon an FDA approval of ILUVIEN             $ 25,000,000psdv_MilestonePaymentReceivedUponFdaApproval    
Collaborative research and development revenue 110,000us-gaap_LicenseAndServicesRevenue 1,676,000us-gaap_LicenseAndServicesRevenue 25,355,000us-gaap_LicenseAndServicesRevenue 2,149,000us-gaap_LicenseAndServicesRevenue          
Deferred revenue 5,600,000us-gaap_DeferredRevenue   5,600,000us-gaap_DeferredRevenue         5,600,000us-gaap_DeferredRevenue  
Percentage of outstanding share capital owned by Pfizer 6.30%psdv_CollaborationAgreementOwnershipPercentageInCompany   6.30%psdv_CollaborationAgreementOwnershipPercentageInCompany            
Royalty income 218,000us-gaap_RoyaltyRevenue 316,000us-gaap_RoyaltyRevenue 801,000us-gaap_RoyaltyRevenue 1,032,000us-gaap_RoyaltyRevenue          
Accounts receivable 430,000us-gaap_AccountsAndOtherReceivablesNetCurrent   430,000us-gaap_AccountsAndOtherReceivablesNetCurrent         517,000us-gaap_AccountsAndOtherReceivablesNetCurrent  
Pfizer Collaboration Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Collaborative research and development revenue 0us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
9,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
0us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
65,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
         
Upfront payment         2,300,000psdv_UpfrontCashPayment
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
       
Contingent option exercise period     90 days            
License option upfront payment upon exercise     20,000,000psdv_LicenseOptionExerciseUpfrontPayment
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
           
Estimated selling price of the deliverables for revenue recognition         6,700,000us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
/ us-gaap_TypeOfArrangementAxis
= psdv_PfizerCollaborationAgreementMember
       
Enigma Therapeutics Limited [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Percentage of royalties received from sublicensee     8.00%psdv_RoyaltyRatePercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
           
Percentage of non-royalty consideration received from sublicensee     20.00%psdv_NonRoyaltyConsiderationPercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
           
Collaborative research and development revenue 0us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
0us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
100,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
102,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
         
Upfront payment           100,000psdv_UpfrontCashPayment
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
     
Deferred revenue 0us-gaap_DeferredRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
  0us-gaap_DeferredRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
           
License agreement commencement date     2012-12            
Annual license maintenance fee     100,000psdv_AnnualLicenseMaintenanceFee
/ us-gaap_TypeOfArrangementAxis
= psdv_EnigmaTherapeuticsMember
           
Alimera [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Milestone payment received upon an FDA approval of ILUVIEN                 25,000,000psdv_MilestonePaymentReceivedUponFdaApproval
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
Percentage of company's share of net profits     20.00%psdv_ProfitSharingOnSaleOfProductPercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
           
Pre-profitability net losses percentage     20.00%psdv_SharePercentageOfPreProfitabilityNetLossesOnSaleOfProduct
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
           
Maximum Percentage offset of previously incurred and unapplied pre-profitability quarterly net losses     4.00%psdv_MaximumPercentageOfQuarterlyProfitSharingOffsettableByPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
           
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses     16.00%psdv_ProfitSharingOnSaleOfProductMinimumPercentageAfterMaximumAllowableOffsetOfPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
           
Percentage of royalties received from sublicensee     20.00%psdv_RoyaltyRatePercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
           
Percentage of non-royalty consideration received from sublicensee     33.00%psdv_NonRoyaltyConsiderationPercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
           
Collaborative research and development revenue 70,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
47,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
25,100,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
95,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
         
Bausch and Lomb [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Royalty income 218,000us-gaap_RoyaltyRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
316,000us-gaap_RoyaltyRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
801,000us-gaap_RoyaltyRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
1,000,000us-gaap_RoyaltyRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
         
Accounts receivable 223,000us-gaap_AccountsAndOtherReceivablesNetCurrent
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
  223,000us-gaap_AccountsAndOtherReceivablesNetCurrent
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
        302,000us-gaap_AccountsAndOtherReceivablesNetCurrent
/ us-gaap_TypeOfArrangementAxis
= psdv_BauschAndLombMember
 
Evaluation Agreements [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Collaborative research and development revenue $ 35,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EvaluationAgreementsMember
$ 1,600,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EvaluationAgreementsMember
$ 104,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EvaluationAgreementsMember
$ 1,900,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_TypeOfArrangementAxis
= psdv_EvaluationAgreementsMember
         
XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Operations and Basis of Presentation
9 Months Ended
Mar. 31, 2015
Accounting Policies [Abstract]  
Operations and Basis of Presentation

 

1. Operations and Basis of Presentation

The accompanying condensed consolidated financial statements of pSivida Corp. and subsidiaries (the “Company”) as of March 31, 2015 and for the three and nine months ended March 31, 2015 and 2014 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2014, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive (loss) income and cash flows for the periods indicated. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.

The Company is a leader in the development of sustained-release pharmaceutical products for treating eye diseases. Its approved products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of the four approved sustained-release products for treating retinal diseases. The Company’s lead product candidate Medidur™ for posterior uveitis is in pivotal clinical trials. Marketing of its lead licensed product ILUVIEN® for diabetic macular edema (“DME”) commenced in the U.S. in the fiscal 2015 third quarter. The Company’s pre-clinical development program is focused on developing products for chronic retinal diseases utilizing our core technology platforms. The Company’s strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements.

Medidur, the Company’s lead development product, is an injectable, micro-insert designed to treat posterior uveitis, a blinding eye disease, on a sustained basis for 36 months. Medidur uses the same micro-insert used in ILUVIEN for DME (same design, same drug, same polymers, same release rate) and delivers a lower dose of the same drug as Retisert®, the Company’s approved implant for posterior uveitis. The Company is developing Medidur independently.

In recent meetings, the Company reached agreement with the U.S. Food and Drug Administration (“FDA”) on a regulatory path for Medidur that should allow a new drug application (“NDA”) to be filed in the first half of 2017. The FDA indicated that, pending clinical trial results, it would accept an NDA based on data from the ongoing Medidur Phase III trial (which has a 12-month primary endpoint), data from a second Phase III trial with a shorter six-month primary endpoint and data referenced from the already completed Phase III ILUVIEN trials. The ongoing Phase III trial for Medidur completed enrollment with 129 patients in the fiscal 2015 third quarter. The last 12-month follow-up visit is scheduled in March 2016, and the Company expects top-line data in the second calendar quarter of 2016. The Company has already initiated a second Phase III Medidur trial, which will recruit up to 150 patients in India. Both trials will follow participants for three years.

The Company had previously planned to file an NDA with data from only the first Phase III trial and data referenced from the ILUVIEN studies, subject to FDA confirmation. Because of the shorter six-month primary endpoint permitted for the second trial, the Company expects that the new regulatory path will allow it to file the Medidur NDA with only a several month delay from the time frame anticipated with one Phase III trial. The Company had budgeted for a second Phase III trial, pending FDA guidance, so the second trial does not affect the Company’s liquidity projections.

The Company plans to commercialize Medidur with a newly designed, proprietary inserter that uses a standard 27 gauge needle routinely used in intraocular injections. As a result of the new design, the Company will conduct a utilization study on the new inserter, with data to be submitted as part of the Medidur NDA. Data from this study is expected to be available before data from the other trials and should not delay the NDA submission.

 

ILUVIEN, the Company’s most recently approved product, is an injectable, sustained-release micro-insert that provides treatment of DME for three years from a single administration. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (“Alimera”), and the Company is entitled to a share of the net profits (as defined) from Alimera’s sales of ILUVIEN on a country-by-country basis. ILUVIEN was launched in the U.S. in late February 2015 and is now widely available to physicians in the U.S. It is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.

ILUVIEN was also launched in Portugal in January 2015, and has been commercially available in the United Kingdom and Germany since June 2013. ILUVIEN has marketing approvals in 17 EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies.

Distribution, regulatory and reimbursement matters for ILUVIEN for DME in Australia and New Zealand have been sublicensed. The Company is entitled to 20% of any royalties and 33% of all other payments received by our licensee, including any milestone payments.

The Company’s pre-clinical research is primarily focused on developing pharmaceutical products to provide targeted and systemic sustained delivery of drugs and large biologic molecules for treatment of various conditions, and to provide sustained delivery of therapeutic agents to treat wet and dry age-related macular degeneration, glaucoma and osteoarthritis.

The Company has a history of operating losses and has financed its operations primarily from the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners and from proceeds of sales of its equity securities. The Company believes that its cash, cash equivalents and marketable securities of $31.7 million at March 31, 2015 will enable the Company to maintain its current and planned operations (including its two Medidur trials) into calendar year 2017. This estimate excludes any potential net profits receipts from sales of ILUVIEN.

New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which requires an entity to recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP. In April 2015, the FASB tentatively deferred the effective date of ASU 2014-09, while also tentatively permitting early adoption. If such deferral is ratified, ASU 2014-09 will become effective on July 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the impact this standard will have on its financial statements.

XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2015
Jun. 30, 2014
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare
Preferred stock, shares authorized 5,000,000us-gaap_PreferredStockSharesAuthorized 5,000,000us-gaap_PreferredStockSharesAuthorized
Preferred stock, shares issued 0us-gaap_PreferredStockSharesIssued 0us-gaap_PreferredStockSharesIssued
Preferred stock, shares outstanding 0us-gaap_PreferredStockSharesOutstanding 0us-gaap_PreferredStockSharesOutstanding
Common stock, par value $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare
Common stock, shares authorized 60,000,000us-gaap_CommonStockSharesAuthorized 60,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares issued 29,412,365us-gaap_CommonStockSharesIssued 29,298,558us-gaap_CommonStockSharesIssued
Common stock, shares outstanding 29,412,365us-gaap_CommonStockSharesOutstanding 29,298,558us-gaap_CommonStockSharesOutstanding
XML 35 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Tables)
9 Months Ended
Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Reconciliation of Intangible Assets

The reconciliation of intangible assets for the nine months ended March 31, 2015 and for the year ended June 30, 2014 was as follows (in thousands):

 

     Nine Months Ended
March 31, 2015
     Year Ended
June 30, 2014
 

Patented technologies

     

Gross carrying amount at beginning of period

   $ 41,689       $ 38,941   

Foreign currency translation adjustments

     (3,313      2,748   
  

 

 

    

 

 

 

Gross carrying amount at end of period

  38,376      41,689   
  

 

 

    

 

 

 

Accumulated amortization at beginning of period

  (38,924   (35,511

Amortization expense

  (579   (778

Foreign currency translation adjustments

  3,207      (2,635
  

 

 

    

 

 

 

Accumulated amortization at end of period

  (36,296   (38,924
  

 

 

    

 

 

 

Net book value at end of period

$ 2,080    $ 2,765   
  

 

 

    

 

 

 

XML 36 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information
9 Months Ended
Mar. 31, 2015
May 06, 2015
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q3  
Trading Symbol PSDV  
Entity Registrant Name pSivida Corp.  
Entity Central Index Key 0001314102  
Current Fiscal Year End Date --06-30  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   29,412,365dei_EntityCommonStockSharesOutstanding
XML 37 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Marketable Securities (Tables)
9 Months Ended
Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]  
Schedule of Amortized Cost, Unrealized Loss and Fair Value of Available-for-Sale Marketable Securities

The amortized cost, unrealized loss and fair value of the Company’s available-for-sale marketable securities at March 31, 2015 and June 30, 2014 were as follows (in thousands):

 

     March 31, 2015  
     Amortized
Cost
     Unrealized
Loss
     Fair Value  

Corporate bonds

   $ 8,656       $ (5    $ 8,651   
  

 

 

    

 

 

    

 

 

 

 

     June 30, 2014  
     Amortized
Cost
     Unrealized
Loss
     Fair Value  

Corporate bonds

   $ 2,446       $ (1    $ 2,445   

Commercial paper

     499         —           499   
  

 

 

    

 

 

    

 

 

 

Total marketable securities

$ 2,945    $ (1 $ 2,944   
  

 

 

    

 

 

    

 

 

 

XML 38 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Comprehensive (Loss) Income (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Revenues:        
Collaborative research and development $ 110us-gaap_LicenseAndServicesRevenue $ 1,676us-gaap_LicenseAndServicesRevenue $ 25,355us-gaap_LicenseAndServicesRevenue $ 2,149us-gaap_LicenseAndServicesRevenue
Royalty income 218us-gaap_RoyaltyRevenue 316us-gaap_RoyaltyRevenue 801us-gaap_RoyaltyRevenue 1,032us-gaap_RoyaltyRevenue
Total revenues 328us-gaap_Revenues 1,992us-gaap_Revenues 26,156us-gaap_Revenues 3,181us-gaap_Revenues
Operating expenses:        
Research and development 3,339us-gaap_ResearchAndDevelopmentExpense 2,269us-gaap_ResearchAndDevelopmentExpense 8,890us-gaap_ResearchAndDevelopmentExpense 7,267us-gaap_ResearchAndDevelopmentExpense
General and administrative 2,041us-gaap_GeneralAndAdministrativeExpense 1,946us-gaap_GeneralAndAdministrativeExpense 5,645us-gaap_GeneralAndAdministrativeExpense 5,468us-gaap_GeneralAndAdministrativeExpense
Gain on sale of property and equipment   (4)us-gaap_GainLossOnSaleOfPropertyPlantEquipment   (76)us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Total operating expenses 5,380us-gaap_OperatingExpenses 4,211us-gaap_OperatingExpenses 14,535us-gaap_OperatingExpenses 12,659us-gaap_OperatingExpenses
(Loss) income from operations (5,052)us-gaap_OperatingIncomeLoss (2,219)us-gaap_OperatingIncomeLoss 11,621us-gaap_OperatingIncomeLoss (9,478)us-gaap_OperatingIncomeLoss
Other income:        
Interest income 6us-gaap_InvestmentIncomeInterest 1us-gaap_InvestmentIncomeInterest 12us-gaap_InvestmentIncomeInterest 3us-gaap_InvestmentIncomeInterest
Other income, net 4us-gaap_OtherNonoperatingIncomeExpense   4us-gaap_OtherNonoperatingIncomeExpense  
Total other income 10us-gaap_NonoperatingIncomeExpense 1us-gaap_NonoperatingIncomeExpense 16us-gaap_NonoperatingIncomeExpense 3us-gaap_NonoperatingIncomeExpense
(Loss) income before income taxes (5,042)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (2,218)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest 11,637us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (9,475)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax benefit (expense) 44us-gaap_IncomeTaxExpenseBenefit 31us-gaap_IncomeTaxExpenseBenefit (144)us-gaap_IncomeTaxExpenseBenefit 87us-gaap_IncomeTaxExpenseBenefit
Net (loss) income (4,998)us-gaap_NetIncomeLoss (2,187)us-gaap_NetIncomeLoss 11,493us-gaap_NetIncomeLoss (9,388)us-gaap_NetIncomeLoss
Net (loss) income per common share:        
Basic $ (0.17)us-gaap_EarningsPerShareBasic $ (0.08)us-gaap_EarningsPerShareBasic $ 0.39us-gaap_EarningsPerShareBasic $ (0.35)us-gaap_EarningsPerShareBasic
Diluted $ (0.17)us-gaap_EarningsPerShareDiluted $ (0.08)us-gaap_EarningsPerShareDiluted $ 0.38us-gaap_EarningsPerShareDiluted $ (0.35)us-gaap_EarningsPerShareDiluted
Weighted average common shares:        
Basic 29,412,365us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,672,327us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 29,366,919us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 26,841,623us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Diluted 29,412,365us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,672,327us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 30,612,210us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 26,841,623us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
Net (loss) income (4,998)us-gaap_NetIncomeLoss (2,187)us-gaap_NetIncomeLoss 11,493us-gaap_NetIncomeLoss (9,388)us-gaap_NetIncomeLoss
Other comprehensive (loss) income:        
Foreign currency translation adjustments (45)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax 5us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax (141)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax 100us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
Net unrealized gain (loss) on marketable securities 1us-gaap_MarketableSecuritiesUnrealizedGainLoss (1)us-gaap_MarketableSecuritiesUnrealizedGainLoss (4)us-gaap_MarketableSecuritiesUnrealizedGainLoss (1)us-gaap_MarketableSecuritiesUnrealizedGainLoss
Other comprehensive (loss) income (44)us-gaap_OtherComprehensiveIncomeLossNetOfTax 4us-gaap_OtherComprehensiveIncomeLossNetOfTax (145)us-gaap_OtherComprehensiveIncomeLossNetOfTax 99us-gaap_OtherComprehensiveIncomeLossNetOfTax
Comprehensive (loss) income $ (5,042)us-gaap_ComprehensiveIncomeNetOfTax $ (2,183)us-gaap_ComprehensiveIncomeNetOfTax $ 11,348us-gaap_ComprehensiveIncomeNetOfTax $ (9,289)us-gaap_ComprehensiveIncomeNetOfTax
XML 39 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accrued Expenses
9 Months Ended
Mar. 31, 2015
Payables and Accruals [Abstract]  
Accrued Expenses
6. Accrued Expenses

Accrued expenses consisted of the following at March 31, 2015 and June 30, 2014 (in thousands):

 

     March 31, 2015      June 30, 2014  

Personnel costs

   $ 618       $ 952   

Professional fees

     286         249   

Clinical

     418         316   

Other

     49         7   
  

 

 

    

 

 

 
$ 1,371    $ 1,524   
  

 

 

    

 

 

 

XML 40 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements
9 Months Ended
Mar. 31, 2015
Fair Value Disclosures [Abstract]  
Fair Value Measurements
5. Fair Value Measurements

The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

 

    Level 1 – Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities.

 

    Level 2 – Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets).

 

    Level 3 – Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities.

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At March 31, 2015 and June 30, 2014, substantially all of the Company’s interest-bearing cash equivalent balances were concentrated in one institutional money market fund that has investments consisting primarily of certificates of deposit, commercial paper, time deposits, U.S. government agencies, treasury bills and treasury repurchase agreements. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.

 

The Company’s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. Certain of the Company’s corporate debt securities were valued based on quoted prices for the specific securities in an active market and were therefore classified as Level 1. The remaining marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services’ pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2. The following tables summarize the Company’s assets carried at fair value measured on a recurring basis at March 31, 2015 and June 30, 2014 by valuation hierarchy (in thousands):

 

     March 31, 2015  
     Total carrying
value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 17,205       $ 17,205       $ —         $ —     

Marketable securities

           

Corporate bonds

     8,651         8,651         —           —     
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 25,856    $ 25,856    $ —      $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     June 30, 2014  
     Total carrying
value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 14,260       $ 14,260       $ —         $ —     

Marketable securities

           

Corporate bonds

     2,444         1,936         508         —     

Commercial paper

     500         —           500         —     
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 17,204    $ 16,196    $ 1,008    $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 41 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Operations and Basis of Presentation - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2015
Country
Operations [Line Items]    
Period in which Company will follow participants in both trials 3 years  
Cash equivalents and marketable securities $ 31.7psdv_CashAndCashEquivalentsAndMarketableSecuritiesFairValue 31.7psdv_CashAndCashEquivalentsAndMarketableSecuritiesFairValue
Medidur Phase III Trial [Member]    
Operations [Line Items]    
Number of Patients who completed enrollment for Medidur Phase III trial 129psdv_NumberOfPatientsEnrolled
/ us-gaap_ProductOrServiceAxis
= psdv_PhaseThreeMember
129psdv_NumberOfPatientsEnrolled
/ us-gaap_ProductOrServiceAxis
= psdv_PhaseThreeMember
Second Medidur Phase III Trial [Member] | Maximum [Member]    
Operations [Line Items]    
Maximum amount of patients that can be recruited for a second Phase III Medidur trial 150psdv_NumberOfPatientsCompanyPlansToEnroll
/ us-gaap_ProductOrServiceAxis
= psdv_SecondPhaseThreeMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
 
Europe [Member] | ILUVIEN [Member]    
Operations [Line Items]    
Number of countries approved lead product   17psdv_NumberOfCountriesApprovedForProduct
/ us-gaap_ProductOrServiceAxis
= psdv_IluvienMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_EuropeMember
Alimera [Member]    
Operations [Line Items]    
Percentage of royalties received from sublicensee   20.00%psdv_RoyaltyRatePercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
Other percentage of non-royalty consideration received from sublicensee   33.00%psdv_OtherPaymentsPercentage
/ us-gaap_TypeOfArrangementAxis
= psdv_AlimeraSciencesIncMember
XML 42 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements (Tables)
9 Months Ended
Mar. 31, 2015
Fair Value Disclosures [Abstract]  
Assets Carried at Fair Value Measured on Recurring Basis

The following tables summarize the Company’s assets carried at fair value measured on a recurring basis at March 31, 2015 and June 30, 2014 by valuation hierarchy (in thousands):

 

     March 31, 2015  
     Total carrying
value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 17,205       $ 17,205       $ —         $ —     

Marketable securities

           

Corporate bonds

     8,651         8,651         —           —     
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 25,856    $ 25,856    $ —      $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     June 30, 2014  
     Total carrying
value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 14,260       $ 14,260       $ —         $ —     

Marketable securities

           

Corporate bonds

     2,444         1,936         508         —     

Commercial paper

     500         —           500         —     
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 17,204    $ 16,196    $ 1,008    $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 43 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies
9 Months Ended
Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
9. Commitments and Contingencies

The Company’s lease for its U.S. office and laboratory space in Watertown, Massachusetts extends through April 2019, with a five-year renewal option at market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. The Company’s obligations under the lease are secured by a cash-collateralized $150,000 irrevocable standby letter of credit.

At March 31, 2015, the Company was subject to various routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company’s financial position, results of operations or cash flows.

XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity
9 Months Ended
Mar. 31, 2015
Equity [Abstract]  
Stockholders' Equity
7. Stockholders’ Equity

In March 2014, the Company sold 1,700,000 shares of its common stock in a registered direct offering to a single institutional investor at a price of $4.11 per share for gross proceeds of $7.0 million. Placement agent fees and other share issue costs approximated $191,000.

In December 2013, the Company entered into an at-the-market (“ATM”) program pursuant to which the Company may, at its option, offer and sell shares of its common stock from time to time for an aggregate offering price of up to $19.2 million, representing the then remaining balance of the Company’s shelf registration statement. In connection with execution of the ATM program, the Company incurred transaction costs of $153,000. In addition, the Company pays the sales agent a commission of up to 3.0% of the gross proceeds from the sale of such shares. During the three and nine month periods ended March 31, 2015, the Company did not sell any shares under this program. During the three and nine months ended March 31, 2014, the Company sold 57,770 and 381,562 common shares, respectively, for net proceeds of $224,000 and $1.5 million, respectively, reflecting a weighted-average gross selling price of $3.98 per share.

In July 2013, the Company sold 3,494,550 shares of its common stock in an underwritten public offering at a price of $3.10 per share for gross proceeds of $10.8 million. Underwriting commissions and other share issue costs approximated $890,000.

 

Warrants to Purchase Common Shares

During each of the nine month periods ended March 31, 2015 and 2014, there were a total of 1,176,105 outstanding and exercisable warrants to purchase common shares at a weighted-average exercise price of $3.67. At March 31, 2015, the remaining term of these warrants ranged from 0.8 to 2.4 years, representing a weighted average period of 1.6 years.

Incentive Plan

The Company’s 2008 Incentive Plan (the “2008 Plan”) provides for the issuance of stock options and other stock awards to directors, employees and consultants. At March 31, 2015, a total of 6,341,255 shares of common stock were authorized for issuance under the 2008 Plan, of which 1,080,817 were available for grant of future awards. The total number of shares issuable under the 2008 Plan is subject to annual increases pursuant to the terms of the plan. The following table provides a reconciliation of stock option activity under the 2008 Plan for the nine months ended March 31, 2015:

 

     Number of
Options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2014

     3,791,001       $ 3.08         

Granted

     831,200         4.48         

Exercised

     (113,807      2.07         

Forfeited

     (17,445      3.88         
  

 

 

    

 

 

       

Outstanding at March 31, 2015

  4,490,949    $ 3.36      6.43    $ 3,653   
  

 

 

    

 

 

    

 

 

    

 

 

 

Outstanding at March 31, 2015 - vested or unvested and expected to vest

  4,407,364    $ 3.35      6.39    $ 3,623   
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at March 31, 2015

  2,931,157    $ 3.04      5.28    $ 3,143   
  

 

 

    

 

 

    

 

 

    

 

 

 

Option grants for the nine months ended March 31, 2015 consisted of 701,200 options to employees with ratable annual vesting over 4 years, 90,000 options to non-executive directors with 1-year cliff vesting and 40,000 options to a newly appointed non-executive director with ratable annual vesting over 3 years. All option grants have a 10-year contractual life. The weighted-average grant date fair value of these option grants was $3.33 per share. A total of 579,408 options vested during the nine months ended March 31, 2015. In determining the grant date fair value of options, the Company uses the Black-Scholes option pricing model. The Company calculated the Black-Scholes value of options awarded during the nine months ended March 31, 2015 based on the following key assumptions:

 

Option life (in years)

5.50 - 6.25

Stock volatility

79% - 93%

Risk-free interest rate

1.70% - 2.00%

Expected dividends

0%

 

Stock-Based Compensation Expense

The Company’s statements of comprehensive (loss) income included total compensation expense from stock-based payment awards for the three and nine months ended March 31, 2015 and 2014, as follows (in thousands):

 

     Three Months Ended
March 31,
     Nine Months Ended
March 31,
 
     2015      2014      2015      2014  

Compensation expense included in:

           

Research and development

   $ 182       $ 142       $ 492       $ 373   

General and administrative

     432         299         848         590   
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 614    $ 441    $ 1,340    $ 963   
  

 

 

    

 

 

    

 

 

    

 

 

 

At March 31, 2015, there was approximately $2.3 million of unrecognized compensation expense related to unvested options under the 2008 Plan, which is expected to be recognized as expense over a weighted-average period of approximately 1.8 years.

XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes
9 Months Ended
Mar. 31, 2015
Income Tax Disclosure [Abstract]  
Income Taxes
8. Income Taxes

The Company recognizes deferred tax assets and liabilities for estimated future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established if, based on management’s review of both positive and negative evidence, it is more likely than not that all or a portion of the deferred tax assets will not be realized. Because of its historical losses from operations, the Company established a valuation allowance for the net deferred tax assets. The Company recorded an income tax benefit of $44,000 for the three months ended March 31, 2015 and an income tax expense of $144,000 for the nine months ended March 31, 2015. The Company recorded an income tax benefit of $31,000 and $87,000 for the three and nine months ended March 31, 2014, respectively. The current year-to-date income tax expense predominantly reflects $263,000 of federal alternative minimum tax payments based upon taxable income for the tax year ended December 31, 2014, which was primarily attributable to receipt of the $25.0 million FDA approval milestone. The tax benefits in each period predominantly represented earned foreign research and development tax credits.

For the three and nine months ended March 31, 2015 and 2014, the Company had no significant unrecognized tax benefits. At March 31, 2015 and June 30, 2014, the Company had no accrued penalties or interest related to uncertain tax positions.

XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Net (Loss) Income per Share
9 Months Ended
Mar. 31, 2015
Earnings Per Share [Abstract]  
Net (Loss) Income per Share
10. Net (Loss) Income per Share

Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the basic weighted average number of common shares outstanding the total number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.

 

The following table reconciles the number of shares used to compute basic and diluted net (loss) income per share:

 

     Three Months Ended March 31,      Nine Months Ended March 31,  
     2015      2014      2015      2014  

Number of common shares - basic

     29,412,365         27,672,327         29,366,919         26,841,623   

Effect of dilutive securities:

           

Stock options

     —           —           989,990         —     

Warrants

     —           —           255,301         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Number of common shares - diluted

  29,412,365      27,672,327      30,612,210      26,841,623   
  

 

 

    

 

 

    

 

 

    

 

 

 

Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:

 

     Three Months Ended March 31,      Nine Months Ended March 31,  
     2015      2014      2015      2014  

Options outstanding

     4,490,949         3,893,739         1,881,524         3,893,739   

Warrants outstanding

     1,176,105         1,176,105         552,500         1,176,105   
  

 

 

    

 

 

    

 

 

    

 

 

 
  5,667,054      5,069,844      2,434,024      5,069,844   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 47 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity - Compensation Expense from Stock-Based Payment Awards (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock-based compensation expense $ 614us-gaap_AllocatedShareBasedCompensationExpense $ 441us-gaap_AllocatedShareBasedCompensationExpense $ 1,340us-gaap_AllocatedShareBasedCompensationExpense $ 963us-gaap_AllocatedShareBasedCompensationExpense
Research and Development Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock-based compensation expense 182us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
142us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
492us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
373us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
General and Administrative Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Stock-based compensation expense $ 432us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
$ 299us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
$ 848us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
$ 590us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
XML 48 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity (Tables)
9 Months Ended
Mar. 31, 2015
Equity [Abstract]  
Stock Option Activity under Plan

The following table provides a reconciliation of stock option activity under the 2008 Plan for the nine months ended March 31, 2015:

 

     Number of
Options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2014

     3,791,001       $ 3.08         

Granted

     831,200         4.48         

Exercised

     (113,807      2.07         

Forfeited

     (17,445      3.88         
  

 

 

    

 

 

       

Outstanding at March 31, 2015

  4,490,949    $ 3.36      6.43    $ 3,653   
  

 

 

    

 

 

    

 

 

    

 

 

 

Outstanding at March 31, 2015 - vested or unvested and expected to vest

  4,407,364    $ 3.35      6.39    $ 3,623   
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at March 31, 2015

  2,931,157    $ 3.04      5.28    $ 3,143   
  

 

 

    

 

 

    

 

 

    

 

 

 
Key Assumptions used to Apply Option Pricing Model for Options Awarded

The Company calculated the Black-Scholes value of options awarded during the nine months ended March 31, 2015 based on the following key assumptions:

 

Option life (in years)

5.50 - 6.25

Stock volatility

79% - 93%

Risk-free interest rate

1.70% - 2.00%

Expected dividends

0%

Compensation Expense from Stock-Based Payment Awards

The Company’s statements of comprehensive (loss) income included total compensation expense from stock-based payment awards for the three and nine months ended March 31, 2015 and 2014, as follows (in thousands):

 

     Three Months Ended
March 31,
     Nine Months Ended
March 31,
 
     2015      2014      2015      2014  

Compensation expense included in:

           

Research and development

   $ 182       $ 142       $ 492       $ 373   

General and administrative

     432         299         848         590   
  

 

 

    

 

 

    

 

 

    

 

 

 
$ 614    $ 441    $ 1,340    $ 963   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 49 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]          
Amortization expense $ 190,000us-gaap_AmortizationOfIntangibleAssets $ 196,000us-gaap_AmortizationOfIntangibleAssets $ 579,000us-gaap_AmortizationOfIntangibleAssets $ 582,000us-gaap_AmortizationOfIntangibleAssets  
Intangible assets, net 2,080,000us-gaap_FiniteLivedIntangibleAssetsNet   2,080,000us-gaap_FiniteLivedIntangibleAssetsNet   2,765,000us-gaap_FiniteLivedIntangibleAssetsNet
Amortization expense per year 756,000psdv_EstimatedAnnualAmortizationOfIntangibleAssets   756,000psdv_EstimatedAnnualAmortizationOfIntangibleAssets    
Remaining estimated useful life 2 years 9 months        
Durasert [Member]          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets, net 1,500,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= psdv_DurasertMember
  1,500,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= psdv_DurasertMember
   
BioSilicon [Member]          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets, net $ 600,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= psdv_BioSiliconMember
  $ 600,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= psdv_BioSiliconMember
   
XML 50 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statement of Stockholders' Equity (USD $)
In Thousands, except Share data
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Balance at Jun. 30, 2014 $ 14,924us-gaap_StockholdersEquity $ 29us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
$ 290,864us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
$ (277,013)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
$ 1,044us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember
Balance, shares at Jun. 30, 2014 29,298,558us-gaap_CommonStockSharesIssued 29,298,558us-gaap_CommonStockSharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Net income 11,493us-gaap_NetIncomeLoss     11,493us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
 
Other comprehensive loss (145)us-gaap_OtherComprehensiveIncomeLossNetOfTax       (145)us-gaap_OtherComprehensiveIncomeLossNetOfTax
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember
Exercise of stock options 235us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised   235us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   
Exercise of stock options, shares   113,807us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Stock-based compensation 1,340us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue   1,340us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   
Balance at Mar. 31, 2015 $ 27,847us-gaap_StockholdersEquity $ 29us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
$ 292,439us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
$ (265,520)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
$ 899us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember
Balance, shares at Mar. 31, 2015 29,412,365us-gaap_CommonStockSharesIssued 29,412,365us-gaap_CommonStockSharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
XML 51 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Marketable Securities
9 Months Ended
Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
4. Marketable Securities

The amortized cost, unrealized loss and fair value of the Company’s available-for-sale marketable securities at March 31, 2015 and June 30, 2014 were as follows (in thousands):

 

     March 31, 2015  
     Amortized
Cost
     Unrealized
Loss
     Fair Value  

Corporate bonds

   $ 8,656       $ (5    $ 8,651   
  

 

 

    

 

 

    

 

 

 

 

     June 30, 2014  
     Amortized
Cost
     Unrealized
Loss
     Fair Value  

Corporate bonds

   $ 2,446       $ (1    $ 2,445   

Commercial paper

     499         —           499   
  

 

 

    

 

 

    

 

 

 

Total marketable securities

$ 2,945    $ (1 $ 2,944   
  

 

 

    

 

 

    

 

 

 

During the nine months ended March 31, 2015, $8.7 million of marketable securities were purchased and $2.9 million of such securities matured. At March 31, 2015, the marketable securities had maturities ranging from 38 days to 11 months, with a weighted average maturity of 7.1 months.

 

XML 52 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
Marketable Securities - Schedule of Amortized Cost, Unrealized Loss and Fair Value of Available-for-Sale Marketable Securities (Detail) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Jun. 30, 2014
Schedule of Available-for-sale Securities [Line Items]    
Marketable securities, Amortized Cost   $ 2,945us-gaap_AvailableForSaleSecuritiesAmortizedCost
Marketable securities, Unrealized Loss   (1)us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
Marketable securities, Fair Value   2,944us-gaap_AvailableForSaleSecuritiesCurrent
Corporate Bonds [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Marketable securities, Amortized Cost 8,656us-gaap_AvailableForSaleSecuritiesAmortizedCost
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CorporateDebtSecuritiesMember
2,446us-gaap_AvailableForSaleSecuritiesAmortizedCost
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CorporateDebtSecuritiesMember
Marketable securities, Unrealized Loss (5)us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CorporateDebtSecuritiesMember
(1)us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CorporateDebtSecuritiesMember
Marketable securities, Fair Value 8,651us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CorporateDebtSecuritiesMember
2,445us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CorporateDebtSecuritiesMember
Commercial Paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Marketable securities, Amortized Cost   499us-gaap_AvailableForSaleSecuritiesAmortizedCost
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CommercialPaperMember
Marketable securities, Fair Value   $ 499us-gaap_AvailableForSaleSecuritiesCurrent
/ us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis
= us-gaap_CommercialPaperMember
XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 104 203 1 false 34 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.psivida.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.psivida.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.psivida.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income Sheet http://www.psivida.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Comprehensive (Loss) Income false false R5.htm 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.psivida.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Condensed Consolidated Statement of Stockholders' Equity false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.psivida.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows false false R7.htm 108 - Disclosure - Operations and Basis of Presentation Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Operations and Basis of Presentation false false R8.htm 109 - Disclosure - License and Collaboration Agreements Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock License and Collaboration Agreements false false R9.htm 110 - Disclosure - Intangible Assets Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets false false R10.htm 111 - Disclosure - Marketable Securities Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Marketable Securities false false R11.htm 112 - Disclosure - Fair Value Measurements Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R12.htm 113 - Disclosure - Accrued Expenses Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R13.htm 114 - Disclosure - Stockholders' Equity Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R14.htm 115 - Disclosure - Income Taxes Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R16.htm 117 - Disclosure - Net (Loss) Income per Share Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net (Loss) Income per Share false false R17.htm 118 - Disclosure - Intangible Assets (Tables) Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) false false R18.htm 119 - Disclosure - Marketable Securities (Tables) Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Marketable Securities (Tables) false false R19.htm 120 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) false false R20.htm 121 - Disclosure - Accrued Expenses (Tables) Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R21.htm 122 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R22.htm 123 - Disclosure - Net (Loss) Income per Share (Tables) Sheet http://www.psivida.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net (Loss) Income per Share (Tables) false false R23.htm 124 - Disclosure - Operations and Basis of Presentation - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureOperationsAndBasisOfPresentationAdditionalInformation Operations and Basis of Presentation - Additional Information (Detail) false false R24.htm 125 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation License and Collaboration Agreements - Additional Information (Detail) false false R25.htm 126 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssets Intangible Assets - Reconciliation of Intangible Assets (Detail) false false R26.htm 127 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) false false R27.htm 128 - Disclosure - Marketable Securities - Schedule of Amortized Cost, Unrealized Loss and Fair Value of Available-for-Sale Marketable Securities (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfAmortizedCostUnrealizedLossAndFairValueOfAvailableforSaleMarketableSecurities Marketable Securities - Schedule of Amortized Cost, Unrealized Loss and Fair Value of Available-for-Sale Marketable Securities (Detail) false false R28.htm 129 - Disclosure - Marketable Securities - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation Marketable Securities - Additional Information (Detail) false false R29.htm 130 - Disclosure - Fair Value Measurements - Assets Carried at Fair Value Measured on Recurring Basis (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureFairValueMeasurementsAssetsCarriedAtFairValueMeasuredOnRecurringBasis Fair Value Measurements - Assets Carried at Fair Value Measured on Recurring Basis (Detail) false false R30.htm 131 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) false false R31.htm 132 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R32.htm 133 - Disclosure - Stockholders' Equity - Stock Option Activity Under Plan (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureStockholdersEquityStockOptionActivityUnderPlan Stockholders' Equity - Stock Option Activity Under Plan (Detail) false false R33.htm 134 - Disclosure - Stockholders' Equity - Key Assumptions Used to Apply Option Pricing Model for Options Awarded (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureStockholdersEquityKeyAssumptionsUsedToApplyOptionPricingModelForOptionsAwarded Stockholders' Equity - Key Assumptions Used to Apply Option Pricing Model for Options Awarded (Detail) false false R34.htm 135 - Disclosure - Stockholders' Equity - Compensation Expense from Stock-Based Payment Awards (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureStockholdersEquityCompensationExpenseFromStockBasedPaymentAwards Stockholders' Equity - Compensation Expense from Stock-Based Payment Awards (Detail) false false R35.htm 136 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R36.htm 137 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R37.htm 138 - Disclosure - Net (Loss) Income per Share - Schedule that Reconciles the Number of Shares Used to Compute Basic and Diluted Net (Loss) Income per Share (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureNetLossIncomePerShareScheduleThatReconcilesTheNumberOfSharesUsedToComputeBasicAndDilutedNetLossIncomePerShare Net (Loss) Income per Share - Schedule that Reconciles the Number of Shares Used to Compute Basic and Diluted Net (Loss) Income per Share (Detail) false false R38.htm 139 - Disclosure - Net (Loss) Income per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) Sheet http://www.psivida.com/taxonomy/role/DisclosureNetLossIncomePerSharePotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageShares Net (Loss) Income per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) false false All Reports Book All Reports Element psdv_UpfrontCashPayment had a mix of decimals attribute values: -5 0. Element us-gaap_AccountsAndOtherReceivablesNetCurrent had a mix of decimals attribute values: -3 0. Element us-gaap_DeferredRevenue had a mix of decimals attribute values: -5 0. Element us-gaap_LicenseAndServicesRevenue had a mix of decimals attribute values: -3 0. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 0. Element us-gaap_RoyaltyRevenue had a mix of decimals attribute values: -5 -3 0. Columns in Cash Flows statement 'Condensed Consolidated Statements of Cash Flows (USD $)' have maximum duration 273 days and at least 27 values. Shorter duration columns must have at least one fourth (6) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 4 values, so it is being removed. Columns in Cash Flows statement 'Condensed Consolidated Statements of Cash Flows (USD $)' have maximum duration 273 days and at least 27 values. Shorter duration columns must have at least one fourth (6) as many values. Column '1/1/2015 - 3/31/2015' is shorter (89 days) and has only 3 values, so it is being removed. 'Monetary' elements on report '125 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '127 - Disclosure - Intangible Assets - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '136 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income Process Flow-Through: 107 - Statement - Condensed Consolidated Statements of Cash Flows psdv-20150331.xml psdv-20150331.xsd psdv-20150331_cal.xml psdv-20150331_def.xml psdv-20150331_lab.xml psdv-20150331_pre.xml true true XML 54 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
Net (Loss) Income per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail)
3 Months Ended 9 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 5,667,054us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 5,069,844us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 2,434,024us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 5,069,844us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Options [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 4,490,949us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_EmployeeStockOptionMember
3,893,739us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_EmployeeStockOptionMember
1,881,524us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_EmployeeStockOptionMember
3,893,739us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_EmployeeStockOptionMember
Warrants [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 1,176,105us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember
1,176,105us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember
552,500us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember
1,176,105us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember
XML 55 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accrued Expenses (Tables)
9 Months Ended
Mar. 31, 2015
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following at March 31, 2015 and June 30, 2014 (in thousands):

 

     March 31, 2015      June 30, 2014  

Personnel costs

   $ 618       $ 952   

Professional fees

     286         249   

Clinical

     418         316   

Other

     49         7   
  

 

 

    

 

 

 
$ 1,371    $ 1,524